[
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "G/G",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，需较高剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较高，神经毒性综合征的严重程度可能降低",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，药物代谢较快",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "A/A",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/G",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "G/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，药物代谢较快",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "T/G",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/C",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "C/A",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "C/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "杂合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/G",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/6TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢增加",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "C/T",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/A",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "G/G",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/G",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副低，代谢增加",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-11",
                "updateTime": "."
            }
        ],
        "clinical": [
            {
                "brief_summary": "  This phase III trial studies if selumetinib works just as well as the standard treatment with  carboplatine/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to  see if selumetinib is better than CV in improving vision in subjects with LGG of the optic  pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that tumor  cells need for their growth. This results in killing tumor cells. Drugs used in chemotherapy,  such as carboplatin and vincristine, work in different ways to stop the growth of tumor  cells, either by killing the cells, by stopping them from dividing, or by stopping them from  spreading. It is not yet known whether selumetinib works better in treating patients with NF1  associated low-grade glioma compared to standard therapy with carboplatin and vincristine.",
                "brief_title": "A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma",
                "condition": "Neurofibromatosis Type 1;Low Grade Glioma;Visual Pathway Glioma",
                "country": ".",
                "geneName": "NF1",
                "intervention_name": "Selumetinib Sulfate;Carboplatin;Questionnaire Administration;Quality-of-Life Assessment;Selumetinib;Vincristine Sulfate;Vincristine",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03871257",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 3",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "March 12, 2019"
            },
            {
                "brief_summary": "  This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene  relative to fulvestrant for the treatment of postmenopausal women with locally advanced or  metastatic ER+/HER2− breast cancer with an acquired ESR1 mutation and who have disease  progression on an aromatase inhibitor (AI) in combination with a cyclin dependent kinase  (CDK) 4/6 inhibitor.  The primary objective is to evaluate the progression free survival (PFS) of 5 mg lasofoxifene  relative to fulvestrant for the treatment of postmenopausal women with locally advanced or  metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2−)  breast cancer with an ESR1 mutation.  The secondary objectives are to evaluate:    1. Clinical benefit rate (CBR) and Objective Response Rate (ORR)    2. Duration of response    3. Time to response    4. Overall Survival (OS)    5. Pharmacokinetics of lasofoxifene    6. Quality of life (QoL): Quality of Life (QoL): vaginal assessment scale (VAS) and vulvar     assessment scale (VuAS) questionnaires    7. Safety of lasofoxifene    8. Response to various ESR1 mutation (Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H,     L536H, L536P, L536R, L536Q, or Y537N)    9. The presence of the following mutations from tumor free DNA will be documented and part     of an exploratory analysis:     1. erbb2 extracellular domain mutation 5310;     2. erbb2 kinase domain mutations V777, L755, and Exon 20 insertion;     3. all NF1 mutations that are truncating, frame shifting and nonsense or homozygous      deletions; and     4. KRAS (Kirsten RAt Sarcoma).",
                "brief_title": "Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation",
                "condition": "Locally Advanced or Metastatic Breast Cancer",
                "country": "United States",
                "geneName": "NF1",
                "intervention_name": "Lasofoxifene;Fulvestrant",
                "intervention_type": "Drug",
                "nct_num": "NCT03781063",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "December 19, 2018"
            },
            {
                "brief_summary": "  This trial, Treatment of NF1-related plexiform neurofibroma with trametinib; a single  arm,open-label study with the goals of volumetric partial remission and pain relief (EudraCT  2018-001846-32, Sponsor protocol number BUS2018-1, related Novartis reference number  CTMT212ASE01T) is a pediatric clinical trial that investigates the potential use of the drug  trametinib (Mekinist®) as treatment for symptomatic or likely to become symptomatic  NF1-related plexiform neurofibromas (PN) in children between 1 year and 17 year and 11 months  of age.  Trametinib is orally administered qd at 0.025 mg/kg up to a maximum of 2 mg from six years of  age and 0.032mg/kilo up to 5 years of age, provided either as tablets or as oral solution. It  is manufactured and distributed by Novartis under the trade name Mekinist®.  The primary endpoint is remission of tumor volume ≥20%, evaluated using volumetric MRI at 18  and 30 months of treatment.  The secondary endpoint is reversal of pain from NF1-related PN, evaluated monthly with  agespecific pain scales; VAS scale (from 8 years) or Faces Pain Scale (from 3 to 8 years).  As an exploratory measure, the potential effects of the treatment on the cognitive function  will be assessed using well-established tests such as WISC-V (age range 6:0 - 16:11),  NEPSY-II (age range 3:0-16:11), and CPT-3 (age range 8:0 - adult).  Cognitive dysfunction is well described in patients with NF1, and the MAPK/ERK-pathway has  been indicated to be involved in cognition.",
                "brief_title": "Treatment of NF1-related Plexiform Neurofibroma With Trametinib",
                "condition": "Child;Neurofibromatosis 1;Neurofibroma, Plexiform",
                "country": "Sweden",
                "geneName": "NF1",
                "intervention_name": "Trametinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03741101",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "November 14, 2018"
            },
            {
                "brief_summary": "  This study will evaluate bioavailability and food effect of selumetinib (AZD6244) in healthy  male participants. A total of 24 healthy male participants will be included to ensure at  least 20 evaluable participants. The study is divided in 2 study parts; the same participants  will participate in both parts of the study. Part 1 of the study is to investigate the  pharmacokinetics (PK) of the selumetinib granule compared to the PK of selumetinib capsule,  when administered with water under the fasted conditions. Part 2 of the study is to  investigate the PK of selumetinib granule and capsule under fed conditions. Participants will  also receive a single 500 mg dose of acetaminophen at the same time as selumetinib  administration.",
                "brief_title": "A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants",
                "condition": "Healthy Participants;Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)",
                "country": "United States",
                "geneName": "NF1",
                "intervention_name": "Treatment A;Treatment C;Treatment B;Acetaminophen;Treatment D",
                "intervention_type": "Drug",
                "nct_num": "NCT03649165",
                "overall_status": "Completed",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "August 28, 2018"
            },
            {
                "brief_summary": "  To determine the clinical benefit rate of selumetinib in combination with sirolimus in  patients with unresectable or metastatic neurofibromatosis type 1 (NF1) associated or  sporadic MPNST.",
                "brief_title": "SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors",
                "condition": "Malignant Peripheral Nerve Sheath Tumors;Neurofibromatosis 1",
                "country": "United States",
                "geneName": "NF1",
                "intervention_name": "Selumetinib;Sirolimus",
                "intervention_type": "Drug",
                "nct_num": "NCT03433183",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "February 14, 2018"
            },
            {
                "brief_summary": "  This is a phase 1/2, open-label, interventional clinical trial that will study the response  rate of pediatric glioma and plexiform neurofibroma (PN) to oral administration of  trametinib. Patients meeting all inclusion criteria for a given study group will receive the  study medication at a daily dose of 0.025 mg/kg up to a total of 18 cycles, in 28-day cycles.  A total of 150 patients will be recruited as part of this clinical study.  Patients aged between 1 month (corrected age) and 25 years old will be eligible, in order to  include a maximum of patients affected by low-grade glioma (LGG) and PN. This study includes  four groups: patients with neurofibromatosis type 1 (NF1) and LGG, NF1 patients with PN,  patients with LGG with a B-Raf Serine/Threonine-protein Kinase/Proto-oncogene Encoding B-Raf  (BRAF) fusion and patients with glioma of any grade with activation of the Mitogen-activated  Protein Kinase/Extracellular Signal-regulated Kinases (MAPK/ERK) pathway. All patients except  patients with PN must have failed at least one line of treatment.  The study will also explore the molecular mechanisms behind tumor development, progression  and resistance to treatment. Furthermore, this study will also explore important aspects for  patients with brain tumors by including assessment of quality of life and neuropsychological  evaluation.",
                "brief_title": "Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.",
                "condition": "Central Nervous System Glioma;Low-grade Glioma;Plexiform Neurofibroma",
                "country": "Canada",
                "geneName": "NF1",
                "intervention_name": "Trametinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03363217",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "December 6, 2017"
            },
            {
                "brief_summary": "  Phase I and II study of the MEK inhibitor Selumetinib given twice daily on 5 out of 7 days in  children with NF1 and inoperable plexiform neurofibromas or progressive/relapsed optic  pathway gliomas.  This study will test the early and late toxicities of selumetinib when it is given in this  intermittent schedule (in 5 out of 7 days) and will also test the effectiveness of the drug  in reducing the size of plexiform neurofibromas and optic pathway gliomas in children with  NF1. It will also test the effectiveness of the drug in improving the participants function  in day to day life.",
                "brief_title": "Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours",
                "condition": "Neurofibromatosis Type 1;Optic Nerve Glioma;Plexiform Neurofibroma",
                "country": "United Kingdom",
                "geneName": "NF1",
                "intervention_name": "Selumetinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03326388",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "October 31, 2017"
            },
            {
                "brief_summary": "  This will be an open-label, single-arm, multicenter intermediate access protocol which  provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1  (NF1) who have inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any  alternative therapeutic options. All patients will continue to receive drug while they are  deriving clinical benefit.  Approximately 100 patients in the US will be treated as part of this protocol",
                "brief_title": "An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1",
                "condition": "NF type1 With Inoperable Plexiform Neurofibromas",
                "country": "United States",
                "geneName": "NF1",
                "intervention_name": "Selumetinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03259633",
                "overall_status": "Available",
                "phase": ".",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "August 24, 2017"
            },
            {
                "brief_summary": "  Phase II trial to evaluate trametinib in patients with locally advanced non-squamous,  non-small cell lung cancer (NSCLC) whose tumors harbor a non-synonymous NF-1 mutation, with  progressive disease on at least one prior line of therapy.",
                "brief_title": "Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer",
                "condition": "Non-small Cell Lung Cancer",
                "country": "United States",
                "geneName": "NF1",
                "intervention_name": "Trametinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03232892",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "July 28, 2017"
            },
            {
                "brief_summary": "  This is a phase II open label study that will evaluate children ≥ 1 year of age and adults  with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK  inhibitor, binimetinib. The primary objective is to determine if there is an adequate level  of disease responsiveness to binimetinib in children and adults with NF1 and inoperable  plexiform neurofibromas. The objective response to binimetinib is defined as ≥ 20% decrease  in tumor volume reduction by 12 courses.",
                "brief_title": "Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas",
                "condition": "Neurofibromatosis Type 1;Plexiform Neurofibroma",
                "country": "United States",
                "geneName": "NF1",
                "intervention_name": "Binimetinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03231306",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "July 27, 2017"
            },
            {
                "brief_summary": "  Objective:    -  To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil,     leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver     metastases, with the objective to downstage hepatic disease and enable complete     resection of residual disease.  Primary Objective:    -  To evaluate the resection rate in patients with initially unresectable hepatic     colorectal metastases downstaged with FOLFOX-B. Complete resection of all liver lesions     is the goal.  Secondary Objectives:    -  To evaluate the probability of complete response, partial response or stable disease.    -  To evaluate the proportion of patients who are resected, and the proportion of patients     achieving an R0 resection (among those receiving surgery).    -  To correlate survival with downstaging and resection based on metastatic colorectal     prognostic score.    -  To evaluate the disease-free survival and overall survival.    -  To evaluate the positron emission tomography response rate.    -  To explore correlations of clinical response with telomerase and hTERT expression.",
                "brief_title": "Folfox-B Study for Patients With Colorectal Liver Metastases",
                "condition": "Colorectal Liver Metastases",
                "country": "United States",
                "geneName": "TERT",
                "intervention_name": "5-Fluorouracil;Oxaliplatin;Bevacizumab;Leucovorin",
                "intervention_type": "Drug",
                "nct_num": "NCT00508872",
                "overall_status": "Terminated",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "July 30, 2007"
            },
            {
                "brief_summary": "  70% all cases of cervical cancer, 95% of anal cancers and about 70% of oropharyngeal cancers  are linked to Human Papillomavirus (HPV) infection. HPV oncogenic proteins are  trans-activators of telomerase. Indeed, E6 oncoprotein transactivates the human telomerase  (hTert). Our group has conducted a clinical trial (NCT02402842) in advanced squamous cell  anal cancer (SCCA) and investigators have shown a correlation between the presence of  anti-HPV immunity and anti-telomerase T helpher 1 (TH1) CD4 T cell responses, establishing  telomerase as an appropriate antigen in HPV-related cancers.  Tumor-reactive CD4+ T cells have been found to ensure efficient effector Cytotoxic T  Lymphocytes (CTL) recruitment at the tumor site. Promoting tumor specific TH1 CD4 activation  might be an attractive therapeutic option to enhance anti-PD-1/PD-L1 (Programmed cell  Death-1/Programmed cell Death-Ligand1) efficacy. However, no option is currently available to  expand tumor specific TH1 lymphocytes in most patients. Then, investigators have identified  four novel MHC (Major Histocompatibility Complex) class II-restricted peptides derived from  human telomerase reverse transcriptase (TERT) referred as &quot;Universal Cancer Peptides&quot; (UCP).  UCPVax is a therapeutic cancer vaccine developed by our team and composed of two separate  peptides called UCP2 and UCP4 derived from telomerase. This UCPVax vaccine is currently  evaluated in a multicenter phase I/II study in Non Small Lung Cancer (NSCLC) (NCT2818426) and  seems to show to be safe and immunogenic.  PD-1/PD-L1 immune checkpoint is a relevant candidate target for immunotherapy in HPV+  cancers, based on the prominent role of PD-1 and its ligand PD-L1 in HPV-driven  immune-evasion. There is a strong rational of using PD-1 therapy in HPV+ cancers, however  anti-PD-1/PD-L1 treatment induces a limited number of long term responses in HPV disease.  Combining anti-PD-1/PD-L1 therapy with an antitumor vaccine gains serious consideration in  HPV+ cancers. Indeed, anti-cancer vaccines can induce tumor-specific T cells expansion and  activation and therefore restore the cancer-immunity cycle in patients lacking pre-existing  anti-tumor responses.  So investigators propose to determine the clinical interest and immunological efficacy of a  treatment combining the CD4 helper T-inducer cancer vaccine (UCPVax) with atezolizumab in  patients with HPV+ cancers by evaluation of the objective response rate at 4 months according  to iRecist criteria.",
                "brief_title": "Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)",
                "condition": "Cervical Cancer;Anal Canal Cancer;Squamous Cell Carcinoma of the Head and Neck",
                "country": "France",
                "geneName": "TERT",
                "intervention_name": "Atezolizumab;Tumor biopsies;UCPVax;Blood sample collection;CT scan",
                "intervention_type": "Biological;Procedure;Drug;Other",
                "nct_num": "NCT03946358",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "May 10, 2019"
            },
            {
                "brief_summary": "  Part A (dose-optimization)- to determine the recommended phase 2 dose (RP2D) taking into  account dose-limiting toxicity (DLT/s) in Cycle 1, overall safety/tolerability and  pharmacokinetic (PK), by optimizing doses of Debio 1143 when combined with the standard dose  of nivolumab, as well as treatment compliance in participants with advanced solid  malignancies who failed prior systemic standard treatments.  Part B (basket trial)- to evaluate the preliminary anti-tumor activity of Debio 1143 at the  RP2D in combination with nivolumab at the standard dose, overall and in each participant  cohort (Cohort 1: small cell lung cancer [SCLC]; Cohort 2: squamous cell carcinoma of the  head and neck [SCCHN]; Cohort 3: gastrointestinal (GI) cancers with known microsatellite  instability-high/mismatch repair deficiency (MSI-H/MMRd) or other deoxyribonucleic acid (DNA)  damage repair (DDR) abnormalities, including homologous recombination deficiency (HRD);  Cohort 4: platinum-resistant epithelial ovarian cancer [EOC], endometrial cancer, primary  peritoneal cancer (PPC) or cervical cancer, with known MSIH/MMRd, hereditary/somatic  mutations of the breast cancer 1 (BRCA1) and BRCA2 genes or other DNA DDR abnormalities  (incl. HRD).",
                "brief_title": "Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143",
                "condition": "Solid Tumor",
                "country": "France;Spain",
                "geneName": "BRCA2",
                "intervention_name": "Nivolumab;Debio 1143",
                "intervention_type": "Drug",
                "nct_num": "NCT04122625",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "October 10, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating  patients with germline BRCA mutated breast cancer that has spread to other places in the body  (advanced or metastatic). Olaparib, cediranib, and AZD6738 may stop the growth of tumor cells  by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer",
                "condition": "Prognostic Stage IIIB Breast Cancer AJCC v8;Anatomic Stage IIIB Breast Cancer AJCC v8;Prognostic Stage IIIA Breast Cancer AJCC v8;HER2/Neu Negative;Prognostic Stage IIIC Breast Cancer AJCC v8;Prognostic Stage IV Breast Cancer AJCC v8;Anatomic Stage IIIA Breast Cancer AJCC v8;Advanced Breast Carcinoma;Anatomic Stage III Breast Cancer AJCC v8;Germline BRCA1 Gene Mutation;Anatomic Stage IV Breast Cancer AJCC v8;Metastatic Breast Carcinoma;Prognostic Stage III Breast Cancer AJCC v8;Germline BRCA2 Gene Mutation;Anatomic Stage IIIC Breast Cancer AJCC v8",
                "country": "United States",
                "geneName": "BRCA2",
                "intervention_name": "Ceralasertib;Cediranib;Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT04090567",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "September 16, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib works in treating patients with biliary tract  cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair  gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth.",
                "brief_title": "Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations",
                "condition": "PALB2 Gene Mutation;NBN Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;PTEN Gene Deletion;ATR Gene Mutation;BRCA1 Gene Mutation;ATM Gene Mutation;Metastatic Bile Duct Carcinoma;ARID1A Gene Mutation;RAD51 Gene Mutation;CHEK2 Gene Mutation;MRE11 Gene Mutation;BRIP1 Gene Mutation;Bile Duct Adenocarcinoma;EMSY Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "BRCA2",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT04042831",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "August 2, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well niraparib, when given before surgery, works in treating  patients with high risk prostate cancer that has not spread to other parts of the body  (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may  stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects",
                "condition": "Prostate Carcinoma;DNA Repair Gene Mutation;NBN Gene Mutation;FANCA Gene Mutation;FANCD2 Gene Mutation;BRCA1 Gene Mutation;FANCL Gene Mutation;ATM Gene Mutation;CHEK1 Gene Mutation;RAD51 Gene Mutation;RAD51C Gene Mutation;CHEK2 Gene Mutation;GEN1 Gene Mutation;BRIP1 Gene Mutation;CDK12 Gene Mutation;DNA Damage Response Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "BRCA2",
                "intervention_name": "Niraparib Tosylate Monohydrate;Niraparib;Radical Prostatectomy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT04030559",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "July 24, 2019"
            },
            {
                "brief_summary": "  This early phase I trial studies how well olaparib works in treating patients with newly  diagnosed BRCA-mutant ovarian, primary peritoneal, or fallopian cancer before surgery.  Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell  growth.",
                "brief_title": "Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery",
                "condition": "BRCA-Mutated Ovarian Carcinoma;Stage IIIA Ovarian Cancer AJCC v8;Stage IV Primary Peritoneal Cancer AJCC v8;Stage IIIA Fallopian Tube Cancer AJCC v8;Stage IIIB Fallopian Tube Cancer AJCC v8;Stage IV Fallopian Tube Cancer AJCC v8;Stage IIIB Ovarian Cancer AJCC v8;Stage III Ovarian Cancer AJCC v8;Stage IIIA1 Fallopian Tube Cancer AJCC v8;Stage IIIA2 Fallopian Tube Cancer AJCC v8;Stage IVA Fallopian Tube Cancer AJCC v8;Stage IVA Primary Peritoneal Cancer AJCC v8;Stage IIIA2 Ovarian Cancer AJCC v8;BRCA2 Gene Mutation;Stage IVA Ovarian Cancer AJCC v8;High Grade Fallopian Tube Serous Adenocarcinoma;Stage IIIC Primary Peritoneal Cancer AJCC v8;Stage III Fallopian Tube Cancer AJCC v8;Stage IIIB Primary Peritoneal Cancer AJCC v8;Stage IVB Fallopian Tube Cancer AJCC v8;Stage IIIC Fallopian Tube Cancer AJCC v8;Stage IVB Primary Peritoneal Cancer AJCC v8;High Grade Ovarian Serous Adenocarcinoma;Stage IVB Ovarian Cancer AJCC v8;Stage IV Ovarian Cancer AJCC v8;Stage IIIA Primary Peritoneal Cancer AJCC v8;BRCA1 Gene Mutation;Stage IIIC Ovarian Cancer AJCC v8;Stage III Primary Peritoneal Cancer AJCC v8;Primary Peritoneal High Grade Serous Adenocarcinoma;Stage IIIA1 Ovarian Cancer AJCC v8",
                "country": "United States",
                "geneName": "BRCA2",
                "intervention_name": "Olaparib;Therapeutic Conventional Surgery;Chemotherapy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT03943173",
                "overall_status": "Recruiting",
                "phase": "Early Phase 1",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "May 9, 2019"
            },
            {
                "brief_summary": "  This is two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with  Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is  dose escalation and Part 2 is a Simon 2-Stage design",
                "brief_title": "A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer",
                "condition": "Triple Negative Breast Cancer",
                "country": "United States;Belgium",
                "geneName": "BRCA2",
                "intervention_name": "ZEN003694;Talazoparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03901469",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "April 3, 2019"
            },
            {
                "brief_summary": "  This phase II Lung-MAP trial studies how well rucaparib works in treating patients with  genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV  non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor  cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)",
                "condition": "Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;Stage IV Lung Cancer AJCC v8;Recurrent Lung Non-Small Cell Carcinoma;Deleterious BRCA2 Gene Mutation;Deleterious BRCA1 Gene Mutation;Recurrent Large Cell Lung Carcinoma;Recurrent Lung Adenocarcinoma;Stage IVB Lung Cancer AJCC v8;Lung Non-Small Cell Squamous Carcinoma;Stage IVA Lung Cancer AJCC v8;Loss of Heterozygosity",
                "country": "United States",
                "geneName": "BRCA2",
                "intervention_name": "Rucaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03845296",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "February 19, 2019"
            },
            {
                "brief_summary": "  Single arm, single site, open-label Phase II study of the effects of oral olaparib in  participants with metastatic renal cell carcinoma that harbor an inactivating mutation in  BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,  RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint  inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1  criteria.",
                "brief_title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",
                "condition": "Kidney Cancer;Renal Carcinoma;Renal Cell Carcinoma;Kidney Cancer Metastatic;Metastatic Renal Cell Carcinoma",
                "country": "United States",
                "geneName": "BRCA2",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03786796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "December 25, 2018"
            },
            {
                "brief_summary": "  The main purpose of this research study is to learn whether the investigational combination  of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive  breast cancer and BRCA1 or BRCA2 mutations.",
                "brief_title": "Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer",
                "condition": "Locally Advanced Breast Cancer;Advanced Breast Cancer;Metastatic Breast Cancer;BRCA2 Mutation;BRCA1 Mutation",
                "country": "United States",
                "geneName": "BRCA2",
                "intervention_name": "Olaparib;Palbociclib;Fulvestrant",
                "intervention_type": "Drug",
                "nct_num": "NCT03685331",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "September 26, 2018"
            },
            {
                "brief_summary": "  The main purpose of this research study is to learn whether the investigational combination  of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive  breast cancer and BRCA1 or BRCA2 mutations.",
                "brief_title": "Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer",
                "condition": "Locally Advanced Breast Cancer;Advanced Breast Cancer;Metastatic Breast Cancer;BRCA2 Mutation;BRCA1 Mutation",
                "country": "United States",
                "geneName": "BRCA2",
                "intervention_name": "Olaparib;Palbociclib;Fulvestrant",
                "intervention_type": "Drug",
                "nct_num": "NCT03685331",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "September 26, 2018"
            },
            {
                "brief_summary": "  The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP  regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.",
                "brief_title": "Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.",
                "condition": "Sintilimab;TP53 Mutation;Diffuse Large B-Cell Lymphoma",
                "country": ".",
                "geneName": "TP53",
                "intervention_name": "Sintilimab-R-CHOP",
                "intervention_type": "Drug",
                "nct_num": "NCT04023916",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "July 18, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  CLL is an incurable disease with conventional chemotherapy. In the absence of TP53  disruption, a chemoimmunotherapy (CIT) regimen is recommended as front-line and second-line  treatment in those patients who attained a long progression-free survival (PFS) with the  previous regimen. Bendamustine and rituximab (BR) is one of the most widely adopted CIT  regimens, including second-line treatment. Unfortunately, durations of remission following BR  combination therapy tend to be short in patients with heavily pre-treated disease or who have  already received rituximab. The incorporation of a maintenance following induction  chemotherapy to overcome the shorter remission durations in this population is a reasonable  option.",
                "brief_title": "Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia",
                "condition": "Chronic Lymphocytic Leukemia",
                "country": "Russian Federation",
                "geneName": "TP53",
                "intervention_name": "BR as Maintenance",
                "intervention_type": "Drug",
                "nct_num": "NCT03847727",
                "overall_status": "Active, not recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "February 20, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission  tomography (PET) and osimertinib works in evaluating glucose utilization in patients with  EGFR activated glioblastoma. Osimertinib may stop the growth of tumor cells by blocking some  of the enzymes needed for cell growth. 18F-FDG PET imaging may help to detect changes in  tumor glucose utilization, which may allow investigators to obtain an early read out on the  impact of osimertinib on recurrent glioblastoma patients whose tumors have EGFR activation.",
                "brief_title": "18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma",
                "condition": "EGFR Gene Mutation;Recurrent Glioblastoma;TP53 wt Allele;EGFR Gene Amplification;Supratentorial Glioblastoma;Glioblastoma",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Fludeoxyglucose F-18;Osimertinib;Positron Emission Tomography",
                "intervention_type": "Procedure;Drug;Other",
                "nct_num": "NCT03732352",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "November 6, 2018"
            },
            {
                "brief_summary": "  Recent preclinical studies suggest that combining MEK and MDM2 inhibition synergize to induce  apoptosis in RAS/BRAF-mutant and TP53 wild-type CRC models. In vitro, in RKO cell lines  (poorly differentiated colon carcinoma cell line resistant to single agent targeting MDM2 and  MEK and BRAF inhibition), the MDM2 plus MEK inhibitor combination generated a synergistic  increase in apoptotic index. In vivo, in mice harboring human RKO colon tumor xenografts the  combination of MDM2 plus MEK inhibition elicited 93% decreases in tumor volume.  This trial is to conduct a single-center, Phase 1 dose escalation study of trametinib  combined with HDM201 (a HDM2 inhibitor) in patients with advanced/metastatic RAS/RAF mutant  and TP53 wt CRC.",
                "brief_title": "Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type",
                "condition": "Advanced Cancer;Metastatic Cancer;Colorectal Cancer",
                "country": "France",
                "geneName": "TP53",
                "intervention_name": "Trametinib;HDM201",
                "intervention_type": "Drug",
                "nct_num": "NCT03714958",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "October 22, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in  treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that  is untreated or has come back. Quizartinib may stop the growth of cancer cells by blocking  some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine  and venetoclax, work in different ways to stop the growth of cancer cells, either by killing  the cells, by stopping them from dividing, or by stopping them from spreading. Giving  quizartinib and decitabine may work better at treating acute myeloid leukemia and  myelodysplastic syndrome.",
                "brief_title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",
                "condition": "TP53 Gene Deletion;Blasts More Than 10 Percent of Peripheral Blood White Cells;Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;TP53 Gene Mutation;Myelodysplastic Syndrome;Recurrent Acute Myeloid Leukemia;Acute Myeloid Leukemia;High Risk Myelodysplastic Syndrome;Recurrent Myelodysplastic Syndrome;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Quizartinib;Venetoclax;Decitabine",
                "intervention_type": "Drug",
                "nct_num": "NCT03661307",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "September 7, 2018"
            },
            {
                "brief_summary": "  Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the  treatment of advanced refractory solid tumors with TP53 harmful mutations.",
                "brief_title": "Treatment of Carrying TP53 Harmful Mutations",
                "condition": "Advanced Cancer",
                "country": "China",
                "geneName": "TP53",
                "intervention_name": "Fluzoparib combined with Apatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03645200",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "August 24, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  This phase II trial studies how well talazoparib works in treating patients with homologous  recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has  come back after previous treatment. Talazoparib may stop the growth of tumor cells by  blocking some of the enzymes needed for cell growth.",
                "brief_title": "Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer",
                "condition": "FANCM Gene Mutation;BARD1 Gene Mutation;BRCA2 Gene Mutation;Recurrent Squamous Cell Lung Carcinoma;RAD51 Gene Mutation;Stage IV Squamous Cell Lung Carcinoma AJCC v7;FANCD2 Gene Mutation;ATM Gene Mutation;FANCF Gene Mutation;CHEK2 Gene Mutation;BRIP1 Gene Mutation;RAD54L Gene Mutation;NBN Gene Mutation;RAD51B Gene Mutation;FANCC Gene Mutation;PALB2 Gene Mutation;FANCA Gene Mutation;ATR Gene Mutation;BRCA1 Gene Mutation;CHEK1 Gene Mutation;RPA1 Gene Mutation",
                "country": "Canada;United States",
                "geneName": "BARD1",
                "intervention_name": "Talazoparib;Pharmacological Study;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03377556",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "December 19, 2017"
            },
            {
                "brief_summary": "  Single arm, single site, open-label Phase II study of the effects of oral olaparib in  participants with metastatic renal cell carcinoma that harbor an inactivating mutation in  BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,  RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint  inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1  criteria.",
                "brief_title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",
                "condition": "Kidney Cancer;Renal Carcinoma;Renal Cell Carcinoma;Kidney Cancer Metastatic;Metastatic Renal Cell Carcinoma",
                "country": "United States",
                "geneName": "BARD1",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03786796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-11",
                "study_first_posted": "December 25, 2018"
            }
        ],
        "cms": [
            {
                "age": "54",
                "agentName": "洛阳市中心医院（韩莉）",
                "areaAgentName": "罗鹏",
                "backStatus": "1",
                "backStatusShow": "未返款",
                "barcode": "8101015326",
                "bedNumber": ".",
                "bingli": "2007940-13",
                "birthday": ".",
                "checkTime": ".",
                "contact": "13837964746",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": "妇科一病区",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-22 11:52:00",
                "expressName": ".",
                "expressNum": ".",
                "fenziBingli": ".",
                "financeId": "232520",
                "gender": "女",
                "historyNum": "0",
                "hospitalName": "洛阳市中心医院",
                "idCard": ".",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-13 16:30:17",
                "invoiceApplyMoney": "0.00",
                "invoiceName": "高红霞",
                "invoiceReceivePhone": ".",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "0",
                "invoiceTypeShow": ".",
                "itemName": "0201028.OncoDrug-Seq全实体瘤110基因（组织/细胞学样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-13 16:28:00",
                "medicalRecord": ".",
                "name": "高红霞",
                "nickName": "hanli",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "2",
                "paymentTypeShow": "月结",
                "receiveStatus": "1",
                "receiveStatusShow": "未收款",
                "receiveTime": "2020-07-15 11:52:23",
                "remark": ".",
                "reportAddress": ".",
                "reportAddressName": ".",
                "reportCheckTime": ".",
                "reportEmail": ".",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": ".",
                "reportStyle": ".",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "234042",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200715-11",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": ".",
                "sickAge": ".",
                "sickFamilyHistory": ".",
                "source": "石蜡包埋组织",
                "sourceFrom": "WX",
                "testDoctor": "马丹丹",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "卵巢癌",
                "treatHistory": ".",
                "treatID": "TS1301",
                "treatResult": "卵巢癌",
                "treatmentNo": ".",
                "unitAgentName": "洛阳项目",
                "url": "[]",
                "userId": "320",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [],
        "fusion": [],
        "heredity": [
            {
                "aachangeRefgene": "BRCA2:NM_000059:exon11:c.5719T>G:p.Ser1907Ala",
                "ajsGb": "p.Ser1907Ala",
                "alt": "G",
                "alteration": "S1907A",
                "barcode": ".",
                "chr": "chr13",
                "clinsig": "Uncertain_significance",
                "description": "该基因的胚系致病突变可引起BRCA相关乳腺癌-卵巢癌综合征，并以常染色体显性方式遗传。",
                "diseaseInfo": ".",
                "evidenceLevel": "完善",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.4932",
                "funcRefgene": "exonic",
                "geneInfo": "BRCA2是一种肿瘤抑制蛋白；如果基因的一个拷贝在体系中失活，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（综述于PMID：22193408）。 BRCA2基因位于染色体13q12-q13上（PMID：8091231）。 BRCA2的主要功能是同源重组（HR）。 BRCA2介导RAD51招募到双链DNA断裂；反过来，RAD51允许HR和BRCA2介导的DNA损伤应答的肿瘤抑制功能（PMID：11239455）。 BRCA2基因的功能重要区域是：N末端（氨基酸21-39），其直接结合PALB2并间接结合BRCA1，并且对HR修复的功能至关重要（PMID：19369211,19584259,19268590，19609323） ； BRC重复（氨基酸1009-2083），其与RAD51结合； DNA结合结构域，其促进与DSS1和单链和双链DNA（PMID：12228710,16205630,14580353,20817001）的结合；和C末端含有一个核定位序列和CDK2磷酸化位点s3291，也结合RAD51（PMID：15800615）。 BRCA2突变使乳腺癌的终生风险为50-60％，终生患卵巢癌的风险为30％，前列腺癌风险增加20倍，胰腺癌风险增加10倍，相关胃癌报道有限，Fanconi贫血亚型D1相关的脑癌，髓母细胞瘤，咽癌，慢性淋巴细胞性白血病和急性骨髓性白血病的风险（综述于PMID：22193408）。在BRCA2缺陷型肿瘤中使用PARP抑制剂的临床前数据显示，在裸鼠的体外和体内处理的细胞系中，敲除BRCA2基因导致对PARP抑制剂NU1025和AG14361剧烈的敏感性；相反，敲入小鼠模型中的BRCA2导致对AG14361的耐药性（PMID：15829966）。随附的文章显示，PARP耗竭，无论通过siRNA敲除或用PARP抑制剂KU0058684或KU0058948治疗，结合BRCA1或BRCA2缺陷，对胚胎干细胞是致死性的。此外，该组证明PARP抑制在杀伤BRCA1或BRCA2突变细胞方面比DNA损伤性细胞毒性化疗剂顺铂更有选择性（PMID：15829967）。",
                "geneName": "BRCA2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA2基因exon11第5719位碱基T置换为G使得第1907位氨基酸由丝氨酸转变成了丙氨酸",
                "geneYcType": "常染色体显性遗传（AD）",
                "hgsGb": "c.5719T>G",
                "hgvs": "BRCA2:NM_000059:exon11:c.5719T>G:p.Ser1907Ala",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "mutationType": "杂合突变",
                "ominId": "600185",
                "posEnd": "32914211",
                "posStart": "32914211",
                "projectAbbr": "DE",
                "ref": "T",
                "relativeDisease": "BRCA相关乳腺癌-卵巢癌综合征，Wilms瘤，男性乳腺癌易感，髓母细胞瘤易感，前列腺癌易感",
                "riskLevel": "高",
                "sampleSn": "NGS200715-11",
                "tumorProfiles": ".",
                "vcfFormat": "GT:AD:DP:GQ:PL",
                "vcfFormatInfo": "0/1:412,401:813:99:8044,0,8428",
                "wxz": "exon11",
                "zlb": "NM_000059"
            }
        ],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:1.61%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "1.61%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "如果使用免疫检查点抑制剂治疗，疗效可能较好",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "检测到变异/基因突变（NM_000059:exon11:c.2176del:p.Val726Phefs*4）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": "BRCA2:NM_000059:exon11:c.2176del:p.Val726Phefs*4",
                "Unnamed: 8": ".",
                "Unnamed: 9": "NGS200715-11",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": "TP53:NM_000546:exon6:c.584T>C:p.Ile195Thr",
                "Unnamed: 8": ".",
                "Unnamed: 9": "NGS200715-11",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "如果使用免疫检查点抑制剂治疗，疗效可能较好",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "检测到变异/基因突变（NM_000546:exon6:c.584T>C:p.Ile195Thr）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 1,
                "percent": 1.61,
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-11",
                "totalSites": 62
            }
        ],
        "qc": [
            {
                "cleanBases": 1379780785,
                "cleanReads": 10763200,
                "coverage>0.2x": 96.99,
                "coverage>0.5x": 75.93,
                "effectCoverage500": 73.52,
                "effectDepth": 926,
                "insert": 147.3,
                "mapping": 99.88,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 1653296400,
                "rawDuplication": 18.69,
                "rawReads": 11021976,
                "readPercent": 97.65,
                "samplePurity": "43.64",
                "sampleSn": "NGS200715-11",
                "sampleType": "FFPE",
                "targetMapping": 59.2,
                "trimDuplication": 21.92,
                "tumorCoverage": 99.86,
                "tumorDepth": 1281,
                "tumorQ30": 90.17
            }
        ],
        "target": [
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "1.104e-05",
                "GeneName": "BARD1",
                "NM_ID": "NM_000465",
                "ajsGb": "p.Cys336Tyr",
                "alt": "T",
                "alteration": "C336Y",
                "avsnp150": "rs779527817",
                "cancerType": ".",
                "chr": "chr2",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.487",
                "funcRefgene": "exonic",
                "geneInfo": "BARD1 (BRCA1 Associated RING Domain 1，BRCA1相关的RING结构域1)是一个蛋白质编码基因。与之相关的疾病包括乳腺癌和Bard1相关乳腺癌易感性。与之相关的途径包括影响BARD1信号传导和DNA双链断裂修复。GO（Gene Ontology基因本体论）对其功能注释包括影响蛋白质同源二聚化活性和蛋白质异源二聚化活性。",
                "geneName": "BARD1",
                "geneType": "geneQt,geneHRD",
                "geneVar": "BARD1基因exon4第1007位碱基G置换为A使得第336位氨基酸由半胱氨酸转变成了酪氨酸",
                "hgsGb": "c.1007G>A",
                "hgvs": "BARD1:NM_000465:exon4:c.1007G>A:p.Cys336Tyr",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "215645591",
                "posStart": "215645591",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:120,114:0.487:52,52:68,62:25:160,177:60:32:0.477,0.455,0.487:0.007,0.061,0.932",
                "wxz": "exon4",
                "zlb": "NM_000465"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "1.104e-05",
                "GeneName": "BARD1",
                "NM_ID": "NM_000465",
                "ajsGb": "p.Cys336Tyr",
                "alt": "T",
                "alteration": "C336Y",
                "avsnp150": "rs779527817",
                "cancerType": ".",
                "chr": "chr2",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.487",
                "funcRefgene": "exonic",
                "geneInfo": "BARD1 (BRCA1 Associated RING Domain 1，BRCA1相关的RING结构域1)是一个蛋白质编码基因。与之相关的疾病包括乳腺癌和Bard1相关乳腺癌易感性。与之相关的途径包括影响BARD1信号传导和DNA双链断裂修复。GO（Gene Ontology基因本体论）对其功能注释包括影响蛋白质同源二聚化活性和蛋白质异源二聚化活性。",
                "geneName": "BARD1",
                "geneType": "geneQt,geneHRD",
                "geneVar": "BARD1基因exon4第1007位碱基G置换为A使得第336位氨基酸由半胱氨酸转变成了酪氨酸",
                "hgsGb": "c.1007G>A",
                "hgvs": "BARD1:NM_000465:exon4:c.1007G>A:p.Cys336Tyr",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "215645591",
                "posStart": "215645591",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:120,114:0.487:52,52:68,62:25:160,177:60:32:0.477,0.455,0.487:0.007,0.061,0.932",
                "wxz": "exon4",
                "zlb": "NM_000465"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": ".",
                "DNA_change": ".",
                "ExAC_nonpsych_ALL": "2.254e-05",
                "GeneName": ".",
                "NM_ID": ".",
                "ajsGb": "p.Val1035Ile",
                "alt": "T",
                "alteration": "V1035I",
                "avsnp150": "rs374968697",
                "cancerType": ".",
                "chr": "chr5",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.629",
                "funcRefgene": "exonic",
                "geneInfo": "TERT基因编码端粒酶的催化亚基，端粒酶是维持端粒长度和基因组完整性的酶。体细胞中TERT表达低或不存在;然而，端粒酶活性在绝大多数肿瘤中上调，并可能导致癌细胞永生（PMID：24657534,9282118）。 TERT启动子的测序鉴定了许多癌症类型中的活化突变，包括黑素瘤，肝细胞癌，尿路上皮癌，成神经管细胞瘤和神经胶质瘤（PMID：23348506,23530248）。具有高度复发性TERT启动子突变的肿瘤倾向于源自具有较低自我更新率的组织（PMID：23530248）。 TERT启动子突变，C228T和C250T，占大多数体细胞TERT启动子改变，并分别在TERT的ATG起始密码子上游发生124和146个碱基对。两种启动子突变均产生针对成红细胞转化特异性（ETS）/ T细胞因子（TCF）转录因子的结合基序并增强端粒酶活性（PMID：23348503,23348506,26194807）。除了启动子突变，位于染色体5p上的TERT在许多癌症类型中被扩增（PMID：20164920）。",
                "geneName": "TERT",
                "geneType": "geneQt",
                "geneVar": "TERT基因exon14第3103位碱基G置换为A使得第1035位氨基酸由缬氨酸转变成了异亮氨酸",
                "hgsGb": "c.3103G>A",
                "hgvs": "TERT:NM_198253:exon14:c.3103G>A:p.Val1035Ile",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "1255456",
                "posStart": "1255456",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:140,237:0.621:57,92:83,145:25:155,161:60:33:0.620,0.611,0.629:0.012,0.023,0.966",
                "wxz": "exon14",
                "zlb": "NM_198253"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "BRCA2",
                "NM_ID": "NM_000059",
                "ajsGb": "p.Val726Phefs*4",
                "alt": "-",
                "alteration": "V726Ffs*4",
                "avsnp150": ".",
                "cancerType": "卵巢癌",
                "chr": "chr13",
                "clinsig": "Likely_pathogenic",
                "cosmic70": ".",
                "drugLevel": "1",
                "drugs": "奥拉帕利，Rucaparib[芦卡帕尼]，尼拉帕利",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.149",
                "funcRefgene": "exonic",
                "geneInfo": "BRCA2是一种肿瘤抑制蛋白；如果基因的一个拷贝在体系中失活，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（综述于PMID：22193408）。 BRCA2基因位于染色体13q12-q13上（PMID：8091231）。 BRCA2的主要功能是同源重组（HR）。 BRCA2介导RAD51招募到双链DNA断裂；反过来，RAD51允许HR和BRCA2介导的DNA损伤应答的肿瘤抑制功能（PMID：11239455）。 BRCA2基因的功能重要区域是：N末端（氨基酸21-39），其直接结合PALB2并间接结合BRCA1，并且对HR修复的功能至关重要（PMID：19369211,19584259,19268590，19609323） ； BRC重复（氨基酸1009-2083），其与RAD51结合； DNA结合结构域，其促进与DSS1和单链和双链DNA（PMID：12228710,16205630,14580353,20817001）的结合；和C末端含有一个核定位序列和CDK2磷酸化位点s3291，也结合RAD51（PMID：15800615）。 BRCA2突变使乳腺癌的终生风险为50-60％，终生患卵巢癌的风险为30％，前列腺癌风险增加20倍，胰腺癌风险增加10倍，相关胃癌报道有限，Fanconi贫血亚型D1相关的脑癌，髓母细胞瘤，咽癌，慢性淋巴细胞性白血病和急性骨髓性白血病的风险（综述于PMID：22193408）。在BRCA2缺陷型肿瘤中使用PARP抑制剂的临床前数据显示，在裸鼠的体外和体内处理的细胞系中，敲除BRCA2基因导致对PARP抑制剂NU1025和AG14361剧烈的敏感性；相反，敲入小鼠模型中的BRCA2导致对AG14361的耐药性（PMID：15829966）。随附的文章显示，PARP耗竭，无论通过siRNA敲除或用PARP抑制剂KU0058684或KU0058948治疗，结合BRCA1或BRCA2缺陷，对胚胎干细胞是致死性的。此外，该组证明PARP抑制在杀伤BRCA1或BRCA2突变细胞方面比DNA损伤性细胞毒性化疗剂顺铂更有选择性（PMID：15829967）。",
                "geneName": "BRCA2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA2基因exon11第2176位碱基缺失使得第726位氨基酸由缬氨酸转变成了苯丙氨酸且发生移码",
                "hgsGb": "c.2176del",
                "hgvs": "BRCA2:NM_000059:exon11:c.2176del:p.Val726Phefs*4",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "32910668",
                "posStart": "32910668",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:405,71:0.167:178,30:227,41:27:158,150:60:35:0.136,0.142,0.149:0.010,0.004,0.985",
                "wxz": "exon11",
                "zlb": "NM_000059"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "BRCA2",
                "NM_ID": "NM_000059",
                "ajsGb": "p.Val726Phefs*4",
                "alt": "-",
                "alteration": "V726Ffs*4",
                "avsnp150": ".",
                "cancerType": "前列腺癌",
                "chr": "chr13",
                "clinsig": "Likely_pathogenic",
                "cosmic70": ".",
                "drugLevel": "1",
                "drugs": "奥拉帕利，Rucaparib[芦卡帕尼]",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.149",
                "funcRefgene": "exonic",
                "geneInfo": "BRCA2是一种肿瘤抑制蛋白；如果基因的一个拷贝在体系中失活，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（综述于PMID：22193408）。 BRCA2基因位于染色体13q12-q13上（PMID：8091231）。 BRCA2的主要功能是同源重组（HR）。 BRCA2介导RAD51招募到双链DNA断裂；反过来，RAD51允许HR和BRCA2介导的DNA损伤应答的肿瘤抑制功能（PMID：11239455）。 BRCA2基因的功能重要区域是：N末端（氨基酸21-39），其直接结合PALB2并间接结合BRCA1，并且对HR修复的功能至关重要（PMID：19369211,19584259,19268590，19609323） ； BRC重复（氨基酸1009-2083），其与RAD51结合； DNA结合结构域，其促进与DSS1和单链和双链DNA（PMID：12228710,16205630,14580353,20817001）的结合；和C末端含有一个核定位序列和CDK2磷酸化位点s3291，也结合RAD51（PMID：15800615）。 BRCA2突变使乳腺癌的终生风险为50-60％，终生患卵巢癌的风险为30％，前列腺癌风险增加20倍，胰腺癌风险增加10倍，相关胃癌报道有限，Fanconi贫血亚型D1相关的脑癌，髓母细胞瘤，咽癌，慢性淋巴细胞性白血病和急性骨髓性白血病的风险（综述于PMID：22193408）。在BRCA2缺陷型肿瘤中使用PARP抑制剂的临床前数据显示，在裸鼠的体外和体内处理的细胞系中，敲除BRCA2基因导致对PARP抑制剂NU1025和AG14361剧烈的敏感性；相反，敲入小鼠模型中的BRCA2导致对AG14361的耐药性（PMID：15829966）。随附的文章显示，PARP耗竭，无论通过siRNA敲除或用PARP抑制剂KU0058684或KU0058948治疗，结合BRCA1或BRCA2缺陷，对胚胎干细胞是致死性的。此外，该组证明PARP抑制在杀伤BRCA1或BRCA2突变细胞方面比DNA损伤性细胞毒性化疗剂顺铂更有选择性（PMID：15829967）。",
                "geneName": "BRCA2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA2基因exon11第2176位碱基缺失使得第726位氨基酸由缬氨酸转变成了苯丙氨酸且发生移码",
                "hgsGb": "c.2176del",
                "hgvs": "BRCA2:NM_000059:exon11:c.2176del:p.Val726Phefs*4",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "32910668",
                "posStart": "32910668",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:405,71:0.167:178,30:227,41:27:158,150:60:35:0.136,0.142,0.149:0.010,0.004,0.985",
                "wxz": "exon11",
                "zlb": "NM_000059"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "BRCA2",
                "NM_ID": "NM_000059",
                "ajsGb": "p.Val726Phefs*4",
                "alt": "-",
                "alteration": "V726Ffs*4",
                "avsnp150": ".",
                "cancerType": "胰腺癌",
                "chr": "chr13",
                "clinsig": "Likely_pathogenic",
                "cosmic70": ".",
                "drugLevel": "1",
                "drugs": "奥拉帕利",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.149",
                "funcRefgene": "exonic",
                "geneInfo": "BRCA2是一种肿瘤抑制蛋白；如果基因的一个拷贝在体系中失活，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（综述于PMID：22193408）。 BRCA2基因位于染色体13q12-q13上（PMID：8091231）。 BRCA2的主要功能是同源重组（HR）。 BRCA2介导RAD51招募到双链DNA断裂；反过来，RAD51允许HR和BRCA2介导的DNA损伤应答的肿瘤抑制功能（PMID：11239455）。 BRCA2基因的功能重要区域是：N末端（氨基酸21-39），其直接结合PALB2并间接结合BRCA1，并且对HR修复的功能至关重要（PMID：19369211,19584259,19268590，19609323） ； BRC重复（氨基酸1009-2083），其与RAD51结合； DNA结合结构域，其促进与DSS1和单链和双链DNA（PMID：12228710,16205630,14580353,20817001）的结合；和C末端含有一个核定位序列和CDK2磷酸化位点s3291，也结合RAD51（PMID：15800615）。 BRCA2突变使乳腺癌的终生风险为50-60％，终生患卵巢癌的风险为30％，前列腺癌风险增加20倍，胰腺癌风险增加10倍，相关胃癌报道有限，Fanconi贫血亚型D1相关的脑癌，髓母细胞瘤，咽癌，慢性淋巴细胞性白血病和急性骨髓性白血病的风险（综述于PMID：22193408）。在BRCA2缺陷型肿瘤中使用PARP抑制剂的临床前数据显示，在裸鼠的体外和体内处理的细胞系中，敲除BRCA2基因导致对PARP抑制剂NU1025和AG14361剧烈的敏感性；相反，敲入小鼠模型中的BRCA2导致对AG14361的耐药性（PMID：15829966）。随附的文章显示，PARP耗竭，无论通过siRNA敲除或用PARP抑制剂KU0058684或KU0058948治疗，结合BRCA1或BRCA2缺陷，对胚胎干细胞是致死性的。此外，该组证明PARP抑制在杀伤BRCA1或BRCA2突变细胞方面比DNA损伤性细胞毒性化疗剂顺铂更有选择性（PMID：15829967）。",
                "geneName": "BRCA2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA2基因exon11第2176位碱基缺失使得第726位氨基酸由缬氨酸转变成了苯丙氨酸且发生移码",
                "hgsGb": "c.2176del",
                "hgvs": "BRCA2:NM_000059:exon11:c.2176del:p.Val726Phefs*4",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "32910668",
                "posStart": "32910668",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:405,71:0.167:178,30:227,41:27:158,150:60:35:0.136,0.142,0.149:0.010,0.004,0.985",
                "wxz": "exon11",
                "zlb": "NM_000059"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "BRCA2",
                "NM_ID": "NM_000059",
                "ajsGb": "p.Val726Phefs*4",
                "alt": "-",
                "alteration": "V726Ffs*4",
                "avsnp150": ".",
                "cancerType": "胰腺癌",
                "chr": "chr13",
                "clinsig": "Likely_pathogenic",
                "cosmic70": ".",
                "drugLevel": "3A",
                "drugs": "Rucaparib[芦卡帕尼]",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.149",
                "funcRefgene": "exonic",
                "geneInfo": "BRCA2是一种肿瘤抑制蛋白；如果基因的一个拷贝在体系中失活，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（综述于PMID：22193408）。 BRCA2基因位于染色体13q12-q13上（PMID：8091231）。 BRCA2的主要功能是同源重组（HR）。 BRCA2介导RAD51招募到双链DNA断裂；反过来，RAD51允许HR和BRCA2介导的DNA损伤应答的肿瘤抑制功能（PMID：11239455）。 BRCA2基因的功能重要区域是：N末端（氨基酸21-39），其直接结合PALB2并间接结合BRCA1，并且对HR修复的功能至关重要（PMID：19369211,19584259,19268590，19609323） ； BRC重复（氨基酸1009-2083），其与RAD51结合； DNA结合结构域，其促进与DSS1和单链和双链DNA（PMID：12228710,16205630,14580353,20817001）的结合；和C末端含有一个核定位序列和CDK2磷酸化位点s3291，也结合RAD51（PMID：15800615）。 BRCA2突变使乳腺癌的终生风险为50-60％，终生患卵巢癌的风险为30％，前列腺癌风险增加20倍，胰腺癌风险增加10倍，相关胃癌报道有限，Fanconi贫血亚型D1相关的脑癌，髓母细胞瘤，咽癌，慢性淋巴细胞性白血病和急性骨髓性白血病的风险（综述于PMID：22193408）。在BRCA2缺陷型肿瘤中使用PARP抑制剂的临床前数据显示，在裸鼠的体外和体内处理的细胞系中，敲除BRCA2基因导致对PARP抑制剂NU1025和AG14361剧烈的敏感性；相反，敲入小鼠模型中的BRCA2导致对AG14361的耐药性（PMID：15829966）。随附的文章显示，PARP耗竭，无论通过siRNA敲除或用PARP抑制剂KU0058684或KU0058948治疗，结合BRCA1或BRCA2缺陷，对胚胎干细胞是致死性的。此外，该组证明PARP抑制在杀伤BRCA1或BRCA2突变细胞方面比DNA损伤性细胞毒性化疗剂顺铂更有选择性（PMID：15829967）。",
                "geneName": "BRCA2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA2基因exon11第2176位碱基缺失使得第726位氨基酸由缬氨酸转变成了苯丙氨酸且发生移码",
                "hgsGb": "c.2176del",
                "hgvs": "BRCA2:NM_000059:exon11:c.2176del:p.Val726Phefs*4",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "32910668",
                "posStart": "32910668",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:405,71:0.167:178,30:227,41:27:158,150:60:35:0.136,0.142,0.149:0.010,0.004,0.985",
                "wxz": "exon11",
                "zlb": "NM_000059"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "BRCA2",
                "NM_ID": "NM_000059",
                "ajsGb": "p.Val726Phefs*4",
                "alt": "-",
                "alteration": "V726Ffs*4",
                "avsnp150": ".",
                "cancerType": "乳腺癌",
                "chr": "chr13",
                "clinsig": "Likely_pathogenic",
                "cosmic70": ".",
                "drugLevel": "2",
                "drugs": "奥拉帕利，Talazoparib[他拉唑帕尼]",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.149",
                "funcRefgene": "exonic",
                "geneInfo": "BRCA2是一种肿瘤抑制蛋白；如果基因的一个拷贝在体系中失活，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（综述于PMID：22193408）。 BRCA2基因位于染色体13q12-q13上（PMID：8091231）。 BRCA2的主要功能是同源重组（HR）。 BRCA2介导RAD51招募到双链DNA断裂；反过来，RAD51允许HR和BRCA2介导的DNA损伤应答的肿瘤抑制功能（PMID：11239455）。 BRCA2基因的功能重要区域是：N末端（氨基酸21-39），其直接结合PALB2并间接结合BRCA1，并且对HR修复的功能至关重要（PMID：19369211,19584259,19268590，19609323） ； BRC重复（氨基酸1009-2083），其与RAD51结合； DNA结合结构域，其促进与DSS1和单链和双链DNA（PMID：12228710,16205630,14580353,20817001）的结合；和C末端含有一个核定位序列和CDK2磷酸化位点s3291，也结合RAD51（PMID：15800615）。 BRCA2突变使乳腺癌的终生风险为50-60％，终生患卵巢癌的风险为30％，前列腺癌风险增加20倍，胰腺癌风险增加10倍，相关胃癌报道有限，Fanconi贫血亚型D1相关的脑癌，髓母细胞瘤，咽癌，慢性淋巴细胞性白血病和急性骨髓性白血病的风险（综述于PMID：22193408）。在BRCA2缺陷型肿瘤中使用PARP抑制剂的临床前数据显示，在裸鼠的体外和体内处理的细胞系中，敲除BRCA2基因导致对PARP抑制剂NU1025和AG14361剧烈的敏感性；相反，敲入小鼠模型中的BRCA2导致对AG14361的耐药性（PMID：15829966）。随附的文章显示，PARP耗竭，无论通过siRNA敲除或用PARP抑制剂KU0058684或KU0058948治疗，结合BRCA1或BRCA2缺陷，对胚胎干细胞是致死性的。此外，该组证明PARP抑制在杀伤BRCA1或BRCA2突变细胞方面比DNA损伤性细胞毒性化疗剂顺铂更有选择性（PMID：15829967）。",
                "geneName": "BRCA2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA2基因exon11第2176位碱基缺失使得第726位氨基酸由缬氨酸转变成了苯丙氨酸且发生移码",
                "hgsGb": "c.2176del",
                "hgvs": "BRCA2:NM_000059:exon11:c.2176del:p.Val726Phefs*4",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "32910668",
                "posStart": "32910668",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:405,71:0.167:178,30:227,41:27:158,150:60:35:0.136,0.142,0.149:0.010,0.004,0.985",
                "wxz": "exon11",
                "zlb": "NM_000059"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "3.326e-05",
                "GeneName": "BRCA2",
                "NM_ID": "NM_000059",
                "ajsGb": "p.Ser1907Ala",
                "alt": "G",
                "alteration": "S1907A",
                "avsnp150": "rs753445027",
                "cancerType": ".",
                "chr": "chr13",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.5",
                "funcRefgene": "exonic",
                "geneInfo": "BRCA2是一种肿瘤抑制蛋白；如果基因的一个拷贝在体系中失活，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（综述于PMID：22193408）。 BRCA2基因位于染色体13q12-q13上（PMID：8091231）。 BRCA2的主要功能是同源重组（HR）。 BRCA2介导RAD51招募到双链DNA断裂；反过来，RAD51允许HR和BRCA2介导的DNA损伤应答的肿瘤抑制功能（PMID：11239455）。 BRCA2基因的功能重要区域是：N末端（氨基酸21-39），其直接结合PALB2并间接结合BRCA1，并且对HR修复的功能至关重要（PMID：19369211,19584259,19268590，19609323） ； BRC重复（氨基酸1009-2083），其与RAD51结合； DNA结合结构域，其促进与DSS1和单链和双链DNA（PMID：12228710,16205630,14580353,20817001）的结合；和C末端含有一个核定位序列和CDK2磷酸化位点s3291，也结合RAD51（PMID：15800615）。 BRCA2突变使乳腺癌的终生风险为50-60％，终生患卵巢癌的风险为30％，前列腺癌风险增加20倍，胰腺癌风险增加10倍，相关胃癌报道有限，Fanconi贫血亚型D1相关的脑癌，髓母细胞瘤，咽癌，慢性淋巴细胞性白血病和急性骨髓性白血病的风险（综述于PMID：22193408）。在BRCA2缺陷型肿瘤中使用PARP抑制剂的临床前数据显示，在裸鼠的体外和体内处理的细胞系中，敲除BRCA2基因导致对PARP抑制剂NU1025和AG14361剧烈的敏感性；相反，敲入小鼠模型中的BRCA2导致对AG14361的耐药性（PMID：15829966）。随附的文章显示，PARP耗竭，无论通过siRNA敲除或用PARP抑制剂KU0058684或KU0058948治疗，结合BRCA1或BRCA2缺陷，对胚胎干细胞是致死性的。此外，该组证明PARP抑制在杀伤BRCA1或BRCA2突变细胞方面比DNA损伤性细胞毒性化疗剂顺铂更有选择性（PMID：15829967）。",
                "geneName": "BRCA2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA2基因exon11第5719位碱基T置换为G使得第1907位氨基酸由丝氨酸转变成了丙氨酸",
                "hgsGb": "c.5719T>G",
                "hgvs": "BRCA2:NM_000059:exon11:c.5719T>G:p.Ser1907Ala",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "32914211",
                "posStart": "32914211",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:238,238:0.500:90,85:148,153:26:167,159:60:27:0.489,0.485,0.500:0.009,0.017,0.974",
                "wxz": "exon11",
                "zlb": "NM_000059"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "3.326e-05",
                "GeneName": "BRCA2",
                "NM_ID": "NM_000059",
                "ajsGb": "p.Ser1907Ala",
                "alt": "G",
                "alteration": "S1907A",
                "avsnp150": "rs753445027",
                "cancerType": ".",
                "chr": "chr13",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.5",
                "funcRefgene": "exonic",
                "geneInfo": "BRCA2是一种肿瘤抑制蛋白；如果基因的一个拷贝在体系中失活，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（综述于PMID：22193408）。 BRCA2基因位于染色体13q12-q13上（PMID：8091231）。 BRCA2的主要功能是同源重组（HR）。 BRCA2介导RAD51招募到双链DNA断裂；反过来，RAD51允许HR和BRCA2介导的DNA损伤应答的肿瘤抑制功能（PMID：11239455）。 BRCA2基因的功能重要区域是：N末端（氨基酸21-39），其直接结合PALB2并间接结合BRCA1，并且对HR修复的功能至关重要（PMID：19369211,19584259,19268590，19609323） ； BRC重复（氨基酸1009-2083），其与RAD51结合； DNA结合结构域，其促进与DSS1和单链和双链DNA（PMID：12228710,16205630,14580353,20817001）的结合；和C末端含有一个核定位序列和CDK2磷酸化位点s3291，也结合RAD51（PMID：15800615）。 BRCA2突变使乳腺癌的终生风险为50-60％，终生患卵巢癌的风险为30％，前列腺癌风险增加20倍，胰腺癌风险增加10倍，相关胃癌报道有限，Fanconi贫血亚型D1相关的脑癌，髓母细胞瘤，咽癌，慢性淋巴细胞性白血病和急性骨髓性白血病的风险（综述于PMID：22193408）。在BRCA2缺陷型肿瘤中使用PARP抑制剂的临床前数据显示，在裸鼠的体外和体内处理的细胞系中，敲除BRCA2基因导致对PARP抑制剂NU1025和AG14361剧烈的敏感性；相反，敲入小鼠模型中的BRCA2导致对AG14361的耐药性（PMID：15829966）。随附的文章显示，PARP耗竭，无论通过siRNA敲除或用PARP抑制剂KU0058684或KU0058948治疗，结合BRCA1或BRCA2缺陷，对胚胎干细胞是致死性的。此外，该组证明PARP抑制在杀伤BRCA1或BRCA2突变细胞方面比DNA损伤性细胞毒性化疗剂顺铂更有选择性（PMID：15829967）。",
                "geneName": "BRCA2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA2基因exon11第5719位碱基T置换为G使得第1907位氨基酸由丝氨酸转变成了丙氨酸",
                "hgsGb": "c.5719T>G",
                "hgvs": "BRCA2:NM_000059:exon11:c.5719T>G:p.Ser1907Ala",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "32914211",
                "posStart": "32914211",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:238,238:0.500:90,85:148,153:26:167,159:60:27:0.489,0.485,0.500:0.009,0.017,0.974",
                "wxz": "exon11",
                "zlb": "NM_000059"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "3.326e-05",
                "GeneName": "BRCA2",
                "NM_ID": "NM_000059",
                "ajsGb": "p.Ser1907Ala",
                "alt": "G",
                "alteration": "S1907A",
                "avsnp150": "rs753445027",
                "cancerType": ".",
                "chr": "chr13",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.5",
                "funcRefgene": "exonic",
                "geneInfo": "BRCA2是一种肿瘤抑制蛋白；如果基因的一个拷贝在体系中失活，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（综述于PMID：22193408）。 BRCA2基因位于染色体13q12-q13上（PMID：8091231）。 BRCA2的主要功能是同源重组（HR）。 BRCA2介导RAD51招募到双链DNA断裂；反过来，RAD51允许HR和BRCA2介导的DNA损伤应答的肿瘤抑制功能（PMID：11239455）。 BRCA2基因的功能重要区域是：N末端（氨基酸21-39），其直接结合PALB2并间接结合BRCA1，并且对HR修复的功能至关重要（PMID：19369211,19584259,19268590，19609323） ； BRC重复（氨基酸1009-2083），其与RAD51结合； DNA结合结构域，其促进与DSS1和单链和双链DNA（PMID：12228710,16205630,14580353,20817001）的结合；和C末端含有一个核定位序列和CDK2磷酸化位点s3291，也结合RAD51（PMID：15800615）。 BRCA2突变使乳腺癌的终生风险为50-60％，终生患卵巢癌的风险为30％，前列腺癌风险增加20倍，胰腺癌风险增加10倍，相关胃癌报道有限，Fanconi贫血亚型D1相关的脑癌，髓母细胞瘤，咽癌，慢性淋巴细胞性白血病和急性骨髓性白血病的风险（综述于PMID：22193408）。在BRCA2缺陷型肿瘤中使用PARP抑制剂的临床前数据显示，在裸鼠的体外和体内处理的细胞系中，敲除BRCA2基因导致对PARP抑制剂NU1025和AG14361剧烈的敏感性；相反，敲入小鼠模型中的BRCA2导致对AG14361的耐药性（PMID：15829966）。随附的文章显示，PARP耗竭，无论通过siRNA敲除或用PARP抑制剂KU0058684或KU0058948治疗，结合BRCA1或BRCA2缺陷，对胚胎干细胞是致死性的。此外，该组证明PARP抑制在杀伤BRCA1或BRCA2突变细胞方面比DNA损伤性细胞毒性化疗剂顺铂更有选择性（PMID：15829967）。",
                "geneName": "BRCA2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA2基因exon11第5719位碱基T置换为G使得第1907位氨基酸由丝氨酸转变成了丙氨酸",
                "hgsGb": "c.5719T>G",
                "hgvs": "BRCA2:NM_000059:exon11:c.5719T>G:p.Ser1907Ala",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "32914211",
                "posStart": "32914211",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:238,238:0.500:90,85:148,153:26:167,159:60:27:0.489,0.485,0.500:0.009,0.017,0.974",
                "wxz": "exon11",
                "zlb": "NM_000059"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "3.326e-05",
                "GeneName": "BRCA2",
                "NM_ID": "NM_000059",
                "ajsGb": "p.Ser1907Ala",
                "alt": "G",
                "alteration": "S1907A",
                "avsnp150": "rs753445027",
                "cancerType": ".",
                "chr": "chr13",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.5",
                "funcRefgene": "exonic",
                "geneInfo": "BRCA2是一种肿瘤抑制蛋白；如果基因的一个拷贝在体系中失活，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（综述于PMID：22193408）。 BRCA2基因位于染色体13q12-q13上（PMID：8091231）。 BRCA2的主要功能是同源重组（HR）。 BRCA2介导RAD51招募到双链DNA断裂；反过来，RAD51允许HR和BRCA2介导的DNA损伤应答的肿瘤抑制功能（PMID：11239455）。 BRCA2基因的功能重要区域是：N末端（氨基酸21-39），其直接结合PALB2并间接结合BRCA1，并且对HR修复的功能至关重要（PMID：19369211,19584259,19268590，19609323） ； BRC重复（氨基酸1009-2083），其与RAD51结合； DNA结合结构域，其促进与DSS1和单链和双链DNA（PMID：12228710,16205630,14580353,20817001）的结合；和C末端含有一个核定位序列和CDK2磷酸化位点s3291，也结合RAD51（PMID：15800615）。 BRCA2突变使乳腺癌的终生风险为50-60％，终生患卵巢癌的风险为30％，前列腺癌风险增加20倍，胰腺癌风险增加10倍，相关胃癌报道有限，Fanconi贫血亚型D1相关的脑癌，髓母细胞瘤，咽癌，慢性淋巴细胞性白血病和急性骨髓性白血病的风险（综述于PMID：22193408）。在BRCA2缺陷型肿瘤中使用PARP抑制剂的临床前数据显示，在裸鼠的体外和体内处理的细胞系中，敲除BRCA2基因导致对PARP抑制剂NU1025和AG14361剧烈的敏感性；相反，敲入小鼠模型中的BRCA2导致对AG14361的耐药性（PMID：15829966）。随附的文章显示，PARP耗竭，无论通过siRNA敲除或用PARP抑制剂KU0058684或KU0058948治疗，结合BRCA1或BRCA2缺陷，对胚胎干细胞是致死性的。此外，该组证明PARP抑制在杀伤BRCA1或BRCA2突变细胞方面比DNA损伤性细胞毒性化疗剂顺铂更有选择性（PMID：15829967）。",
                "geneName": "BRCA2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA2基因exon11第5719位碱基T置换为G使得第1907位氨基酸由丝氨酸转变成了丙氨酸",
                "hgsGb": "c.5719T>G",
                "hgvs": "BRCA2:NM_000059:exon11:c.5719T>G:p.Ser1907Ala",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "32914211",
                "posStart": "32914211",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:238,238:0.500:90,85:148,153:26:167,159:60:27:0.489,0.485,0.500:0.009,0.017,0.974",
                "wxz": "exon11",
                "zlb": "NM_000059"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "3.326e-05",
                "GeneName": "BRCA2",
                "NM_ID": "NM_000059",
                "ajsGb": "p.Ser1907Ala",
                "alt": "G",
                "alteration": "S1907A",
                "avsnp150": "rs753445027",
                "cancerType": ".",
                "chr": "chr13",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.5",
                "funcRefgene": "exonic",
                "geneInfo": "BRCA2是一种肿瘤抑制蛋白；如果基因的一个拷贝在体系中失活，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（综述于PMID：22193408）。 BRCA2基因位于染色体13q12-q13上（PMID：8091231）。 BRCA2的主要功能是同源重组（HR）。 BRCA2介导RAD51招募到双链DNA断裂；反过来，RAD51允许HR和BRCA2介导的DNA损伤应答的肿瘤抑制功能（PMID：11239455）。 BRCA2基因的功能重要区域是：N末端（氨基酸21-39），其直接结合PALB2并间接结合BRCA1，并且对HR修复的功能至关重要（PMID：19369211,19584259,19268590，19609323） ； BRC重复（氨基酸1009-2083），其与RAD51结合； DNA结合结构域，其促进与DSS1和单链和双链DNA（PMID：12228710,16205630,14580353,20817001）的结合；和C末端含有一个核定位序列和CDK2磷酸化位点s3291，也结合RAD51（PMID：15800615）。 BRCA2突变使乳腺癌的终生风险为50-60％，终生患卵巢癌的风险为30％，前列腺癌风险增加20倍，胰腺癌风险增加10倍，相关胃癌报道有限，Fanconi贫血亚型D1相关的脑癌，髓母细胞瘤，咽癌，慢性淋巴细胞性白血病和急性骨髓性白血病的风险（综述于PMID：22193408）。在BRCA2缺陷型肿瘤中使用PARP抑制剂的临床前数据显示，在裸鼠的体外和体内处理的细胞系中，敲除BRCA2基因导致对PARP抑制剂NU1025和AG14361剧烈的敏感性；相反，敲入小鼠模型中的BRCA2导致对AG14361的耐药性（PMID：15829966）。随附的文章显示，PARP耗竭，无论通过siRNA敲除或用PARP抑制剂KU0058684或KU0058948治疗，结合BRCA1或BRCA2缺陷，对胚胎干细胞是致死性的。此外，该组证明PARP抑制在杀伤BRCA1或BRCA2突变细胞方面比DNA损伤性细胞毒性化疗剂顺铂更有选择性（PMID：15829967）。",
                "geneName": "BRCA2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA2基因exon11第5719位碱基T置换为G使得第1907位氨基酸由丝氨酸转变成了丙氨酸",
                "hgsGb": "c.5719T>G",
                "hgvs": "BRCA2:NM_000059:exon11:c.5719T>G:p.Ser1907Ala",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "32914211",
                "posStart": "32914211",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:238,238:0.500:90,85:148,153:26:167,159:60:27:0.489,0.485,0.500:0.009,0.017,0.974",
                "wxz": "exon11",
                "zlb": "NM_000059"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "I195T",
                "DNA_change": "I195T",
                "ExAC_nonpsych_ALL": "0",
                "GeneName": "TP53",
                "NM_ID": "NM_000546",
                "ajsGb": "p.Ile195Thr",
                "alt": "G",
                "alteration": "I195T",
                "avsnp150": "rs760043106",
                "cancerType": "卵巢癌",
                "chr": "chr17",
                "clinsig": "Pathogenic|Likely_pathogenic",
                "cosmic70": "ID\\x3dCOSM116924",
                "drugLevel": "3A",
                "drugs": "AZD1775",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.165",
                "funcRefgene": "exonic",
                "geneInfo": "TP53通过诱导下游抗肿瘤反应如DNA修复和细胞凋亡（PMID：11099028）编码p53肿瘤抑制蛋白，该蛋白是一种对细胞应激（包括DNA损伤和致癌激活）反应的转录因子。 TP53是人类癌症中最常见的突变基因，并且其胚系突变导致广泛癌症倾向的Li-Fraumeni综合征（PMID：22713868,21765642）。 p53蛋白由N末端反式激活结构域，中央DNA结合结构域，寡聚化结构域和C末端调节结构域（PMID：22713868）组成。",
                "geneName": "TP53",
                "geneType": "geneBx,geneHl,geneMy",
                "geneVar": "TP53基因exon6第584位碱基T置换为C使得第195位氨基酸由异亮氨酸转变成了苏氨酸",
                "hgsGb": "c.584T>C",
                "hgvs": "TP53:NM_000546:exon6:c.584T>C:p.Ile195Thr",
                "intervarAutomated": "Likely_pathogenic",
                "level": "4/5（可能致病/致病）",
                "posEnd": "7578265",
                "posStart": "7578265",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:212,42:0.178:100,12:112,30:28:150,150:60:28:0.160,0.129,0.165:0.003,0.058,0.939",
                "wxz": "exon6",
                "zlb": "NM_000546"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "I195T",
                "DNA_change": "I195T",
                "ExAC_nonpsych_ALL": "0",
                "GeneName": "TP53",
                "NM_ID": "NM_000546",
                "ajsGb": "p.Ile195Thr",
                "alt": "G",
                "alteration": "I195T",
                "avsnp150": "rs760043106",
                "cancerType": "头颈鳞癌",
                "chr": "chr17",
                "clinsig": "Pathogenic|Likely_pathogenic",
                "cosmic70": "ID\\x3dCOSM116924",
                "drugLevel": "3A",
                "drugs": "AZD1775",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.165",
                "funcRefgene": "exonic",
                "geneInfo": "TP53通过诱导下游抗肿瘤反应如DNA修复和细胞凋亡（PMID：11099028）编码p53肿瘤抑制蛋白，该蛋白是一种对细胞应激（包括DNA损伤和致癌激活）反应的转录因子。 TP53是人类癌症中最常见的突变基因，并且其胚系突变导致广泛癌症倾向的Li-Fraumeni综合征（PMID：22713868,21765642）。 p53蛋白由N末端反式激活结构域，中央DNA结合结构域，寡聚化结构域和C末端调节结构域（PMID：22713868）组成。",
                "geneName": "TP53",
                "geneType": "geneBx,geneHl,geneMy",
                "geneVar": "TP53基因exon6第584位碱基T置换为C使得第195位氨基酸由异亮氨酸转变成了苏氨酸",
                "hgsGb": "c.584T>C",
                "hgvs": "TP53:NM_000546:exon6:c.584T>C:p.Ile195Thr",
                "intervarAutomated": "Likely_pathogenic",
                "level": "4/5（可能致病/致病）",
                "posEnd": "7578265",
                "posStart": "7578265",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:212,42:0.178:100,12:112,30:28:150,150:60:28:0.160,0.129,0.165:0.003,0.058,0.939",
                "wxz": "exon6",
                "zlb": "NM_000546"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "NF1",
                "NM_ID": "NM_001042492",
                "ajsGb": "p.Asn1619Metfs*4",
                "alt": "-",
                "alteration": "N1619Mfs*4",
                "avsnp150": ".",
                "cancerType": "实体瘤",
                "chr": "chr17",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": "4",
                "drugs": "Cobimetinib[考比替尼]，曲美替尼",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.112",
                "funcRefgene": "exonic",
                "geneInfo": "NF1基因编码作用于小GTP酶HRAS，KRAS和NRAS的GTP酶活化蛋白（GAP）（PMID：2121370,1946382）。当与RAS结合时，NF1蛋白稳定RAS蛋白的GTP酶活性，其将RAS从其活性的GTP结合状态转换为其无活性的GDP结合状态（PMID：9219684,9302992）。 GAP相关结构域（GRD）是NF1的催化结构域，其直接负责其GAP活性，但仅包含约10％的蛋白质。 NF1在癌易感综合征1型神经纤维瘤病中发生胚系改变，并且在许多肿瘤类型包括乳腺癌，黑素瘤和神经胶质瘤中发生体细胞改变（PMID：2134734,1946382,18772890,23000897,9639526,18948947,22817889）。由于基因缺失，基因突变或蛋白质降解而使NF1失活导致活性GTP结合的RAS水平升高以及下游途径例如MAPK / ERK途径和PI3K途径的激活（PMID：19573811,24576830,8563751， 7542586，8052307，12509763）。错义和截短突变发生在整个基因中，而不是以热点突变的方式存在。在NF1的一个等位基因上发生的变异可能导致蛋白质的单倍体不足（PMID：7920653,18089636），因此尽管表现出该综合征的症状，但许多神经纤维瘤病1型患者具有未改变的第二等位基因。此外，杂合性的功能性丧失可能发生在第二个NF1等位基因上，因为具有NF1点突变的肿瘤具有比野生型肿瘤更低水平的mRNA（cBioPortal，MSKCC，2015年5月）。",
                "geneName": "NF1",
                "geneType": "geneBx,geneYc",
                "geneVar": "NF1基因exon37第4856_4877位碱基缺失使得第1619位氨基酸由天冬酰胺转变成了甲硫氨酸且发生移码",
                "hgsGb": "c.4856_4877del",
                "hgvs": "NF1:NM_001042492:exon37:c.4856_4877del:p.Asn1619Metfs*4",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "29652877",
                "posStart": "29652856",
                "projectAbbr": "DE",
                "ref": "CAATGGTGATTTGCTGATATAC",
                "sampleSn": "NGS200715-11",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:269,34:0.130:122,17:147,17:26:156,179:60:32:0.099,0.104,0.112:0.008,0.006,0.986",
                "wxz": "exon37",
                "zlb": "NM_001042492"
            }
        ],
        "tmb": [],
        "tnb": []
    },
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副中度",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "G/A",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，需较高剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较低，神经毒性综合征的严重程度可能降低",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "C/T",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "A/A",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/G",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "G/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "T/G",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/C",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "A/A",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "C/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "G/T",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "野生型",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/G",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副中度",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/7TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "C/C",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢降低",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "T/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/A",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "G/G",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/A",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副高，代谢降低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-20",
                "updateTime": "."
            }
        ],
        "clinical": [
            {
                "brief_summary": "  Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+)  and/or BCR-ABL1 positive CML can be included in the study until 3 months after diagnosis. A  &lt;4 week pretreatment with hydroxyurea is permitted. Patients treated for &lt;6 weeks with  nilotinib 300 mg BID, imatinib 400 mg QD, or dasatinib 100 mg QD are eligible for recruitment  and will be allocated to the respective cohort. All patients must provide written informed  consent to be enrolled in the trial. Cohorts were designed to allow assessment of QD and BID  asciminib based combinations to optimize quality of life and compliance. Patients will not be  randomized. In general, cohorts will be filled consecutively. Asciminib therapy will be  commenced 12 weeks after start of nilotinib, imatinib or dasatinib and after recovery of  hematopoiesis. Referred patients already treated with imatinib, nilotinib or dasatinib will  remain on the initial drug and will be allocated to the respective cohort.",
                "brief_title": "Frontline Asciminib Combination in Chronic Phase CML",
                "condition": "Chronic Myeloid Leukemia",
                "country": "Germany",
                "geneName": "ABL1",
                "intervention_name": "Dasatinib;Imatinib;Nilotinib 300 mg;Asciminib",
                "intervention_type": "Drug",
                "nct_num": "NCT03906292",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "April 8, 2019"
            },
            {
                "brief_summary": "  Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+)  and/or BCR-ABL1 positive CML can be included in the study until 3 months after diagnosis. A  &lt;4 week pretreatment with hydroxyurea is permitted. Patients treated for &lt;6 weeks with  nilotinib 300 mg BID, imatinib 400 mg QD, or dasatinib 100 mg QD are eligible for recruitment  and will be allocated to the respective cohort. All patients must provide written informed  consent to be enrolled in the trial. Cohorts were designed to allow assessment of QD and BID  asciminib based combinations to optimize quality of life and compliance. Patients will not be  randomized. In general, cohorts will be filled consecutively. Asciminib therapy will be  commenced 12 weeks after start of nilotinib, imatinib or dasatinib and after recovery of  hematopoiesis. Referred patients already treated with imatinib, nilotinib or dasatinib will  remain on the initial drug and will be allocated to the respective cohort.",
                "brief_title": "Frontline Asciminib Combination in Chronic Phase CML",
                "condition": "Chronic Myeloid Leukemia",
                "country": "Germany",
                "geneName": "ABL1",
                "intervention_name": "Dasatinib;Imatinib;Nilotinib 300 mg;Asciminib",
                "intervention_type": "Drug",
                "nct_num": "NCT03906292",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "April 8, 2019"
            },
            {
                "brief_summary": "  Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+)  and/or BCR-ABL1 positive CML can be included in the study until 3 months after diagnosis. A  &lt;4 week pretreatment with hydroxyurea is permitted. Patients treated for &lt;6 weeks with  nilotinib 300 mg BID, imatinib 400 mg QD, or dasatinib 100 mg QD are eligible for recruitment  and will be allocated to the respective cohort. All patients must provide written informed  consent to be enrolled in the trial. Cohorts were designed to allow assessment of QD and BID  asciminib based combinations to optimize quality of life and compliance. Patients will not be  randomized. In general, cohorts will be filled consecutively. Asciminib therapy will be  commenced 12 weeks after start of nilotinib, imatinib or dasatinib and after recovery of  hematopoiesis. Referred patients already treated with imatinib, nilotinib or dasatinib will  remain on the initial drug and will be allocated to the respective cohort.",
                "brief_title": "Frontline Asciminib Combination in Chronic Phase CML",
                "condition": "Chronic Myeloid Leukemia",
                "country": "Germany",
                "geneName": "ABL1",
                "intervention_name": "Dasatinib;Imatinib;Nilotinib 300 mg;Asciminib",
                "intervention_type": "Drug",
                "nct_num": "NCT03906292",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "April 8, 2019"
            },
            {
                "brief_summary": "  Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+)  and/or BCR-ABL1 positive CML can be included in the study until 3 months after diagnosis. A  &lt;4 week pretreatment with hydroxyurea is permitted. Patients treated for &lt;6 weeks with  nilotinib 300 mg BID, imatinib 400 mg QD, or dasatinib 100 mg QD are eligible for recruitment  and will be allocated to the respective cohort. All patients must provide written informed  consent to be enrolled in the trial. Cohorts were designed to allow assessment of QD and BID  asciminib based combinations to optimize quality of life and compliance. Patients will not be  randomized. In general, cohorts will be filled consecutively. Asciminib therapy will be  commenced 12 weeks after start of nilotinib, imatinib or dasatinib and after recovery of  hematopoiesis. Referred patients already treated with imatinib, nilotinib or dasatinib will  remain on the initial drug and will be allocated to the respective cohort.",
                "brief_title": "Frontline Asciminib Combination in Chronic Phase CML",
                "condition": "Chronic Myeloid Leukemia",
                "country": "Germany",
                "geneName": "ABL1",
                "intervention_name": "Dasatinib;Imatinib;Nilotinib 300 mg;Asciminib",
                "intervention_type": "Drug",
                "nct_num": "NCT03906292",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "April 8, 2019"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well ruxolitinib phosphate and dasatinib or  nilotinib work in treating patients with chronic myeloid leukemia. Ruxolitinib, dasatinib,  and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for  cell growth.",
                "brief_title": "Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia",
                "condition": "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
                "country": "United States",
                "geneName": "ABL1",
                "intervention_name": "Dasatinib;Ruxolitinib Phosphate;Nilotinib;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03654768",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "August 31, 2018"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well ruxolitinib phosphate and dasatinib or  nilotinib work in treating patients with chronic myeloid leukemia. Ruxolitinib, dasatinib,  and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for  cell growth.",
                "brief_title": "Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia",
                "condition": "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
                "country": "United States",
                "geneName": "ABL1",
                "intervention_name": "Dasatinib;Ruxolitinib Phosphate;Nilotinib;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03654768",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "August 31, 2018"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well ruxolitinib phosphate and dasatinib or  nilotinib work in treating patients with chronic myeloid leukemia. Ruxolitinib, dasatinib,  and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for  cell growth.",
                "brief_title": "Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia",
                "condition": "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
                "country": "United States",
                "geneName": "ABL1",
                "intervention_name": "Dasatinib;Ruxolitinib Phosphate;Nilotinib;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03654768",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "August 31, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the best dose of venetoclax when given together with ponatinib  and dexamethasone and to see how well they work in treating participants with Philadelphia  chromosome or BCR-ABL positive acute lymphoblastic leukemia or chronic myelogenous leukemia  that has come back or does not respond to treatment. Drugs used in chemotherapy, such as  venetoclax and dexamethasone, work in different ways to stop the growth of cancer cells,  either by killing the cells, by stopping them from dividing, or by stopping them from  spreading. Ponatinib may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Giving venetoclax, ponatinib, and dexamethasone may work better in  treating participants with acute lymphoblastic leukemia or chronic myelogenous leukemia.",
                "brief_title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",
                "condition": "t(9;22);Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Recurrent Acute Lymphoblastic Leukemia;Philadelphia Chromosome Positive;Refractory Acute Lymphoblastic Leukemia",
                "country": "United States",
                "geneName": "ABL1",
                "intervention_name": "Ponatinib Hydrochloride;Dexamethasone;Venetoclax;Rituximab",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03576547",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "July 3, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the best dose of venetoclax when given together with ponatinib  and dexamethasone and to see how well they work in treating participants with Philadelphia  chromosome or BCR-ABL positive acute lymphoblastic leukemia or chronic myelogenous leukemia  that has come back or does not respond to treatment. Drugs used in chemotherapy, such as  venetoclax and dexamethasone, work in different ways to stop the growth of cancer cells,  either by killing the cells, by stopping them from dividing, or by stopping them from  spreading. Ponatinib may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Giving venetoclax, ponatinib, and dexamethasone may work better in  treating participants with acute lymphoblastic leukemia or chronic myelogenous leukemia.",
                "brief_title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",
                "condition": "t(9;22);Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Recurrent Acute Lymphoblastic Leukemia;Philadelphia Chromosome Positive;Refractory Acute Lymphoblastic Leukemia",
                "country": "United States",
                "geneName": "ABL1",
                "intervention_name": "Ponatinib Hydrochloride;Dexamethasone;Venetoclax;Rituximab",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03576547",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "July 3, 2018"
            },
            {
                "brief_summary": "  This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or  nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of  minimal residual disease, defined as the levels of a gene product called bcr-abl in the  blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer  cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of  cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and  dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic  myeloid leukemia.",
                "brief_title": "Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease",
                "condition": "Minimal Residual Disease;Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
                "country": "United States",
                "geneName": "ABL1",
                "intervention_name": "Pembrolizumab;Imatinib Mesylate;Nilotinib;Dasatinib;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Drug;Other",
                "nct_num": "NCT03516279",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "May 4, 2018"
            },
            {
                "brief_summary": "  This study is aimed to explore the antitumor activity, safety and efficacy profile of  cabozantinib in pretreated, advanced RET-rearranged non-small cell lung cancer patients",
                "brief_title": "Phase II Study With Cabozantinib in Patients With RET Positive NSCLC",
                "condition": "Non Small Cell Lung Cancer",
                "country": "Italy",
                "geneName": "RET",
                "intervention_name": "Cabozantinib 40 MG;Cabozantinib 20 MG;Cabozantinib 60 MG",
                "intervention_type": "Drug",
                "nct_num": "NCT04131543",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "October 18, 2019"
            },
            {
                "brief_summary": "  Expanded access for patients with cancer with RET activation who are ineligible for an  ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292  through an existing clinical trial.",
                "brief_title": "Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation",
                "condition": "Pancreatic Cancer;Colon Cancer;Medullary Thyroid Cancer;Breast Cancer;Other Solid Tumors With Evidence of Activating RET Alteration;Papillary Thyroid Cancer;Non Small Cell Lung Cancer",
                "country": "Spain;United States",
                "geneName": "RET",
                "intervention_name": "LOXO-292",
                "intervention_type": "Drug",
                "nct_num": "NCT03906331",
                "overall_status": "Available",
                "phase": ".",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "April 8, 2019"
            },
            {
                "brief_summary": "  This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric patients  with an activating RET alteration and an advanced solid or primary CNS tumor.",
                "brief_title": "A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors",
                "condition": "Infantile Fibrosarcoma;Medullary Thyroid Cancer;Soft Tissue Sarcoma;Infantile Myofibromatosis;Papillary Thyroid Cancer",
                "country": "United States",
                "geneName": "RET",
                "intervention_name": "LOXO-292",
                "intervention_type": "Drug",
                "nct_num": "NCT03899792",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "April 2, 2019"
            },
            {
                "brief_summary": "  The primary objective of this study is to determine in an exploratory manner the objective  overall response rate to ponatinib in the treatment of patients with advanced or metastatic  MTC previously treated with cabozantinib or vandetanib who have tumors with  rearranged-during-transfection (RET) mutations and have tumors without RET mutations.",
                "brief_title": "Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer",
                "condition": "Medullary Thyroid Cancer",
                "country": ".",
                "geneName": "RET",
                "intervention_name": "Ponatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03838692",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 12, 2019"
            },
            {
                "brief_summary": "  A research study to evaluate the activity of alectinib for the Treatment of pretreated  patients with advanced NSCLC that have confirmed RETrearrangement.",
                "brief_title": "ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer",
                "condition": "Non-small Cell Lung Cancer;Non-small Cell Lung Cancer Recurrent;Non-small Cell Lung Cancer Metastatic",
                "country": "Netherlands;Slovenia;Portugal;Belgium;France;Italy;Germany;Ireland;Spain;Switzerland",
                "geneName": "RET",
                "intervention_name": "Alectinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03445000",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 26, 2018"
            },
            {
                "brief_summary": "  Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are  Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor  1-3 (VEGFR1-3), RET, AXL, FLT3 and KIT. Cabozantinib has been approved by the FDA for  clinical treatment of progressive, metastatic medullary thyroid cancer. Recently published  trials have demonstrated activity for cabozantinib in patients with advanced renal cell  carcinoma and metastatic castration-resistant prostate cancer (mCRPC). Furthermore, in  preclinical models of urothelial carcinoma (UC) of the bladder, cabozantinib has demonstrated  the ability to inhibit tumor xenograft growth. It has been suggested that levels of soluble  Met ectodomain (sMet) can be measured in the urine as a useful biomarker to monitor the  efficacy of c-Met therapy in bladder cancer patients. Moreover, cabozantinib has demonstrated  activity in heavily pretreated, advanced bladder cancer patients, with a response rate of  19.5% and manageable toxicities.  In the phase I of this study it is proposed to evaluate DLTs of niraparib and cabozantinib  combination and determine maximum tolerated dose (MTD) in patients with advanced urothelial  or renal cell carcinoma. In the phase II it is proposed to make a preliminary evaluation of  the efficacy of this combination in patients with urothelial cell carcinoma. Efficacy results  will be correlated with genomic alterations related to c-Met and Poly [ADP-ribose] polymerase  (PARP) inhibitor activity.",
                "brief_title": "Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)",
                "condition": "Urothelial Cancer",
                "country": "Spain",
                "geneName": "RET",
                "intervention_name": "Niraparib plus Cabozantinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03425201",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 7, 2018"
            },
            {
                "brief_summary": "  Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are  Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor  1-3 (VEGFR1-3), RET, AXL, FLT3 and KIT. Cabozantinib has been approved by the FDA for  clinical treatment of progressive, metastatic medullary thyroid cancer. Recently published  trials have demonstrated activity for cabozantinib in patients with advanced renal cell  carcinoma and metastatic castration-resistant prostate cancer (mCRPC). Furthermore, in  preclinical models of urothelial carcinoma (UC) of the bladder, cabozantinib has demonstrated  the ability to inhibit tumor xenograft growth. It has been suggested that levels of soluble  Met ectodomain (sMet) can be measured in the urine as a useful biomarker to monitor the  efficacy of c-Met therapy in bladder cancer patients. Moreover, cabozantinib has demonstrated  activity in heavily pretreated, advanced bladder cancer patients, with a response rate of  19.5% and manageable toxicities.  In the phase I of this study it is proposed to evaluate DLTs of niraparib and cabozantinib  combination and determine maximum tolerated dose (MTD) in patients with advanced urothelial  or renal cell carcinoma. In the phase II it is proposed to make a preliminary evaluation of  the efficacy of this combination in patients with urothelial cell carcinoma. Efficacy results  will be correlated with genomic alterations related to c-Met and Poly [ADP-ribose] polymerase  (PARP) inhibitor activity.",
                "brief_title": "Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)",
                "condition": "Urothelial Cancer",
                "country": "Spain",
                "geneName": "RET",
                "intervention_name": "Niraparib plus Cabozantinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03425201",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 7, 2018"
            },
            {
                "brief_summary": "  This phase III trial studies how well nivolumab and ipilimumab works with or without local  consolidation therapy in treating patients with stage IV non-small cell lung cancer.  Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the  body's immune system attack the cancer, and may interfere with the ability of tumor cells to  grow and spread. Local consolidation therapy, such as surgery or radiation therapy, may  improve survival outcomes in patients with non-small cell lung cancer. It is not yet known  whether giving nivolumab and ipilimumab with local consolidation therapy works better than  nivolumab and ipilimumab alone in treating patients with stage IV non-small cell lung cancer.",
                "brief_title": "Phase III Trial of (LCT) After Nivolumab and Ipilimumab",
                "condition": "RET Gene Mutation;Stage IV Lung Cancer AJCC v8;Non-small Cell Lung Cancer;Malignant Neoplasms of Respiratory and Intrathoracic Organs;Lung Non-Small Cell Carcinoma;Lung Adenocarcinoma;EGFR wt Allele;ROS1 Gene Mutation;ALK wt Allele",
                "country": "United States",
                "geneName": "RET",
                "intervention_name": "Nivolumab;Therapeutic Conventional Surgery;Radiation Therapy;Local Consolidation Therapy;Quality-of-Life Assessment;Ipilimumab",
                "intervention_type": "Biological;Procedure;Radiation;Other",
                "nct_num": "NCT03391869",
                "overall_status": "Recruiting",
                "phase": "Phase 3",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "January 5, 2018"
            },
            {
                "brief_summary": "  This phase III trial studies how well nivolumab and ipilimumab works with or without local  consolidation therapy in treating patients with stage IV non-small cell lung cancer.  Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the  body's immune system attack the cancer, and may interfere with the ability of tumor cells to  grow and spread. Local consolidation therapy, such as surgery or radiation therapy, may  improve survival outcomes in patients with non-small cell lung cancer. It is not yet known  whether giving nivolumab and ipilimumab with local consolidation therapy works better than  nivolumab and ipilimumab alone in treating patients with stage IV non-small cell lung cancer.",
                "brief_title": "Phase III Trial of (LCT) After Nivolumab and Ipilimumab",
                "condition": "RET Gene Mutation;Stage IV Lung Cancer AJCC v8;Non-small Cell Lung Cancer;Malignant Neoplasms of Respiratory and Intrathoracic Organs;Lung Non-Small Cell Carcinoma;Lung Adenocarcinoma;EGFR wt Allele;ROS1 Gene Mutation;ALK wt Allele",
                "country": "United States",
                "geneName": "RET",
                "intervention_name": "Nivolumab;Therapeutic Conventional Surgery;Radiation Therapy;Local Consolidation Therapy;Quality-of-Life Assessment;Ipilimumab",
                "intervention_type": "Biological;Procedure;Radiation;Other",
                "nct_num": "NCT03391869",
                "overall_status": "Recruiting",
                "phase": "Phase 3",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "January 5, 2018"
            },
            {
                "brief_summary": "  The purpose of this study is to provide continued treatment with alectinib or crizotinib as  applicable to participants with ALK- or RET positive cancer who were previously enrolled in  any Roche-sponsored alectinib study and who are deriving continued clinical benefit from  alectinib or crizotinib in the parent trial at the time of parent trial closure.",
                "brief_title": "A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer",
                "condition": "Neoplasms",
                "country": "Hong Kong;Poland;France;Korea, Republic of;Russian Federation;Turkey;Italy;Spain;United States",
                "geneName": "RET",
                "intervention_name": "Alectinib;Crizotinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03194893",
                "overall_status": "Recruiting",
                "phase": "Phase 3",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "June 21, 2017"
            },
            {
                "brief_summary": "  The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP  regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.",
                "brief_title": "Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.",
                "condition": "Sintilimab;TP53 Mutation;Diffuse Large B-Cell Lymphoma",
                "country": ".",
                "geneName": "TP53",
                "intervention_name": "Sintilimab-R-CHOP",
                "intervention_type": "Drug",
                "nct_num": "NCT04023916",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "July 18, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  CLL is an incurable disease with conventional chemotherapy. In the absence of TP53  disruption, a chemoimmunotherapy (CIT) regimen is recommended as front-line and second-line  treatment in those patients who attained a long progression-free survival (PFS) with the  previous regimen. Bendamustine and rituximab (BR) is one of the most widely adopted CIT  regimens, including second-line treatment. Unfortunately, durations of remission following BR  combination therapy tend to be short in patients with heavily pre-treated disease or who have  already received rituximab. The incorporation of a maintenance following induction  chemotherapy to overcome the shorter remission durations in this population is a reasonable  option.",
                "brief_title": "Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia",
                "condition": "Chronic Lymphocytic Leukemia",
                "country": "Russian Federation",
                "geneName": "TP53",
                "intervention_name": "BR as Maintenance",
                "intervention_type": "Drug",
                "nct_num": "NCT03847727",
                "overall_status": "Active, not recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 20, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission  tomography (PET) and osimertinib works in evaluating glucose utilization in patients with  EGFR activated glioblastoma. Osimertinib may stop the growth of tumor cells by blocking some  of the enzymes needed for cell growth. 18F-FDG PET imaging may help to detect changes in  tumor glucose utilization, which may allow investigators to obtain an early read out on the  impact of osimertinib on recurrent glioblastoma patients whose tumors have EGFR activation.",
                "brief_title": "18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma",
                "condition": "EGFR Gene Mutation;Recurrent Glioblastoma;TP53 wt Allele;EGFR Gene Amplification;Supratentorial Glioblastoma;Glioblastoma",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Fludeoxyglucose F-18;Osimertinib;Positron Emission Tomography",
                "intervention_type": "Procedure;Drug;Other",
                "nct_num": "NCT03732352",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "November 6, 2018"
            },
            {
                "brief_summary": "  Recent preclinical studies suggest that combining MEK and MDM2 inhibition synergize to induce  apoptosis in RAS/BRAF-mutant and TP53 wild-type CRC models. In vitro, in RKO cell lines  (poorly differentiated colon carcinoma cell line resistant to single agent targeting MDM2 and  MEK and BRAF inhibition), the MDM2 plus MEK inhibitor combination generated a synergistic  increase in apoptotic index. In vivo, in mice harboring human RKO colon tumor xenografts the  combination of MDM2 plus MEK inhibition elicited 93% decreases in tumor volume.  This trial is to conduct a single-center, Phase 1 dose escalation study of trametinib  combined with HDM201 (a HDM2 inhibitor) in patients with advanced/metastatic RAS/RAF mutant  and TP53 wt CRC.",
                "brief_title": "Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type",
                "condition": "Advanced Cancer;Metastatic Cancer;Colorectal Cancer",
                "country": "France",
                "geneName": "TP53",
                "intervention_name": "Trametinib;HDM201",
                "intervention_type": "Drug",
                "nct_num": "NCT03714958",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "October 22, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in  treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that  is untreated or has come back. Quizartinib may stop the growth of cancer cells by blocking  some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine  and venetoclax, work in different ways to stop the growth of cancer cells, either by killing  the cells, by stopping them from dividing, or by stopping them from spreading. Giving  quizartinib and decitabine may work better at treating acute myeloid leukemia and  myelodysplastic syndrome.",
                "brief_title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",
                "condition": "TP53 Gene Deletion;Blasts More Than 10 Percent of Peripheral Blood White Cells;Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;TP53 Gene Mutation;Myelodysplastic Syndrome;Recurrent Acute Myeloid Leukemia;Acute Myeloid Leukemia;High Risk Myelodysplastic Syndrome;Recurrent Myelodysplastic Syndrome;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Quizartinib;Venetoclax;Decitabine",
                "intervention_type": "Drug",
                "nct_num": "NCT03661307",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "September 7, 2018"
            },
            {
                "brief_summary": "  Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the  treatment of advanced refractory solid tumors with TP53 harmful mutations.",
                "brief_title": "Treatment of Carrying TP53 Harmful Mutations",
                "condition": "Advanced Cancer",
                "country": "China",
                "geneName": "TP53",
                "intervention_name": "Fluzoparib combined with Apatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03645200",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "August 24, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  In this research study, the investigators are evaluating the clinical benefit of everolimus  in cancer patients with inactivating TSC1 or TSC2 mutations or activating MTOR mutations.  This research study is a Phase II clinical trial, which tests the safety and effectiveness of  an investigational drug called everolimus to learn whether the drug works in treating a  specific cancer. &quot;Investigational&quot; means that the drug is being studied. It also means that  the FDA (the U.S. Food and Drug Administration) has not yet approved everolimus for your type  of cancer.  Everolimus is a drug that may stop cancer cells from growing by blocking an important factor  (mTOR) involved in the growth of cells. This drug has been used in treatment for other  cancers and is approved by the Food and Drug Administration for treatment of several types of  cancer, including renal cell carcinoma. Treatment with this drug has been associated with  responses in some patients whose cancers had mutations in TSC1 or TSC2. The investigators  think that patients whose tumors have mutations in TSC1 or TSC2 may have a good chance of  responding to treatment with drugs like everolimus.",
                "brief_title": "Everolimus for Cancer With TSC1 or TSC2 Mutation",
                "condition": "MTOR;TSC1;Tuberous Sclerosis Complex;TSC2",
                "country": "United States",
                "geneName": "MTOR",
                "intervention_name": "Everolimus",
                "intervention_type": "Drug",
                "nct_num": "NCT02201212",
                "overall_status": "Completed",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "July 28, 2014"
            },
            {
                "brief_summary": "  Gastric cancer (GC) is the second most common cause of cancer related mortality and the  fourth most common cancer worldwide. The molecular classification of GC and the relevance of  pre-clinical models are not well established, creating challenges in discovering novel  molecularly targeted therapies. In order to address these issues, we conducted an integrated  molecular data analysis of three hundred Asian Gastric tumors through the Asian Cancer  Research Group (ACRG). We performed an integrated genomic analyses based on target  sequencing, gene expression profiling, copy number variations, Lauren's histological  classification, Epstein Barr Virus (EBV) status, TP53 status in three hundred GC specimens.  We first divided GC into four subgroups based on gene expression profiling and TP53 status:    1. epithelial MSS-TP53 inactive;    2. epithelial MSS-TP53 active;    3. MSI; and    4. mesenchymal.  With an integrative analysis with target sequencing and copy number variations, epithelial  MSS-TP53 inactive GCs are characterized by predominantly hypermutated intestinal tumors  (including majority of mutations in KRAS) with MLH1 loss through promoter methylation and  MSS-TP53 active GCs are characterized by intact TP53 pathway with high frequency of EBV  infection or frequently mutated oncogenes (e.g. PIK3CA). MSI subtype with TP53 pathway  inactive characterized by TP53 loss through deleterious mutations in TP53 or MDM2  amplification and further characterized by both focal amplifications in oncogenes such as  HER2, EGFR, cMET, CCNE1 as well as large scale chromosomal gains and losses. The above  subtypes exhibited differential prognosis with the mesenchymal subtype displaying the worst  survival (2.2 years) and the MSI subtype the most favorable survival (5.6 years). The GC  subtypes and their association with prognosis were independently validated in three GC  cohorts. We additionally showed significant association of global gene expression immune  patterns, like adaptive immune system and inflammation, as well as expression of PD-L1, with  the genomic defined subtypes.  In the phase Ib KEYNOTE-012 study which evaluated pembrolizumab monotherapy at 10 mg/kg ever  2 weeks in patients with gastric cancer were recently reported. Most patients had two or more  prior lines of therapy. In the study, 41% of evaluable patients showed tumor shrinkage. The  overall response rate in 39 patients were 31%.  The preliminary data showed a Not significant correlation between PD-L-1 expression and ORR  (P=0.071).  Given the mutual association of tumor genetic markers, gene expression and potential markers  of response to immune therapy identified through the collaborative work between SMC and MERCK  MSD and Lilly, we plan to perform a phase II study with integrative genomic analysis (whole  exome and RNA sequencing) in pre and post biopsy specimens to better define those GCs who may  benefit from pembro.",
                "brief_title": "Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis",
                "condition": "Gastroesophageal Junction Adenocarcinoma;Gastric Adenocarcinoma",
                "country": "Korea, Republic of",
                "geneName": "MLH1",
                "intervention_name": "pembrolizumab",
                "intervention_type": "Drug",
                "nct_num": "NCT02589496",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "October 28, 2015"
            },
            {
                "brief_summary": "  This pilot clinical trial studies the side effects and how well durvalumab and tremelimumab  work in treating patients with microsatellite stable colorectal cancer that has spread to the  liver. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the  ability of tumor cells to grow and spread.",
                "brief_title": "Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver",
                "condition": "MLH1 Gene Mutation;MSH6 Gene Mutation;Stage IVA Colorectal Cancer;PMS2 Gene Mutation;Metastatic Carcinoma in the Liver;Stage IV Colorectal Cancer;Stage IVB Colorectal Cancer",
                "country": "United States",
                "geneName": "MLH1",
                "intervention_name": "Tremelimumab;Durvalumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Other",
                "nct_num": "NCT03005002",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "December 29, 2016"
            },
            {
                "brief_summary": "  This phase II trial studies how well nivolumab works in preventing colon adenomas in  participants with Lynch syndrome and a history of surgery to remove part of the colon.  Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to  grow and spread.",
                "brief_title": "Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy",
                "condition": "Colon Carcinoma;Colon Adenoma;MLH1 Gene Mutation;MSH2 Gene Mutation;Lynch Syndrome",
                "country": "United States",
                "geneName": "MLH1",
                "intervention_name": "Nivolumab",
                "intervention_type": "Biological",
                "nct_num": "NCT03631641",
                "overall_status": "Suspended",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "August 15, 2018"
            },
            {
                "brief_summary": "  This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and  safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27  patients with MSS, MGMT-silenced mCRC with initial clinical benefit following lead-in  treatment with single-agent TMZ.  Immune checkpoint inhibitors have been shown to trigger durable antitumor effects in a subset  of patients. A high number of tumor mutations (so called 'tumor mutational burden') has  recently been found associated with increased immunogenicity (due to a high number of  neoantigens) and improved treatment efficacy across several different solid tumors. In mCRCs,  only a small fraction of tumors (&lt;5%) display a high mutational load and are usually  associated with inactivation of mismatch repair genes such as MLH1, MSH2 and MSH6. Checkpoint  inhibitors may have increased activity in dMMR/microsatellite instability-high (MSI-H)  tumors, a hypothesis which was tested in various Phase II trials with positive results. On  the opposite, mismatch repair proficient colorectal cancer is unresponsive to immune  checkpoint inhibitors.  Previous reports indicate that acquired resistance to TMZ may emerge through the induction of  a microsatellite-instability-positive phenotype and recent data showed that inactivation of  MMR, driven by acquired resistance to the clinical agent temozolomide, increased mutational  load, promoted continuous renewal of neoantigens in human colorectal cancers and triggered  immune surveillance in mouse models.  On all of the above grounds, the investigators hypothesize that treatment of microsatellite  stable MGMT hypermethylated CRCs with alkylating agents could reshape the tumor genetic  landscape by increasing the tumor mutational burden, leading to achieve potential  sensitization to immunotherapy.",
                "brief_title": "NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer",
                "condition": "Metastatic Colorectal Cancer",
                "country": "Italy",
                "geneName": "MLH1",
                "intervention_name": "Ipilimumab;Temozolomide;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03832621",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 6, 2019"
            },
            {
                "brief_summary": "  This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and  safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27  patients with MSS, MGMT-silenced mCRC with initial clinical benefit following lead-in  treatment with single-agent TMZ.  Immune checkpoint inhibitors have been shown to trigger durable antitumor effects in a subset  of patients. A high number of tumor mutations (so called 'tumor mutational burden') has  recently been found associated with increased immunogenicity (due to a high number of  neoantigens) and improved treatment efficacy across several different solid tumors. In mCRCs,  only a small fraction of tumors (&lt;5%) display a high mutational load and are usually  associated with inactivation of mismatch repair genes such as MLH1, MSH2 and MSH6. Checkpoint  inhibitors may have increased activity in dMMR/microsatellite instability-high (MSI-H)  tumors, a hypothesis which was tested in various Phase II trials with positive results. On  the opposite, mismatch repair proficient colorectal cancer is unresponsive to immune  checkpoint inhibitors.  Previous reports indicate that acquired resistance to TMZ may emerge through the induction of  a microsatellite-instability-positive phenotype and recent data showed that inactivation of  MMR, driven by acquired resistance to the clinical agent temozolomide, increased mutational  load, promoted continuous renewal of neoantigens in human colorectal cancers and triggered  immune surveillance in mouse models.  On all of the above grounds, the investigators hypothesize that treatment of microsatellite  stable MGMT hypermethylated CRCs with alkylating agents could reshape the tumor genetic  landscape by increasing the tumor mutational burden, leading to achieve potential  sensitization to immunotherapy.",
                "brief_title": "NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer",
                "condition": "Metastatic Colorectal Cancer",
                "country": "Italy",
                "geneName": "MLH1",
                "intervention_name": "Ipilimumab;Temozolomide;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03832621",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 6, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well pembrolizumab works before surgery in treating patients  with mismatch repair deficient solid cancers that have spread to nearby tissue or lymph nodes  (locally advanced). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help  the body's immune system attack the cancer, and may interfere with the ability of tumor cells  to grow and spread.",
                "brief_title": "Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers",
                "condition": "Mismatch Repair Protein Deficiency;High-Frequency Microsatellite Instability;Loss of PMS2 Expression;Locally Advanced Malignant Solid Neoplasm;Loss of MSH2 Expression;Loss of MSH6 Expression;Loss of MLH1 Expression",
                "country": "United States",
                "geneName": "MLH1",
                "intervention_name": "Pembrolizumab",
                "intervention_type": "Biological",
                "nct_num": "NCT04082572",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "September 9, 2019"
            },
            {
                "brief_summary": "  This pilot clinical trial studies the side effects and how well durvalumab and tremelimumab  work in treating patients with microsatellite stable colorectal cancer that has spread to the  liver. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the  ability of tumor cells to grow and spread.",
                "brief_title": "Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver",
                "condition": "MLH1 Gene Mutation;MSH6 Gene Mutation;Stage IVA Colorectal Cancer;PMS2 Gene Mutation;Metastatic Carcinoma in the Liver;Stage IV Colorectal Cancer;Stage IVB Colorectal Cancer",
                "country": "United States",
                "geneName": "MSH6",
                "intervention_name": "Tremelimumab;Durvalumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Other",
                "nct_num": "NCT03005002",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "December 29, 2016"
            },
            {
                "brief_summary": "  This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men  with metastatic castration resistant prostate cancer (mCRPC). Patients with tumors that have  ATM, BRCA1 and/or BRCA2 mutations/deletions/loss of heterozygosity will be randomized in a  1:1:1 fashion to each arm. Patients with mutations in noncanonical DNA repair genes including  FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2,  MSH6, BRIP1, or FAM175A defects will be assigned to Arm IV with single agent olaparib.",
                "brief_title": "Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects",
                "condition": "Metastatic Prostate Carcinoma;Abnormal DNA Repair;Stage IV Prostate Cancer;Prostate Cancer Metastatic Castration-Resistant",
                "country": "United States",
                "geneName": "MSH6",
                "intervention_name": "Olaparib;Abiraterone Acetate;Prednisone",
                "intervention_type": "Drug",
                "nct_num": "NCT03012321",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "January 6, 2017"
            },
            {
                "brief_summary": "  This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and  safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27  patients with MSS, MGMT-silenced mCRC with initial clinical benefit following lead-in  treatment with single-agent TMZ.  Immune checkpoint inhibitors have been shown to trigger durable antitumor effects in a subset  of patients. A high number of tumor mutations (so called 'tumor mutational burden') has  recently been found associated with increased immunogenicity (due to a high number of  neoantigens) and improved treatment efficacy across several different solid tumors. In mCRCs,  only a small fraction of tumors (&lt;5%) display a high mutational load and are usually  associated with inactivation of mismatch repair genes such as MLH1, MSH2 and MSH6. Checkpoint  inhibitors may have increased activity in dMMR/microsatellite instability-high (MSI-H)  tumors, a hypothesis which was tested in various Phase II trials with positive results. On  the opposite, mismatch repair proficient colorectal cancer is unresponsive to immune  checkpoint inhibitors.  Previous reports indicate that acquired resistance to TMZ may emerge through the induction of  a microsatellite-instability-positive phenotype and recent data showed that inactivation of  MMR, driven by acquired resistance to the clinical agent temozolomide, increased mutational  load, promoted continuous renewal of neoantigens in human colorectal cancers and triggered  immune surveillance in mouse models.  On all of the above grounds, the investigators hypothesize that treatment of microsatellite  stable MGMT hypermethylated CRCs with alkylating agents could reshape the tumor genetic  landscape by increasing the tumor mutational burden, leading to achieve potential  sensitization to immunotherapy.",
                "brief_title": "NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer",
                "condition": "Metastatic Colorectal Cancer",
                "country": "Italy",
                "geneName": "MSH6",
                "intervention_name": "Ipilimumab;Temozolomide;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03832621",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 6, 2019"
            },
            {
                "brief_summary": "  This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and  safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27  patients with MSS, MGMT-silenced mCRC with initial clinical benefit following lead-in  treatment with single-agent TMZ.  Immune checkpoint inhibitors have been shown to trigger durable antitumor effects in a subset  of patients. A high number of tumor mutations (so called 'tumor mutational burden') has  recently been found associated with increased immunogenicity (due to a high number of  neoantigens) and improved treatment efficacy across several different solid tumors. In mCRCs,  only a small fraction of tumors (&lt;5%) display a high mutational load and are usually  associated with inactivation of mismatch repair genes such as MLH1, MSH2 and MSH6. Checkpoint  inhibitors may have increased activity in dMMR/microsatellite instability-high (MSI-H)  tumors, a hypothesis which was tested in various Phase II trials with positive results. On  the opposite, mismatch repair proficient colorectal cancer is unresponsive to immune  checkpoint inhibitors.  Previous reports indicate that acquired resistance to TMZ may emerge through the induction of  a microsatellite-instability-positive phenotype and recent data showed that inactivation of  MMR, driven by acquired resistance to the clinical agent temozolomide, increased mutational  load, promoted continuous renewal of neoantigens in human colorectal cancers and triggered  immune surveillance in mouse models.  On all of the above grounds, the investigators hypothesize that treatment of microsatellite  stable MGMT hypermethylated CRCs with alkylating agents could reshape the tumor genetic  landscape by increasing the tumor mutational burden, leading to achieve potential  sensitization to immunotherapy.",
                "brief_title": "NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer",
                "condition": "Metastatic Colorectal Cancer",
                "country": "Italy",
                "geneName": "MSH6",
                "intervention_name": "Ipilimumab;Temozolomide;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03832621",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 6, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well pembrolizumab works before surgery in treating patients  with mismatch repair deficient solid cancers that have spread to nearby tissue or lymph nodes  (locally advanced). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help  the body's immune system attack the cancer, and may interfere with the ability of tumor cells  to grow and spread.",
                "brief_title": "Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers",
                "condition": "Mismatch Repair Protein Deficiency;High-Frequency Microsatellite Instability;Loss of PMS2 Expression;Locally Advanced Malignant Solid Neoplasm;Loss of MSH2 Expression;Loss of MSH6 Expression;Loss of MLH1 Expression",
                "country": "United States",
                "geneName": "MSH6",
                "intervention_name": "Pembrolizumab",
                "intervention_type": "Biological",
                "nct_num": "NCT04082572",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "September 9, 2019"
            },
            {
                "brief_summary": "  This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men  with metastatic castration resistant prostate cancer (mCRPC). Patients with tumors that have  ATM, BRCA1 and/or BRCA2 mutations/deletions/loss of heterozygosity will be randomized in a  1:1:1 fashion to each arm. Patients with mutations in noncanonical DNA repair genes including  FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2,  MSH6, BRIP1, or FAM175A defects will be assigned to Arm IV with single agent olaparib.",
                "brief_title": "Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects",
                "condition": "Metastatic Prostate Carcinoma;Abnormal DNA Repair;Stage IV Prostate Cancer;Prostate Cancer Metastatic Castration-Resistant",
                "country": "United States",
                "geneName": "CHEK2",
                "intervention_name": "Olaparib;Abiraterone Acetate;Prednisone",
                "intervention_type": "Drug",
                "nct_num": "NCT03012321",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "January 6, 2017"
            },
            {
                "brief_summary": "  Prostate Cancer (PC) is the most frequent cancer in men, accounting for 21% of new cases of  cancer in men in the United States. Among the four most incident tumors (breast, lung and  colorectal cancer); prostate cancer is the only that does not have any predictive biomarker  to guide the treatment. Even though the molecular heterogeneity of PC is well-documented,  treatment has not been molecularly stratified and the need for genetic prognostic and  predictive markers is critical.  DNA repair defects (DRD), mainly in the Homologous Recombination (HR) pathway (such as BRCA1,  BRCA2, ATM and CHEK2) are emerging as potential biomarkers in prostate cancer. It is well  known BRCA1 and BRCA2 carriers have better Progression-Free Survival (PFS) and Overall  Survival (OS) than non-carriers in ovarian cancer. Differently than ovarian tumors that BRCA  mutations provides a good prognosis, PC patients who harbor HR defects have a higher Gleason  score 6, an increased risk of recurrence and poor prognosis. The predictive role of DRD in PC  was demonstrated in a recent trial using Olaparib, a PARP inhibitor, in DRD carriers. This  trial showed 88% of response rate with Olaparib, a PARP inhibitor that acts in HR pathway by  synthetic lethality.  Recent data demonstrated important association between HR deficient high-grade serous ovarian  cancer (HGSOC), high neoantigen load and high expression of PD-1/PD-L1 compared with HR  proficient HGSOCs 10. This study showed that BRCA1 and BRCA2 mutations increase the number of  tumor-infiltrating lymphocytes (TILs) and confer a better prognosis. The unprecedented  success of immunotherapy in malignant disorders has provided evidence that the patient's  immune system can be improved to attack established tumors, mainly melanoma, non-small cell  lung cancer and kidney cancer. A high mutational burden increases the likelihood of the  development of specific neoepitopes that would confer clinical benefit from CTLA-4 and PD-1  blockade.  These data showed that specific DNA repair defects increase the mutational burden, the  expression of PD-1/PD-L1 and TILs; and could improve the response to immunotherapy in cancer.  This rationale was already tested in a trial that evaluated the PD-1 checkpoint inhibitor  Pembrolizumab in mismatch-repair deficient patients, a kind of DNA repair defect by  definition. This important trial showed that this DRD predicted clinical benefit of immune  checkpoint blockade in many types of cancer, especially colorectal cancer.",
                "brief_title": "Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)",
                "condition": "Prostate Cancer",
                "country": "Brazil",
                "geneName": "CHEK2",
                "intervention_name": "Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03040791",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 2, 2017"
            },
            {
                "brief_summary": "  Prostate Cancer (PC) is the most frequent cancer in men, accounting for 21% of new cases of  cancer in men in the United States. Among the four most incident tumors (breast, lung and  colorectal cancer); prostate cancer is the only that does not have any predictive biomarker  to guide the treatment. Even though the molecular heterogeneity of PC is well-documented,  treatment has not been molecularly stratified and the need for genetic prognostic and  predictive markers is critical.  DNA repair defects (DRD), mainly in the Homologous Recombination (HR) pathway (such as BRCA1,  BRCA2, ATM and CHEK2) are emerging as potential biomarkers in prostate cancer. It is well  known BRCA1 and BRCA2 carriers have better Progression-Free Survival (PFS) and Overall  Survival (OS) than non-carriers in ovarian cancer. Differently than ovarian tumors that BRCA  mutations provides a good prognosis, PC patients who harbor HR defects have a higher Gleason  score 6, an increased risk of recurrence and poor prognosis. The predictive role of DRD in PC  was demonstrated in a recent trial using Olaparib, a PARP inhibitor, in DRD carriers. This  trial showed 88% of response rate with Olaparib, a PARP inhibitor that acts in HR pathway by  synthetic lethality.  Recent data demonstrated important association between HR deficient high-grade serous ovarian  cancer (HGSOC), high neoantigen load and high expression of PD-1/PD-L1 compared with HR  proficient HGSOCs 10. This study showed that BRCA1 and BRCA2 mutations increase the number of  tumor-infiltrating lymphocytes (TILs) and confer a better prognosis. The unprecedented  success of immunotherapy in malignant disorders has provided evidence that the patient's  immune system can be improved to attack established tumors, mainly melanoma, non-small cell  lung cancer and kidney cancer. A high mutational burden increases the likelihood of the  development of specific neoepitopes that would confer clinical benefit from CTLA-4 and PD-1  blockade.  These data showed that specific DNA repair defects increase the mutational burden, the  expression of PD-1/PD-L1 and TILs; and could improve the response to immunotherapy in cancer.  This rationale was already tested in a trial that evaluated the PD-1 checkpoint inhibitor  Pembrolizumab in mismatch-repair deficient patients, a kind of DNA repair defect by  definition. This important trial showed that this DRD predicted clinical benefit of immune  checkpoint blockade in many types of cancer, especially colorectal cancer.",
                "brief_title": "Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)",
                "condition": "Prostate Cancer",
                "country": "Brazil",
                "geneName": "CHEK2",
                "intervention_name": "Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03040791",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 2, 2017"
            },
            {
                "brief_summary": "  Prostate Cancer (PC) is the most frequent cancer in men, accounting for 21% of new cases of  cancer in men in the United States. Among the four most incident tumors (breast, lung and  colorectal cancer); prostate cancer is the only that does not have any predictive biomarker  to guide the treatment. Even though the molecular heterogeneity of PC is well-documented,  treatment has not been molecularly stratified and the need for genetic prognostic and  predictive markers is critical.  DNA repair defects (DRD), mainly in the Homologous Recombination (HR) pathway (such as BRCA1,  BRCA2, ATM and CHEK2) are emerging as potential biomarkers in prostate cancer. It is well  known BRCA1 and BRCA2 carriers have better Progression-Free Survival (PFS) and Overall  Survival (OS) than non-carriers in ovarian cancer. Differently than ovarian tumors that BRCA  mutations provides a good prognosis, PC patients who harbor HR defects have a higher Gleason  score 6, an increased risk of recurrence and poor prognosis. The predictive role of DRD in PC  was demonstrated in a recent trial using Olaparib, a PARP inhibitor, in DRD carriers. This  trial showed 88% of response rate with Olaparib, a PARP inhibitor that acts in HR pathway by  synthetic lethality.  Recent data demonstrated important association between HR deficient high-grade serous ovarian  cancer (HGSOC), high neoantigen load and high expression of PD-1/PD-L1 compared with HR  proficient HGSOCs 10. This study showed that BRCA1 and BRCA2 mutations increase the number of  tumor-infiltrating lymphocytes (TILs) and confer a better prognosis. The unprecedented  success of immunotherapy in malignant disorders has provided evidence that the patient's  immune system can be improved to attack established tumors, mainly melanoma, non-small cell  lung cancer and kidney cancer. A high mutational burden increases the likelihood of the  development of specific neoepitopes that would confer clinical benefit from CTLA-4 and PD-1  blockade.  These data showed that specific DNA repair defects increase the mutational burden, the  expression of PD-1/PD-L1 and TILs; and could improve the response to immunotherapy in cancer.  This rationale was already tested in a trial that evaluated the PD-1 checkpoint inhibitor  Pembrolizumab in mismatch-repair deficient patients, a kind of DNA repair defect by  definition. This important trial showed that this DRD predicted clinical benefit of immune  checkpoint blockade in many types of cancer, especially colorectal cancer.",
                "brief_title": "Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)",
                "condition": "Prostate Cancer",
                "country": "Brazil",
                "geneName": "CHEK2",
                "intervention_name": "Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03040791",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "February 2, 2017"
            },
            {
                "brief_summary": "  This research study is for patients with metastatic breast cancer.    -  Metastatic means that the cancer has spread beyond the breast. In addition, through     genetic testing of the blood or tumor, an altered gene has been found that suggests the     tumor may not be able to repair its genetic material (DNA) when it becomes damaged.    -  This aspect of the cancer may cause it to be more sensitive - that is, more effectively     killed by certain types of drugs such as the study agent being evaluated in this trial,     Olaparib.     -  Olaparib is a type of drug known as a PARP inhibitor. Some types of breast cancer      and ovarian cancer share some basic features that make them sensitive to similar      treatments. Information from those other research studies suggests that this drug      may help to treat metastatic breast cancer.      -  This study will evaluate whether olaparib is effective in breast cancer       patients whose tumor has a mutation in one of the other genes that function       with BRCA1 and BRCA2 to repair damaged DNA .This mutation may have been       inherited from a parent, or may have developed only in the tumor.      -  This study will also evaluate whether olaparib is effective in breast cancer       patients whose tumor has a mutation in BRCA1 or BRCA2 that was acquired by the       tumor, but not inherited.",
                "brief_title": "Olaparib In Metastatic Breast Cancer",
                "condition": "PALB2 Gene Mutation;NBN Gene Mutation;Somatic Mutation Breast Cancer (BRCA1);Invasive Breast Cancer;Somatic Mutation Breast Cancer (BRCA2);ATM Gene Mutation;RAD51 Gene Mutation;CHEK2 Gene Mutation;BRIP1 Gene Mutation;Metastatic Breast Cancer",
                "country": "United States",
                "geneName": "CHEK2",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03344965",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "November 17, 2017"
            },
            {
                "brief_summary": "  This phase II trial studies how well talazoparib works in treating patients with homologous  recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has  come back after previous treatment. Talazoparib may stop the growth of tumor cells by  blocking some of the enzymes needed for cell growth.",
                "brief_title": "Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer",
                "condition": "FANCM Gene Mutation;BARD1 Gene Mutation;BRCA2 Gene Mutation;Recurrent Squamous Cell Lung Carcinoma;RAD51 Gene Mutation;Stage IV Squamous Cell Lung Carcinoma AJCC v7;FANCD2 Gene Mutation;ATM Gene Mutation;FANCF Gene Mutation;CHEK2 Gene Mutation;BRIP1 Gene Mutation;RAD54L Gene Mutation;NBN Gene Mutation;RAD51B Gene Mutation;FANCC Gene Mutation;PALB2 Gene Mutation;FANCA Gene Mutation;ATR Gene Mutation;BRCA1 Gene Mutation;CHEK1 Gene Mutation;RPA1 Gene Mutation",
                "country": "Canada;United States",
                "geneName": "CHEK2",
                "intervention_name": "Talazoparib;Pharmacological Study;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03377556",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "December 19, 2017"
            },
            {
                "brief_summary": "  Single arm, single site, open-label Phase II study of the effects of oral olaparib in  participants with metastatic renal cell carcinoma that harbor an inactivating mutation in  BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,  RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint  inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1  criteria.",
                "brief_title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",
                "condition": "Kidney Cancer;Renal Carcinoma;Renal Cell Carcinoma;Kidney Cancer Metastatic;Metastatic Renal Cell Carcinoma",
                "country": "United States",
                "geneName": "CHEK2",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03786796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "December 25, 2018"
            },
            {
                "brief_summary": "  This phase II trial studies how well niraparib, when given before surgery, works in treating  patients with high risk prostate cancer that has not spread to other parts of the body  (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may  stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects",
                "condition": "Prostate Carcinoma;DNA Repair Gene Mutation;NBN Gene Mutation;FANCA Gene Mutation;FANCD2 Gene Mutation;BRCA1 Gene Mutation;FANCL Gene Mutation;ATM Gene Mutation;CHEK1 Gene Mutation;RAD51 Gene Mutation;RAD51C Gene Mutation;CHEK2 Gene Mutation;GEN1 Gene Mutation;BRIP1 Gene Mutation;CDK12 Gene Mutation;DNA Damage Response Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "CHEK2",
                "intervention_name": "Niraparib Tosylate Monohydrate;Niraparib;Radical Prostatectomy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT04030559",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "July 24, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib works in treating patients with biliary tract  cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair  gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth.",
                "brief_title": "Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations",
                "condition": "PALB2 Gene Mutation;NBN Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;PTEN Gene Deletion;ATR Gene Mutation;BRCA1 Gene Mutation;ATM Gene Mutation;Metastatic Bile Duct Carcinoma;ARID1A Gene Mutation;RAD51 Gene Mutation;CHEK2 Gene Mutation;MRE11 Gene Mutation;BRIP1 Gene Mutation;Bile Duct Adenocarcinoma;EMSY Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "CHEK2",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT04042831",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-20",
                "study_first_posted": "August 2, 2019"
            }
        ],
        "cms": [
            {
                "age": "47",
                "agentName": "北京恒和医院",
                "areaAgentName": "潘缪春",
                "backStatus": "1",
                "backStatusShow": "未返款",
                "barcode": "8101016900",
                "bedNumber": ".",
                "bingli": ".",
                "birthday": ".",
                "checkTime": ".",
                "contact": ".",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": ".",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-22 11:25:00",
                "expressName": ".",
                "expressNum": "sf1192183492496",
                "fenziBingli": ".",
                "financeId": "230923",
                "gender": "男",
                "historyNum": "0",
                "hospitalName": "北京恒和医院",
                "idCard": ".",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-08 16:59:12",
                "invoiceApplyMoney": "0.00",
                "invoiceName": ".",
                "invoiceReceivePhone": ".",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "6",
                "invoiceTypeShow": "不开发票",
                "itemName": "0201028.OncoDrug-Seq全实体瘤110基因（组织/细胞学样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-08 16:48:56",
                "medicalRecord": ".",
                "name": "何海锋",
                "nickName": "马虎彪",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "1",
                "paymentTypeShow": "现结",
                "receiveStatus": "1",
                "receiveStatusShow": "未收款",
                "receiveTime": "2020-07-15 11:25:38",
                "remark": "样本到了先别检测。等病理结果。取得的肺部组织。患者以前有肾癌和睾丸癌，最后病理出来再确定检测哪个!",
                "reportAddress": "山西省太原市小店区龙城大街龙城新居3-5",
                "reportAddressName": "何海锋",
                "reportCheckTime": ".",
                "reportEmail": ".",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": "13546461766",
                "reportStyle": ".",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "232633",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200715-20",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": ".",
                "sickAge": ".",
                "sickFamilyHistory": ".",
                "source": "新鲜组织(专用保存液)",
                "sourceFrom": ".",
                "testDoctor": ".",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "膀胱癌",
                "treatHistory": "取得的肺部组织。患者以前有肾癌和睾丸癌",
                "treatID": "TS14",
                "treatResult": "膀胱癌转移肺肿瘤",
                "treatmentNo": ".",
                "unitAgentName": "马虎彪",
                "url": "[]",
                "userId": "1501",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [],
        "fusion": [],
        "heredity": [
            {
                "aachangeRefgene": "MSH6:NM_000179:exon4:c.1063G>A:p.Gly355Ser",
                "ajsGb": "p.Gly355Ser",
                "alt": "A",
                "alteration": "G355S",
                "barcode": ".",
                "chr": "chr2",
                "clinsig": "Conflicting_interpretations_of_pathogenicity",
                "description": "该基因的胚系致病性突变可引起林奇综合征。该疾病为常染色体显性遗传病。",
                "diseaseInfo": "林奇综合征的临床特征为多种原发性肿瘤高发，早期发病倾向，且预后较散发患者更好。",
                "evidenceLevel": "完善",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.458",
                "funcRefgene": "exonic",
                "geneInfo": "MSH6（mutS同源物6）基因编码DNA修复错配蛋白MSH6。 MSH6是肿瘤抑制因子，其与MSH2异二聚化以形成MutS-α。该复合物识别单碱基对错配和二核苷酸插入 - 缺失环，启动错配修复（MMR）过程（PMID：8816473）。 MSH6和其他MMR基因最显着地涉及遗传性非息肉病结肠癌（HNPCC），也称为Lynch综合征（PMID：428275,1648437）。在种系和体细胞环境中丧失功能突变或表观遗传沉默导致突变率增加，从而导致致癌作用以及微卫星不稳定性（MSI）。尽管在结肠癌中最常见，但MSH6突变也在多种其他癌症类型和综合征中被报道，包括子宫内膜癌和子宫癌（PMID：19078925,16106253）。由于错配修复缺陷而具有大量体细胞突变的肿瘤已经预测了某些免疫检查点阻断疗法的临床益处（PMID：26028255,25409260,29489427）。最近，FDA批准pembrolizumab（PD-1阻断）用于所有错配修复缺陷和微卫星不稳定（MSI-高）肿瘤，而不考虑特定的肿瘤病因。",
                "geneName": "MSH6",
                "geneType": "geneYc,geneMy",
                "geneVar": "MSH6基因exon4第1063位碱基G置换为A使得第355位氨基酸由甘氨酸转变成了丝氨酸",
                "geneYcType": "常染色体显性遗传（AD）",
                "hgsGb": "c.1063G>A",
                "hgvs": "MSH6:NM_000179:exon4:c.1063G>A:p.Gly355Ser",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "mutationType": "杂合突变",
                "ominId": "600678",
                "posEnd": "48026185",
                "posStart": "48026185",
                "projectAbbr": "DE",
                "ref": "G",
                "relativeDisease": "林奇综合征（LS）",
                "riskLevel": "高",
                "sampleSn": "NGS200715-20",
                "tumorProfiles": "结直肠癌;子宫内膜癌;乳腺癌;卵巢癌;胃癌;胰腺癌;尿路上皮癌;胆道癌;小肠癌;前列腺癌;脑/CNS肿瘤",
                "vcfFormat": "GT:AD:DP:GQ:PL",
                "vcfFormatInfo": "0/1:439,371:810:99:6954,0,9112",
                "wxz": "exon4",
                "zlb": "NM_000179"
            },
            {
                "aachangeRefgene": "CHEK2:NM_007194:exon11:c.1111C>T:p.His371Tyr",
                "ajsGb": "p.His371Tyr",
                "alt": "A",
                "alteration": "H371Y",
                "barcode": ".",
                "chr": "chr22",
                "clinsig": "Uncertain_significance",
                "description": "该基因的胚系突变可引起乳腺癌/结肠癌/家族性前列腺癌或其他癌症易感风险增高，并以常染色体显性方式遗传。",
                "diseaseInfo": ".",
                "evidenceLevel": "尚不明确",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.4687",
                "funcRefgene": "exonic",
                "geneInfo": "CHEK2（Checkpoint Kinase 2）是一种丝氨酸/苏氨酸激酶，在DNA损伤检查点途径中起着不可或缺的作用，可防止受损细胞继续通过细胞周期。响应于DNA损伤，CHEK2被激酶ATR和ATM通过磷酸化激活（PMID：12781359）。一旦被激活，CHEK2充当效应激酶，介导下游信号传导，其导致多种细胞应答，包括细胞周期检查点激活，细胞周期停滞和DNA修复和/或凋亡（PMID：25404613）。通过维持染色体稳定性，CHEK2在有丝分裂期间也起重要作用（PMID：24798733,20364141）。鉴于其在维持基因组稳定性中的作用，在一系列癌症中发现CHEK2改变，包括胶质母细胞瘤，乳腺癌，卵巢癌，前列腺癌，结肠直肠癌，胃癌，甲状腺癌和肺癌（PMID：23296741,24713400,25583358,12052256,15125777）。 CHEK2中的种系突变与乳腺癌，前列腺癌和结肠癌的风险增加相关（PMID：21701879,12533788,17106448）。",
                "geneName": "CHEK2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "CHEK2基因exon11第1111位碱基C置换为T使得第371位氨基酸由组氨酸转变成了酪氨酸",
                "geneYcType": "常染色体显性遗传（AD）",
                "hgsGb": "c.1111C>T",
                "hgvs": "CHEK2:NM_007194:exon11:c.1111C>T:p.His371Tyr",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "mutationType": "杂合突变",
                "ominId": "604373",
                "posEnd": "29091846",
                "posStart": "29091846",
                "projectAbbr": "DE",
                "ref": "G",
                "relativeDisease": "乳腺癌/结肠癌/家族性前列腺癌或其他癌症易感",
                "riskLevel": "中等",
                "sampleSn": "NGS200715-20",
                "tumorProfiles": "乳腺癌;大肠癌;前列腺癌",
                "vcfFormat": "GT:AD:DP:GQ:PL",
                "vcfFormatInfo": "0/1:229,202:431:99:3870,0,4710",
                "wxz": "exon11",
                "zlb": "NM_007194"
            }
        ],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:3.23%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "3.23%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": "TP53:NM_000546:exon8:c.838A>G:p.Arg280Gly",
                "Unnamed: 8": ".",
                "Unnamed: 9": "NGS200715-20",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "如果使用免疫检查点抑制剂治疗，疗效可能较好",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "检测到变异/基因突变（NM_000546:exon8:c.838A>G:p.Arg280Gly）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 2,
                "percent": 3.23,
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-20",
                "totalSites": 62
            }
        ],
        "qc": [
            {
                "cleanBases": 828129343,
                "cleanReads": 6058214,
                "coverage>0.2x": 98.99,
                "coverage>0.5x": 90.73,
                "effectCoverage500": 74.04,
                "effectDepth": 662,
                "insert": 166.4,
                "mapping": 99.89,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 931830600,
                "rawDuplication": 11.12,
                "rawReads": 6212204,
                "readPercent": 97.52,
                "samplePurity": "16.05",
                "sampleSn": "NGS200715-20",
                "sampleType": "Tissue",
                "targetMapping": 63.0,
                "trimDuplication": 16.37,
                "tumorCoverage": 99.82,
                "tumorDepth": 820,
                "tumorQ30": 91.04
            }
        ],
        "target": [
            {
                "1000g2015aug_all": "0.000599041988607496",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "5.77e-05",
                "GeneName": "MTOR",
                "NM_ID": "NM_004958",
                "ajsGb": "p.Ala1836Thr",
                "alt": "T",
                "alteration": "A1836T",
                "avsnp150": "rs180992388",
                "cancerType": ".",
                "chr": "chr1",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.532",
                "funcRefgene": "exonic",
                "geneInfo": "MTOR蛋白是协调细胞生长，蛋白质合成和代谢信号传导的丝氨酸 - 苏氨酸激酶（PMID：22500797,21157483）。 MTOR活性通过由常见亚基（mTOR，mLST8，DEPTOR）（PMID：12718876,19446321）组成并由特定亚基唯一定义的两种不同的多蛋白复合物mTORC1和mTORC2（PMID：22500797,21157483）介导。 mTORC1由PRAS40和RAPTOR亚基（PMID：12150926,12150925,17386266,17510057）确定，而mTORC2由RICTOR，mSIN1和PROTOR1 / 2（PMID：15268862,15718470,16919458）确定。 mTORC1，S6K和4EBP1的两个最佳特征性下游靶标决定了蛋白质合成速率，营养物应答以及快速肿瘤生长所需的许多附加特征（PMID：15314020）。因此，mTORC1的抑制剂已被治疗性地用于各种恶性肿瘤。 mTORC2与PDK1协同磷酸化并激活AKT。已知mTORC2调节肌动蛋白细胞骨架，细胞周期进展和细胞存活（PMID：18566586）。 MTOR基因的错义突变发生在许多肿瘤中，特别是发生在约6％透明细胞肾细胞癌，7.5％肺腺癌，5％子宫内膜癌和4％结肠和直肠癌中（PMID：24132290）。此外，已经报道了各种mTOR突变，其导致MTOR途径活化增加和对雷帕霉素敏感性增加（PMID：24631838,24625776）。文献中的一些病例报道报道，在未经治疗的重症转移性癌症并具有激活性mTOR突变的患者中雷帕霉素类似物（rapalogue）治疗具有极度持久的反应（PMID：24622468,24625776）。此外，两种rapalogue mTOR抑制剂everolimus和temsirolimus经FDA批准用于治疗人类癌症，许多具有其他作用机制的化合物处于不同研发阶段（PMID：26299952）。",
                "geneName": "MTOR",
                "geneType": "geneBx",
                "geneVar": "MTOR基因exon39第5506位碱基G置换为A使得第1836位氨基酸由丙氨酸转变成了苏氨酸",
                "hgsGb": "c.5506G>A",
                "hgvs": "MTOR:NM_004958:exon39:c.5506G>A:p.Ala1836Thr",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "11190693",
                "posStart": "11190693",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-20",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:317,361:0.531:149,134:168,227:28:165,163:60:36:0.528,0.500,0.532:0.005,0.064,0.931",
                "wxz": "exon39",
                "zlb": "NM_004958"
            },
            {
                "1000g2015aug_all": "0.000599041988607496",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "5.77e-05",
                "GeneName": "MTOR",
                "NM_ID": "NM_004958",
                "ajsGb": "p.Ala1836Thr",
                "alt": "T",
                "alteration": "A1836T",
                "avsnp150": "rs180992388",
                "cancerType": ".",
                "chr": "chr1",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.532",
                "funcRefgene": "exonic",
                "geneInfo": "MTOR蛋白是协调细胞生长，蛋白质合成和代谢信号传导的丝氨酸 - 苏氨酸激酶（PMID：22500797,21157483）。 MTOR活性通过由常见亚基（mTOR，mLST8，DEPTOR）（PMID：12718876,19446321）组成并由特定亚基唯一定义的两种不同的多蛋白复合物mTORC1和mTORC2（PMID：22500797,21157483）介导。 mTORC1由PRAS40和RAPTOR亚基（PMID：12150926,12150925,17386266,17510057）确定，而mTORC2由RICTOR，mSIN1和PROTOR1 / 2（PMID：15268862,15718470,16919458）确定。 mTORC1，S6K和4EBP1的两个最佳特征性下游靶标决定了蛋白质合成速率，营养物应答以及快速肿瘤生长所需的许多附加特征（PMID：15314020）。因此，mTORC1的抑制剂已被治疗性地用于各种恶性肿瘤。 mTORC2与PDK1协同磷酸化并激活AKT。已知mTORC2调节肌动蛋白细胞骨架，细胞周期进展和细胞存活（PMID：18566586）。 MTOR基因的错义突变发生在许多肿瘤中，特别是发生在约6％透明细胞肾细胞癌，7.5％肺腺癌，5％子宫内膜癌和4％结肠和直肠癌中（PMID：24132290）。此外，已经报道了各种mTOR突变，其导致MTOR途径活化增加和对雷帕霉素敏感性增加（PMID：24631838,24625776）。文献中的一些病例报道报道，在未经治疗的重症转移性癌症并具有激活性mTOR突变的患者中雷帕霉素类似物（rapalogue）治疗具有极度持久的反应（PMID：24622468,24625776）。此外，两种rapalogue mTOR抑制剂everolimus和temsirolimus经FDA批准用于治疗人类癌症，许多具有其他作用机制的化合物处于不同研发阶段（PMID：26299952）。",
                "geneName": "MTOR",
                "geneType": "geneBx",
                "geneVar": "MTOR基因exon39第5506位碱基G置换为A使得第1836位氨基酸由丙氨酸转变成了苏氨酸",
                "hgsGb": "c.5506G>A",
                "hgvs": "MTOR:NM_004958:exon39:c.5506G>A:p.Ala1836Thr",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "11190693",
                "posStart": "11190693",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-20",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:317,361:0.531:149,134:168,227:28:165,163:60:36:0.528,0.500,0.532:0.005,0.064,0.931",
                "wxz": "exon39",
                "zlb": "NM_004958"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": ".",
                "DNA_change": ".",
                "ExAC_nonpsych_ALL": "8.827e-05",
                "GeneName": ".",
                "NM_ID": ".",
                "ajsGb": "p.Gly355Ser",
                "alt": "A",
                "alteration": "G355S",
                "avsnp150": "rs587778531",
                "cancerType": ".",
                "chr": "chr2",
                "clinsig": "Conflicting_interpretations_of_pathogenicity",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.468",
                "funcRefgene": "exonic",
                "geneInfo": "MSH6（mutS同源物6）基因编码DNA修复错配蛋白MSH6。 MSH6是肿瘤抑制因子，其与MSH2异二聚化以形成MutS-α。该复合物识别单碱基对错配和二核苷酸插入 - 缺失环，启动错配修复（MMR）过程（PMID：8816473）。 MSH6和其他MMR基因最显着地涉及遗传性非息肉病结肠癌（HNPCC），也称为Lynch综合征（PMID：428275,1648437）。在种系和体细胞环境中丧失功能突变或表观遗传沉默导致突变率增加，从而导致致癌作用以及微卫星不稳定性（MSI）。尽管在结肠癌中最常见，但MSH6突变也在多种其他癌症类型和综合征中被报道，包括子宫内膜癌和子宫癌（PMID：19078925,16106253）。由于错配修复缺陷而具有大量体细胞突变的肿瘤已经预测了某些免疫检查点阻断疗法的临床益处（PMID：26028255,25409260,29489427）。最近，FDA批准pembrolizumab（PD-1阻断）用于所有错配修复缺陷和微卫星不稳定（MSI-高）肿瘤，而不考虑特定的肿瘤病因。",
                "geneName": "MSH6",
                "geneType": "geneYc,geneMy",
                "geneVar": "MSH6基因exon4第1063位碱基G置换为A使得第355位氨基酸由甘氨酸转变成了丝氨酸",
                "hgsGb": "c.1063G>A",
                "hgvs": "MSH6:NM_000179:exon4:c.1063G>A:p.Gly355Ser",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "48026185",
                "posStart": "48026185",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-20",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:249,219:0.469:109,106:140,113:31:166,161:60:31:0.435,0.461,0.468:0.124,0.004,0.872",
                "wxz": "exon4",
                "zlb": "NM_000179"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": ".",
                "DNA_change": ".",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": ".",
                "NM_ID": ".",
                "ajsGb": "p.Leu998Pro",
                "alt": "C",
                "alteration": "L998P",
                "avsnp150": "rs368891101",
                "cancerType": ".",
                "chr": "chr2",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.491",
                "funcRefgene": "exonic",
                "geneInfo": "SPTBN1（Spectrin Beta，Non-Erythrocytic 1）是蛋白质编码基因。Spectrin是肌动蛋白交联和分子支架蛋白，其将质膜与肌动蛋白细胞骨架连接，并且在确定细胞形状，跨膜蛋白的排列和细胞器组织中起作用。它由两个反向平行的α-和β-亚基二聚体组成。该基因是β-血影蛋白基因家族的一员。编码的蛋白质含有N末端肌动蛋白结合结构域和17个参与二聚体形成的血影蛋白重复序列​​。与SPTBN1相关的疾病包括Beckwith-Wiedemann综合征。其相关途径包括Nephrin相互作用和RET信号传导。",
                "geneName": "SPTBN1",
                "geneType": "g,e,n,e,Q,t",
                "geneVar": "SPTBN1基因exon16第2993位碱基T置换为C使得第998位氨基酸由亮氨酸转变成了脯氨酸",
                "hgsGb": "c.2993T>C",
                "hgvs": "SPTBN1:NM_003128:exon16:c.2993T>C:p.Leu998Pro",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "54858177",
                "posStart": "54858177",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-20",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:296,285:0.491:139,144:157,141:31:168,165:60:32:0.477,0.480,0.491:0.013,0.010,0.977",
                "wxz": "exon16",
                "zlb": "NM_003128"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "A889T",
                "DNA_change": "A889T",
                "ExAC_nonpsych_ALL": "3.944e-05",
                "GeneName": "ABL1",
                "NM_ID": "NM_007313",
                "ajsGb": "p.Ala889Thr",
                "alt": "A",
                "alteration": "A889T",
                "avsnp150": "rs763746423",
                "cancerType": ".",
                "chr": "chr9",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.522",
                "funcRefgene": "exonic",
                "geneInfo": "ABL1（ABL原癌基因1）是一种广泛表达的非受体酪氨酸激酶。响应于各种信号，取决于刺激物和靶标，ABL信号传导可导致细胞增殖或分化，存活或死亡以及细胞回缩或迁移（PMID：7651539,7512450）。ABL同时位于细胞质和细胞核中，可被生长因子受体，DNA损伤和细胞激酶激活（PMID：24421390,1591775）。 BCR和ABL基因之间的易位导致BCR-ABL，是结构变异，激活致癌性酪氨酸激酶，在慢性粒细胞性白血病（CML）和费城染色体阳性的急性淋巴细胞性白血病（Ph + ALL）中被发现（PMID：3460176,2825022）。在髓系疾病中也观察到其他的ABL1易位（PMID：9695962）。 BCR-ABL融合蛋白导致ABL自身抑制的丧失，于此同时，其低聚作用导致转磷酸化和激酶激活（PMID：8246975）。BCR-ABL的小分子抑制剂，伊马替尼和达沙替尼已经FDA批准用于CML和Ph+ALL（PMID：11870241,21931113）。ABL激酶结构域中的突变导致对这些治疗的耐药性并决定了所选药物的敏感性（PMID：15256671）。",
                "geneName": "ABL1",
                "geneType": "geneBx",
                "geneVar": "ABL1基因exon11第2665位碱基G置换为A使得第889位氨基酸由丙氨酸转变成了苏氨酸",
                "hgsGb": "c.2665G>A",
                "hgvs": "ABL1:NM_007313:exon11:c.2665G>A:p.Ala889Thr",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "133760285",
                "posStart": "133760285",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-20",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:187,204:0.507:87,87:100,117:27:165,160:60:24:0.512,0.504,0.522:0.011,0.017,0.972",
                "wxz": "exon11",
                "zlb": "NM_007313"
            },
            {
                "1000g2015aug_all": "0.003793929936364293",
                "AA_change": "V292M",
                "DNA_change": "V292M",
                "ExAC_nonpsych_ALL": "0.0005",
                "GeneName": "RET",
                "NM_ID": "NM_020975",
                "ajsGb": "p.Val292Met",
                "alt": "A",
                "alteration": "V292M",
                "avsnp150": "rs34682185",
                "cancerType": ".",
                "chr": "chr10",
                "clinsig": "Conflicting_interpretations_of_pathogenicity",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.523",
                "funcRefgene": "exonic",
                "geneInfo": "RET是一种受体酪氨酸激酶，其结合神经胶质细胞系衍生的神经营养因子（GDNF）家族的配体并通过促癌促分裂原活化蛋白激酶（MAPK）和磷酸肌醇3-激酶（PI3K）途径传递细胞内信号（PMID： 24561444）。 RET通常在发育中的胚胎中表达，在神经和神经内分泌谱系中发挥特别重要的作用（PMID：8306871）。在癌症中，RET可通过点突变或与各种易位伴侣的基因重排活化，导致结构型活化的胞质癌基因蛋白（PMID：24561444）。 RET遗传性突变导致高度外显的家族性多发性内分泌腺瘤2A型（MEN2A：甲状腺髓样癌，嗜铬细胞瘤，甲状旁腺功能亢进），2B型多发性内分泌腺瘤（MEN2B：甲状腺髓样癌，嗜铬细胞瘤，多发性粘膜神经瘤和肠神经节瘤，马凡综合征样特性）和家族性甲状腺髓样癌（FMTC）（PMID：15322516）。致癌体细胞突变包括RET基因座的点突变和基因组重排，导致倒位或易位。这些已在包括乳头状甲状腺癌，肺腺癌和慢性粒单核细胞性白血病（CMML）在内的各种癌症中发现。另外，异常表达或激活野生型RET与乳腺癌胰腺癌和内分泌治疗耐药肿瘤的侵袭和转移密切相关（PMID：24561444）。",
                "geneName": "RET",
                "geneType": "geneBx,geneYc",
                "geneVar": "RET基因exon5第874位碱基G置换为A使得第292位氨基酸由缬氨酸转变成了甲硫氨酸",
                "hgsGb": "c.874G>A",
                "hgvs": "RET:NM_020975:exon5:c.874G>A:p.Val292Met",
                "intervarAutomated": "Benign",
                "level": "3（临床意义未明）",
                "posEnd": "43601830",
                "posStart": "43601830",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-20",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:115,126:0.519:62,68:53,58:28:184,170:60:21:0.494,0.515,0.523:0.027,0.011,0.962",
                "wxz": "exon5",
                "zlb": "NM_020975"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "TP53",
                "NM_ID": "NM_000546",
                "ajsGb": "p.Arg280Gly",
                "alt": "C",
                "alteration": "R280G",
                "avsnp150": "rs753660142",
                "cancerType": ".",
                "chr": "chr17",
                "clinsig": "Conflicting_interpretations_of_pathogenicity",
                "cosmic70": "ID\\x3dCOSM1649339",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.129",
                "funcRefgene": "exonic",
                "geneInfo": "TP53通过诱导下游抗肿瘤反应如DNA修复和细胞凋亡（PMID：11099028）编码p53肿瘤抑制蛋白，该蛋白是一种对细胞应激（包括DNA损伤和致癌激活）反应的转录因子。 TP53是人类癌症中最常见的突变基因，并且其胚系突变导致广泛癌症倾向的Li-Fraumeni综合征（PMID：22713868,21765642）。 p53蛋白由N末端反式激活结构域，中央DNA结合结构域，寡聚化结构域和C末端调节结构域（PMID：22713868）组成。",
                "geneName": "TP53",
                "geneType": "geneBx,geneHl,geneMy",
                "geneVar": "TP53基因exon8第838位碱基A置换为G使得第280位氨基酸由精氨酸转变成了甘氨酸",
                "hgsGb": "c.838A>G",
                "hgvs": "TP53:NM_000546:exon8:c.838A>G:p.Arg280Gly",
                "intervarAutomated": "Likely_pathogenic",
                "level": "3（临床意义未明）",
                "posEnd": "7577100",
                "posStart": "7577100",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-20",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:472,70:0.151:210,34:262,36:31:173,162:60:34:0.119,0.122,0.129:0.008,0.004,0.988",
                "wxz": "exon8",
                "zlb": "NM_000546"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "TP53",
                "NM_ID": "NM_000546",
                "ajsGb": "p.Arg280Gly",
                "alt": "C",
                "alteration": "R280G",
                "avsnp150": "rs753660142",
                "cancerType": ".",
                "chr": "chr17",
                "clinsig": "Conflicting_interpretations_of_pathogenicity",
                "cosmic70": "ID\\x3dCOSM1649339",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.129",
                "funcRefgene": "exonic",
                "geneInfo": "TP53通过诱导下游抗肿瘤反应如DNA修复和细胞凋亡（PMID：11099028）编码p53肿瘤抑制蛋白，该蛋白是一种对细胞应激（包括DNA损伤和致癌激活）反应的转录因子。 TP53是人类癌症中最常见的突变基因，并且其胚系突变导致广泛癌症倾向的Li-Fraumeni综合征（PMID：22713868,21765642）。 p53蛋白由N末端反式激活结构域，中央DNA结合结构域，寡聚化结构域和C末端调节结构域（PMID：22713868）组成。",
                "geneName": "TP53",
                "geneType": "geneBx,geneHl,geneMy",
                "geneVar": "TP53基因exon8第838位碱基A置换为G使得第280位氨基酸由精氨酸转变成了甘氨酸",
                "hgsGb": "c.838A>G",
                "hgvs": "TP53:NM_000546:exon8:c.838A>G:p.Arg280Gly",
                "intervarAutomated": "Likely_pathogenic",
                "level": "3（临床意义未明）",
                "posEnd": "7577100",
                "posStart": "7577100",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-20",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:472,70:0.151:210,34:262,36:31:173,162:60:34:0.119,0.122,0.129:0.008,0.004,0.988",
                "wxz": "exon8",
                "zlb": "NM_000546"
            },
            {
                "1000g2015aug_all": "0.000199681002413854",
                "AA_change": "H371Y",
                "DNA_change": "H371Y",
                "ExAC_nonpsych_ALL": "0.0004",
                "GeneName": "CHEK2",
                "NM_ID": "NM_007194",
                "ajsGb": "p.His371Tyr",
                "alt": "A",
                "alteration": "H371Y",
                "avsnp150": "rs531398630",
                "cancerType": ".",
                "chr": "chr22",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.47",
                "funcRefgene": "exonic",
                "geneInfo": "CHEK2（Checkpoint Kinase 2）是一种丝氨酸/苏氨酸激酶，在DNA损伤检查点途径中起着不可或缺的作用，可防止受损细胞继续通过细胞周期。响应于DNA损伤，CHEK2被激酶ATR和ATM通过磷酸化激活（PMID：12781359）。一旦被激活，CHEK2充当效应激酶，介导下游信号传导，其导致多种细胞应答，包括细胞周期检查点激活，细胞周期停滞和DNA修复和/或凋亡（PMID：25404613）。通过维持染色体稳定性，CHEK2在有丝分裂期间也起重要作用（PMID：24798733,20364141）。鉴于其在维持基因组稳定性中的作用，在一系列癌症中发现CHEK2改变，包括胶质母细胞瘤，乳腺癌，卵巢癌，前列腺癌，结肠直肠癌，胃癌，甲状腺癌和肺癌（PMID：23296741,24713400,25583358,12052256,15125777）。 CHEK2中的种系突变与乳腺癌，前列腺癌和结肠癌的风险增加相关（PMID：21701879,12533788,17106448）。",
                "geneName": "CHEK2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "CHEK2基因exon11第1111位碱基C置换为T使得第371位氨基酸由组氨酸转变成了酪氨酸",
                "hgsGb": "c.1111C>T",
                "hgvs": "CHEK2:NM_007194:exon11:c.1111C>T:p.His371Tyr",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "29091846",
                "posStart": "29091846",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-20",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:133,118:0.472:57,55:76,63:27:163,166:60:30:0.456,0.452,0.470:0.014,0.015,0.971",
                "wxz": "exon11",
                "zlb": "NM_007194"
            },
            {
                "1000g2015aug_all": "0.000199681002413854",
                "AA_change": "H371Y",
                "DNA_change": "H371Y",
                "ExAC_nonpsych_ALL": "0.0004",
                "GeneName": "CHEK2",
                "NM_ID": "NM_007194",
                "ajsGb": "p.His371Tyr",
                "alt": "A",
                "alteration": "H371Y",
                "avsnp150": "rs531398630",
                "cancerType": ".",
                "chr": "chr22",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.47",
                "funcRefgene": "exonic",
                "geneInfo": "CHEK2（Checkpoint Kinase 2）是一种丝氨酸/苏氨酸激酶，在DNA损伤检查点途径中起着不可或缺的作用，可防止受损细胞继续通过细胞周期。响应于DNA损伤，CHEK2被激酶ATR和ATM通过磷酸化激活（PMID：12781359）。一旦被激活，CHEK2充当效应激酶，介导下游信号传导，其导致多种细胞应答，包括细胞周期检查点激活，细胞周期停滞和DNA修复和/或凋亡（PMID：25404613）。通过维持染色体稳定性，CHEK2在有丝分裂期间也起重要作用（PMID：24798733,20364141）。鉴于其在维持基因组稳定性中的作用，在一系列癌症中发现CHEK2改变，包括胶质母细胞瘤，乳腺癌，卵巢癌，前列腺癌，结肠直肠癌，胃癌，甲状腺癌和肺癌（PMID：23296741,24713400,25583358,12052256,15125777）。 CHEK2中的种系突变与乳腺癌，前列腺癌和结肠癌的风险增加相关（PMID：21701879,12533788,17106448）。",
                "geneName": "CHEK2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "CHEK2基因exon11第1111位碱基C置换为T使得第371位氨基酸由组氨酸转变成了酪氨酸",
                "hgsGb": "c.1111C>T",
                "hgvs": "CHEK2:NM_007194:exon11:c.1111C>T:p.His371Tyr",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "29091846",
                "posStart": "29091846",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-20",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:133,118:0.472:57,55:76,63:27:163,166:60:30:0.456,0.452,0.470:0.014,0.015,0.971",
                "wxz": "exon11",
                "zlb": "NM_007194"
            }
        ],
        "tmb": [],
        "tnb": []
    },
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副中度",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "G/A",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/T",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，需较低剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/T",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较高，神经毒性综合征的严重程度可能降低",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "G/G",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "A/G",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/T",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/T",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/T",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "T/G",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/C",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "C/A",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/T",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "C/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/G",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/6TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢增加",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/G",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "C/T",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "G/G",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "G/A",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/G",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/T",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副高，代谢降低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-50",
                "updateTime": "."
            }
        ],
        "clinical": [
            {
                "brief_summary": "  Part A (dose-optimization)- to determine the recommended phase 2 dose (RP2D) taking into  account dose-limiting toxicity (DLT/s) in Cycle 1, overall safety/tolerability and  pharmacokinetic (PK), by optimizing doses of Debio 1143 when combined with the standard dose  of nivolumab, as well as treatment compliance in participants with advanced solid  malignancies who failed prior systemic standard treatments.  Part B (basket trial)- to evaluate the preliminary anti-tumor activity of Debio 1143 at the  RP2D in combination with nivolumab at the standard dose, overall and in each participant  cohort (Cohort 1: small cell lung cancer [SCLC]; Cohort 2: squamous cell carcinoma of the  head and neck [SCCHN]; Cohort 3: gastrointestinal (GI) cancers with known microsatellite  instability-high/mismatch repair deficiency (MSI-H/MMRd) or other deoxyribonucleic acid (DNA)  damage repair (DDR) abnormalities, including homologous recombination deficiency (HRD);  Cohort 4: platinum-resistant epithelial ovarian cancer [EOC], endometrial cancer, primary  peritoneal cancer (PPC) or cervical cancer, with known MSIH/MMRd, hereditary/somatic  mutations of the breast cancer 1 (BRCA1) and BRCA2 genes or other DNA DDR abnormalities  (incl. HRD).",
                "brief_title": "Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143",
                "condition": "Solid Tumor",
                "country": "France;Spain",
                "geneName": "BRCA1",
                "intervention_name": "Nivolumab;Debio 1143",
                "intervention_type": "Drug",
                "nct_num": "NCT04122625",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "October 10, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating  patients with germline BRCA mutated breast cancer that has spread to other places in the body  (advanced or metastatic). Olaparib, cediranib, and AZD6738 may stop the growth of tumor cells  by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer",
                "condition": "Prognostic Stage IIIB Breast Cancer AJCC v8;Anatomic Stage IIIB Breast Cancer AJCC v8;Prognostic Stage IIIA Breast Cancer AJCC v8;HER2/Neu Negative;Prognostic Stage IIIC Breast Cancer AJCC v8;Prognostic Stage IV Breast Cancer AJCC v8;Anatomic Stage IIIA Breast Cancer AJCC v8;Advanced Breast Carcinoma;Anatomic Stage III Breast Cancer AJCC v8;Germline BRCA1 Gene Mutation;Anatomic Stage IV Breast Cancer AJCC v8;Metastatic Breast Carcinoma;Prognostic Stage III Breast Cancer AJCC v8;Germline BRCA2 Gene Mutation;Anatomic Stage IIIC Breast Cancer AJCC v8",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Ceralasertib;Cediranib;Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT04090567",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "September 16, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib works in treating patients with biliary tract  cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair  gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth.",
                "brief_title": "Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations",
                "condition": "PALB2 Gene Mutation;NBN Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;PTEN Gene Deletion;ATR Gene Mutation;BRCA1 Gene Mutation;ATM Gene Mutation;Metastatic Bile Duct Carcinoma;ARID1A Gene Mutation;RAD51 Gene Mutation;CHEK2 Gene Mutation;MRE11 Gene Mutation;BRIP1 Gene Mutation;Bile Duct Adenocarcinoma;EMSY Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT04042831",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "August 2, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well niraparib, when given before surgery, works in treating  patients with high risk prostate cancer that has not spread to other parts of the body  (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may  stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects",
                "condition": "Prostate Carcinoma;DNA Repair Gene Mutation;NBN Gene Mutation;FANCA Gene Mutation;FANCD2 Gene Mutation;BRCA1 Gene Mutation;FANCL Gene Mutation;ATM Gene Mutation;CHEK1 Gene Mutation;RAD51 Gene Mutation;RAD51C Gene Mutation;CHEK2 Gene Mutation;GEN1 Gene Mutation;BRIP1 Gene Mutation;CDK12 Gene Mutation;DNA Damage Response Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Niraparib Tosylate Monohydrate;Niraparib;Radical Prostatectomy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT04030559",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "July 24, 2019"
            },
            {
                "brief_summary": "  At present targeted therapy with the PARP inhibitor olaparib has become standard of care in  advanced platinum sensitive BRCA1/2 mutant ovarian cancer. The key in this sensitivity is the  loss of homologous recombination (HR) function. The current project aims to treat patients  with any type of cancer carrying in their germline a mutation in genes that generate such an  homologous recombination deficiency (HRD) or have an acquired somatic mutation in their tumor  with the targeted PARP inhibitor olaparib. The project would thus bring access to a targeted  drug matched to the genomic profile of the tumor of these patients and provide oncologists  with information regarding efficacy and safety of olaparib in these patients. This evidence  could then later lead to a more routine regulatory access.",
                "brief_title": "Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes",
                "condition": "Advanced Cancers Harbouring Mutations in HRG",
                "country": "Belgium",
                "geneName": "BRCA1",
                "intervention_name": "Olaparib Oral Capsule",
                "intervention_type": "Drug",
                "nct_num": "NCT03967938",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "May 30, 2019"
            },
            {
                "brief_summary": "  This early phase I trial studies how well olaparib works in treating patients with newly  diagnosed BRCA-mutant ovarian, primary peritoneal, or fallopian cancer before surgery.  Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell  growth.",
                "brief_title": "Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery",
                "condition": "BRCA-Mutated Ovarian Carcinoma;Stage IIIA Ovarian Cancer AJCC v8;Stage IV Primary Peritoneal Cancer AJCC v8;Stage IIIA Fallopian Tube Cancer AJCC v8;Stage IIIB Fallopian Tube Cancer AJCC v8;Stage IV Fallopian Tube Cancer AJCC v8;Stage IIIB Ovarian Cancer AJCC v8;Stage III Ovarian Cancer AJCC v8;Stage IIIA1 Fallopian Tube Cancer AJCC v8;Stage IIIA2 Fallopian Tube Cancer AJCC v8;Stage IVA Fallopian Tube Cancer AJCC v8;Stage IVA Primary Peritoneal Cancer AJCC v8;Stage IIIA2 Ovarian Cancer AJCC v8;BRCA2 Gene Mutation;Stage IVA Ovarian Cancer AJCC v8;High Grade Fallopian Tube Serous Adenocarcinoma;Stage IIIC Primary Peritoneal Cancer AJCC v8;Stage III Fallopian Tube Cancer AJCC v8;Stage IIIB Primary Peritoneal Cancer AJCC v8;Stage IVB Fallopian Tube Cancer AJCC v8;Stage IIIC Fallopian Tube Cancer AJCC v8;Stage IVB Primary Peritoneal Cancer AJCC v8;High Grade Ovarian Serous Adenocarcinoma;Stage IVB Ovarian Cancer AJCC v8;Stage IV Ovarian Cancer AJCC v8;Stage IIIA Primary Peritoneal Cancer AJCC v8;BRCA1 Gene Mutation;Stage IIIC Ovarian Cancer AJCC v8;Stage III Primary Peritoneal Cancer AJCC v8;Primary Peritoneal High Grade Serous Adenocarcinoma;Stage IIIA1 Ovarian Cancer AJCC v8",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Olaparib;Therapeutic Conventional Surgery;Chemotherapy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT03943173",
                "overall_status": "Recruiting",
                "phase": "Early Phase 1",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "May 9, 2019"
            },
            {
                "brief_summary": "  This study is designed to determine the RP2D of gedatolisib in combination with talazoparib  and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that  is triple negative or BRCA1/2 positive (deficient).",
                "brief_title": "Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers",
                "condition": "TNBC - Triple-Negative Breast Cancer",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Gedatolisib;Talazoparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03911973",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "April 11, 2019"
            },
            {
                "brief_summary": "  This is two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with  Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is  dose escalation and Part 2 is a Simon 2-Stage design",
                "brief_title": "A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer",
                "condition": "Triple Negative Breast Cancer",
                "country": "United States;Belgium",
                "geneName": "BRCA1",
                "intervention_name": "ZEN003694;Talazoparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03901469",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "April 3, 2019"
            },
            {
                "brief_summary": "  This phase II Lung-MAP trial studies how well rucaparib works in treating patients with  genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV  non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor  cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)",
                "condition": "Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;Stage IV Lung Cancer AJCC v8;Recurrent Lung Non-Small Cell Carcinoma;Deleterious BRCA2 Gene Mutation;Deleterious BRCA1 Gene Mutation;Recurrent Large Cell Lung Carcinoma;Recurrent Lung Adenocarcinoma;Stage IVB Lung Cancer AJCC v8;Lung Non-Small Cell Squamous Carcinoma;Stage IVA Lung Cancer AJCC v8;Loss of Heterozygosity",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Rucaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03845296",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "February 19, 2019"
            },
            {
                "brief_summary": "  Single arm, single site, open-label Phase II study of the effects of oral olaparib in  participants with metastatic renal cell carcinoma that harbor an inactivating mutation in  BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,  RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint  inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1  criteria.",
                "brief_title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",
                "condition": "Kidney Cancer;Renal Carcinoma;Renal Cell Carcinoma;Kidney Cancer Metastatic;Metastatic Renal Cell Carcinoma",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03786796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "December 25, 2018"
            },
            {
                "brief_summary": "  Gastric cancer (GC) is the second most common cause of cancer related mortality and the  fourth most common cancer worldwide. The molecular classification of GC and the relevance of  pre-clinical models are not well established, creating challenges in discovering novel  molecularly targeted therapies. In order to address these issues, we conducted an integrated  molecular data analysis of three hundred Asian Gastric tumors through the Asian Cancer  Research Group (ACRG). We performed an integrated genomic analyses based on target  sequencing, gene expression profiling, copy number variations, Lauren's histological  classification, Epstein Barr Virus (EBV) status, TP53 status in three hundred GC specimens.  We first divided GC into four subgroups based on gene expression profiling and TP53 status:    1. epithelial MSS-TP53 inactive;    2. epithelial MSS-TP53 active;    3. MSI; and    4. mesenchymal.  With an integrative analysis with target sequencing and copy number variations, epithelial  MSS-TP53 inactive GCs are characterized by predominantly hypermutated intestinal tumors  (including majority of mutations in KRAS) with MLH1 loss through promoter methylation and  MSS-TP53 active GCs are characterized by intact TP53 pathway with high frequency of EBV  infection or frequently mutated oncogenes (e.g. PIK3CA). MSI subtype with TP53 pathway  inactive characterized by TP53 loss through deleterious mutations in TP53 or MDM2  amplification and further characterized by both focal amplifications in oncogenes such as  HER2, EGFR, cMET, CCNE1 as well as large scale chromosomal gains and losses. The above  subtypes exhibited differential prognosis with the mesenchymal subtype displaying the worst  survival (2.2 years) and the MSI subtype the most favorable survival (5.6 years). The GC  subtypes and their association with prognosis were independently validated in three GC  cohorts. We additionally showed significant association of global gene expression immune  patterns, like adaptive immune system and inflammation, as well as expression of PD-L1, with  the genomic defined subtypes.  In the phase Ib KEYNOTE-012 study which evaluated pembrolizumab monotherapy at 10 mg/kg ever  2 weeks in patients with gastric cancer were recently reported. Most patients had two or more  prior lines of therapy. In the study, 41% of evaluable patients showed tumor shrinkage. The  overall response rate in 39 patients were 31%.  The preliminary data showed a Not significant correlation between PD-L-1 expression and ORR  (P=0.071).  Given the mutual association of tumor genetic markers, gene expression and potential markers  of response to immune therapy identified through the collaborative work between SMC and MERCK  MSD and Lilly, we plan to perform a phase II study with integrative genomic analysis (whole  exome and RNA sequencing) in pre and post biopsy specimens to better define those GCs who may  benefit from pembro.",
                "brief_title": "Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis",
                "condition": "Gastroesophageal Junction Adenocarcinoma;Gastric Adenocarcinoma",
                "country": "Korea, Republic of",
                "geneName": "MLH1",
                "intervention_name": "pembrolizumab",
                "intervention_type": "Drug",
                "nct_num": "NCT02589496",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "October 28, 2015"
            },
            {
                "brief_summary": "  This pilot clinical trial studies the side effects and how well durvalumab and tremelimumab  work in treating patients with microsatellite stable colorectal cancer that has spread to the  liver. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the  ability of tumor cells to grow and spread.",
                "brief_title": "Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver",
                "condition": "MLH1 Gene Mutation;MSH6 Gene Mutation;Stage IVA Colorectal Cancer;PMS2 Gene Mutation;Metastatic Carcinoma in the Liver;Stage IV Colorectal Cancer;Stage IVB Colorectal Cancer",
                "country": "United States",
                "geneName": "MLH1",
                "intervention_name": "Tremelimumab;Durvalumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Other",
                "nct_num": "NCT03005002",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "December 29, 2016"
            },
            {
                "brief_summary": "  This phase II trial studies how well nivolumab works in preventing colon adenomas in  participants with Lynch syndrome and a history of surgery to remove part of the colon.  Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to  grow and spread.",
                "brief_title": "Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy",
                "condition": "Colon Carcinoma;Colon Adenoma;MLH1 Gene Mutation;MSH2 Gene Mutation;Lynch Syndrome",
                "country": "United States",
                "geneName": "MLH1",
                "intervention_name": "Nivolumab",
                "intervention_type": "Biological",
                "nct_num": "NCT03631641",
                "overall_status": "Suspended",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "August 15, 2018"
            },
            {
                "brief_summary": "  This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and  safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27  patients with MSS, MGMT-silenced mCRC with initial clinical benefit following lead-in  treatment with single-agent TMZ.  Immune checkpoint inhibitors have been shown to trigger durable antitumor effects in a subset  of patients. A high number of tumor mutations (so called 'tumor mutational burden') has  recently been found associated with increased immunogenicity (due to a high number of  neoantigens) and improved treatment efficacy across several different solid tumors. In mCRCs,  only a small fraction of tumors (&lt;5%) display a high mutational load and are usually  associated with inactivation of mismatch repair genes such as MLH1, MSH2 and MSH6. Checkpoint  inhibitors may have increased activity in dMMR/microsatellite instability-high (MSI-H)  tumors, a hypothesis which was tested in various Phase II trials with positive results. On  the opposite, mismatch repair proficient colorectal cancer is unresponsive to immune  checkpoint inhibitors.  Previous reports indicate that acquired resistance to TMZ may emerge through the induction of  a microsatellite-instability-positive phenotype and recent data showed that inactivation of  MMR, driven by acquired resistance to the clinical agent temozolomide, increased mutational  load, promoted continuous renewal of neoantigens in human colorectal cancers and triggered  immune surveillance in mouse models.  On all of the above grounds, the investigators hypothesize that treatment of microsatellite  stable MGMT hypermethylated CRCs with alkylating agents could reshape the tumor genetic  landscape by increasing the tumor mutational burden, leading to achieve potential  sensitization to immunotherapy.",
                "brief_title": "NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer",
                "condition": "Metastatic Colorectal Cancer",
                "country": "Italy",
                "geneName": "MLH1",
                "intervention_name": "Ipilimumab;Temozolomide;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03832621",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "February 6, 2019"
            },
            {
                "brief_summary": "  This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and  safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27  patients with MSS, MGMT-silenced mCRC with initial clinical benefit following lead-in  treatment with single-agent TMZ.  Immune checkpoint inhibitors have been shown to trigger durable antitumor effects in a subset  of patients. A high number of tumor mutations (so called 'tumor mutational burden') has  recently been found associated with increased immunogenicity (due to a high number of  neoantigens) and improved treatment efficacy across several different solid tumors. In mCRCs,  only a small fraction of tumors (&lt;5%) display a high mutational load and are usually  associated with inactivation of mismatch repair genes such as MLH1, MSH2 and MSH6. Checkpoint  inhibitors may have increased activity in dMMR/microsatellite instability-high (MSI-H)  tumors, a hypothesis which was tested in various Phase II trials with positive results. On  the opposite, mismatch repair proficient colorectal cancer is unresponsive to immune  checkpoint inhibitors.  Previous reports indicate that acquired resistance to TMZ may emerge through the induction of  a microsatellite-instability-positive phenotype and recent data showed that inactivation of  MMR, driven by acquired resistance to the clinical agent temozolomide, increased mutational  load, promoted continuous renewal of neoantigens in human colorectal cancers and triggered  immune surveillance in mouse models.  On all of the above grounds, the investigators hypothesize that treatment of microsatellite  stable MGMT hypermethylated CRCs with alkylating agents could reshape the tumor genetic  landscape by increasing the tumor mutational burden, leading to achieve potential  sensitization to immunotherapy.",
                "brief_title": "NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer",
                "condition": "Metastatic Colorectal Cancer",
                "country": "Italy",
                "geneName": "MLH1",
                "intervention_name": "Ipilimumab;Temozolomide;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03832621",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "February 6, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well pembrolizumab works before surgery in treating patients  with mismatch repair deficient solid cancers that have spread to nearby tissue or lymph nodes  (locally advanced). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help  the body's immune system attack the cancer, and may interfere with the ability of tumor cells  to grow and spread.",
                "brief_title": "Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers",
                "condition": "Mismatch Repair Protein Deficiency;High-Frequency Microsatellite Instability;Loss of PMS2 Expression;Locally Advanced Malignant Solid Neoplasm;Loss of MSH2 Expression;Loss of MSH6 Expression;Loss of MLH1 Expression",
                "country": "United States",
                "geneName": "MLH1",
                "intervention_name": "Pembrolizumab",
                "intervention_type": "Biological",
                "nct_num": "NCT04082572",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-50",
                "study_first_posted": "September 9, 2019"
            }
        ],
        "cms": [
            {
                "age": "43",
                "agentName": "不体现医院（宝树科研）",
                "areaAgentName": "孙霄飞",
                "backStatus": "1",
                "backStatusShow": "未返款",
                "barcode": "2007141116341",
                "bedNumber": ".",
                "bingli": ".",
                "birthday": ".",
                "checkTime": ".",
                "contact": ".",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": ".",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-22 13:12:00",
                "expressName": "顺丰",
                "expressNum": "SF1091100018166",
                "fenziBingli": ".",
                "financeId": "232754",
                "gender": "男",
                "historyNum": "0",
                "hospitalName": ".",
                "idCard": ".",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-14 11:19:07",
                "invoiceApplyMoney": "0.00",
                "invoiceName": ".",
                "invoiceReceivePhone": ".",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "0",
                "invoiceTypeShow": ".",
                "itemName": "0201027.OncoDrug-Seq全实体瘤110基因（血液ctDNA样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-11 11:16:39",
                "medicalRecord": ".",
                "name": "董从光",
                "nickName": "首度基因",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "2",
                "paymentTypeShow": "月结",
                "receiveStatus": "1",
                "receiveStatusShow": "未收款",
                "receiveTime": "2020-07-15 13:12:20",
                "remark": ".",
                "reportAddress": ".",
                "reportAddressName": ".",
                "reportCheckTime": ".",
                "reportEmail": "all@treasuretree.cn,gallici@vip.qq.com",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": ".",
                "reportStyle": "电子",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "234275",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200715-50",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": "2020-07-14 11:20:56",
                "sickAge": ".",
                "sickFamilyHistory": ".",
                "source": "血液(cfDNA)",
                "sourceFrom": ".",
                "testDoctor": ".",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "结肠腺癌",
                "treatHistory": ".",
                "treatID": "TS050101",
                "treatResult": "升结肠腺癌",
                "treatmentNo": ".",
                "unitAgentName": "苏州首度基因",
                "url": "[]",
                "userId": "1428",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [],
        "fusion": [],
        "heredity": [
            {
                "aachangeRefgene": "BRCA1:NM_007294:exon10:c.2726A>T:p.Asn909Ile",
                "ajsGb": "p.Asn909Ile",
                "alt": "A",
                "alteration": "N909I",
                "barcode": ".",
                "chr": "chr17",
                "clinsig": "Conflicting_interpretations_of_pathogenicity",
                "description": "该基因的胚系致病突变可引起BRCA相关乳腺癌-卵巢癌综合征，并以常染色体显性方式遗传。",
                "diseaseInfo": ".",
                "evidenceLevel": "完善",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.5378",
                "funcRefgene": "exonic",
                "geneInfo": "具有抑癌作用的乳腺癌易感基因1（BRCA1），是一种多功能泛素E3连接酶。它具有许多细胞功能，包括转录，蛋白质泛素化，细胞周期调控和DNA损伤应答，在同源重组中，DNA双链断裂修复途径中具有特别重要的作用。BRCA1是第一个鉴定和克隆的乳腺癌和卵巢癌易感基因；该基因中的遗传突变导致发展这些癌症的终身风险增加。 BRCA1突变使患有乳腺癌的终生风险达到70-80％，卵巢癌的终生风险达到50％，并且在德系犹太人群中，有BRCA1基因突变的患者中，增加前列腺癌的风险增加（PMID：22193408）。如果BRCA1的一个拷贝在胚系中发生突变，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（PMID：22193408）。 BRCA1最近也被确定为FANCS中的一种明确的Fanconi贫血易感基因，FANCS是一种罕见的Fanconi贫血亚型，由该基因中的双等位基因突变（PMID：25472942）引起。 BRCA1有三个主要结构域：N-末端指环（非常有趣的新基因）域（外显子2-7）包含活性锌指基序，外显子11-13和BRCT（BRCA1 C-末端）域. BRCA1的许多临床上显着的突变位于指环(RING)域的锌指基序中，这对许多蛋白质 之间相互作用是很重要的（PMID：11573085）。外显子11-13含有蛋白质的结合位点，包括RB，c-MYC，RAD50和RAD51（在PMID：10918303中综述）。尽管事实上外显子11-13包含许多临床上显着的BRCA1突变，但与RING或BRCT结构域相比，该区域的结构或功能知之甚少（PMID：18273555）。 BRCT结构域通过其在转录调节和DNA修复中的关键作用对BRCA1蛋白的肿瘤抑制功能是必不可少的（PMID：11877378,11118345）。乳腺肿瘤中的p53突变几乎完全与BRCA1和BRCA2突变相关，表明p53功能丧失可能是BRCA相关癌症的肿瘤发生的必要步骤（PMID：14672397）。",
                "geneName": "BRCA1",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA1基因exon10第2726位碱基A置换为T使得第909位氨基酸由天冬酰胺转变成了异亮氨酸",
                "geneYcType": "常染色体显性遗传（AD）",
                "hgsGb": "c.2726A>T",
                "hgvs": "BRCA1:NM_007294:exon10:c.2726A>T:p.Asn909Ile",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "mutationType": "杂合突变",
                "ominId": "113705",
                "posEnd": "41244822",
                "posStart": "41244822",
                "projectAbbr": "DE",
                "ref": "T",
                "relativeDisease": "BRCA相关乳腺癌-卵巢癌综合征",
                "riskLevel": "高",
                "sampleSn": "NGS200715-50",
                "tumorProfiles": ".",
                "vcfFormat": "GT:AD:DP:GQ:PL",
                "vcfFormatInfo": "0/1:759,883:1642:99:21622,0,17521",
                "wxz": "exon10",
                "zlb": "NM_007294"
            }
        ],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:4.62%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "4.62%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 3,
                "percent": 4.62,
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-50",
                "totalSites": 65
            }
        ],
        "qc": [
            {
                "cleanBases": 2939940112,
                "cleanReads": 21217832,
                "coverage>0.2x": 98.41,
                "coverage>0.5x": 89.54,
                "effectCoverage500": 71.12,
                "effectDepth": 1279,
                "insert": 344.9,
                "mapping": 99.87,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 3357891300,
                "rawDuplication": 17.0,
                "rawReads": 22385942,
                "readPercent": 94.78,
                "samplePurity": ".",
                "sampleSn": "NGS200715-50",
                "sampleType": "ctDNA",
                "targetMapping": 58.68,
                "trimDuplication": 0.0,
                "tumorCoverage": 99.82,
                "tumorDepth": 2631,
                "tumorQ30": 88.58
            }
        ],
        "target": [
            {
                "1000g2015aug_all": ".",
                "AA_change": "N909I",
                "DNA_change": "N909I",
                "ExAC_nonpsych_ALL": "1.102e-05",
                "GeneName": "BRCA1",
                "NM_ID": "NM_007294",
                "ajsGb": "p.Asn909Ile",
                "alt": "A",
                "alteration": "N909I",
                "avsnp150": "rs80357127",
                "cancerType": ".",
                "chr": "chr17",
                "clinsig": "Conflicting_interpretations_of_pathogenicity",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.539",
                "funcRefgene": "exonic",
                "geneInfo": "具有抑癌作用的乳腺癌易感基因1（BRCA1），是一种多功能泛素E3连接酶。它具有许多细胞功能，包括转录，蛋白质泛素化，细胞周期调控和DNA损伤应答，在同源重组中，DNA双链断裂修复途径中具有特别重要的作用。BRCA1是第一个鉴定和克隆的乳腺癌和卵巢癌易感基因；该基因中的遗传突变导致发展这些癌症的终身风险增加。 BRCA1突变使患有乳腺癌的终生风险达到70-80％，卵巢癌的终生风险达到50％，并且在德系犹太人群中，有BRCA1基因突变的患者中，增加前列腺癌的风险增加（PMID：22193408）。如果BRCA1的一个拷贝在胚系中发生突变，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（PMID：22193408）。 BRCA1最近也被确定为FANCS中的一种明确的Fanconi贫血易感基因，FANCS是一种罕见的Fanconi贫血亚型，由该基因中的双等位基因突变（PMID：25472942）引起。 BRCA1有三个主要结构域：N-末端指环（非常有趣的新基因）域（外显子2-7）包含活性锌指基序，外显子11-13和BRCT（BRCA1 C-末端）域. BRCA1的许多临床上显着的突变位于指环(RING)域的锌指基序中，这对许多蛋白质 之间相互作用是很重要的（PMID：11573085）。外显子11-13含有蛋白质的结合位点，包括RB，c-MYC，RAD50和RAD51（在PMID：10918303中综述）。尽管事实上外显子11-13包含许多临床上显着的BRCA1突变，但与RING或BRCT结构域相比，该区域的结构或功能知之甚少（PMID：18273555）。 BRCT结构域通过其在转录调节和DNA修复中的关键作用对BRCA1蛋白的肿瘤抑制功能是必不可少的（PMID：11877378,11118345）。乳腺肿瘤中的p53突变几乎完全与BRCA1和BRCA2突变相关，表明p53功能丧失可能是BRCA相关癌症的肿瘤发生的必要步骤（PMID：14672397）。",
                "geneName": "BRCA1",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA1基因exon10第2726位碱基A置换为T使得第909位氨基酸由天冬酰胺转变成了异亮氨酸",
                "hgsGb": "c.2726A>T",
                "hgvs": "BRCA1:NM_007294:exon10:c.2726A>T:p.Asn909Ile",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "41244822",
                "posStart": "41244822",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-50",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:618,724:0.539:320,384:298,340:29:359,369:60:29:0.532,0.531,0.539:0.008,0.010,0.982",
                "wxz": "exon10",
                "zlb": "NM_007294"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "N909I",
                "DNA_change": "N909I",
                "ExAC_nonpsych_ALL": "1.102e-05",
                "GeneName": "BRCA1",
                "NM_ID": "NM_007294",
                "ajsGb": "p.Asn909Ile",
                "alt": "A",
                "alteration": "N909I",
                "avsnp150": "rs80357127",
                "cancerType": ".",
                "chr": "chr17",
                "clinsig": "Conflicting_interpretations_of_pathogenicity",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.539",
                "funcRefgene": "exonic",
                "geneInfo": "具有抑癌作用的乳腺癌易感基因1（BRCA1），是一种多功能泛素E3连接酶。它具有许多细胞功能，包括转录，蛋白质泛素化，细胞周期调控和DNA损伤应答，在同源重组中，DNA双链断裂修复途径中具有特别重要的作用。BRCA1是第一个鉴定和克隆的乳腺癌和卵巢癌易感基因；该基因中的遗传突变导致发展这些癌症的终身风险增加。 BRCA1突变使患有乳腺癌的终生风险达到70-80％，卵巢癌的终生风险达到50％，并且在德系犹太人群中，有BRCA1基因突变的患者中，增加前列腺癌的风险增加（PMID：22193408）。如果BRCA1的一个拷贝在胚系中发生突变，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（PMID：22193408）。 BRCA1最近也被确定为FANCS中的一种明确的Fanconi贫血易感基因，FANCS是一种罕见的Fanconi贫血亚型，由该基因中的双等位基因突变（PMID：25472942）引起。 BRCA1有三个主要结构域：N-末端指环（非常有趣的新基因）域（外显子2-7）包含活性锌指基序，外显子11-13和BRCT（BRCA1 C-末端）域. BRCA1的许多临床上显着的突变位于指环(RING)域的锌指基序中，这对许多蛋白质 之间相互作用是很重要的（PMID：11573085）。外显子11-13含有蛋白质的结合位点，包括RB，c-MYC，RAD50和RAD51（在PMID：10918303中综述）。尽管事实上外显子11-13包含许多临床上显着的BRCA1突变，但与RING或BRCT结构域相比，该区域的结构或功能知之甚少（PMID：18273555）。 BRCT结构域通过其在转录调节和DNA修复中的关键作用对BRCA1蛋白的肿瘤抑制功能是必不可少的（PMID：11877378,11118345）。乳腺肿瘤中的p53突变几乎完全与BRCA1和BRCA2突变相关，表明p53功能丧失可能是BRCA相关癌症的肿瘤发生的必要步骤（PMID：14672397）。",
                "geneName": "BRCA1",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA1基因exon10第2726位碱基A置换为T使得第909位氨基酸由天冬酰胺转变成了异亮氨酸",
                "hgsGb": "c.2726A>T",
                "hgvs": "BRCA1:NM_007294:exon10:c.2726A>T:p.Asn909Ile",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "41244822",
                "posStart": "41244822",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-50",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:618,724:0.539:320,384:298,340:29:359,369:60:29:0.532,0.531,0.539:0.008,0.010,0.982",
                "wxz": "exon10",
                "zlb": "NM_007294"
            }
        ],
        "tmb": [],
        "tnb": []
    },
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副中度",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "G/A",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，需较低剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/T",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较低，神经毒性综合征的严重程度可能增加",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "T/T",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/G",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "G/G",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/TTAAAG",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "A/G",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/T",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/C",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/T",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/T",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较低",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/TTAAAG",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "T/G",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/C",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "2R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "A/A",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/T",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "TTAAAG/TTAAAG",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "C/C",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "C/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/T",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "杂合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "2R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/G",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/6TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢降低",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "T/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "C/T",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/A",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "G/G",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "G/A",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/A",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副高，代谢降低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-12",
                "updateTime": "."
            }
        ],
        "clinical": [
            {
                "brief_summary": "  This phase I trial studies the side effects and best dose of alpha-TEA when given together  with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that  does not respond to treatment (refractory) and has spread to other places in the body  (metastatic). Anti-cancer treatment, such as alpha-TEA, work in different ways to stop the  growth of tumor cells, either by killing the cells, by stopping them from dividing, or by  stopping them from spreading. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Giving alpha-TEA and trastuzumab may work better for the treatment of breast cancer  compared to usual treatments.",
                "brief_title": "Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer",
                "condition": "Refractory Breast Carcinoma;ERBB2 Overexpression;Prognostic Stage IV Breast Cancer AJCC v8;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": "United States",
                "geneName": "ERBB2",
                "intervention_name": "Alpha-tocopheryloxyacetic Acid;Trastuzumab",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04120246",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "October 9, 2019"
            },
            {
                "brief_summary": "  This phase Ib/II trial studies the side effects and best dose of copanlisib when given  together with trastuzumab and pertuzumab and to see how well ithey work after induction  treatment in treating patients with HER2 positive stage IV breast cancer with PIK3CA or PTEN  mutation. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Monoclonal antibodies, such as pertuzumab, may kill tumor cells that are left after  chemotherapy. The addition of copanlisib to the usual treatment (trastuzumab and pertuzumab)  could shrink the cancer or stabilize it for longer duration as compared to the usual  treatment alone.",
                "brief_title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",
                "condition": "ERBB2 Gene Amplification;PTEN Gene Mutation;PIK3CA Gene Mutation;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": ".",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Trastuzumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04108858",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "September 30, 2019"
            },
            {
                "brief_summary": "  This phase Ib/II trial studies the side effects and best dose of copanlisib when given  together with trastuzumab and pertuzumab and to see how well ithey work after induction  treatment in treating patients with HER2 positive stage IV breast cancer with PIK3CA or PTEN  mutation. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Monoclonal antibodies, such as pertuzumab, may kill tumor cells that are left after  chemotherapy. The addition of copanlisib to the usual treatment (trastuzumab and pertuzumab)  could shrink the cancer or stabilize it for longer duration as compared to the usual  treatment alone.",
                "brief_title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",
                "condition": "ERBB2 Gene Amplification;PTEN Gene Mutation;PIK3CA Gene Mutation;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": ".",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Trastuzumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04108858",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "September 30, 2019"
            },
            {
                "brief_summary": "  This phase Ib/II trial studies the side effects and best dose of copanlisib when given  together with trastuzumab and pertuzumab and to see how well ithey work after induction  treatment in treating patients with HER2 positive stage IV breast cancer with PIK3CA or PTEN  mutation. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Monoclonal antibodies, such as pertuzumab, may kill tumor cells that are left after  chemotherapy. The addition of copanlisib to the usual treatment (trastuzumab and pertuzumab)  could shrink the cancer or stabilize it for longer duration as compared to the usual  treatment alone.",
                "brief_title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",
                "condition": "ERBB2 Gene Amplification;PTEN Gene Mutation;PIK3CA Gene Mutation;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": ".",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Trastuzumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04108858",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "September 30, 2019"
            },
            {
                "brief_summary": "  This is a Phase 2, open-label study to evaluate the efficacy and the safety/tolerability of  pyrotinib in previously treated NSCLC patients with EGFR exon 20 insertion mutations or HER2  exon 20 insertion mutations. Patient has had at least one prior systemic treatment for  locally advanced or metastatic NSCLC.",
                "brief_title": "Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation",
                "condition": "Non Small Cell Lung Cancer",
                "country": "China",
                "geneName": "ERBB2",
                "intervention_name": "Pyrotinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04063462",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "August 21, 2019"
            },
            {
                "brief_summary": "  This is a multi-center, observational genomic screening protocol to identify patients whose  tumors harbor somatic mutations in the ERBB2 (HER2) gene, as measured in circulating tumor  DNA (ctDNA) . Patients with histologically confirmed metastatic breast cancer (MBC) or  metastatic cervical cancer (MCC) are eligible for screening at 3 to 6 months intervals, or if  disease progression is suspected/confirmed. Blood samples will be collected from eligible  patients and ctDNA will be extracted and sequenced at a central laboratory, using  HER2-targeted next generation sequencing (NGS). A certified molecular test report will be  issued from the central laboratory and provided to the investigators and the study sponsor.  Patients who are identified with HER2 mutations by this screening protocol will subsequently  have access to an appropriate neratinib treatment protocol, pending medical eligibility.",
                "brief_title": "HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib",
                "condition": "Metastatic Cervical Cancer;Metastatic Breast Cancer",
                "country": "Serbia;Ireland;Spain",
                "geneName": "ERBB2",
                "intervention_name": "Almac HER-Seq Assay Kit",
                "intervention_type": "Diagnostic Test",
                "nct_num": "NCT03786107",
                "overall_status": "Recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "December 24, 2018"
            },
            {
                "brief_summary": "  Lung cancer is the most leading cause of cancer-related mortality worldwide. Most of the  patients with lung cancer are advanced stage at the time of diagnosis.  The two oncogenes that are important in lung cancer are epidermal growth factor receptor  (EGFR) and K-ras, mutated in 10% and 15% of non-small cell lung cancer (NSCLC) patients.  Large-scale DNA sequencing efforts have identified mutations in BRAF, PI3KCA and ERBB2 that  together represent another 5% of NSCLC patients. The success of EGFR tyrosine kinase  inhibitors (TKIs), such as gefitinib or erlotinib, and more recently ALK/MET TKI, crizotinib,  highlights the need to develop more genetically matched therapies. Therefore, genetic  classification of lung cancer has become increasingly important along with the advances with  targeted therapies.  ROS1 is a receptor tyrosine kinase with constitutive kinase activity. ROS1 was previously  discovered in cell lines where ROS1 fused with other proteins to act as a driver oncogene. In  2007, Rikova et al reported ROS1 fusion as driver mutations in NSCLC cell line (HCC78;  SLC34A2-ROS1) and NSCLC patient (CD74-ROS1). Li et al also found about 1% of samples  harboring CD74-ROS1 fusion in 202 resected lung adenocarcinomas from never smokers. The  incidence was as high as 10% in East Asian population. Currently there are now at least 13  ROS1 fusion variants involving 8 fusion partners (CD74-, SLC34A2-, FIG-, TPM3-, SDC4-,  LRIG3-, ERZ-, KDERL2-) identified in ROS1 positive NSCLC.  Interestingly, preclinical and clinical data have shown ROS1-positive tumors are sensitive to  crizotinib, because of potentially high common amino acid residues in the kinase domain  between ALK and ROS1, which explain why crizotinib can inhibit both ROS1 and ALK to similar  extent. Preliminary report from a phase I clinical trial of crizotinib in the ROS1-positive  NSCLC expansion cohort showed an overall response rate (ORR) of 57%. Given that crizotinib  has made remarkable clinical outcomes in phase I trial of ALK-positive NSCLC patients,  clinical development of ROS1 inhibitors, including crizotinib, should be accelerated to  provide targeted therapies to ROS1-positive NSCLC patients.",
                "brief_title": "A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement",
                "condition": "Non-small Cell Lung Cancer Harboring ROS1 Rearrangement",
                "country": "Korea, Republic of",
                "geneName": "ERBB2",
                "intervention_name": "LDK378(Ceritinib)",
                "intervention_type": "Drug",
                "nct_num": "NCT03399487",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "January 16, 2018"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to  cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified  colorectal cancer that has spread from where it started to other places in the body and  cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may  interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,  such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of  tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them  from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and  irinotecan hydrochloride in treating patients with colorectal cancer.",
                "brief_title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
                "condition": "Stage IVA Colon Cancer AJCC v7;Stage IIIA Colon Cancer AJCC v7;Stage IIIB Rectal Cancer AJCC v7;Stage IVB Colon Cancer AJCC v7;Recurrent Colon Carcinoma;Stage III Rectal Cancer AJCC v7;Stage III Colon Cancer AJCC v7;Stage IIIA Rectal Cancer AJCC v7;Stage IIIC Colon Cancer AJCC v7;Recurrent Rectal Carcinoma;Stage IVB Rectal Cancer AJCC v7;Rectal Adenocarcinoma;Colon Adenocarcinoma;ERBB2 Gene Amplification;Stage IVA Rectal Cancer AJCC v7;Stage IIIC Rectal Cancer AJCC v7;Stage IIIB Colon Cancer AJCC v7;Stage IV Rectal Cancer AJCC v7;Stage IV Colon Cancer AJCC v7",
                "country": "Puerto Rico;United States",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Irinotecan Hydrochloride;HER-2 testing;Cetuximab;Trastuzumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Drug;Other;Device",
                "nct_num": "NCT03365882",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "December 7, 2017"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to  cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified  colorectal cancer that has spread from where it started to other places in the body and  cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may  interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,  such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of  tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them  from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and  irinotecan hydrochloride in treating patients with colorectal cancer.",
                "brief_title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
                "condition": "Stage IVA Colon Cancer AJCC v7;Stage IIIA Colon Cancer AJCC v7;Stage IIIB Rectal Cancer AJCC v7;Stage IVB Colon Cancer AJCC v7;Recurrent Colon Carcinoma;Stage III Rectal Cancer AJCC v7;Stage III Colon Cancer AJCC v7;Stage IIIA Rectal Cancer AJCC v7;Stage IIIC Colon Cancer AJCC v7;Recurrent Rectal Carcinoma;Stage IVB Rectal Cancer AJCC v7;Rectal Adenocarcinoma;Colon Adenocarcinoma;ERBB2 Gene Amplification;Stage IVA Rectal Cancer AJCC v7;Stage IIIC Rectal Cancer AJCC v7;Stage IIIB Colon Cancer AJCC v7;Stage IV Rectal Cancer AJCC v7;Stage IV Colon Cancer AJCC v7",
                "country": "Puerto Rico;United States",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Irinotecan Hydrochloride;HER-2 testing;Cetuximab;Trastuzumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Drug;Other;Device",
                "nct_num": "NCT03365882",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "December 7, 2017"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to  cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified  colorectal cancer that has spread from where it started to other places in the body and  cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may  interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,  such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of  tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them  from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and  irinotecan hydrochloride in treating patients with colorectal cancer.",
                "brief_title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
                "condition": "Stage IVA Colon Cancer AJCC v7;Stage IIIA Colon Cancer AJCC v7;Stage IIIB Rectal Cancer AJCC v7;Stage IVB Colon Cancer AJCC v7;Recurrent Colon Carcinoma;Stage III Rectal Cancer AJCC v7;Stage III Colon Cancer AJCC v7;Stage IIIA Rectal Cancer AJCC v7;Stage IIIC Colon Cancer AJCC v7;Recurrent Rectal Carcinoma;Stage IVB Rectal Cancer AJCC v7;Rectal Adenocarcinoma;Colon Adenocarcinoma;ERBB2 Gene Amplification;Stage IVA Rectal Cancer AJCC v7;Stage IIIC Rectal Cancer AJCC v7;Stage IIIB Colon Cancer AJCC v7;Stage IV Rectal Cancer AJCC v7;Stage IV Colon Cancer AJCC v7",
                "country": "Puerto Rico;United States",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Irinotecan Hydrochloride;HER-2 testing;Cetuximab;Trastuzumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Drug;Other;Device",
                "nct_num": "NCT03365882",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "December 7, 2017"
            },
            {
                "brief_summary": "  Part A (dose-optimization)- to determine the recommended phase 2 dose (RP2D) taking into  account dose-limiting toxicity (DLT/s) in Cycle 1, overall safety/tolerability and  pharmacokinetic (PK), by optimizing doses of Debio 1143 when combined with the standard dose  of nivolumab, as well as treatment compliance in participants with advanced solid  malignancies who failed prior systemic standard treatments.  Part B (basket trial)- to evaluate the preliminary anti-tumor activity of Debio 1143 at the  RP2D in combination with nivolumab at the standard dose, overall and in each participant  cohort (Cohort 1: small cell lung cancer [SCLC]; Cohort 2: squamous cell carcinoma of the  head and neck [SCCHN]; Cohort 3: gastrointestinal (GI) cancers with known microsatellite  instability-high/mismatch repair deficiency (MSI-H/MMRd) or other deoxyribonucleic acid (DNA)  damage repair (DDR) abnormalities, including homologous recombination deficiency (HRD);  Cohort 4: platinum-resistant epithelial ovarian cancer [EOC], endometrial cancer, primary  peritoneal cancer (PPC) or cervical cancer, with known MSIH/MMRd, hereditary/somatic  mutations of the breast cancer 1 (BRCA1) and BRCA2 genes or other DNA DDR abnormalities  (incl. HRD).",
                "brief_title": "Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143",
                "condition": "Solid Tumor",
                "country": "France;Spain",
                "geneName": "BRCA1",
                "intervention_name": "Nivolumab;Debio 1143",
                "intervention_type": "Drug",
                "nct_num": "NCT04122625",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "October 10, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating  patients with germline BRCA mutated breast cancer that has spread to other places in the body  (advanced or metastatic). Olaparib, cediranib, and AZD6738 may stop the growth of tumor cells  by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer",
                "condition": "Prognostic Stage IIIB Breast Cancer AJCC v8;Anatomic Stage IIIB Breast Cancer AJCC v8;Prognostic Stage IIIA Breast Cancer AJCC v8;HER2/Neu Negative;Prognostic Stage IIIC Breast Cancer AJCC v8;Prognostic Stage IV Breast Cancer AJCC v8;Anatomic Stage IIIA Breast Cancer AJCC v8;Advanced Breast Carcinoma;Anatomic Stage III Breast Cancer AJCC v8;Germline BRCA1 Gene Mutation;Anatomic Stage IV Breast Cancer AJCC v8;Metastatic Breast Carcinoma;Prognostic Stage III Breast Cancer AJCC v8;Germline BRCA2 Gene Mutation;Anatomic Stage IIIC Breast Cancer AJCC v8",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Ceralasertib;Cediranib;Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT04090567",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "September 16, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib works in treating patients with biliary tract  cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair  gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth.",
                "brief_title": "Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations",
                "condition": "PALB2 Gene Mutation;NBN Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;PTEN Gene Deletion;ATR Gene Mutation;BRCA1 Gene Mutation;ATM Gene Mutation;Metastatic Bile Duct Carcinoma;ARID1A Gene Mutation;RAD51 Gene Mutation;CHEK2 Gene Mutation;MRE11 Gene Mutation;BRIP1 Gene Mutation;Bile Duct Adenocarcinoma;EMSY Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT04042831",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "August 2, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well niraparib, when given before surgery, works in treating  patients with high risk prostate cancer that has not spread to other parts of the body  (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may  stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects",
                "condition": "Prostate Carcinoma;DNA Repair Gene Mutation;NBN Gene Mutation;FANCA Gene Mutation;FANCD2 Gene Mutation;BRCA1 Gene Mutation;FANCL Gene Mutation;ATM Gene Mutation;CHEK1 Gene Mutation;RAD51 Gene Mutation;RAD51C Gene Mutation;CHEK2 Gene Mutation;GEN1 Gene Mutation;BRIP1 Gene Mutation;CDK12 Gene Mutation;DNA Damage Response Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Niraparib Tosylate Monohydrate;Niraparib;Radical Prostatectomy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT04030559",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "July 24, 2019"
            },
            {
                "brief_summary": "  At present targeted therapy with the PARP inhibitor olaparib has become standard of care in  advanced platinum sensitive BRCA1/2 mutant ovarian cancer. The key in this sensitivity is the  loss of homologous recombination (HR) function. The current project aims to treat patients  with any type of cancer carrying in their germline a mutation in genes that generate such an  homologous recombination deficiency (HRD) or have an acquired somatic mutation in their tumor  with the targeted PARP inhibitor olaparib. The project would thus bring access to a targeted  drug matched to the genomic profile of the tumor of these patients and provide oncologists  with information regarding efficacy and safety of olaparib in these patients. This evidence  could then later lead to a more routine regulatory access.",
                "brief_title": "Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes",
                "condition": "Advanced Cancers Harbouring Mutations in HRG",
                "country": "Belgium",
                "geneName": "BRCA1",
                "intervention_name": "Olaparib Oral Capsule",
                "intervention_type": "Drug",
                "nct_num": "NCT03967938",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "May 30, 2019"
            },
            {
                "brief_summary": "  This early phase I trial studies how well olaparib works in treating patients with newly  diagnosed BRCA-mutant ovarian, primary peritoneal, or fallopian cancer before surgery.  Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell  growth.",
                "brief_title": "Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery",
                "condition": "BRCA-Mutated Ovarian Carcinoma;Stage IIIA Ovarian Cancer AJCC v8;Stage IV Primary Peritoneal Cancer AJCC v8;Stage IIIA Fallopian Tube Cancer AJCC v8;Stage IIIB Fallopian Tube Cancer AJCC v8;Stage IV Fallopian Tube Cancer AJCC v8;Stage IIIB Ovarian Cancer AJCC v8;Stage III Ovarian Cancer AJCC v8;Stage IIIA1 Fallopian Tube Cancer AJCC v8;Stage IIIA2 Fallopian Tube Cancer AJCC v8;Stage IVA Fallopian Tube Cancer AJCC v8;Stage IVA Primary Peritoneal Cancer AJCC v8;Stage IIIA2 Ovarian Cancer AJCC v8;BRCA2 Gene Mutation;Stage IVA Ovarian Cancer AJCC v8;High Grade Fallopian Tube Serous Adenocarcinoma;Stage IIIC Primary Peritoneal Cancer AJCC v8;Stage III Fallopian Tube Cancer AJCC v8;Stage IIIB Primary Peritoneal Cancer AJCC v8;Stage IVB Fallopian Tube Cancer AJCC v8;Stage IIIC Fallopian Tube Cancer AJCC v8;Stage IVB Primary Peritoneal Cancer AJCC v8;High Grade Ovarian Serous Adenocarcinoma;Stage IVB Ovarian Cancer AJCC v8;Stage IV Ovarian Cancer AJCC v8;Stage IIIA Primary Peritoneal Cancer AJCC v8;BRCA1 Gene Mutation;Stage IIIC Ovarian Cancer AJCC v8;Stage III Primary Peritoneal Cancer AJCC v8;Primary Peritoneal High Grade Serous Adenocarcinoma;Stage IIIA1 Ovarian Cancer AJCC v8",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Olaparib;Therapeutic Conventional Surgery;Chemotherapy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT03943173",
                "overall_status": "Recruiting",
                "phase": "Early Phase 1",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "May 9, 2019"
            },
            {
                "brief_summary": "  This study is designed to determine the RP2D of gedatolisib in combination with talazoparib  and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that  is triple negative or BRCA1/2 positive (deficient).",
                "brief_title": "Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers",
                "condition": "TNBC - Triple-Negative Breast Cancer",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Gedatolisib;Talazoparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03911973",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "April 11, 2019"
            },
            {
                "brief_summary": "  This is two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with  Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is  dose escalation and Part 2 is a Simon 2-Stage design",
                "brief_title": "A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer",
                "condition": "Triple Negative Breast Cancer",
                "country": "United States;Belgium",
                "geneName": "BRCA1",
                "intervention_name": "ZEN003694;Talazoparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03901469",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "April 3, 2019"
            },
            {
                "brief_summary": "  This phase II Lung-MAP trial studies how well rucaparib works in treating patients with  genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV  non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor  cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)",
                "condition": "Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;Stage IV Lung Cancer AJCC v8;Recurrent Lung Non-Small Cell Carcinoma;Deleterious BRCA2 Gene Mutation;Deleterious BRCA1 Gene Mutation;Recurrent Large Cell Lung Carcinoma;Recurrent Lung Adenocarcinoma;Stage IVB Lung Cancer AJCC v8;Lung Non-Small Cell Squamous Carcinoma;Stage IVA Lung Cancer AJCC v8;Loss of Heterozygosity",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Rucaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03845296",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "February 19, 2019"
            },
            {
                "brief_summary": "  Single arm, single site, open-label Phase II study of the effects of oral olaparib in  participants with metastatic renal cell carcinoma that harbor an inactivating mutation in  BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,  RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint  inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1  criteria.",
                "brief_title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",
                "condition": "Kidney Cancer;Renal Carcinoma;Renal Cell Carcinoma;Kidney Cancer Metastatic;Metastatic Renal Cell Carcinoma",
                "country": "United States",
                "geneName": "BRCA1",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03786796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "December 25, 2018"
            },
            {
                "brief_summary": "  The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP  regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.",
                "brief_title": "Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.",
                "condition": "Sintilimab;TP53 Mutation;Diffuse Large B-Cell Lymphoma",
                "country": ".",
                "geneName": "TP53",
                "intervention_name": "Sintilimab-R-CHOP",
                "intervention_type": "Drug",
                "nct_num": "NCT04023916",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "July 18, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  CLL is an incurable disease with conventional chemotherapy. In the absence of TP53  disruption, a chemoimmunotherapy (CIT) regimen is recommended as front-line and second-line  treatment in those patients who attained a long progression-free survival (PFS) with the  previous regimen. Bendamustine and rituximab (BR) is one of the most widely adopted CIT  regimens, including second-line treatment. Unfortunately, durations of remission following BR  combination therapy tend to be short in patients with heavily pre-treated disease or who have  already received rituximab. The incorporation of a maintenance following induction  chemotherapy to overcome the shorter remission durations in this population is a reasonable  option.",
                "brief_title": "Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia",
                "condition": "Chronic Lymphocytic Leukemia",
                "country": "Russian Federation",
                "geneName": "TP53",
                "intervention_name": "BR as Maintenance",
                "intervention_type": "Drug",
                "nct_num": "NCT03847727",
                "overall_status": "Active, not recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "February 20, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission  tomography (PET) and osimertinib works in evaluating glucose utilization in patients with  EGFR activated glioblastoma. Osimertinib may stop the growth of tumor cells by blocking some  of the enzymes needed for cell growth. 18F-FDG PET imaging may help to detect changes in  tumor glucose utilization, which may allow investigators to obtain an early read out on the  impact of osimertinib on recurrent glioblastoma patients whose tumors have EGFR activation.",
                "brief_title": "18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma",
                "condition": "EGFR Gene Mutation;Recurrent Glioblastoma;TP53 wt Allele;EGFR Gene Amplification;Supratentorial Glioblastoma;Glioblastoma",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Fludeoxyglucose F-18;Osimertinib;Positron Emission Tomography",
                "intervention_type": "Procedure;Drug;Other",
                "nct_num": "NCT03732352",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "November 6, 2018"
            },
            {
                "brief_summary": "  Recent preclinical studies suggest that combining MEK and MDM2 inhibition synergize to induce  apoptosis in RAS/BRAF-mutant and TP53 wild-type CRC models. In vitro, in RKO cell lines  (poorly differentiated colon carcinoma cell line resistant to single agent targeting MDM2 and  MEK and BRAF inhibition), the MDM2 plus MEK inhibitor combination generated a synergistic  increase in apoptotic index. In vivo, in mice harboring human RKO colon tumor xenografts the  combination of MDM2 plus MEK inhibition elicited 93% decreases in tumor volume.  This trial is to conduct a single-center, Phase 1 dose escalation study of trametinib  combined with HDM201 (a HDM2 inhibitor) in patients with advanced/metastatic RAS/RAF mutant  and TP53 wt CRC.",
                "brief_title": "Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type",
                "condition": "Advanced Cancer;Metastatic Cancer;Colorectal Cancer",
                "country": "France",
                "geneName": "TP53",
                "intervention_name": "Trametinib;HDM201",
                "intervention_type": "Drug",
                "nct_num": "NCT03714958",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "October 22, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in  treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that  is untreated or has come back. Quizartinib may stop the growth of cancer cells by blocking  some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine  and venetoclax, work in different ways to stop the growth of cancer cells, either by killing  the cells, by stopping them from dividing, or by stopping them from spreading. Giving  quizartinib and decitabine may work better at treating acute myeloid leukemia and  myelodysplastic syndrome.",
                "brief_title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",
                "condition": "TP53 Gene Deletion;Blasts More Than 10 Percent of Peripheral Blood White Cells;Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;TP53 Gene Mutation;Myelodysplastic Syndrome;Recurrent Acute Myeloid Leukemia;Acute Myeloid Leukemia;High Risk Myelodysplastic Syndrome;Recurrent Myelodysplastic Syndrome;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Quizartinib;Venetoclax;Decitabine",
                "intervention_type": "Drug",
                "nct_num": "NCT03661307",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "September 7, 2018"
            },
            {
                "brief_summary": "  Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the  treatment of advanced refractory solid tumors with TP53 harmful mutations.",
                "brief_title": "Treatment of Carrying TP53 Harmful Mutations",
                "condition": "Advanced Cancer",
                "country": "China",
                "geneName": "TP53",
                "intervention_name": "Fluzoparib combined with Apatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03645200",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "August 24, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men  with metastatic castration resistant prostate cancer (mCRPC). Patients with tumors that have  ATM, BRCA1 and/or BRCA2 mutations/deletions/loss of heterozygosity will be randomized in a  1:1:1 fashion to each arm. Patients with mutations in noncanonical DNA repair genes including  FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2,  MSH6, BRIP1, or FAM175A defects will be assigned to Arm IV with single agent olaparib.",
                "brief_title": "Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects",
                "condition": "Metastatic Prostate Carcinoma;Abnormal DNA Repair;Stage IV Prostate Cancer;Prostate Cancer Metastatic Castration-Resistant",
                "country": "United States",
                "geneName": "NBN",
                "intervention_name": "Olaparib;Abiraterone Acetate;Prednisone",
                "intervention_type": "Drug",
                "nct_num": "NCT03012321",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "January 6, 2017"
            },
            {
                "brief_summary": "  This research study is for patients with metastatic breast cancer.    -  Metastatic means that the cancer has spread beyond the breast. In addition, through     genetic testing of the blood or tumor, an altered gene has been found that suggests the     tumor may not be able to repair its genetic material (DNA) when it becomes damaged.    -  This aspect of the cancer may cause it to be more sensitive - that is, more effectively     killed by certain types of drugs such as the study agent being evaluated in this trial,     Olaparib.     -  Olaparib is a type of drug known as a PARP inhibitor. Some types of breast cancer      and ovarian cancer share some basic features that make them sensitive to similar      treatments. Information from those other research studies suggests that this drug      may help to treat metastatic breast cancer.      -  This study will evaluate whether olaparib is effective in breast cancer       patients whose tumor has a mutation in one of the other genes that function       with BRCA1 and BRCA2 to repair damaged DNA .This mutation may have been       inherited from a parent, or may have developed only in the tumor.      -  This study will also evaluate whether olaparib is effective in breast cancer       patients whose tumor has a mutation in BRCA1 or BRCA2 that was acquired by the       tumor, but not inherited.",
                "brief_title": "Olaparib In Metastatic Breast Cancer",
                "condition": "PALB2 Gene Mutation;NBN Gene Mutation;Somatic Mutation Breast Cancer (BRCA1);Invasive Breast Cancer;Somatic Mutation Breast Cancer (BRCA2);ATM Gene Mutation;RAD51 Gene Mutation;CHEK2 Gene Mutation;BRIP1 Gene Mutation;Metastatic Breast Cancer",
                "country": "United States",
                "geneName": "NBN",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03344965",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "November 17, 2017"
            },
            {
                "brief_summary": "  This phase II trial studies how well talazoparib works in treating patients with homologous  recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has  come back after previous treatment. Talazoparib may stop the growth of tumor cells by  blocking some of the enzymes needed for cell growth.",
                "brief_title": "Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer",
                "condition": "FANCM Gene Mutation;BARD1 Gene Mutation;BRCA2 Gene Mutation;Recurrent Squamous Cell Lung Carcinoma;RAD51 Gene Mutation;Stage IV Squamous Cell Lung Carcinoma AJCC v7;FANCD2 Gene Mutation;ATM Gene Mutation;FANCF Gene Mutation;CHEK2 Gene Mutation;BRIP1 Gene Mutation;RAD54L Gene Mutation;NBN Gene Mutation;RAD51B Gene Mutation;FANCC Gene Mutation;PALB2 Gene Mutation;FANCA Gene Mutation;ATR Gene Mutation;BRCA1 Gene Mutation;CHEK1 Gene Mutation;RPA1 Gene Mutation",
                "country": "Canada;United States",
                "geneName": "NBN",
                "intervention_name": "Talazoparib;Pharmacological Study;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03377556",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "December 19, 2017"
            },
            {
                "brief_summary": "  This phase II trial studies how well niraparib, when given before surgery, works in treating  patients with high risk prostate cancer that has not spread to other parts of the body  (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may  stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects",
                "condition": "Prostate Carcinoma;DNA Repair Gene Mutation;NBN Gene Mutation;FANCA Gene Mutation;FANCD2 Gene Mutation;BRCA1 Gene Mutation;FANCL Gene Mutation;ATM Gene Mutation;CHEK1 Gene Mutation;RAD51 Gene Mutation;RAD51C Gene Mutation;CHEK2 Gene Mutation;GEN1 Gene Mutation;BRIP1 Gene Mutation;CDK12 Gene Mutation;DNA Damage Response Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "NBN",
                "intervention_name": "Niraparib Tosylate Monohydrate;Niraparib;Radical Prostatectomy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT04030559",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "July 24, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib works in treating patients with biliary tract  cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair  gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth.",
                "brief_title": "Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations",
                "condition": "PALB2 Gene Mutation;NBN Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;PTEN Gene Deletion;ATR Gene Mutation;BRCA1 Gene Mutation;ATM Gene Mutation;Metastatic Bile Duct Carcinoma;ARID1A Gene Mutation;RAD51 Gene Mutation;CHEK2 Gene Mutation;MRE11 Gene Mutation;BRIP1 Gene Mutation;Bile Duct Adenocarcinoma;EMSY Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "NBN",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT04042831",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-12",
                "study_first_posted": "August 2, 2019"
            }
        ],
        "cms": [
            {
                "age": "44",
                "agentName": "洛阳市中心医院（韩莉）",
                "areaAgentName": "罗鹏",
                "backStatus": "1",
                "backStatusShow": "未返款",
                "barcode": "8101015325",
                "bedNumber": ".",
                "bingli": "2007139-4",
                "birthday": ".",
                "checkTime": ".",
                "contact": "13837964746",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": "妇科一病区",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-22 11:51:00",
                "expressName": ".",
                "expressNum": "sf1087971150428",
                "fenziBingli": ".",
                "financeId": "232517",
                "gender": "女",
                "historyNum": "0",
                "hospitalName": "洛阳市中心医院",
                "idCard": ".",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-13 16:27:08",
                "invoiceApplyMoney": "0.00",
                "invoiceName": "丁芬霞",
                "invoiceReceivePhone": ".",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "0",
                "invoiceTypeShow": ".",
                "itemName": "0201028.OncoDrug-Seq全实体瘤110基因（组织/细胞学样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-13 16:25:00",
                "medicalRecord": ".",
                "name": "丁芬霞",
                "nickName": "hanli",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "2",
                "paymentTypeShow": "月结",
                "receiveStatus": "1",
                "receiveStatusShow": "未收款",
                "receiveTime": "2020-07-15 11:51:15",
                "remark": ".",
                "reportAddress": ".",
                "reportAddressName": ".",
                "reportCheckTime": ".",
                "reportEmail": ".",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": ".",
                "reportStyle": ".",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "234039",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200715-12",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": ".",
                "sickAge": ".",
                "sickFamilyHistory": ".",
                "source": "石蜡包埋组织",
                "sourceFrom": "WX",
                "testDoctor": "李莹莹",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "卵巢癌",
                "treatHistory": ".",
                "treatID": "TS1301",
                "treatResult": "卵巢癌",
                "treatmentNo": ".",
                "unitAgentName": "洛阳项目",
                "url": "[]",
                "userId": "320",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [],
        "fusion": [],
        "heredity": [
            {
                "aachangeRefgene": "BRCA1:NM_007294:exon2:c.30del:p.Val11Tyrfs*12",
                "ajsGb": "p.Val11Tyrfs*12",
                "alt": "-",
                "alteration": "V11Yfs*12",
                "barcode": ".",
                "chr": "chr17",
                "clinsig": ".",
                "description": "该基因的胚系致病突变可引起BRCA相关乳腺癌-卵巢癌综合征，并以常染色体显性方式遗传。",
                "diseaseInfo": ".",
                "evidenceLevel": "完善",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.3054",
                "funcRefgene": "exonic",
                "geneInfo": "具有抑癌作用的乳腺癌易感基因1（BRCA1），是一种多功能泛素E3连接酶。它具有许多细胞功能，包括转录，蛋白质泛素化，细胞周期调控和DNA损伤应答，在同源重组中，DNA双链断裂修复途径中具有特别重要的作用。BRCA1是第一个鉴定和克隆的乳腺癌和卵巢癌易感基因；该基因中的遗传突变导致发展这些癌症的终身风险增加。 BRCA1突变使患有乳腺癌的终生风险达到70-80％，卵巢癌的终生风险达到50％，并且在德系犹太人群中，有BRCA1基因突变的患者中，增加前列腺癌的风险增加（PMID：22193408）。如果BRCA1的一个拷贝在胚系中发生突变，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（PMID：22193408）。 BRCA1最近也被确定为FANCS中的一种明确的Fanconi贫血易感基因，FANCS是一种罕见的Fanconi贫血亚型，由该基因中的双等位基因突变（PMID：25472942）引起。 BRCA1有三个主要结构域：N-末端指环（非常有趣的新基因）域（外显子2-7）包含活性锌指基序，外显子11-13和BRCT（BRCA1 C-末端）域. BRCA1的许多临床上显着的突变位于指环(RING)域的锌指基序中，这对许多蛋白质 之间相互作用是很重要的（PMID：11573085）。外显子11-13含有蛋白质的结合位点，包括RB，c-MYC，RAD50和RAD51（在PMID：10918303中综述）。尽管事实上外显子11-13包含许多临床上显着的BRCA1突变，但与RING或BRCT结构域相比，该区域的结构或功能知之甚少（PMID：18273555）。 BRCT结构域通过其在转录调节和DNA修复中的关键作用对BRCA1蛋白的肿瘤抑制功能是必不可少的（PMID：11877378,11118345）。乳腺肿瘤中的p53突变几乎完全与BRCA1和BRCA2突变相关，表明p53功能丧失可能是BRCA相关癌症的肿瘤发生的必要步骤（PMID：14672397）。",
                "geneName": "BRCA1",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA1基因exon2第30位碱基缺失使得第11位氨基酸由缬氨酸转变成了酪氨酸且发生移码",
                "geneYcType": "常染色体显性遗传（AD）",
                "hgsGb": "c.30del",
                "hgvs": "BRCA1:NM_007294:exon2:c.30del:p.Val11Tyrfs*12",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "mutationType": "杂合突变",
                "ominId": "113705",
                "posEnd": "41276084",
                "posStart": "41276084",
                "projectAbbr": "DE",
                "ref": "T",
                "relativeDisease": "BRCA相关乳腺癌-卵巢癌综合征",
                "riskLevel": "高",
                "sampleSn": "NGS200715-12",
                "tumorProfiles": ".",
                "vcfFormat": "GT:AD:DP:GQ:PL",
                "vcfFormatInfo": "0/1:498,219:717:99:5849,0,16372",
                "wxz": "exon2",
                "zlb": "NM_007294"
            }
        ],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:1.64%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "1.64%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "如果使用免疫检查点抑制剂治疗，疗效可能较好",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "检测到变异/基因突变（NM_007294:exon2:c.30del:p.Val11Tyrfs*12）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": "TP53:NM_000546:exon4:c.374C>G:p.Thr125Arg",
                "Unnamed: 8": ".",
                "Unnamed: 9": "NGS200715-12",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": "BRCA1:NM_007294:exon2:c.30del:p.Val11Tyrfs*12",
                "Unnamed: 8": ".",
                "Unnamed: 9": "NGS200715-12",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "如果使用免疫检查点抑制剂治疗，疗效可能较好",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "检测到变异/基因突变（NM_000546:exon4:c.374C>G:p.Thr125Arg）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 1,
                "percent": 1.64,
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-12",
                "totalSites": 61
            }
        ],
        "qc": [
            {
                "cleanBases": 1232748676,
                "cleanReads": 9791230,
                "coverage>0.2x": 98.78,
                "coverage>0.5x": 89.38,
                "effectCoverage500": 80.36,
                "effectDepth": 786,
                "insert": 139.0,
                "mapping": 99.9,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 1502004900,
                "rawDuplication": 19.33,
                "rawReads": 10013366,
                "readPercent": 97.78,
                "samplePurity": "34.46",
                "sampleSn": "NGS200715-12",
                "sampleType": "FFPE",
                "targetMapping": 56.46,
                "trimDuplication": 21.2,
                "tumorCoverage": 99.91,
                "tumorDepth": 1089,
                "tumorQ30": 89.99
            }
        ],
        "target": [
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "TP53",
                "NM_ID": "NM_000546",
                "ajsGb": "p.Thr125Arg",
                "alt": "C",
                "alteration": "T125R",
                "avsnp150": "rs786201057",
                "cancerType": "卵巢癌",
                "chr": "chr17",
                "clinsig": "Pathogenic|Likely_pathogenic",
                "cosmic70": "ID\\x3dCOSM45243\\x3bOCCURENCE\\x3d1(breast)",
                "drugLevel": "3A",
                "drugs": "AZD1775",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.342",
                "funcRefgene": "exonic",
                "geneInfo": "TP53通过诱导下游抗肿瘤反应如DNA修复和细胞凋亡（PMID：11099028）编码p53肿瘤抑制蛋白，该蛋白是一种对细胞应激（包括DNA损伤和致癌激活）反应的转录因子。 TP53是人类癌症中最常见的突变基因，并且其胚系突变导致广泛癌症倾向的Li-Fraumeni综合征（PMID：22713868,21765642）。 p53蛋白由N末端反式激活结构域，中央DNA结合结构域，寡聚化结构域和C末端调节结构域（PMID：22713868）组成。",
                "geneName": "TP53",
                "geneType": "geneBx,geneHl,geneMy",
                "geneVar": "TP53基因exon4第374位碱基C置换为G使得第125位氨基酸由苏氨酸转变成了精氨酸",
                "hgsGb": "c.374C>G",
                "hgvs": "TP53:NM_000546:exon4:c.374C>G:p.Thr125Arg",
                "intervarAutomated": "Likely_pathogenic",
                "level": "4/5（可能致病/致病）",
                "posEnd": "7579313",
                "posStart": "7579313",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-12",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:152,79:0.354:79,39:73,40:30:151,145:60:30:0.324,0.327,0.342:0.014,0.011,0.975",
                "wxz": "exon4",
                "zlb": "NM_000546"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "TP53",
                "NM_ID": "NM_000546",
                "ajsGb": "p.Thr125Arg",
                "alt": "C",
                "alteration": "T125R",
                "avsnp150": "rs786201057",
                "cancerType": "头颈鳞癌",
                "chr": "chr17",
                "clinsig": "Pathogenic|Likely_pathogenic",
                "cosmic70": "ID\\x3dCOSM45243\\x3bOCCURENCE\\x3d1(breast)",
                "drugLevel": "3A",
                "drugs": "AZD1775",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.342",
                "funcRefgene": "exonic",
                "geneInfo": "TP53通过诱导下游抗肿瘤反应如DNA修复和细胞凋亡（PMID：11099028）编码p53肿瘤抑制蛋白，该蛋白是一种对细胞应激（包括DNA损伤和致癌激活）反应的转录因子。 TP53是人类癌症中最常见的突变基因，并且其胚系突变导致广泛癌症倾向的Li-Fraumeni综合征（PMID：22713868,21765642）。 p53蛋白由N末端反式激活结构域，中央DNA结合结构域，寡聚化结构域和C末端调节结构域（PMID：22713868）组成。",
                "geneName": "TP53",
                "geneType": "geneBx,geneHl,geneMy",
                "geneVar": "TP53基因exon4第374位碱基C置换为G使得第125位氨基酸由苏氨酸转变成了精氨酸",
                "hgsGb": "c.374C>G",
                "hgvs": "TP53:NM_000546:exon4:c.374C>G:p.Thr125Arg",
                "intervarAutomated": "Likely_pathogenic",
                "level": "4/5（可能致病/致病）",
                "posEnd": "7579313",
                "posStart": "7579313",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-12",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:152,79:0.354:79,39:73,40:30:151,145:60:30:0.324,0.327,0.342:0.014,0.011,0.975",
                "wxz": "exon4",
                "zlb": "NM_000546"
            },
            {
                "1000g2015aug_all": "0.000399360986193642",
                "AA_change": "A270S",
                "DNA_change": "A270S",
                "ExAC_nonpsych_ALL": "0.0001",
                "GeneName": "ERBB2",
                "NM_ID": "NM_004448",
                "ajsGb": "p.Ala270Ser",
                "alt": "T",
                "alteration": "A270S",
                "avsnp150": "rs200382130",
                "cancerType": ".",
                "chr": "chr17",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.786",
                "funcRefgene": "exonic",
                "geneInfo": "ERBB2，是EGFR酪氨酸激酶家族的成员，在一些癌症中会发生异常扩增或者过表达，这些癌症包括乳腺癌，胃癌/食道癌或子宫内膜癌 (PMID:19536107) 。ERBB2/HER2很独特，它不直接结合自己的配体。相反，它强力活化其他配体结合到ErbB受体，如EGFR（ErbB1）或ErbB3（PMID：12620236）。事实上，ERBB2是所有ERBB受体同种型（PMID：10220407,9130710）的优选结合配偶体，ERBB2 / ERBB3复合物通过激活下游致癌PI3K途径（PMID：12853564）显示出高促有丝分裂活性。或者，ERBB2可同源二聚化并启动细胞内有丝分裂级联，包括RAS / MAPK，PI3K / AKT / mTOR，SRC和STAT信号传导途径（PMID：22785351）。大约17% to 30%的乳腺癌患者会发生ERBB2基因的扩增，这与预后不良和复发相关(PMID: 3798106, 23000897,9552035, 9469329)。扩增的ERBB2与ERBB3异源二聚化以激活PI3K / AKT / mTOR信号传导并驱动乳腺癌中的肿瘤发生（PMID：12853564,23204226,12124352,18632642）。ERBB2在约20％胃或胃食管癌（PMID：24943493,21468131）中也被扩增，并且其过度表达被多种可用药物（例如曲妥珠单抗，阿托珠单抗埃米替宁，拉帕替尼和培妥珠单抗）靶向（PMID：24799465） 。ERBB2扩增的发生率很低在非小细胞细胞肺癌，膀胱癌，宫颈癌，子宫内膜癌，结直肠癌，胰腺癌，涎腺导管癌，软组织癌和胆管癌中(reviewed in PMID: 24656976)。激活的ERBB2突变最近在许多肿瘤中被确定是低频率的，包括肺腺癌，小叶性乳腺癌，膀胱癌，胃癌和子宫内膜癌，其中热点变异主要发生在胞外区和激酶活性区(PMID: 23000897, 23220880, 22908275)。临床前研究表明具有这些突变的患者对FDA批准的用于ERBB2靶向治疗较为敏感。临床试验正在ERBB2突变队列中进行，有一些ERBB2靶向激酶抑制剂功效的阳性证据。结肠直肠癌ERBB2突变常与RAS突变共同发生。",
                "geneName": "ERBB2",
                "geneType": "geneBx",
                "geneVar": "ERBB2基因exon7第808位碱基G置换为T使得第270位氨基酸由丙氨酸转变成了丝氨酸",
                "hgsGb": "c.808G>T",
                "hgvs": "ERBB2:NM_004448:exon7:c.808G>T:p.Ala270Ser",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "37866641",
                "posStart": "37866641",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-12",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:96,352:0.772:47,186:49,166:28:142,148:60:29:0.776,0.778,0.786:0.019,0.017,0.964",
                "wxz": "exon7",
                "zlb": "NM_004448"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "BRCA1",
                "NM_ID": "NM_007294",
                "ajsGb": "p.Val11Tyrfs*12",
                "alt": "-",
                "alteration": "V11Yfs*12",
                "avsnp150": ".",
                "cancerType": "卵巢癌",
                "chr": "chr17",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": "1",
                "drugs": "奥拉帕利，Rucaparib[芦卡帕尼]，尼拉帕利",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.307",
                "funcRefgene": "exonic",
                "geneInfo": "具有抑癌作用的乳腺癌易感基因1（BRCA1），是一种多功能泛素E3连接酶。它具有许多细胞功能，包括转录，蛋白质泛素化，细胞周期调控和DNA损伤应答，在同源重组中，DNA双链断裂修复途径中具有特别重要的作用。BRCA1是第一个鉴定和克隆的乳腺癌和卵巢癌易感基因；该基因中的遗传突变导致发展这些癌症的终身风险增加。 BRCA1突变使患有乳腺癌的终生风险达到70-80％，卵巢癌的终生风险达到50％，并且在德系犹太人群中，有BRCA1基因突变的患者中，增加前列腺癌的风险增加（PMID：22193408）。如果BRCA1的一个拷贝在胚系中发生突变，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（PMID：22193408）。 BRCA1最近也被确定为FANCS中的一种明确的Fanconi贫血易感基因，FANCS是一种罕见的Fanconi贫血亚型，由该基因中的双等位基因突变（PMID：25472942）引起。 BRCA1有三个主要结构域：N-末端指环（非常有趣的新基因）域（外显子2-7）包含活性锌指基序，外显子11-13和BRCT（BRCA1 C-末端）域. BRCA1的许多临床上显着的突变位于指环(RING)域的锌指基序中，这对许多蛋白质 之间相互作用是很重要的（PMID：11573085）。外显子11-13含有蛋白质的结合位点，包括RB，c-MYC，RAD50和RAD51（在PMID：10918303中综述）。尽管事实上外显子11-13包含许多临床上显着的BRCA1突变，但与RING或BRCT结构域相比，该区域的结构或功能知之甚少（PMID：18273555）。 BRCT结构域通过其在转录调节和DNA修复中的关键作用对BRCA1蛋白的肿瘤抑制功能是必不可少的（PMID：11877378,11118345）。乳腺肿瘤中的p53突变几乎完全与BRCA1和BRCA2突变相关，表明p53功能丧失可能是BRCA相关癌症的肿瘤发生的必要步骤（PMID：14672397）。",
                "geneName": "BRCA1",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA1基因exon2第30位碱基缺失使得第11位氨基酸由缬氨酸转变成了酪氨酸且发生移码",
                "hgsGb": "c.30del",
                "hgvs": "BRCA1:NM_007294:exon2:c.30del:p.Val11Tyrfs*12",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "41276084",
                "posStart": "41276084",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-12",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:276,122:0.316:157,57:119,65:29:145,146:60:33:0.298,0.284,0.307:0.005,0.026,0.969",
                "wxz": "exon2",
                "zlb": "NM_007294"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "BRCA1",
                "NM_ID": "NM_007294",
                "ajsGb": "p.Val11Tyrfs*12",
                "alt": "-",
                "alteration": "V11Yfs*12",
                "avsnp150": ".",
                "cancerType": "前列腺癌",
                "chr": "chr17",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": "1",
                "drugs": "奥拉帕利，Rucaparib[芦卡帕尼]",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.307",
                "funcRefgene": "exonic",
                "geneInfo": "具有抑癌作用的乳腺癌易感基因1（BRCA1），是一种多功能泛素E3连接酶。它具有许多细胞功能，包括转录，蛋白质泛素化，细胞周期调控和DNA损伤应答，在同源重组中，DNA双链断裂修复途径中具有特别重要的作用。BRCA1是第一个鉴定和克隆的乳腺癌和卵巢癌易感基因；该基因中的遗传突变导致发展这些癌症的终身风险增加。 BRCA1突变使患有乳腺癌的终生风险达到70-80％，卵巢癌的终生风险达到50％，并且在德系犹太人群中，有BRCA1基因突变的患者中，增加前列腺癌的风险增加（PMID：22193408）。如果BRCA1的一个拷贝在胚系中发生突变，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（PMID：22193408）。 BRCA1最近也被确定为FANCS中的一种明确的Fanconi贫血易感基因，FANCS是一种罕见的Fanconi贫血亚型，由该基因中的双等位基因突变（PMID：25472942）引起。 BRCA1有三个主要结构域：N-末端指环（非常有趣的新基因）域（外显子2-7）包含活性锌指基序，外显子11-13和BRCT（BRCA1 C-末端）域. BRCA1的许多临床上显着的突变位于指环(RING)域的锌指基序中，这对许多蛋白质 之间相互作用是很重要的（PMID：11573085）。外显子11-13含有蛋白质的结合位点，包括RB，c-MYC，RAD50和RAD51（在PMID：10918303中综述）。尽管事实上外显子11-13包含许多临床上显着的BRCA1突变，但与RING或BRCT结构域相比，该区域的结构或功能知之甚少（PMID：18273555）。 BRCT结构域通过其在转录调节和DNA修复中的关键作用对BRCA1蛋白的肿瘤抑制功能是必不可少的（PMID：11877378,11118345）。乳腺肿瘤中的p53突变几乎完全与BRCA1和BRCA2突变相关，表明p53功能丧失可能是BRCA相关癌症的肿瘤发生的必要步骤（PMID：14672397）。",
                "geneName": "BRCA1",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA1基因exon2第30位碱基缺失使得第11位氨基酸由缬氨酸转变成了酪氨酸且发生移码",
                "hgsGb": "c.30del",
                "hgvs": "BRCA1:NM_007294:exon2:c.30del:p.Val11Tyrfs*12",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "41276084",
                "posStart": "41276084",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-12",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:276,122:0.316:157,57:119,65:29:145,146:60:33:0.298,0.284,0.307:0.005,0.026,0.969",
                "wxz": "exon2",
                "zlb": "NM_007294"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "BRCA1",
                "NM_ID": "NM_007294",
                "ajsGb": "p.Val11Tyrfs*12",
                "alt": "-",
                "alteration": "V11Yfs*12",
                "avsnp150": ".",
                "cancerType": "胰腺癌",
                "chr": "chr17",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": "1",
                "drugs": "奥拉帕利",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.307",
                "funcRefgene": "exonic",
                "geneInfo": "具有抑癌作用的乳腺癌易感基因1（BRCA1），是一种多功能泛素E3连接酶。它具有许多细胞功能，包括转录，蛋白质泛素化，细胞周期调控和DNA损伤应答，在同源重组中，DNA双链断裂修复途径中具有特别重要的作用。BRCA1是第一个鉴定和克隆的乳腺癌和卵巢癌易感基因；该基因中的遗传突变导致发展这些癌症的终身风险增加。 BRCA1突变使患有乳腺癌的终生风险达到70-80％，卵巢癌的终生风险达到50％，并且在德系犹太人群中，有BRCA1基因突变的患者中，增加前列腺癌的风险增加（PMID：22193408）。如果BRCA1的一个拷贝在胚系中发生突变，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（PMID：22193408）。 BRCA1最近也被确定为FANCS中的一种明确的Fanconi贫血易感基因，FANCS是一种罕见的Fanconi贫血亚型，由该基因中的双等位基因突变（PMID：25472942）引起。 BRCA1有三个主要结构域：N-末端指环（非常有趣的新基因）域（外显子2-7）包含活性锌指基序，外显子11-13和BRCT（BRCA1 C-末端）域. BRCA1的许多临床上显着的突变位于指环(RING)域的锌指基序中，这对许多蛋白质 之间相互作用是很重要的（PMID：11573085）。外显子11-13含有蛋白质的结合位点，包括RB，c-MYC，RAD50和RAD51（在PMID：10918303中综述）。尽管事实上外显子11-13包含许多临床上显着的BRCA1突变，但与RING或BRCT结构域相比，该区域的结构或功能知之甚少（PMID：18273555）。 BRCT结构域通过其在转录调节和DNA修复中的关键作用对BRCA1蛋白的肿瘤抑制功能是必不可少的（PMID：11877378,11118345）。乳腺肿瘤中的p53突变几乎完全与BRCA1和BRCA2突变相关，表明p53功能丧失可能是BRCA相关癌症的肿瘤发生的必要步骤（PMID：14672397）。",
                "geneName": "BRCA1",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA1基因exon2第30位碱基缺失使得第11位氨基酸由缬氨酸转变成了酪氨酸且发生移码",
                "hgsGb": "c.30del",
                "hgvs": "BRCA1:NM_007294:exon2:c.30del:p.Val11Tyrfs*12",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "41276084",
                "posStart": "41276084",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-12",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:276,122:0.316:157,57:119,65:29:145,146:60:33:0.298,0.284,0.307:0.005,0.026,0.969",
                "wxz": "exon2",
                "zlb": "NM_007294"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "BRCA1",
                "NM_ID": "NM_007294",
                "ajsGb": "p.Val11Tyrfs*12",
                "alt": "-",
                "alteration": "V11Yfs*12",
                "avsnp150": ".",
                "cancerType": "乳腺癌",
                "chr": "chr17",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": "2",
                "drugs": "奥拉帕利，Talazoparib[他拉唑帕尼]",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.307",
                "funcRefgene": "exonic",
                "geneInfo": "具有抑癌作用的乳腺癌易感基因1（BRCA1），是一种多功能泛素E3连接酶。它具有许多细胞功能，包括转录，蛋白质泛素化，细胞周期调控和DNA损伤应答，在同源重组中，DNA双链断裂修复途径中具有特别重要的作用。BRCA1是第一个鉴定和克隆的乳腺癌和卵巢癌易感基因；该基因中的遗传突变导致发展这些癌症的终身风险增加。 BRCA1突变使患有乳腺癌的终生风险达到70-80％，卵巢癌的终生风险达到50％，并且在德系犹太人群中，有BRCA1基因突变的患者中，增加前列腺癌的风险增加（PMID：22193408）。如果BRCA1的一个拷贝在胚系中发生突变，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（PMID：22193408）。 BRCA1最近也被确定为FANCS中的一种明确的Fanconi贫血易感基因，FANCS是一种罕见的Fanconi贫血亚型，由该基因中的双等位基因突变（PMID：25472942）引起。 BRCA1有三个主要结构域：N-末端指环（非常有趣的新基因）域（外显子2-7）包含活性锌指基序，外显子11-13和BRCT（BRCA1 C-末端）域. BRCA1的许多临床上显着的突变位于指环(RING)域的锌指基序中，这对许多蛋白质 之间相互作用是很重要的（PMID：11573085）。外显子11-13含有蛋白质的结合位点，包括RB，c-MYC，RAD50和RAD51（在PMID：10918303中综述）。尽管事实上外显子11-13包含许多临床上显着的BRCA1突变，但与RING或BRCT结构域相比，该区域的结构或功能知之甚少（PMID：18273555）。 BRCT结构域通过其在转录调节和DNA修复中的关键作用对BRCA1蛋白的肿瘤抑制功能是必不可少的（PMID：11877378,11118345）。乳腺肿瘤中的p53突变几乎完全与BRCA1和BRCA2突变相关，表明p53功能丧失可能是BRCA相关癌症的肿瘤发生的必要步骤（PMID：14672397）。",
                "geneName": "BRCA1",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA1基因exon2第30位碱基缺失使得第11位氨基酸由缬氨酸转变成了酪氨酸且发生移码",
                "hgsGb": "c.30del",
                "hgvs": "BRCA1:NM_007294:exon2:c.30del:p.Val11Tyrfs*12",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "41276084",
                "posStart": "41276084",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-12",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:276,122:0.316:157,57:119,65:29:145,146:60:33:0.298,0.284,0.307:0.005,0.026,0.969",
                "wxz": "exon2",
                "zlb": "NM_007294"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "BRCA1",
                "NM_ID": "NM_007294",
                "ajsGb": "p.Val11Tyrfs*12",
                "alt": "-",
                "alteration": "V11Yfs*12",
                "avsnp150": ".",
                "cancerType": "胰腺癌",
                "chr": "chr17",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": "3A",
                "drugs": "Rucaparib[芦卡帕尼]",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.307",
                "funcRefgene": "exonic",
                "geneInfo": "具有抑癌作用的乳腺癌易感基因1（BRCA1），是一种多功能泛素E3连接酶。它具有许多细胞功能，包括转录，蛋白质泛素化，细胞周期调控和DNA损伤应答，在同源重组中，DNA双链断裂修复途径中具有特别重要的作用。BRCA1是第一个鉴定和克隆的乳腺癌和卵巢癌易感基因；该基因中的遗传突变导致发展这些癌症的终身风险增加。 BRCA1突变使患有乳腺癌的终生风险达到70-80％，卵巢癌的终生风险达到50％，并且在德系犹太人群中，有BRCA1基因突变的患者中，增加前列腺癌的风险增加（PMID：22193408）。如果BRCA1的一个拷贝在胚系中发生突变，其结果是一种常染色体显性疾病－遗传性乳腺癌和卵巢癌（HBOC）综合征（PMID：22193408）。 BRCA1最近也被确定为FANCS中的一种明确的Fanconi贫血易感基因，FANCS是一种罕见的Fanconi贫血亚型，由该基因中的双等位基因突变（PMID：25472942）引起。 BRCA1有三个主要结构域：N-末端指环（非常有趣的新基因）域（外显子2-7）包含活性锌指基序，外显子11-13和BRCT（BRCA1 C-末端）域. BRCA1的许多临床上显着的突变位于指环(RING)域的锌指基序中，这对许多蛋白质 之间相互作用是很重要的（PMID：11573085）。外显子11-13含有蛋白质的结合位点，包括RB，c-MYC，RAD50和RAD51（在PMID：10918303中综述）。尽管事实上外显子11-13包含许多临床上显着的BRCA1突变，但与RING或BRCT结构域相比，该区域的结构或功能知之甚少（PMID：18273555）。 BRCT结构域通过其在转录调节和DNA修复中的关键作用对BRCA1蛋白的肿瘤抑制功能是必不可少的（PMID：11877378,11118345）。乳腺肿瘤中的p53突变几乎完全与BRCA1和BRCA2突变相关，表明p53功能丧失可能是BRCA相关癌症的肿瘤发生的必要步骤（PMID：14672397）。",
                "geneName": "BRCA1",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "BRCA1基因exon2第30位碱基缺失使得第11位氨基酸由缬氨酸转变成了酪氨酸且发生移码",
                "hgsGb": "c.30del",
                "hgvs": "BRCA1:NM_007294:exon2:c.30del:p.Val11Tyrfs*12",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "41276084",
                "posStart": "41276084",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-12",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:276,122:0.316:157,57:119,65:29:145,146:60:33:0.298,0.284,0.307:0.005,0.026,0.969",
                "wxz": "exon2",
                "zlb": "NM_007294"
            }
        ],
        "tmb": [],
        "tnb": []
    },
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副中度",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "G/A",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/T",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，需较高剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较高，神经毒性综合征的严重程度可能降低",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/TTAAAG",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，药物代谢较快",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "A/A",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/G",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "G/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/C",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，药物代谢较快",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较低",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/TTAAAG",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "G/G",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/C",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "2R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "C/A",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "TTAAAG/TTAAAG",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "2R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/G",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/6TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢增加",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "C/C",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/A",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/A",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/A",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/T",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副低，代谢增加",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-18",
                "updateTime": "."
            }
        ],
        "clinical": [
            {
                "brief_summary": "  This phase I trial studies the side effects and best dose of alpha-TEA when given together  with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that  does not respond to treatment (refractory) and has spread to other places in the body  (metastatic). Anti-cancer treatment, such as alpha-TEA, work in different ways to stop the  growth of tumor cells, either by killing the cells, by stopping them from dividing, or by  stopping them from spreading. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Giving alpha-TEA and trastuzumab may work better for the treatment of breast cancer  compared to usual treatments.",
                "brief_title": "Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer",
                "condition": "Refractory Breast Carcinoma;ERBB2 Overexpression;Prognostic Stage IV Breast Cancer AJCC v8;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": "United States",
                "geneName": "ERBB2",
                "intervention_name": "Alpha-tocopheryloxyacetic Acid;Trastuzumab",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04120246",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "October 9, 2019"
            },
            {
                "brief_summary": "  This phase Ib/II trial studies the side effects and best dose of copanlisib when given  together with trastuzumab and pertuzumab and to see how well ithey work after induction  treatment in treating patients with HER2 positive stage IV breast cancer with PIK3CA or PTEN  mutation. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Monoclonal antibodies, such as pertuzumab, may kill tumor cells that are left after  chemotherapy. The addition of copanlisib to the usual treatment (trastuzumab and pertuzumab)  could shrink the cancer or stabilize it for longer duration as compared to the usual  treatment alone.",
                "brief_title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",
                "condition": "ERBB2 Gene Amplification;PTEN Gene Mutation;PIK3CA Gene Mutation;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": ".",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Trastuzumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04108858",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "September 30, 2019"
            },
            {
                "brief_summary": "  This phase Ib/II trial studies the side effects and best dose of copanlisib when given  together with trastuzumab and pertuzumab and to see how well ithey work after induction  treatment in treating patients with HER2 positive stage IV breast cancer with PIK3CA or PTEN  mutation. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Monoclonal antibodies, such as pertuzumab, may kill tumor cells that are left after  chemotherapy. The addition of copanlisib to the usual treatment (trastuzumab and pertuzumab)  could shrink the cancer or stabilize it for longer duration as compared to the usual  treatment alone.",
                "brief_title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",
                "condition": "ERBB2 Gene Amplification;PTEN Gene Mutation;PIK3CA Gene Mutation;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": ".",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Trastuzumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04108858",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "September 30, 2019"
            },
            {
                "brief_summary": "  This phase Ib/II trial studies the side effects and best dose of copanlisib when given  together with trastuzumab and pertuzumab and to see how well ithey work after induction  treatment in treating patients with HER2 positive stage IV breast cancer with PIK3CA or PTEN  mutation. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Monoclonal antibodies, such as pertuzumab, may kill tumor cells that are left after  chemotherapy. The addition of copanlisib to the usual treatment (trastuzumab and pertuzumab)  could shrink the cancer or stabilize it for longer duration as compared to the usual  treatment alone.",
                "brief_title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",
                "condition": "ERBB2 Gene Amplification;PTEN Gene Mutation;PIK3CA Gene Mutation;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": ".",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Trastuzumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04108858",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "September 30, 2019"
            },
            {
                "brief_summary": "  This is a Phase 2, open-label study to evaluate the efficacy and the safety/tolerability of  pyrotinib in previously treated NSCLC patients with EGFR exon 20 insertion mutations or HER2  exon 20 insertion mutations. Patient has had at least one prior systemic treatment for  locally advanced or metastatic NSCLC.",
                "brief_title": "Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation",
                "condition": "Non Small Cell Lung Cancer",
                "country": "China",
                "geneName": "ERBB2",
                "intervention_name": "Pyrotinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04063462",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "August 21, 2019"
            },
            {
                "brief_summary": "  This is a multi-center, observational genomic screening protocol to identify patients whose  tumors harbor somatic mutations in the ERBB2 (HER2) gene, as measured in circulating tumor  DNA (ctDNA) . Patients with histologically confirmed metastatic breast cancer (MBC) or  metastatic cervical cancer (MCC) are eligible for screening at 3 to 6 months intervals, or if  disease progression is suspected/confirmed. Blood samples will be collected from eligible  patients and ctDNA will be extracted and sequenced at a central laboratory, using  HER2-targeted next generation sequencing (NGS). A certified molecular test report will be  issued from the central laboratory and provided to the investigators and the study sponsor.  Patients who are identified with HER2 mutations by this screening protocol will subsequently  have access to an appropriate neratinib treatment protocol, pending medical eligibility.",
                "brief_title": "HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib",
                "condition": "Metastatic Cervical Cancer;Metastatic Breast Cancer",
                "country": "Serbia;Ireland;Spain",
                "geneName": "ERBB2",
                "intervention_name": "Almac HER-Seq Assay Kit",
                "intervention_type": "Diagnostic Test",
                "nct_num": "NCT03786107",
                "overall_status": "Recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "December 24, 2018"
            },
            {
                "brief_summary": "  Lung cancer is the most leading cause of cancer-related mortality worldwide. Most of the  patients with lung cancer are advanced stage at the time of diagnosis.  The two oncogenes that are important in lung cancer are epidermal growth factor receptor  (EGFR) and K-ras, mutated in 10% and 15% of non-small cell lung cancer (NSCLC) patients.  Large-scale DNA sequencing efforts have identified mutations in BRAF, PI3KCA and ERBB2 that  together represent another 5% of NSCLC patients. The success of EGFR tyrosine kinase  inhibitors (TKIs), such as gefitinib or erlotinib, and more recently ALK/MET TKI, crizotinib,  highlights the need to develop more genetically matched therapies. Therefore, genetic  classification of lung cancer has become increasingly important along with the advances with  targeted therapies.  ROS1 is a receptor tyrosine kinase with constitutive kinase activity. ROS1 was previously  discovered in cell lines where ROS1 fused with other proteins to act as a driver oncogene. In  2007, Rikova et al reported ROS1 fusion as driver mutations in NSCLC cell line (HCC78;  SLC34A2-ROS1) and NSCLC patient (CD74-ROS1). Li et al also found about 1% of samples  harboring CD74-ROS1 fusion in 202 resected lung adenocarcinomas from never smokers. The  incidence was as high as 10% in East Asian population. Currently there are now at least 13  ROS1 fusion variants involving 8 fusion partners (CD74-, SLC34A2-, FIG-, TPM3-, SDC4-,  LRIG3-, ERZ-, KDERL2-) identified in ROS1 positive NSCLC.  Interestingly, preclinical and clinical data have shown ROS1-positive tumors are sensitive to  crizotinib, because of potentially high common amino acid residues in the kinase domain  between ALK and ROS1, which explain why crizotinib can inhibit both ROS1 and ALK to similar  extent. Preliminary report from a phase I clinical trial of crizotinib in the ROS1-positive  NSCLC expansion cohort showed an overall response rate (ORR) of 57%. Given that crizotinib  has made remarkable clinical outcomes in phase I trial of ALK-positive NSCLC patients,  clinical development of ROS1 inhibitors, including crizotinib, should be accelerated to  provide targeted therapies to ROS1-positive NSCLC patients.",
                "brief_title": "A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement",
                "condition": "Non-small Cell Lung Cancer Harboring ROS1 Rearrangement",
                "country": "Korea, Republic of",
                "geneName": "ERBB2",
                "intervention_name": "LDK378(Ceritinib)",
                "intervention_type": "Drug",
                "nct_num": "NCT03399487",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "January 16, 2018"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to  cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified  colorectal cancer that has spread from where it started to other places in the body and  cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may  interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,  such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of  tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them  from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and  irinotecan hydrochloride in treating patients with colorectal cancer.",
                "brief_title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
                "condition": "Stage IVA Colon Cancer AJCC v7;Stage IIIA Colon Cancer AJCC v7;Stage IIIB Rectal Cancer AJCC v7;Stage IVB Colon Cancer AJCC v7;Recurrent Colon Carcinoma;Stage III Rectal Cancer AJCC v7;Stage III Colon Cancer AJCC v7;Stage IIIA Rectal Cancer AJCC v7;Stage IIIC Colon Cancer AJCC v7;Recurrent Rectal Carcinoma;Stage IVB Rectal Cancer AJCC v7;Rectal Adenocarcinoma;Colon Adenocarcinoma;ERBB2 Gene Amplification;Stage IVA Rectal Cancer AJCC v7;Stage IIIC Rectal Cancer AJCC v7;Stage IIIB Colon Cancer AJCC v7;Stage IV Rectal Cancer AJCC v7;Stage IV Colon Cancer AJCC v7",
                "country": "Puerto Rico;United States",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Irinotecan Hydrochloride;HER-2 testing;Cetuximab;Trastuzumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Drug;Other;Device",
                "nct_num": "NCT03365882",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "December 7, 2017"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to  cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified  colorectal cancer that has spread from where it started to other places in the body and  cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may  interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,  such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of  tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them  from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and  irinotecan hydrochloride in treating patients with colorectal cancer.",
                "brief_title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
                "condition": "Stage IVA Colon Cancer AJCC v7;Stage IIIA Colon Cancer AJCC v7;Stage IIIB Rectal Cancer AJCC v7;Stage IVB Colon Cancer AJCC v7;Recurrent Colon Carcinoma;Stage III Rectal Cancer AJCC v7;Stage III Colon Cancer AJCC v7;Stage IIIA Rectal Cancer AJCC v7;Stage IIIC Colon Cancer AJCC v7;Recurrent Rectal Carcinoma;Stage IVB Rectal Cancer AJCC v7;Rectal Adenocarcinoma;Colon Adenocarcinoma;ERBB2 Gene Amplification;Stage IVA Rectal Cancer AJCC v7;Stage IIIC Rectal Cancer AJCC v7;Stage IIIB Colon Cancer AJCC v7;Stage IV Rectal Cancer AJCC v7;Stage IV Colon Cancer AJCC v7",
                "country": "Puerto Rico;United States",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Irinotecan Hydrochloride;HER-2 testing;Cetuximab;Trastuzumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Drug;Other;Device",
                "nct_num": "NCT03365882",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "December 7, 2017"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to  cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified  colorectal cancer that has spread from where it started to other places in the body and  cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may  interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,  such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of  tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them  from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and  irinotecan hydrochloride in treating patients with colorectal cancer.",
                "brief_title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
                "condition": "Stage IVA Colon Cancer AJCC v7;Stage IIIA Colon Cancer AJCC v7;Stage IIIB Rectal Cancer AJCC v7;Stage IVB Colon Cancer AJCC v7;Recurrent Colon Carcinoma;Stage III Rectal Cancer AJCC v7;Stage III Colon Cancer AJCC v7;Stage IIIA Rectal Cancer AJCC v7;Stage IIIC Colon Cancer AJCC v7;Recurrent Rectal Carcinoma;Stage IVB Rectal Cancer AJCC v7;Rectal Adenocarcinoma;Colon Adenocarcinoma;ERBB2 Gene Amplification;Stage IVA Rectal Cancer AJCC v7;Stage IIIC Rectal Cancer AJCC v7;Stage IIIB Colon Cancer AJCC v7;Stage IV Rectal Cancer AJCC v7;Stage IV Colon Cancer AJCC v7",
                "country": "Puerto Rico;United States",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Irinotecan Hydrochloride;HER-2 testing;Cetuximab;Trastuzumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Drug;Other;Device",
                "nct_num": "NCT03365882",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "December 7, 2017"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib works in treating patients with biliary tract  cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair  gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth.",
                "brief_title": "Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations",
                "condition": "PALB2 Gene Mutation;NBN Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;PTEN Gene Deletion;ATR Gene Mutation;BRCA1 Gene Mutation;ATM Gene Mutation;Metastatic Bile Duct Carcinoma;ARID1A Gene Mutation;RAD51 Gene Mutation;CHEK2 Gene Mutation;MRE11 Gene Mutation;BRIP1 Gene Mutation;Bile Duct Adenocarcinoma;EMSY Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "ATM",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT04042831",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "August 2, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well niraparib, when given before surgery, works in treating  patients with high risk prostate cancer that has not spread to other parts of the body  (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may  stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects",
                "condition": "Prostate Carcinoma;DNA Repair Gene Mutation;NBN Gene Mutation;FANCA Gene Mutation;FANCD2 Gene Mutation;BRCA1 Gene Mutation;FANCL Gene Mutation;ATM Gene Mutation;CHEK1 Gene Mutation;RAD51 Gene Mutation;RAD51C Gene Mutation;CHEK2 Gene Mutation;GEN1 Gene Mutation;BRIP1 Gene Mutation;CDK12 Gene Mutation;DNA Damage Response Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "ATM",
                "intervention_name": "Niraparib Tosylate Monohydrate;Niraparib;Radical Prostatectomy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT04030559",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "July 24, 2019"
            },
            {
                "brief_summary": "  Non-Hodgkin CD20 + Indolent Lymphoma (iNHL) and Chronic Lymphatic Leukemia (CLL) are the most  frequent neoplasms of B lymphocytes. They include various histologies (follicular NHL,  marginal zone NHL and Lymphocytic NHL/ CLL) characterized by a chronic course and prolonged  survival, but while patients with a limited disease could be cured, those with advanced  disease or relapsed after localized radiation therapy are generally considered untreatable  through standard treatments. The options for first-line therapy include the use of the FCR  scheme, based on Fludarabine, Cyclophosphamide and Rituximab or the BR, with Bendamustine and  Rituximab. Despite good results, treatment with these two regimens (FCR or BR) is associated  with severe immunosuppression which worsens the immunological dysfunction already present at  diagnosis in several patients. It has been shown previously that the adoptive transfer of ex  vivo anti-CD3/CD28 co-stimulated autologous T cells can successfully accelerate a robust  early recovery of T cells after autologous transplantation in multiple myeloma. These  CD3/CD28 expanded T cells cannot however be used in NHLi and CLL due to the presence of  contaminating tumor cells in the preparation. Polyclonal T cells can also be expanded in  vitro in presence of Blinatumomab and recombinant human IL2 (rhIL2) and have been called BET  (Blinatumomab-expanded T cells). They are a product of Advanced Therapeutic Medicinal Product  (ATMP) composed of polyclonal CD8 and CD4 T cells that are still functional and devoid of  contaminating CD19+ neoplastic cells. Based on these data, it was hypothesized that infusion  of BET in patients with iNHL/CLL, after the first treatment line (with FCR or BR), could  induce adequate immunological recovery.",
                "brief_title": "Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia",
                "condition": "Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia",
                "country": "Italy",
                "geneName": "ATM",
                "intervention_name": "Blinatumomab Expanded T-cells (BET)",
                "intervention_type": "Biological",
                "nct_num": "NCT03823365",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "January 30, 2019"
            },
            {
                "brief_summary": "  Single arm, single site, open-label Phase II study of the effects of oral olaparib in  participants with metastatic renal cell carcinoma that harbor an inactivating mutation in  BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,  RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint  inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1  criteria.",
                "brief_title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",
                "condition": "Kidney Cancer;Renal Carcinoma;Renal Cell Carcinoma;Kidney Cancer Metastatic;Metastatic Renal Cell Carcinoma",
                "country": "United States",
                "geneName": "ATM",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03786796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "December 25, 2018"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib works in treating participants with prostate  cancer that has not spread to other parts of the body. Olaparib may stop the growth of tumor  cells by interfering with the activity of a substance called PARP, which is inside cells.  Giving olaparib before surgery may make the tumor smaller and reduce the amount of normal  tissue that needs to be removed.",
                "brief_title": "Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer",
                "condition": "PALB2 Gene Mutation;FANCA Biallelic Inactivation;Stage II Prostate Cancer AJCC v8;Stage IIC Prostate Cancer AJCC v8;ATM Biallelic Inactivation;BRCA1 Gene Mutation;Homologous Recombination Deficiency;Prostate Adenocarcinoma Without Evidence of Neuroendocrine Differentiation;ATM Gene Mutation;Stage IIB Prostate Cancer AJCC v8;Stage I Prostate Cancer AJCC v8;BRCA2 Biallelic Inactivation;BRCA1 Biallelic Inactivation;PALB2 Biallelic Inactivation;Stage IIA Prostate Cancer AJCC v8;BRCA2 Gene Mutation;ATM Monoallelic Inactivation",
                "country": "United States",
                "geneName": "ATM",
                "intervention_name": "Olaparib;Radical Prostatectomy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT03570476",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "June 27, 2018"
            },
            {
                "brief_summary": "  The investigators objective is to test the combination directly on organotypic cultures of  tumors from patients after their excision in the Department of Urology and Renal  Transplantation of the University Hospital of Grenoble and to compare their efficacy with  that of currently selected treatments in the clinic.  The population targeted by the combination for use in clinical practice is patients with  metastatic clear cell renal cell carcinoma.  Current treatments for these patients are Sunitinib, Pazopanib and Temsirolimus.",
                "brief_title": "Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors",
                "condition": "Kidney Cancer",
                "country": "France",
                "geneName": "ATM",
                "intervention_name": "CK2 and ATM inhibitors serine/ threonin Kinase combination;Sunitinib;Pazopanib;Temsirolimus",
                "intervention_type": "Combination Product;Drug",
                "nct_num": "NCT03571438",
                "overall_status": "Recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "June 27, 2018"
            },
            {
                "brief_summary": "  The investigators objective is to test the combination directly on organotypic cultures of  tumors from patients after their excision in the Department of Urology and Renal  Transplantation of the University Hospital of Grenoble and to compare their efficacy with  that of currently selected treatments in the clinic.  The population targeted by the combination for use in clinical practice is patients with  metastatic clear cell renal cell carcinoma.  Current treatments for these patients are Sunitinib, Pazopanib and Temsirolimus.",
                "brief_title": "Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors",
                "condition": "Kidney Cancer",
                "country": "France",
                "geneName": "ATM",
                "intervention_name": "CK2 and ATM inhibitors serine/ threonin Kinase combination;Sunitinib;Pazopanib;Temsirolimus",
                "intervention_type": "Combination Product;Drug",
                "nct_num": "NCT03571438",
                "overall_status": "Recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "June 27, 2018"
            },
            {
                "brief_summary": "  Avelumab in combination with talazoparib will be investigated in patients with locally  advanced or metastatic solid tumors with a BRCA or ATM defect.",
                "brief_title": "Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors",
                "condition": "Genes, BRCA 1;Locally Advanced or Metastatic Solid Tumors",
                "country": "Japan;Netherlands;United Kingdom;Belgium;Denmark;France;Italy;Spain;United States",
                "geneName": "ATM",
                "intervention_name": "Avelumab;Talazoparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03565991",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "June 21, 2018"
            },
            {
                "brief_summary": "  A PHASE 2, NON RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI CENTER STUDY OF TALAZOPARIB FOR  NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE NEGATIVE BREAST  CANCER",
                "brief_title": "Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer",
                "condition": "Early Breast Cancer",
                "country": "United States",
                "geneName": "ATM",
                "intervention_name": "TALAZOPARIB",
                "intervention_type": "Drug",
                "nct_num": "NCT03499353",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "April 17, 2018"
            },
            {
                "brief_summary": "  TREATMENT is an observational study addressing the need for knowledge and adequate diagnostic  biomarkers in the response assessment of patients with brain metastasis. Reliable response  assessment will be highly relevant in the coming years given the introduction of  next-generation cancer drugs, including immunotherapy. This project uses advanced Magnetic  Resonance Imaging (MRI) and Vessel Architecture Imaging (VAI) to better understand the  response to traditional stereotactic radiosurgery (SRS) and immunotherapy.  Secondary objectives include:  In patients with brain metastases, use advanced MRI and Vessel Architectural Imaging methods  to reveal parameters of traditional, immunotherapeutic, and anti-angiogenic therapy response.  In patients with brain metastases, use advanced MRI and Vessel Architectural Imaging methods  to compare results with traditional biomarkers.  Use existing infrastructure at Oslo University Hospital to standardize therapy monitoring.  In patients with brain metastases, use advanced MRI and Vessel Architectural Imaging methods  to separate real tumor progression from treatment-induced pseudoprogression or radionecrosis  In patients with brain metastases, use advanced MRI and Vessel Architectural Imaging methods  to assess whether anti-angiogenic drugs improve delivery of chemotherapy.",
                "brief_title": "Improved Therapy Response Assessment in Metastatic Brain Tumors",
                "condition": "Brain Metastases",
                "country": "Norway",
                "geneName": "ATM",
                "intervention_name": "Stereotactic Radiosurgery;Ipilimumab, nivolumab or pembrolizumab;Magnetic Resonance Imaging",
                "intervention_type": "Diagnostic Test;Drug;Radiation",
                "nct_num": "NCT03458455",
                "overall_status": "Recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "March 8, 2018"
            },
            {
                "brief_summary": "  The primary objective of this study is to estimate the response rate to ALKS 4230 in  combination with pembrolizumab in patients with HNSCC who have previously received  anti-PD-(L)1 therapy but who have not achieved a CR.",
                "brief_title": "A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer",
                "condition": "Non-cutaneous Squamous Cell Carcinoma of Head and Neck",
                "country": ".",
                "geneName": "ALK",
                "intervention_name": "ALKS 4230;Pembrolizumab",
                "intervention_type": "Drug",
                "nct_num": "NCT04144517",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "October 30, 2019"
            },
            {
                "brief_summary": "  The purpose is to evaluate the efficacy and safety of the combination of capmatinib with  pembrolizumab compared to pembrolizumab alone as first-line treatment for subjects with  locally advanced or metastatic NSCLC who have PD-L1 expression ≥ 50% and have no EGFR  mutation or ALK rearrangement. Capmatinib has demonstrated immunomodulatory activities when  combined with an anti-PD1 antibody in preclinical tumor models irrespective of MET  dysregulation. The combination of capmatinib with checkpoint inhibitors has been established  to be tolerable and could provide additional clinical benefit to the subjects.",
                "brief_title": "Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%",
                "condition": "Non-small Cell Lung Cancer (NSCLC)",
                "country": ".",
                "geneName": "ALK",
                "intervention_name": "Capmatinib;Pembrolizumab",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04139317",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "October 25, 2019"
            },
            {
                "brief_summary": "  The purpose is to evaluate the efficacy and safety of the combination of capmatinib with  pembrolizumab compared to pembrolizumab alone as first-line treatment for subjects with  locally advanced or metastatic NSCLC who have PD-L1 expression ≥ 50% and have no EGFR  mutation or ALK rearrangement. Capmatinib has demonstrated immunomodulatory activities when  combined with an anti-PD1 antibody in preclinical tumor models irrespective of MET  dysregulation. The combination of capmatinib with checkpoint inhibitors has been established  to be tolerable and could provide additional clinical benefit to the subjects.",
                "brief_title": "Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%",
                "condition": "Non-small Cell Lung Cancer (NSCLC)",
                "country": ".",
                "geneName": "ALK",
                "intervention_name": "Capmatinib;Pembrolizumab",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04139317",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "October 25, 2019"
            },
            {
                "brief_summary": "  This study includes patients diagnosed with a metastatic non small cell lung cancer (NSCLC)  with anaplastic lymphoma kinase (ALK) translocation. The standard treatment for patients with  metastatic non small cell lung cancer with ALK translocation is represented by personalized  treatment with drugs called ALK inhibitors. During the treatment with an ALK inhibitor, the  tumour can start to grow again, because the tumour adapts to the drug and develops escape  mechanisms, becoming resistant. At the tumour cells level, the mechanisms underlying  resistance can include the development of other alterations, mainly mutations, including in  the ALK gene. The alterations that developed depend on the drug the tumour has been exposed  to.  The alterations can be identified by analysing tumour tissue obtained through a biopsy,  however, repeating a tumour biopsy is difficult and risky and might not be able to provide  sufficient tissue for the test. Therefore in the last years, new tests have been developed to  identify the mutations in the blood.  Lorlatinib is a drug that inhibits ALK and has already been identified to be able to control  the tumour growth when ALK mutations are identified and is already approved as standard  treatment after progression to a previous treatment with ALK inhibitors.  The purpose of this study is to identify which patient populations may benefit most from  treatment with lorlatinib, based on the alterations found in their genes.",
                "brief_title": "Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients",
                "condition": "Non Small Cell Lung Cancer",
                "country": ".",
                "geneName": "ALK",
                "intervention_name": "Lorlatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04127110",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "October 15, 2019"
            },
            {
                "brief_summary": "  Crizotinib is a first-generation ALK tyrosine kinase inhibitor (ITK-ALK). It is the standard  first-line treatment for patients with advanced NSCLC with ALK gene rearrangement. Alectinib,  ceritinib and brigatinib are second-generation ITK-ALK. They have been shown to be effective  in the first line of treatment in randomized trials. Alectinib has shown superiority to  crizotinib as the first line of treatment in three randomized therapeutic trials, positioning  this ITK-ALK as the treatment of choice in first-line treatment. Despite the effectiveness of  these new treatments, all patients will virtually experience a relapse. There is no data on  second-generation TKI-ALK resistance mechanisms when given as first-line treatment and the  best therapeutic strategy for progression is undefined.",
                "brief_title": "Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer",
                "condition": "Non Small Cell Lung Cancer Metastatic",
                "country": "France",
                "geneName": "ALK",
                "intervention_name": "Lorlatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04111705",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "October 1, 2019"
            },
            {
                "brief_summary": "  Crizotinib is a first-generation ALK tyrosine kinase inhibitor (ITK-ALK). It is the standard  first-line treatment for patients with advanced NSCLC with ALK gene rearrangement. Alectinib,  ceritinib and brigatinib are second-generation ITK-ALK. They have been shown to be effective  in the first line of treatment in randomized trials. Alectinib has shown superiority to  crizotinib as the first line of treatment in three randomized therapeutic trials, positioning  this ITK-ALK as the treatment of choice in first-line treatment. Despite the effectiveness of  these new treatments, all patients will virtually experience a relapse. There is no data on  second-generation TKI-ALK resistance mechanisms when given as first-line treatment and the  best therapeutic strategy for progression is undefined.",
                "brief_title": "Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer",
                "condition": "Non Small Cell Lung Cancer Metastatic",
                "country": "France",
                "geneName": "ALK",
                "intervention_name": "Lorlatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04111705",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "October 1, 2019"
            },
            {
                "brief_summary": "  Crizotinib is a first-generation ALK tyrosine kinase inhibitor (ITK-ALK). It is the standard  first-line treatment for patients with advanced NSCLC with ALK gene rearrangement. Alectinib,  ceritinib and brigatinib are second-generation ITK-ALK. They have been shown to be effective  in the first line of treatment in randomized trials. Alectinib has shown superiority to  crizotinib as the first line of treatment in three randomized therapeutic trials, positioning  this ITK-ALK as the treatment of choice in first-line treatment. Despite the effectiveness of  these new treatments, all patients will virtually experience a relapse. There is no data on  second-generation TKI-ALK resistance mechanisms when given as first-line treatment and the  best therapeutic strategy for progression is undefined.",
                "brief_title": "Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer",
                "condition": "Non Small Cell Lung Cancer Metastatic",
                "country": "France",
                "geneName": "ALK",
                "intervention_name": "Lorlatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04111705",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "October 1, 2019"
            },
            {
                "brief_summary": "  This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has  spread to other parts of the body) non-small cell lung cancer with a mutation (change) in  genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is  at treating ROS1 or MET mutated non-small cell lung cancer.  Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the  treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.",
                "brief_title": "Study of Crizotinib for ROS1 and MET Activated Lung Cancer",
                "condition": "MET Activating Mutation;ROS1 Gene Rearrangement;Stage IV Non-small Cell Lung Cancer;Non-squamous Non-small-cell Lung Cancer;MET Amplification",
                "country": "Canada",
                "geneName": "ALK",
                "intervention_name": "Crizotinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04084717",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "September 10, 2019"
            },
            {
                "brief_summary": "  This is single-arm, open-label study design. Patients will receive brigatinib until disease  progression, unacceptable toxicity, withdrawal of consent, of death.",
                "brief_title": "Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays",
                "condition": "Non Small Cell Lung Cancer",
                "country": "Korea, Republic of",
                "geneName": "ALK",
                "intervention_name": "Brigatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04074993",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "August 30, 2019"
            },
            {
                "brief_summary": "  This study will research untreated elderly diffuse large B cell lymphoma patients respond and  safty to toripalimab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide,  doxorubicin, vincristine, prednisone) therapy.",
                "brief_title": "Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma",
                "condition": "High-grade B-cell Lymphoma;EBV-Positive DLBCL, Nos;Transformed Lymphoma;Diffuse Large B Cell Lymphoma;ALK-Positive Anaplastic Large Cell Lymphoma;Follicular Lymphoma Grade IIIb",
                "country": "China",
                "geneName": "ALK",
                "intervention_name": "R-CHOP Protocol;Toripalimab",
                "intervention_type": "Drug",
                "nct_num": "NCT04058470",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "August 15, 2019"
            },
            {
                "brief_summary": "  This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in  patients with advanced cancer - and to identify a dose and schedule that can be used in the  future. This study will also investigate how the body handles AZD5363 (ie, how quickly the  body absorbs and removes the drug). This study will also investigate anti-tumour activity of  AZD5363 in patients with advanced / metastatic breast, gynaecological cancers or other solid  cancers bearing either AKT1 / PIK3CA or PTEN mutation.",
                "brief_title": "Safety, Tolerability &amp; Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules",
                "condition": "Cervical Cancer;PTEN;Pharmacokinetics;Advanced or Metastatic Breast Cancer;Ovarian Cancer;Endometrial Cancer;PIK3CA;AKT1;HER2 Positive;Safety and Tolerability;Pharmacodynamics;Advanced Solid Malignancy;Tumour Response;ER Positive",
                "country": "Japan;Netherlands;United Kingdom;Sweden;Canada;Denmark;France;Germany;Singapore;Italy;Spain;United States",
                "geneName": "AKT1",
                "intervention_name": "AZD5363",
                "intervention_type": "Drug",
                "nct_num": "NCT01226316",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "October 22, 2010"
            },
            {
                "brief_summary": "  This project is part of a joint ALFA and GOELAM strategy aiming to improve the survival of  patients with newly diagnosed Acute Myeloid Leukemia (AML) aged 18-70 years. The basis of  this strategy is to evaluate intensified conventional chemotherapy and targeted drugs in  selected disease-risk subgroups of adult patients with non promyelocytic AML. Participation  will be proposed to almost all adult patients in France aged 18-70 years and diagnosed with  AML.  FLT3 genetic alterations include FLT3 somatic point mutations within the second tyrosine  kinase domain and internal duplications of the juxta-membrane domain. This alteration is  refered to as FLT3-ITD. The FLT3-ITD mutation is found in around 30% of patients with  cytogenetically normal AML. Patients with the FLT3-ITD genotype have been reported to have a  poor outcome when treated with conventional chemotherapy with an estimated 4-year  relapse-free survival of 25% (Schlenk et al. N Engl J Med 2008). More recently, the  prognostic relevance of FLT3-ITD has been studied in the context of integrated genetic  profiling. This confirmed the genetic complexity of AML and also that FLT3-ITD was associated  with reduced overall survival in intermediate-risk AML. A multivariate analysis of several  genetic alterations revealed that FLT3-ITD was the primary predictor of patient outcome.  FLT3-ITD mutations were classified in 3 categories: 1) FLT3-ITD with +8, TET2, DNMT3A or  MLL-PTD mutations (3-year OS 14.5%); 2) FLT3-ITD with wild type CEBPA, TET2, DNMT3 and  MLL-PTD (3-year OS 35.2%) and 3) FLT3-ITD with CEBPA mutations (3-year OS 42%) (Patel JP et  al. N Engl J Med 2012). However, FLT3-ITD was not a predictor of response to induction  therapy, allowing the introduction of targeted therapies after the induction course.  Several FLT3 inhibitors have been evaluated or are currently being tested in the setting of  relapsing AML. In most trials to date, patients were only eligible if the FLT3-ITD mutation  was present. Disappointing results were reported with the first generation of FLT3  inhibitors, including lestaurtinib (CEP-701), midostaurin (PKC-412) and sorafenib. Second  generation FLT3 inhibitors such as quizartinib (AC220) are currently under investigation with  promising results. However, the hematologic toxicity of AC220 will likely present a major  limitation in evaluating AC220 combined with standard or high-dose chemotherapy.  Ponatinib (AP24534) is a third generation tyrosine kinase inhibitor targeting the BCR-ABL  tyrosine kinase domain. Ponatinib was rationally designed with an extensive network of  optimized molecular contacts and triple bonds to accommodate the T315I mutation, a major  cause of resistance to tyrosine kinase inhibitors in chronic and advanced phase chronic  myelogenous leukemia (CML). Ponatinib also inhibits SRC (IC50: 5.4 nM) and members of the  VEGFR, FGFR, and PDGFR families of receptor tyrosine kinases (O'Hare T, Cancer Cell 2009).  Despite low activity against FLT3 based on the IC50 value (FLT3 IC50: 12.6 nM compared to BCR  IC50: 0.37 nM), ponatinib has recently been reported to have significant cellular activity  against the MV4-11 cell line which harbors an FLT3-ITD activating mutation. Ponatinib-induced  apoptosis was maximal at 10 nM in vitro and a single dose of 5 and 10 mg/kg had a strong  inhibitory effect in vivo in mice bearing MV4-11 xenografts. Primary blast cells from 4  FLT3-ITD AML patients were also tested and ponatinib reduced their viability (IC50: 4 nM)  whereas no activity was shown on FLT3-ITD-negative blast cells (Gozgit JM et al. Mol Cancer  Ther 2011).  Preliminary data from the phase I clinical trial showed that 15 mg ponatinib was associated  with a Cmax of 51.1 nM. Cmax was increased to 111 nM and 149 nM in the 30 mg and 45 mg  cohorts respectively. The trough concentrations were 55.3 nM and 61.9 nM for the 30 mg and 45  mg doses respectively (Ariad clinical investigator's brochure, version 3). Results from the  ongoing phase II trial in CML patients suggest that the hematological toxicity profile of  ponatinib is comparable with that of nilotinib or dasatinib, both of which have been  successfully combined with conventional chemotherapy.  Investigators thus aim to combine ponatinib with cytarabine in FLT3-ITD AML patients in first  complete remission.",
                "brief_title": "Ponatinib for FLT3-ITD Acute Myelogenous Leukemia",
                "condition": "Acute Myeloid Lukemia",
                "country": "France",
                "geneName": "DNMT3A",
                "intervention_name": "Ponatinib and Cytarabine",
                "intervention_type": "Drug",
                "nct_num": "NCT02428543",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "April 29, 2015"
            },
            {
                "brief_summary": "  Single arm, single site, open-label Phase II study of the effects of oral olaparib in  participants with metastatic renal cell carcinoma that harbor an inactivating mutation in  BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,  RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint  inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1  criteria.",
                "brief_title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",
                "condition": "Kidney Cancer;Renal Carcinoma;Renal Cell Carcinoma;Kidney Cancer Metastatic;Metastatic Renal Cell Carcinoma",
                "country": "United States",
                "geneName": "RAD51D",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03786796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-18",
                "study_first_posted": "December 25, 2018"
            }
        ],
        "cms": [
            {
                "age": "69",
                "agentName": "泰安市中心医院",
                "areaAgentName": "仝彤",
                "backStatus": "1",
                "backStatusShow": "未返款",
                "barcode": "8101025828",
                "bedNumber": ".",
                "bingli": ".",
                "birthday": ".",
                "checkTime": ".",
                "contact": "13793849533",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": "普外科",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-22 11:34:00",
                "expressName": ".",
                "expressNum": "sf1094362887213",
                "fenziBingli": ".",
                "financeId": "232424",
                "gender": "男",
                "historyNum": "0",
                "hospitalName": "泰安市中心医院",
                "idCard": ".",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-13 14:32:05",
                "invoiceApplyMoney": "12800.00",
                "invoiceName": ".",
                "invoiceReceivePhone": ".",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "0",
                "invoiceTypeShow": ".",
                "itemName": "0201028.OncoDrug-Seq全实体瘤110基因（组织/细胞学样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-13 14:30:07",
                "medicalRecord": ".",
                "name": "公方祥",
                "nickName": "李琦",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "1",
                "paymentTypeShow": "现结",
                "receiveStatus": "2",
                "receiveStatusShow": "已收款",
                "receiveTime": "2020-07-15 11:34:03",
                "remark": ".",
                "reportAddress": ".",
                "reportAddressName": "李双才",
                "reportCheckTime": ".",
                "reportEmail": ".",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": ".",
                "reportStyle": "电子 纸质",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "233948",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200715-18",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": ".",
                "sickAge": ".",
                "sickFamilyHistory": ".",
                "source": "石蜡组织卷",
                "sourceFrom": ".",
                "testDoctor": "米磊",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "胃癌",
                "treatHistory": ".",
                "treatID": "TS0302",
                "treatResult": "胃癌",
                "treatmentNo": ".",
                "unitAgentName": "李琦",
                "url": "[]",
                "userId": "73",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [],
        "fusion": [],
        "heredity": [],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:4.84%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "4.84%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 3,
                "percent": 4.84,
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-18",
                "totalSites": 62
            }
        ],
        "qc": [
            {
                "cleanBases": 1633092625,
                "cleanReads": 13026536,
                "coverage>0.2x": 99.12,
                "coverage>0.5x": 92.44,
                "effectCoverage500": 95.05,
                "effectDepth": 1086,
                "insert": 139.7,
                "mapping": 99.93,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 1990004100,
                "rawDuplication": 21.02,
                "rawReads": 13266694,
                "readPercent": 98.19,
                "samplePurity": "30.05",
                "sampleSn": "NGS200715-18",
                "sampleType": "FFPE",
                "targetMapping": 61.56,
                "trimDuplication": 26.73,
                "tumorCoverage": 99.73,
                "tumorDepth": 1625,
                "tumorQ30": 90.7
            }
        ],
        "target": [
            {
                "1000g2015aug_all": ".",
                "AA_change": ".",
                "DNA_change": ".",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": ".",
                "NM_ID": ".",
                "ajsGb": "p.Arg23Gln",
                "alt": "T",
                "alteration": "R23Q",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr2",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.063",
                "funcRefgene": "exonic",
                "geneInfo": "DNMT3A是一种DNA甲基转移酶，负责在CpG位点建立从头基因组DNA甲基化。基因启动子处的DNA甲基化主要通过排除重要转录机制的结合而导致基因抑制（PMID：23400093）。DNMT3A与另一个从头甲基转移酶DNMT3B和维持性甲基转移酶DNMT1协同工作，并由非催化亚基DNMT3L（PMID：21243710）协助。CpG甲基化对于维持表观遗传学组织特异性基因表达模式，基因组印迹，X染色体失活，寄生DNA序列沉默和基因组完整性非常重要（PMID：15215868）。DNMT3A中的种系突变导致Tatton-Brown-Rahman过度生长综合征，这是一种与智力残疾相关的疾病（PMID：24614070），并且过表达与黑色素瘤和肝细胞癌（PMID：24589714）有关。DNMT3A在新发急性髓细胞性白血病（AML）中复发突变（占所有病例的30％）（PMID：23634996），继发性急性髓细胞性白血病（PMID：21993668），骨髓增生性肿瘤（PMID：21537334）发生频率较低。骨髓增生异常综合征（PMID：21519343）和T细胞急性淋巴细胞白血病（T-ALL）（PMID：23687089）。DNMT3A活性增强的癌症可能对DNA甲基转移酶抑制剂敏感（PMID：29033456）。",
                "geneName": "DNMT3A",
                "geneType": "geneMy",
                "geneVar": "DNMT3A基因exon2第68位碱基G置换为A使得第23位氨基酸由精氨酸转变成了谷氨酰胺",
                "hgsGb": "c.68G>A",
                "hgvs": "DNMT3A:NM_022552:exon2:c.68G>A:p.Arg23Gln",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "25536786",
                "posStart": "25536786",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:1168,79:0.084:528,31:640,48:26:158,162:60:29:0.061,0.053,0.063:0.001,0.016,0.983",
                "wxz": "exon2",
                "zlb": "NM_022552"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "G129V",
                "DNA_change": "G129V",
                "ExAC_nonpsych_ALL": "9.056e-05",
                "GeneName": "ALK",
                "NM_ID": "NM_004304",
                "ajsGb": "p.Gly129Val",
                "alt": "A",
                "alteration": "G129V",
                "avsnp150": "rs760041708",
                "cancerType": ".",
                "chr": "chr2",
                "clinsig": "Conflicting_interpretations_of_pathogenicity",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.534",
                "funcRefgene": "exonic",
                "geneInfo": "ALK编码在神经系统发育中起重要作用的胰岛素受体家族中的一种受体酪氨酸激酶。 在癌症中，ALK基因融合与各种基因易位配对，导致有丝分裂和抗凋亡信号传导途径的异常激活，包括STAT3，MAPK和PI3K途径（PMID：24715763）。 ALK基因中的突变和缺失比易位少见。 发生ALK改变的癌症类型包括非小细胞肺癌（NSCLC），间变性大细胞淋巴瘤，炎性肌纤维母细胞瘤（IMT），成神经细胞瘤和横纹肌肉瘤（PMID：24060861）。",
                "geneName": "ALK",
                "geneType": "geneBx,geneMy",
                "geneVar": "ALK基因exon1第386位碱基G置换为T使得第129位氨基酸由甘氨酸转变成了缬氨酸",
                "hgsGb": "c.386G>T",
                "hgvs": "ALK:NM_004304:exon1:c.386G>T:p.Gly129Val",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "30143140",
                "posStart": "30143140",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:537,615:0.533:290,327:247,288:28:174,167:60:29:0.520,0.528,0.534:0.018,0.006,0.976",
                "wxz": "exon1",
                "zlb": "NM_004304"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "ATM",
                "NM_ID": "NM_000051",
                "ajsGb": "p.Leu726Arg",
                "alt": "G",
                "alteration": "L726R",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr11",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.161",
                "funcRefgene": "exonic",
                "geneInfo": "ATM编码共济失调毛细血管扩张突变蛋白（ATM），是磷脂酰肌醇3激酶蛋白超家族的成员，与丝氨酸/苏氨酸激酶（PIKKs）有关。ATM是一种肿瘤抑制基因，最初启动DNA损伤检查点信号，然后积累DNA双链断裂（DSBs）积累或其他形式的细胞应激积累（PMID：23219553）。活化的ATM可以磷酸化数百个底物，以启动和放大的对DNA损伤反应。（PMID：17525332）导致DNA修复、细胞周期阻滞和/或凋亡。在一般人群中，ATM中的胚系和散发性突变发现于多种肿瘤类型中。在实体瘤的大规模研究中，约5％的患者样本显示ATM突变导致蛋白质的失活或缺失，表明ATM是强力有效的肿瘤抑制基因。 ATM是由常染色体隐性遗传性的共济失调性毛细血管扩张症（A-T）命名的，它是由ATM基因中导致蛋白质无功能的各种突变引起的。除了各种神经系统疾病，肺部疾病和皮肤疾病以及免疫缺陷之外，A-T患者还有早期发生各种癌症的倾向，特别是儿童淋巴瘤，白血病和乳腺癌（PMID：21792198）。此外，A-T患者对放疗显示出极大的敏感性，引起人们对ATM作为癌症治疗的治疗靶点的相当大的兴趣（PMID：18813293）。",
                "geneName": "ATM",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "ATM基因exon14第2177位碱基T置换为G使得第726位氨基酸由亮氨酸转变成了精氨酸",
                "hgsGb": "c.2177T>G",
                "hgvs": "ATM:NM_000051:exon14:c.2177T>G:p.Leu726Arg",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "108126994",
                "posStart": "108126994",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:455,87:0.177:217,45:238,42:29:135,142:60:36:0.151,0.151,0.161:0.007,0.006,0.987",
                "wxz": "exon14",
                "zlb": "NM_000051"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "ATM",
                "NM_ID": "NM_000051",
                "ajsGb": "p.Leu726Arg",
                "alt": "G",
                "alteration": "L726R",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr11",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.161",
                "funcRefgene": "exonic",
                "geneInfo": "ATM编码共济失调毛细血管扩张突变蛋白（ATM），是磷脂酰肌醇3激酶蛋白超家族的成员，与丝氨酸/苏氨酸激酶（PIKKs）有关。ATM是一种肿瘤抑制基因，最初启动DNA损伤检查点信号，然后积累DNA双链断裂（DSBs）积累或其他形式的细胞应激积累（PMID：23219553）。活化的ATM可以磷酸化数百个底物，以启动和放大的对DNA损伤反应。（PMID：17525332）导致DNA修复、细胞周期阻滞和/或凋亡。在一般人群中，ATM中的胚系和散发性突变发现于多种肿瘤类型中。在实体瘤的大规模研究中，约5％的患者样本显示ATM突变导致蛋白质的失活或缺失，表明ATM是强力有效的肿瘤抑制基因。 ATM是由常染色体隐性遗传性的共济失调性毛细血管扩张症（A-T）命名的，它是由ATM基因中导致蛋白质无功能的各种突变引起的。除了各种神经系统疾病，肺部疾病和皮肤疾病以及免疫缺陷之外，A-T患者还有早期发生各种癌症的倾向，特别是儿童淋巴瘤，白血病和乳腺癌（PMID：21792198）。此外，A-T患者对放疗显示出极大的敏感性，引起人们对ATM作为癌症治疗的治疗靶点的相当大的兴趣（PMID：18813293）。",
                "geneName": "ATM",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "ATM基因exon14第2177位碱基T置换为G使得第726位氨基酸由亮氨酸转变成了精氨酸",
                "hgsGb": "c.2177T>G",
                "hgvs": "ATM:NM_000051:exon14:c.2177T>G:p.Leu726Arg",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "108126994",
                "posStart": "108126994",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:455,87:0.177:217,45:238,42:29:135,142:60:36:0.151,0.151,0.161:0.007,0.006,0.987",
                "wxz": "exon14",
                "zlb": "NM_000051"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "E17K",
                "DNA_change": "E17K",
                "ExAC_nonpsych_ALL": "1.131e-05",
                "GeneName": "AKT1",
                "NM_ID": "NM_001014431",
                "ajsGb": "p.Glu17Lys",
                "alt": "T",
                "alteration": "E17K",
                "avsnp150": "rs121434592",
                "cancerType": "实体瘤",
                "chr": "chr14",
                "clinsig": "Uncertain_significance",
                "cosmic70": "ID\\x3dCOSM33765\\x3bOCCURENCE\\x3d1(haematopoietic_and_lymphoid_tissue)",
                "drugLevel": "3A",
                "drugs": "Capivasertib[卡帕塞替尼]",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.189",
                "funcRefgene": "exonic",
                "geneInfo": "AKT1基因编码丝氨酸/苏氨酸蛋白激酶，其是PI3K信号传导途径中关键的下游效应子。 AKT1及与其密切相关的AKT2和AKT3是AGC激酶家族的成员。 AKT激活的作用包括改变细胞代谢，加速细胞周期进程，增加细胞大小和逃避细胞死亡。 当它的pleckstrin同源结构域（PHD）从激酶结构域（KD）脱落，定位到细胞膜，并且其几个关键残基变为磷酸化时，AKT1激活发生，包括S473和T308（PMID：9843996,7611497）。 AKT1在癌症中经常被激活，通常是通过P13K基因的突变或活化，或PTEN的失活。已经在人类癌症中鉴定出非磷酸肌醇依赖性的AKT1激活突变（PMID：17611497,23134728,20440266）和罕见的AKT1基因扩增（PMID：18767981）。",
                "geneName": "AKT1",
                "geneType": "geneBx",
                "geneVar": "AKT1基因exon3第48位碱基G置换为A使得第17位氨基酸由谷氨酸转变成了赖氨酸",
                "hgsGb": "c.48G>A",
                "hgvs": "AKT1:NM_001014431:exon3:c.48G>A:p.Glu17Lys",
                "intervarAutomated": "Pathogenic",
                "level": "3（临床意义未明）",
                "posEnd": "105246551",
                "posStart": "105246551",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:300,70:0.209:153,38:147,32:29:150,163:60:22:0.183,0.168,0.189:0.006,0.014,0.981",
                "wxz": "exon3",
                "zlb": "NM_001014431"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Q79K",
                "DNA_change": "Q79K",
                "ExAC_nonpsych_ALL": "1.131e-05",
                "GeneName": "AKT1",
                "NM_ID": "NM_001014431",
                "ajsGb": "p.Glu17Lys",
                "alt": "T",
                "alteration": "E17K",
                "avsnp150": "rs121434592",
                "cancerType": "卵巢癌",
                "chr": "chr14",
                "clinsig": "Uncertain_significance",
                "cosmic70": "ID\\x3dCOSM33765\\x3bOCCURENCE\\x3d1(haematopoietic_and_lymphoid_tissue)",
                "drugLevel": "3B",
                "drugs": "Capivasertib[卡帕塞替尼]",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.189",
                "funcRefgene": "exonic",
                "geneInfo": "AKT1基因编码丝氨酸/苏氨酸蛋白激酶，其是PI3K信号传导途径中关键的下游效应子。 AKT1及与其密切相关的AKT2和AKT3是AGC激酶家族的成员。 AKT激活的作用包括改变细胞代谢，加速细胞周期进程，增加细胞大小和逃避细胞死亡。 当它的pleckstrin同源结构域（PHD）从激酶结构域（KD）脱落，定位到细胞膜，并且其几个关键残基变为磷酸化时，AKT1激活发生，包括S473和T308（PMID：9843996,7611497）。 AKT1在癌症中经常被激活，通常是通过P13K基因的突变或活化，或PTEN的失活。已经在人类癌症中鉴定出非磷酸肌醇依赖性的AKT1激活突变（PMID：17611497,23134728,20440266）和罕见的AKT1基因扩增（PMID：18767981）。",
                "geneName": "AKT1",
                "geneType": "geneBx",
                "geneVar": "AKT1基因exon3第48位碱基G置换为A使得第17位氨基酸由谷氨酸转变成了赖氨酸",
                "hgsGb": "c.48G>A",
                "hgvs": "AKT1:NM_001014431:exon3:c.48G>A:p.Glu17Lys",
                "intervarAutomated": "Pathogenic",
                "level": "3（临床意义未明）",
                "posEnd": "105246551",
                "posStart": "105246551",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:300,70:0.209:153,38:147,32:29:150,163:60:22:0.183,0.168,0.189:0.006,0.014,0.981",
                "wxz": "exon3",
                "zlb": "NM_001014431"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "E40K",
                "DNA_change": "E40K",
                "ExAC_nonpsych_ALL": "1.131e-05",
                "GeneName": "AKT1",
                "NM_ID": "NM_001014431",
                "ajsGb": "p.Glu17Lys",
                "alt": "T",
                "alteration": "E17K",
                "avsnp150": "rs121434592",
                "cancerType": "实体瘤",
                "chr": "chr14",
                "clinsig": "Uncertain_significance",
                "cosmic70": "ID\\x3dCOSM33765\\x3bOCCURENCE\\x3d1(haematopoietic_and_lymphoid_tissue)",
                "drugLevel": "4",
                "drugs": "Capivasertib[卡帕塞替尼]",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.189",
                "funcRefgene": "exonic",
                "geneInfo": "AKT1基因编码丝氨酸/苏氨酸蛋白激酶，其是PI3K信号传导途径中关键的下游效应子。 AKT1及与其密切相关的AKT2和AKT3是AGC激酶家族的成员。 AKT激活的作用包括改变细胞代谢，加速细胞周期进程，增加细胞大小和逃避细胞死亡。 当它的pleckstrin同源结构域（PHD）从激酶结构域（KD）脱落，定位到细胞膜，并且其几个关键残基变为磷酸化时，AKT1激活发生，包括S473和T308（PMID：9843996,7611497）。 AKT1在癌症中经常被激活，通常是通过P13K基因的突变或活化，或PTEN的失活。已经在人类癌症中鉴定出非磷酸肌醇依赖性的AKT1激活突变（PMID：17611497,23134728,20440266）和罕见的AKT1基因扩增（PMID：18767981）。",
                "geneName": "AKT1",
                "geneType": "geneBx",
                "geneVar": "AKT1基因exon3第48位碱基G置换为A使得第17位氨基酸由谷氨酸转变成了赖氨酸",
                "hgsGb": "c.48G>A",
                "hgvs": "AKT1:NM_001014431:exon3:c.48G>A:p.Glu17Lys",
                "intervarAutomated": "Pathogenic",
                "level": "3（临床意义未明）",
                "posEnd": "105246551",
                "posStart": "105246551",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:300,70:0.209:153,38:147,32:29:150,163:60:22:0.183,0.168,0.189:0.006,0.014,0.981",
                "wxz": "exon3",
                "zlb": "NM_001014431"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "L52R",
                "DNA_change": "L52R",
                "ExAC_nonpsych_ALL": "1.131e-05",
                "GeneName": "AKT1",
                "NM_ID": "NM_001014431",
                "ajsGb": "p.Glu17Lys",
                "alt": "T",
                "alteration": "E17K",
                "avsnp150": "rs121434592",
                "cancerType": "实体瘤",
                "chr": "chr14",
                "clinsig": "Uncertain_significance",
                "cosmic70": "ID\\x3dCOSM33765\\x3bOCCURENCE\\x3d1(haematopoietic_and_lymphoid_tissue)",
                "drugLevel": "4",
                "drugs": "Capivasertib[卡帕塞替尼]",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.189",
                "funcRefgene": "exonic",
                "geneInfo": "AKT1基因编码丝氨酸/苏氨酸蛋白激酶，其是PI3K信号传导途径中关键的下游效应子。 AKT1及与其密切相关的AKT2和AKT3是AGC激酶家族的成员。 AKT激活的作用包括改变细胞代谢，加速细胞周期进程，增加细胞大小和逃避细胞死亡。 当它的pleckstrin同源结构域（PHD）从激酶结构域（KD）脱落，定位到细胞膜，并且其几个关键残基变为磷酸化时，AKT1激活发生，包括S473和T308（PMID：9843996,7611497）。 AKT1在癌症中经常被激活，通常是通过P13K基因的突变或活化，或PTEN的失活。已经在人类癌症中鉴定出非磷酸肌醇依赖性的AKT1激活突变（PMID：17611497,23134728,20440266）和罕见的AKT1基因扩增（PMID：18767981）。",
                "geneName": "AKT1",
                "geneType": "geneBx",
                "geneVar": "AKT1基因exon3第48位碱基G置换为A使得第17位氨基酸由谷氨酸转变成了赖氨酸",
                "hgsGb": "c.48G>A",
                "hgvs": "AKT1:NM_001014431:exon3:c.48G>A:p.Glu17Lys",
                "intervarAutomated": "Pathogenic",
                "level": "3（临床意义未明）",
                "posEnd": "105246551",
                "posStart": "105246551",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:300,70:0.209:153,38:147,32:29:150,163:60:22:0.183,0.168,0.189:0.006,0.014,0.981",
                "wxz": "exon3",
                "zlb": "NM_001014431"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "D323H",
                "DNA_change": "D323H",
                "ExAC_nonpsych_ALL": "1.131e-05",
                "GeneName": "AKT1",
                "NM_ID": "NM_001014431",
                "ajsGb": "p.Glu17Lys",
                "alt": "T",
                "alteration": "E17K",
                "avsnp150": "rs121434592",
                "cancerType": "实体瘤",
                "chr": "chr14",
                "clinsig": "Uncertain_significance",
                "cosmic70": "ID\\x3dCOSM33765\\x3bOCCURENCE\\x3d1(haematopoietic_and_lymphoid_tissue)",
                "drugLevel": "4",
                "drugs": "Capivasertib[卡帕塞替尼]",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.189",
                "funcRefgene": "exonic",
                "geneInfo": "AKT1基因编码丝氨酸/苏氨酸蛋白激酶，其是PI3K信号传导途径中关键的下游效应子。 AKT1及与其密切相关的AKT2和AKT3是AGC激酶家族的成员。 AKT激活的作用包括改变细胞代谢，加速细胞周期进程，增加细胞大小和逃避细胞死亡。 当它的pleckstrin同源结构域（PHD）从激酶结构域（KD）脱落，定位到细胞膜，并且其几个关键残基变为磷酸化时，AKT1激活发生，包括S473和T308（PMID：9843996,7611497）。 AKT1在癌症中经常被激活，通常是通过P13K基因的突变或活化，或PTEN的失活。已经在人类癌症中鉴定出非磷酸肌醇依赖性的AKT1激活突变（PMID：17611497,23134728,20440266）和罕见的AKT1基因扩增（PMID：18767981）。",
                "geneName": "AKT1",
                "geneType": "geneBx",
                "geneVar": "AKT1基因exon3第48位碱基G置换为A使得第17位氨基酸由谷氨酸转变成了赖氨酸",
                "hgsGb": "c.48G>A",
                "hgvs": "AKT1:NM_001014431:exon3:c.48G>A:p.Glu17Lys",
                "intervarAutomated": "Pathogenic",
                "level": "3（临床意义未明）",
                "posEnd": "105246551",
                "posStart": "105246551",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:300,70:0.209:153,38:147,32:29:150,163:60:22:0.183,0.168,0.189:0.006,0.014,0.981",
                "wxz": "exon3",
                "zlb": "NM_001014431"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "RAD51D",
                "NM_ID": "NM_002878",
                "ajsGb": "p.Arg24Ser",
                "alt": "G",
                "alteration": "R24S",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr17",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.075",
                "funcRefgene": "exonic",
                "geneInfo": "RAD51D（也称为RAD51L3）是RAD51重组酶家族的成员，其功能在于同源重组（HR）介导的双链DNA断裂修复（DSB）。与RAD51复合的RAD51D作用于DSB途径的早期步骤：切除位于DSB断裂位点侧翼的5'端DNA链，并通过RAD51涂覆单链突出端，形成核蛋白丝（PMID：25833843） ）。然后RAD51探测同源DNA并启动同源DNA之间的链侵入和交换过程（PMID：19122145,20930833）。生化研究表明RAD51D与另外三种RAD51旁系同源物形成复合物：XRCC2，RAD51B和RAD51C（称为BCDX2复合物）（PMID：10871607,11751635,16236763）。在将RAD51募集到受损的DNA病灶之前，该复合物在HR的早期阶段起作用（PMID：11751635,21821141）。 RAD51D还与DNA结合和复制蛋白相互作用，包括SFPQ，NONO，MCM2和MSH2（PMID：19658102），并在端粒维持中起作用（PMID：15109494）。 RAD51D缺陷细胞产生自发的染色体畸变并表现出G2停滞（PMID：11283264,21205838,15781618）。 RAD51D中的种系突变赋予卵巢癌和乳腺癌的风险增加（PMID：21822267,23372765,1903388,15170666）。 RAD51D体细胞突变在人类癌症中很少见，但RAD51D变异与化疗耐药性增加有关（PMID：1903388）。",
                "geneName": "RAD51D",
                "geneType": "geneYc,geneMy,geneHRD",
                "geneVar": "RAD51D基因exon1第72位碱基G置换为C使得第24位氨基酸由精氨酸转变成了丝氨酸",
                "hgsGb": "c.72G>C",
                "hgvs": "RAD51D:NM_002878:exon1:c.72G>C:p.Arg24Ser",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "33446561",
                "posStart": "33446561",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:372,30:0.100:171,19:201,11:30:154,160:60:30:0.062,0.070,0.075:0.011,0.003,0.986",
                "wxz": "exon1",
                "zlb": "NM_002878"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "RAD51D",
                "NM_ID": "NM_002878",
                "ajsGb": "p.Arg24Ser",
                "alt": "G",
                "alteration": "R24S",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr17",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.075",
                "funcRefgene": "exonic",
                "geneInfo": "RAD51D（也称为RAD51L3）是RAD51重组酶家族的成员，其功能在于同源重组（HR）介导的双链DNA断裂修复（DSB）。与RAD51复合的RAD51D作用于DSB途径的早期步骤：切除位于DSB断裂位点侧翼的5'端DNA链，并通过RAD51涂覆单链突出端，形成核蛋白丝（PMID：25833843） ）。然后RAD51探测同源DNA并启动同源DNA之间的链侵入和交换过程（PMID：19122145,20930833）。生化研究表明RAD51D与另外三种RAD51旁系同源物形成复合物：XRCC2，RAD51B和RAD51C（称为BCDX2复合物）（PMID：10871607,11751635,16236763）。在将RAD51募集到受损的DNA病灶之前，该复合物在HR的早期阶段起作用（PMID：11751635,21821141）。 RAD51D还与DNA结合和复制蛋白相互作用，包括SFPQ，NONO，MCM2和MSH2（PMID：19658102），并在端粒维持中起作用（PMID：15109494）。 RAD51D缺陷细胞产生自发的染色体畸变并表现出G2停滞（PMID：11283264,21205838,15781618）。 RAD51D中的种系突变赋予卵巢癌和乳腺癌的风险增加（PMID：21822267,23372765,1903388,15170666）。 RAD51D体细胞突变在人类癌症中很少见，但RAD51D变异与化疗耐药性增加有关（PMID：1903388）。",
                "geneName": "RAD51D",
                "geneType": "geneYc,geneMy,geneHRD",
                "geneVar": "RAD51D基因exon1第72位碱基G置换为C使得第24位氨基酸由精氨酸转变成了丝氨酸",
                "hgsGb": "c.72G>C",
                "hgvs": "RAD51D:NM_002878:exon1:c.72G>C:p.Arg24Ser",
                "intervarAutomated": "Likely_benign",
                "level": "3（临床意义未明）",
                "posEnd": "33446561",
                "posStart": "33446561",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:372,30:0.100:171,19:201,11:30:154,160:60:30:0.062,0.070,0.075:0.011,0.003,0.986",
                "wxz": "exon1",
                "zlb": "NM_002878"
            },
            {
                "1000g2015aug_all": "0.001597439986653626",
                "AA_change": "R143Q",
                "DNA_change": "R143Q",
                "ExAC_nonpsych_ALL": "0.0006",
                "GeneName": "ERBB2",
                "NM_ID": "NM_004448",
                "ajsGb": "p.Arg143Gln",
                "alt": "A",
                "alteration": "R143Q",
                "avsnp150": "rs185670819",
                "cancerType": ".",
                "chr": "chr17",
                "clinsig": "not_provided",
                "cosmic70": "ID\\x3dCOSM1382867\\x3bOCCURENCE\\x3d1(large_intestine)",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.509",
                "funcRefgene": "exonic",
                "geneInfo": "ERBB2，是EGFR酪氨酸激酶家族的成员，在一些癌症中会发生异常扩增或者过表达，这些癌症包括乳腺癌，胃癌/食道癌或子宫内膜癌 (PMID:19536107) 。ERBB2/HER2很独特，它不直接结合自己的配体。相反，它强力活化其他配体结合到ErbB受体，如EGFR（ErbB1）或ErbB3（PMID：12620236）。事实上，ERBB2是所有ERBB受体同种型（PMID：10220407,9130710）的优选结合配偶体，ERBB2 / ERBB3复合物通过激活下游致癌PI3K途径（PMID：12853564）显示出高促有丝分裂活性。或者，ERBB2可同源二聚化并启动细胞内有丝分裂级联，包括RAS / MAPK，PI3K / AKT / mTOR，SRC和STAT信号传导途径（PMID：22785351）。大约17% to 30%的乳腺癌患者会发生ERBB2基因的扩增，这与预后不良和复发相关(PMID: 3798106, 23000897,9552035, 9469329)。扩增的ERBB2与ERBB3异源二聚化以激活PI3K / AKT / mTOR信号传导并驱动乳腺癌中的肿瘤发生（PMID：12853564,23204226,12124352,18632642）。ERBB2在约20％胃或胃食管癌（PMID：24943493,21468131）中也被扩增，并且其过度表达被多种可用药物（例如曲妥珠单抗，阿托珠单抗埃米替宁，拉帕替尼和培妥珠单抗）靶向（PMID：24799465） 。ERBB2扩增的发生率很低在非小细胞细胞肺癌，膀胱癌，宫颈癌，子宫内膜癌，结直肠癌，胰腺癌，涎腺导管癌，软组织癌和胆管癌中(reviewed in PMID: 24656976)。激活的ERBB2突变最近在许多肿瘤中被确定是低频率的，包括肺腺癌，小叶性乳腺癌，膀胱癌，胃癌和子宫内膜癌，其中热点变异主要发生在胞外区和激酶活性区(PMID: 23000897, 23220880, 22908275)。临床前研究表明具有这些突变的患者对FDA批准的用于ERBB2靶向治疗较为敏感。临床试验正在ERBB2突变队列中进行，有一些ERBB2靶向激酶抑制剂功效的阳性证据。结肠直肠癌ERBB2突变常与RAS突变共同发生。",
                "geneName": "ERBB2",
                "geneType": "geneBx",
                "geneVar": "ERBB2基因exon3第428位碱基G置换为A使得第143位氨基酸由精氨酸转变成了谷氨酰胺",
                "hgsGb": "c.428G>A",
                "hgvs": "ERBB2:NM_004448:exon3:c.428G>A:p.Arg143Gln",
                "intervarAutomated": "Benign",
                "level": "3（临床意义未明）",
                "posEnd": "37864776",
                "posStart": "37864776",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:138,143:0.509:67,68:71,75:27:165,150:60:26:0.499,0.488,0.509:0.013,0.017,0.969",
                "wxz": "exon3",
                "zlb": "NM_004448"
            },
            {
                "1000g2015aug_all": "0.001597439986653626",
                "AA_change": "R143Q",
                "DNA_change": "R143Q",
                "ExAC_nonpsych_ALL": "0.0006",
                "GeneName": "ERBB2",
                "NM_ID": "NM_004448",
                "ajsGb": "p.Arg143Gln",
                "alt": "A",
                "alteration": "R143Q",
                "avsnp150": "rs185670819",
                "cancerType": ".",
                "chr": "chr17",
                "clinsig": "not_provided",
                "cosmic70": "ID\\x3dCOSM1382867\\x3bOCCURENCE\\x3d1(large_intestine)",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.509",
                "funcRefgene": "exonic",
                "geneInfo": "ERBB2，是EGFR酪氨酸激酶家族的成员，在一些癌症中会发生异常扩增或者过表达，这些癌症包括乳腺癌，胃癌/食道癌或子宫内膜癌 (PMID:19536107) 。ERBB2/HER2很独特，它不直接结合自己的配体。相反，它强力活化其他配体结合到ErbB受体，如EGFR（ErbB1）或ErbB3（PMID：12620236）。事实上，ERBB2是所有ERBB受体同种型（PMID：10220407,9130710）的优选结合配偶体，ERBB2 / ERBB3复合物通过激活下游致癌PI3K途径（PMID：12853564）显示出高促有丝分裂活性。或者，ERBB2可同源二聚化并启动细胞内有丝分裂级联，包括RAS / MAPK，PI3K / AKT / mTOR，SRC和STAT信号传导途径（PMID：22785351）。大约17% to 30%的乳腺癌患者会发生ERBB2基因的扩增，这与预后不良和复发相关(PMID: 3798106, 23000897,9552035, 9469329)。扩增的ERBB2与ERBB3异源二聚化以激活PI3K / AKT / mTOR信号传导并驱动乳腺癌中的肿瘤发生（PMID：12853564,23204226,12124352,18632642）。ERBB2在约20％胃或胃食管癌（PMID：24943493,21468131）中也被扩增，并且其过度表达被多种可用药物（例如曲妥珠单抗，阿托珠单抗埃米替宁，拉帕替尼和培妥珠单抗）靶向（PMID：24799465） 。ERBB2扩增的发生率很低在非小细胞细胞肺癌，膀胱癌，宫颈癌，子宫内膜癌，结直肠癌，胰腺癌，涎腺导管癌，软组织癌和胆管癌中(reviewed in PMID: 24656976)。激活的ERBB2突变最近在许多肿瘤中被确定是低频率的，包括肺腺癌，小叶性乳腺癌，膀胱癌，胃癌和子宫内膜癌，其中热点变异主要发生在胞外区和激酶活性区(PMID: 23000897, 23220880, 22908275)。临床前研究表明具有这些突变的患者对FDA批准的用于ERBB2靶向治疗较为敏感。临床试验正在ERBB2突变队列中进行，有一些ERBB2靶向激酶抑制剂功效的阳性证据。结肠直肠癌ERBB2突变常与RAS突变共同发生。",
                "geneName": "ERBB2",
                "geneType": "geneBx",
                "geneVar": "ERBB2基因exon3第428位碱基G置换为A使得第143位氨基酸由精氨酸转变成了谷氨酰胺",
                "hgsGb": "c.428G>A",
                "hgvs": "ERBB2:NM_004448:exon3:c.428G>A:p.Arg143Gln",
                "intervarAutomated": "Benign",
                "level": "3（临床意义未明）",
                "posEnd": "37864776",
                "posStart": "37864776",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-18",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:138,143:0.509:67,68:71,75:27:165,150:60:26:0.499,0.488,0.509:0.013,0.017,0.969",
                "wxz": "exon3",
                "zlb": "NM_004448"
            }
        ],
        "tmb": [],
        "tnb": []
    },
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副中度",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "G/A",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，需较高剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较高，神经毒性综合征的严重程度可能降低",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "del/del",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "A/A",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/G",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "del/del",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/T",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "T/G",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "2R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "del/del",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "C/A",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "G/T",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "野生型",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "2R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/G",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副中度",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/7TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢降低",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "T/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "C/T",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/A",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "G/A",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/G",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副高，代谢降低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-33",
                "updateTime": "."
            }
        ],
        "clinical": [
            {
                "brief_summary": "  Objective:    -  To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil,     leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver     metastases, with the objective to downstage hepatic disease and enable complete     resection of residual disease.  Primary Objective:    -  To evaluate the resection rate in patients with initially unresectable hepatic     colorectal metastases downstaged with FOLFOX-B. Complete resection of all liver lesions     is the goal.  Secondary Objectives:    -  To evaluate the probability of complete response, partial response or stable disease.    -  To evaluate the proportion of patients who are resected, and the proportion of patients     achieving an R0 resection (among those receiving surgery).    -  To correlate survival with downstaging and resection based on metastatic colorectal     prognostic score.    -  To evaluate the disease-free survival and overall survival.    -  To evaluate the positron emission tomography response rate.    -  To explore correlations of clinical response with telomerase and hTERT expression.",
                "brief_title": "Folfox-B Study for Patients With Colorectal Liver Metastases",
                "condition": "Colorectal Liver Metastases",
                "country": "United States",
                "geneName": "TERT",
                "intervention_name": "5-Fluorouracil;Oxaliplatin;Bevacizumab;Leucovorin",
                "intervention_type": "Drug",
                "nct_num": "NCT00508872",
                "overall_status": "Terminated",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "July 30, 2007"
            },
            {
                "brief_summary": "  70% all cases of cervical cancer, 95% of anal cancers and about 70% of oropharyngeal cancers  are linked to Human Papillomavirus (HPV) infection. HPV oncogenic proteins are  trans-activators of telomerase. Indeed, E6 oncoprotein transactivates the human telomerase  (hTert). Our group has conducted a clinical trial (NCT02402842) in advanced squamous cell  anal cancer (SCCA) and investigators have shown a correlation between the presence of  anti-HPV immunity and anti-telomerase T helpher 1 (TH1) CD4 T cell responses, establishing  telomerase as an appropriate antigen in HPV-related cancers.  Tumor-reactive CD4+ T cells have been found to ensure efficient effector Cytotoxic T  Lymphocytes (CTL) recruitment at the tumor site. Promoting tumor specific TH1 CD4 activation  might be an attractive therapeutic option to enhance anti-PD-1/PD-L1 (Programmed cell  Death-1/Programmed cell Death-Ligand1) efficacy. However, no option is currently available to  expand tumor specific TH1 lymphocytes in most patients. Then, investigators have identified  four novel MHC (Major Histocompatibility Complex) class II-restricted peptides derived from  human telomerase reverse transcriptase (TERT) referred as &quot;Universal Cancer Peptides&quot; (UCP).  UCPVax is a therapeutic cancer vaccine developed by our team and composed of two separate  peptides called UCP2 and UCP4 derived from telomerase. This UCPVax vaccine is currently  evaluated in a multicenter phase I/II study in Non Small Lung Cancer (NSCLC) (NCT2818426) and  seems to show to be safe and immunogenic.  PD-1/PD-L1 immune checkpoint is a relevant candidate target for immunotherapy in HPV+  cancers, based on the prominent role of PD-1 and its ligand PD-L1 in HPV-driven  immune-evasion. There is a strong rational of using PD-1 therapy in HPV+ cancers, however  anti-PD-1/PD-L1 treatment induces a limited number of long term responses in HPV disease.  Combining anti-PD-1/PD-L1 therapy with an antitumor vaccine gains serious consideration in  HPV+ cancers. Indeed, anti-cancer vaccines can induce tumor-specific T cells expansion and  activation and therefore restore the cancer-immunity cycle in patients lacking pre-existing  anti-tumor responses.  So investigators propose to determine the clinical interest and immunological efficacy of a  treatment combining the CD4 helper T-inducer cancer vaccine (UCPVax) with atezolizumab in  patients with HPV+ cancers by evaluation of the objective response rate at 4 months according  to iRecist criteria.",
                "brief_title": "Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)",
                "condition": "Cervical Cancer;Anal Canal Cancer;Squamous Cell Carcinoma of the Head and Neck",
                "country": "France",
                "geneName": "TERT",
                "intervention_name": "Atezolizumab;Tumor biopsies;UCPVax;Blood sample collection;CT scan",
                "intervention_type": "Biological;Procedure;Drug;Other",
                "nct_num": "NCT03946358",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "May 10, 2019"
            },
            {
                "brief_summary": "  The mean survival time in the advanced tumor stage in the presence of distant metastases in  malignant melanoma was less than 9 months until a few years ago. Intensive research efforts  have led to the development of promising new therapeutic strategies and their clinical  application. These include on the one hand mutation-specific inhibitors of important for cell  division serine-threonine kinase BRAF such as vemurafenib, dabrafenib and encorafenib and  inhibitors of the downstream target protein, the mitogen-activated protein kinase kinase  (MEK), such as trametinib, binimetinib and cobimetinib.  The group of immunotherapeutics is a second new class of drugs, in which great hope for the  treatment of metastatic melanoma is placed. Antibody-mediated blockage of surface molecules  expressed on immune cells, referred to as immune checkpoints, results in activation of the  immune system. As a result, an anti-tumor immune response is triggered, which has led to  considerable therapeutic success in metastatic melanoma. To date, three checkpoint inhibitors  have been approved for the treatment of metastatic melanoma. Ipilimumab is an antibody that  binds cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4); Pembrolizumab and nivolumab cause  immune stimulation by binding the Programmed Death Receptor (PD1).  However, the impact of the therapy on the immune system as a whole is largely unknown. A  comprehensive understanding of these effects is crucial to be able to further develop the  therapy and to evaluate useful combination therapies with other immunomodulatory agents.  Within the framework of this project changes of the immune response under a systemic therapy  of the malignant melanoma are to be characterized. The material for the analysis comes from  blood samples collected during routine patient check-ups.  The aim of the analyzes is to precisely characterize the effects of the different  therapeutics on the function of the immune system. In particular, the study will investigate  whether certain therapeutic agents can weaken or activate the immune system and thus, in  addition to the direct effect on the tumor cells, mediate indirect therapeutic effects via  immune modulation. In the long term, the investigators want to use the knowledge gained to  further improve the already existing therapeutic strategies of malignant melanoma by  additional modulation of the immune system.",
                "brief_title": "Immune Monitoring in Metastatic Melanoma",
                "condition": "Metastatic Melanoma",
                "country": "Germany",
                "geneName": "BRAF",
                "intervention_name": ".",
                "intervention_type": ".",
                "nct_num": "NCT04158544",
                "overall_status": "Recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "November 8, 2019"
            },
            {
                "brief_summary": "  The mean survival time in the advanced tumor stage in the presence of distant metastases in  malignant melanoma was less than 9 months until a few years ago. Intensive research efforts  have led to the development of promising new therapeutic strategies and their clinical  application. These include on the one hand mutation-specific inhibitors of important for cell  division serine-threonine kinase BRAF such as vemurafenib, dabrafenib and encorafenib and  inhibitors of the downstream target protein, the mitogen-activated protein kinase kinase  (MEK), such as trametinib, binimetinib and cobimetinib.  The group of immunotherapeutics is a second new class of drugs, in which great hope for the  treatment of metastatic melanoma is placed. Antibody-mediated blockage of surface molecules  expressed on immune cells, referred to as immune checkpoints, results in activation of the  immune system. As a result, an anti-tumor immune response is triggered, which has led to  considerable therapeutic success in metastatic melanoma. To date, three checkpoint inhibitors  have been approved for the treatment of metastatic melanoma. Ipilimumab is an antibody that  binds cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4); Pembrolizumab and nivolumab cause  immune stimulation by binding the Programmed Death Receptor (PD1).  However, the impact of the therapy on the immune system as a whole is largely unknown. A  comprehensive understanding of these effects is crucial to be able to further develop the  therapy and to evaluate useful combination therapies with other immunomodulatory agents.  Within the framework of this project changes of the immune response under a systemic therapy  of the malignant melanoma are to be characterized. The material for the analysis comes from  blood samples collected during routine patient check-ups.  The aim of the analyzes is to precisely characterize the effects of the different  therapeutics on the function of the immune system. In particular, the study will investigate  whether certain therapeutic agents can weaken or activate the immune system and thus, in  addition to the direct effect on the tumor cells, mediate indirect therapeutic effects via  immune modulation. In the long term, the investigators want to use the knowledge gained to  further improve the already existing therapeutic strategies of malignant melanoma by  additional modulation of the immune system.",
                "brief_title": "Immune Monitoring in Metastatic Melanoma",
                "condition": "Metastatic Melanoma",
                "country": "Germany",
                "geneName": "BRAF",
                "intervention_name": ".",
                "intervention_type": ".",
                "nct_num": "NCT04158544",
                "overall_status": "Recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "November 8, 2019"
            },
            {
                "brief_summary": "  DONIMI is a phase 1b trial testing the combination of domatinostat + nivolumab or nivolumab  monotherapy in IFN-gamma signature high patients and of domatinostat + nivolumab or  domatinostat + nivolumab + ipilimumab in IFN-gamma signature low patients with de-novo or  recurrent macroscopic stage III cutaneous or unknown primary melanoma.  The trial will include 40 stage III cutaneous or unknown primary melanoma patients with  RECIST 1.1 measurable de-novo or recurrent disease (short axis lymph node metastasis ≥1.5cm).  IFN-gamma signature low patients will be randomized to be treated pre-surgically for 6 weeks  with domatinostat + nivolumab or domatinostat + nivolumab + ipilimumab (each 10 patients).  NanoString IFN-gamma signature high patients will be randomized to be treated pre-surgically  for 6 weeks with nivolumab or domatinostat + nivolumab (each 10 patients).  Post-surgery (starting at week 12), the patients will start with adjuvant nivolumab or  pembrolizumab for 52 weeks according to institute's standard. BRAF V600E/K mutation positive  patients with no pathologic response after neoadjuvant therapy may also receive adjuvant BRAF  + MEK inhibition if commercially available and according to the patient's and the treating  physician's decision.  Follow-up after the adjuvant therapy will be for 2 years, according to the institutes'  standard.  Toxicity and pathologic response rates will be descriptive. In case of 2/5 or 4/10 patients  not undergoing their lymph node dissection at week 6 +/- 1 week due to treatment related  toxicity, this arm will be declared unfeasible.",
                "brief_title": "Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma",
                "condition": "Malignant Melanoma Stage III",
                "country": "Netherlands",
                "geneName": "BRAF",
                "intervention_name": "Ipilimumab;Domatinostat;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT04133948",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "October 21, 2019"
            },
            {
                "brief_summary": "  DONIMI is a phase 1b trial testing the combination of domatinostat + nivolumab or nivolumab  monotherapy in IFN-gamma signature high patients and of domatinostat + nivolumab or  domatinostat + nivolumab + ipilimumab in IFN-gamma signature low patients with de-novo or  recurrent macroscopic stage III cutaneous or unknown primary melanoma.  The trial will include 40 stage III cutaneous or unknown primary melanoma patients with  RECIST 1.1 measurable de-novo or recurrent disease (short axis lymph node metastasis ≥1.5cm).  IFN-gamma signature low patients will be randomized to be treated pre-surgically for 6 weeks  with domatinostat + nivolumab or domatinostat + nivolumab + ipilimumab (each 10 patients).  NanoString IFN-gamma signature high patients will be randomized to be treated pre-surgically  for 6 weeks with nivolumab or domatinostat + nivolumab (each 10 patients).  Post-surgery (starting at week 12), the patients will start with adjuvant nivolumab or  pembrolizumab for 52 weeks according to institute's standard. BRAF V600E/K mutation positive  patients with no pathologic response after neoadjuvant therapy may also receive adjuvant BRAF  + MEK inhibition if commercially available and according to the patient's and the treating  physician's decision.  Follow-up after the adjuvant therapy will be for 2 years, according to the institutes'  standard.  Toxicity and pathologic response rates will be descriptive. In case of 2/5 or 4/10 patients  not undergoing their lymph node dissection at week 6 +/- 1 week due to treatment related  toxicity, this arm will be declared unfeasible.",
                "brief_title": "Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma",
                "condition": "Malignant Melanoma Stage III",
                "country": "Netherlands",
                "geneName": "BRAF",
                "intervention_name": "Ipilimumab;Domatinostat;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT04133948",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "October 21, 2019"
            },
            {
                "brief_summary": "  This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab)  works for the treatment of patients with colorectal cancer that cannot be removed by surgery  (unresectable), has spread to nearby tissue or lymph nodes (locally advanced), or has spread  to other places in the body (metastatic). Regorafenib may stop the growth of cancer cells by  blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab  or panitumumab, may interfere with the ability of cancer cells to grow and spread. Drugs used  in chemotherapy, such as irinotecan, work in different ways to stop the growth of cancer  cells, either by killing the cells, by stopping them from dividing, or by stopping them from  spreading. The purpose of this research study is to compare the effects, good and/or bad, of  taking regorafenib follow by cetuximab or panitumumab, to those that receive cetuximab or  panitumumab before regorafenib.",
                "brief_title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
                "condition": "KRAS Gene Mutation Negative;BRAF V600E Negative;Stage IIIA Colorectal Cancer AJCC v8;Stage IVA Colorectal Cancer AJCC v8;Locally Advanced Unresectable Colorectal Adenocarcinoma;Stage IV Colorectal Cancer AJCC v8;Stage IIIB Colorectal Cancer AJCC v8;Stage IVC Colorectal Cancer AJCC v8;Stage IVB Colorectal Cancer AJCC v8;NRAS Gene Mutation Negative;Stage III Colorectal Cancer AJCC v8;Metastatic Colorectal Adenocarcinoma;Stage IIIC Colorectal Cancer AJCC v8",
                "country": "United States",
                "geneName": "BRAF",
                "intervention_name": "Panitumumab;Cetuximab;Regorafenib;Irinotecan",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04117945",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "October 7, 2019"
            },
            {
                "brief_summary": "  This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab)  works for the treatment of patients with colorectal cancer that cannot be removed by surgery  (unresectable), has spread to nearby tissue or lymph nodes (locally advanced), or has spread  to other places in the body (metastatic). Regorafenib may stop the growth of cancer cells by  blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab  or panitumumab, may interfere with the ability of cancer cells to grow and spread. Drugs used  in chemotherapy, such as irinotecan, work in different ways to stop the growth of cancer  cells, either by killing the cells, by stopping them from dividing, or by stopping them from  spreading. The purpose of this research study is to compare the effects, good and/or bad, of  taking regorafenib follow by cetuximab or panitumumab, to those that receive cetuximab or  panitumumab before regorafenib.",
                "brief_title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
                "condition": "KRAS Gene Mutation Negative;BRAF V600E Negative;Stage IIIA Colorectal Cancer AJCC v8;Stage IVA Colorectal Cancer AJCC v8;Locally Advanced Unresectable Colorectal Adenocarcinoma;Stage IV Colorectal Cancer AJCC v8;Stage IIIB Colorectal Cancer AJCC v8;Stage IVC Colorectal Cancer AJCC v8;Stage IVB Colorectal Cancer AJCC v8;NRAS Gene Mutation Negative;Stage III Colorectal Cancer AJCC v8;Metastatic Colorectal Adenocarcinoma;Stage IIIC Colorectal Cancer AJCC v8",
                "country": "United States",
                "geneName": "BRAF",
                "intervention_name": "Panitumumab;Cetuximab;Regorafenib;Irinotecan",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04117945",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "October 7, 2019"
            },
            {
                "brief_summary": "  This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab)  works for the treatment of patients with colorectal cancer that cannot be removed by surgery  (unresectable), has spread to nearby tissue or lymph nodes (locally advanced), or has spread  to other places in the body (metastatic). Regorafenib may stop the growth of cancer cells by  blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab  or panitumumab, may interfere with the ability of cancer cells to grow and spread. Drugs used  in chemotherapy, such as irinotecan, work in different ways to stop the growth of cancer  cells, either by killing the cells, by stopping them from dividing, or by stopping them from  spreading. The purpose of this research study is to compare the effects, good and/or bad, of  taking regorafenib follow by cetuximab or panitumumab, to those that receive cetuximab or  panitumumab before regorafenib.",
                "brief_title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
                "condition": "KRAS Gene Mutation Negative;BRAF V600E Negative;Stage IIIA Colorectal Cancer AJCC v8;Stage IVA Colorectal Cancer AJCC v8;Locally Advanced Unresectable Colorectal Adenocarcinoma;Stage IV Colorectal Cancer AJCC v8;Stage IIIB Colorectal Cancer AJCC v8;Stage IVC Colorectal Cancer AJCC v8;Stage IVB Colorectal Cancer AJCC v8;NRAS Gene Mutation Negative;Stage III Colorectal Cancer AJCC v8;Metastatic Colorectal Adenocarcinoma;Stage IIIC Colorectal Cancer AJCC v8",
                "country": "United States",
                "geneName": "BRAF",
                "intervention_name": "Panitumumab;Cetuximab;Regorafenib;Irinotecan",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04117945",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "October 7, 2019"
            },
            {
                "brief_summary": "  This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib  Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF wild-type patients with  Metastatic Colorectal Carcinoma(CRC) as 1st Therapy. In order to observe and evaluate the  efficacy and safety of Anlotinib Hydrochloride Capsules combined with CAPEOX in treatment of  patients with mCRC. The patients who are pathologically confirmed as RAS and BRAF wild-type  mCRC will be enrolled.  Condition or disease Invention/treatment Phase Colorectal Cancer Drug: Anlotinib  Hydrochloride Drug: Capecitabine Drug: Oxaliplatin Phase 2",
                "brief_title": "Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients",
                "condition": "Digestive System Neoplasms;Neoplasms by Site;Digestive System Diseases;Rectal Diseases;Colonic Diseases;Intestinal Neoplasms;Gastrointestinal Neoplasms;Gastrointestinal Diseases;RAS and BRAF Wild-type;Colorectal Cancer;Neoplasms;Colorectal Neoplasms;Intestinal Diseases",
                "country": "China",
                "geneName": "BRAF",
                "intervention_name": "Oxaliplatin;Capecitabine;Anlotinib Hydrochloride",
                "intervention_type": "Drug",
                "nct_num": "NCT04080843",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "September 6, 2019"
            },
            {
                "brief_summary": "  This study evaluates the addition of stereotactic radiosurgery (SRS) to the combination of  binimetinib plus encorafenib in the treatment of BRAFV600 mutation-positive Melanoma with  brain metastases (MBM).",
                "brief_title": "Stereotactic Radiosurgery Added to Binimetinib and Encorafenib in Patients With BRAFV600 Melanoma With Brain Metastasis",
                "condition": "Brain-only Metastased BRAFV600 Melanoma",
                "country": ".",
                "geneName": "BRAF",
                "intervention_name": "Stereotaxic radiosurgery (SRS);Encorafenib Oral Capsule;Binimetinib Oral Tablet",
                "intervention_type": "Drug;Radiation",
                "nct_num": "NCT04074096",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "August 29, 2019"
            },
            {
                "brief_summary": "  This study evaluates the addition of stereotactic radiosurgery (SRS) to the combination of  binimetinib plus encorafenib in the treatment of BRAFV600 mutation-positive Melanoma with  brain metastases (MBM).",
                "brief_title": "Stereotactic Radiosurgery Added to Binimetinib and Encorafenib in Patients With BRAFV600 Melanoma With Brain Metastasis",
                "condition": "Brain-only Metastased BRAFV600 Melanoma",
                "country": ".",
                "geneName": "BRAF",
                "intervention_name": "Stereotaxic radiosurgery (SRS);Encorafenib Oral Capsule;Binimetinib Oral Tablet",
                "intervention_type": "Drug;Radiation",
                "nct_num": "NCT04074096",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "August 29, 2019"
            },
            {
                "brief_summary": "  This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has  spread to other parts of the body) non-small cell lung cancer with a mutation (change) in  genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is  at treating ROS1 or MET mutated non-small cell lung cancer.  Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the  treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.",
                "brief_title": "Study of Crizotinib for ROS1 and MET Activated Lung Cancer",
                "condition": "MET Activating Mutation;ROS1 Gene Rearrangement;Stage IV Non-small Cell Lung Cancer;Non-squamous Non-small-cell Lung Cancer;MET Amplification",
                "country": "Canada",
                "geneName": "ROS1",
                "intervention_name": "Crizotinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04084717",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "September 10, 2019"
            },
            {
                "brief_summary": "  The objective of this study is to assess the efficacy of the combination of Platinum  (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage  IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations  following targeted therapies.",
                "brief_title": "A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies",
                "condition": "NSCLC Stage IV;NSCLC Stage IIIB;EGFR Gene Mutation;ROS1 Gene Mutation;ALK Gene Rearrangement Positive",
                "country": "France",
                "geneName": "ROS1",
                "intervention_name": "Carboplatin + Pemetrexed + Atezolizumab;Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab",
                "intervention_type": "Drug",
                "nct_num": "NCT04042558",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "August 2, 2019"
            },
            {
                "brief_summary": "  The objective of this study is to assess the efficacy of the combination of Platinum  (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage  IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations  following targeted therapies.",
                "brief_title": "A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies",
                "condition": "NSCLC Stage IV;NSCLC Stage IIIB;EGFR Gene Mutation;ROS1 Gene Mutation;ALK Gene Rearrangement Positive",
                "country": "France",
                "geneName": "ROS1",
                "intervention_name": "Carboplatin + Pemetrexed + Atezolizumab;Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab",
                "intervention_type": "Drug",
                "nct_num": "NCT04042558",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "August 2, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies the side effects and best dose of brigatinib and binimetinib in  treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation  called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the  growth of tumor cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer",
                "condition": "ROS1 Gene Rearrangement;Stage IVA Lung Cancer;Lung Non-Small Cell Carcinoma;Stage IVB Lung Cancer;Progressive Disease;ALK Gene Rearrangement;Stage IIIB Lung Cancer;Stage IIIC Lung Cancer;Stage IV Lung Cancer",
                "country": "United States",
                "geneName": "ROS1",
                "intervention_name": "Binimetinib;Brigatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04005144",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "July 2, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies the side effects and best dose of brigatinib and binimetinib in  treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation  called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the  growth of tumor cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer",
                "condition": "ROS1 Gene Rearrangement;Stage IVA Lung Cancer;Lung Non-Small Cell Carcinoma;Stage IVB Lung Cancer;Progressive Disease;ALK Gene Rearrangement;Stage IIIB Lung Cancer;Stage IIIC Lung Cancer;Stage IV Lung Cancer",
                "country": "United States",
                "geneName": "ROS1",
                "intervention_name": "Binimetinib;Brigatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04005144",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "July 2, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well genetic testing works in guiding treatment for patients  with solid tumors that have spread to the brain. Several genes have been found to be altered  or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these  genes such as abemaciclib, GDC-0084, and entrectinib may stop the growth of tumor cells by  blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor  treatment for each mutation.",
                "brief_title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases",
                "condition": "Metastatic Malignant Solid Neoplasm;PI3K Gene Mutation;ROS1 Gene Mutation;Metastatic Malignant Neoplasm in the Brain;NTRK Family Gene Mutation;CDK Gene Mutation",
                "country": "United States",
                "geneName": "ROS1",
                "intervention_name": "Entrectinib;PI3K Inhibitor GDC-0084;Abemaciclib",
                "intervention_type": "Drug",
                "nct_num": "NCT03994796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "June 21, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well genetic testing works in guiding treatment for patients  with solid tumors that have spread to the brain. Several genes have been found to be altered  or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these  genes such as abemaciclib, GDC-0084, and entrectinib may stop the growth of tumor cells by  blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor  treatment for each mutation.",
                "brief_title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases",
                "condition": "Metastatic Malignant Solid Neoplasm;PI3K Gene Mutation;ROS1 Gene Mutation;Metastatic Malignant Neoplasm in the Brain;NTRK Family Gene Mutation;CDK Gene Mutation",
                "country": "United States",
                "geneName": "ROS1",
                "intervention_name": "Entrectinib;PI3K Inhibitor GDC-0084;Abemaciclib",
                "intervention_type": "Drug",
                "nct_num": "NCT03994796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "June 21, 2019"
            },
            {
                "brief_summary": "  Targeted therapy based on target identification by genetic examinations is a promising  direction in the treatment of patients with a complicated course of inflammatory  myofibroblastic tumor. Recently, the main work covered in foreign publications, aimed at  finding additional methods of treatment, by identifying new targets for targeted therapy in  patients with unresectable IMT, but currently there is no standardized approach to the  treatment of IMT in children worldwide.  This study can show the benefits of the usage of crizotinib as targeted therapy in children  with ALK/ROS1 positive unresectable, progressive or reccurent inflammatory myofibroblastic  tumors. The main hypothesis is that crizotinib would increase an objective response rate in  this group of patients.",
                "brief_title": "Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors",
                "condition": "Inflammatory Myofibroblastic Tumor",
                "country": "Russian Federation",
                "geneName": "ROS1",
                "intervention_name": "Crizotinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03874273",
                "overall_status": "Recruiting",
                "phase": "Phase 2/Phase 3",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "March 14, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well brigatinib works in treating patients with ALK and ROS1  gene alterations and solid cancers that have spread to nearby tissue and lymph nodes or other  places in the body. Brigatinib may stop the growth of tumor cells by blocking some of the  enzymes needed for cell growth.",
                "brief_title": "Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers",
                "condition": "ALK Gene Amplification;Metastatic Malignant Solid Neoplasm;ROS1 Fusion Positive;Metastatic Malignant Neoplasm in the Central Nervous System;Locally Advanced Malignant Solid Neoplasm;ALK Gene Mutation;ROS1 Gene Mutation;ROS1 Gene Amplification;Metastatic Malignant Neoplasm in the Brain;ALK Fusion Protein Expression;Advanced Malignant Neoplasm",
                "country": "United States",
                "geneName": "ROS1",
                "intervention_name": "Questionnaire Administration;Brigatinib;Quality-of-Life Assessment;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03868423",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "March 11, 2019"
            },
            {
                "brief_summary": "  The study aim to Evaluate the combination of ididilimumab and docetaxel alone in the  treatment of previous platinum-containing double-drug chemotherapy according to RECIST  1.1Objective remission rate of advanced or metastatic non-small cell lung cancer with  negative, driving gene negative (EGFR, ALK, ROS1); (ORR).",
                "brief_title": "Phase II Study on Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer",
                "condition": "Non-small Cell Lung Cancer",
                "country": "China",
                "geneName": "ROS1",
                "intervention_name": "Sintilimab Combined With Docetaxel",
                "intervention_type": "Drug",
                "nct_num": "NCT03798743",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "January 10, 2019"
            },
            {
                "brief_summary": "  The treatment of advanced GIST patients is based on imatinib followed with sunitinib in case  of resistance/intolerance. However, the median progression-free survival (PFS) on sunitinib  is frequently short, and after failure with both imatinib and sunitinib, treatment remains  controversial.  Previous studies on GISTs have linked 9p21 alterations to tumor progression (El-Rifai et al.  2000; Kim et al., 2000; Schneider-Stock et al., 2003; Schneider-Stock et al., 2005; Romeo et  al. 2009; Haller et al., 2008) but the driver gene was not positively identified (CDKN2A,  CDKN2B, or MTAP) (Astolfi et al., 2010; Belinsky et al., 2009; Perrone et al., 2005; Assamaki  et al. 2007; Huang et al., 2009). A recent study has shown that homozygous 9p21 deletions  target CDKN2A and more specifically p16INK4a 4. Most of the CINSARC genes are known to be  under the transcriptional control of E2F. RB1 sequesters E2F, which is released from the  complex upon RB1 phosphorylation by CDK4. CDK4 is, in turn, inhibited by p16INK4a. Hence, we  hypothesize that alteration of the restriction point via deletion of p16INK4a (and more  rarely of RB1: 20% of cases) gene in GISTs is likely to be a causative event that leads to  the overexpression of CINSARC genes, which in turn induce chromosome instability and  ultimately metastasis. Low p16INK4a expression was associated with response to PD-0332991 in  several in vitro tumor model(Konecny et al. 2011; Katsumi et al. 2011; Finn et al. 2009).  Considering our molecular data, we believed that PD-0332991 warrants clinical investigation  in advanced gastrointestinal stromal tumors with alteration of p16INK4a. This alteration is  detectable by comparative genomic hybridization which is a technique highly manageable in the  context of routine clinical care and clinical trial.  Exploratory, one-arm, multicenter, phase II clinical trial based on twostage Simon's design  To assess the antitumor activity of PD-0332991 in terms of non-progression at 16 weeks (after  centralized review) in patients with documented disease progression while on therapy with  imatinib and sunitinib for unresectable and/or metastatic GIST.  This is a multicentre single-arm Phase II study evaluating the efficacy and safety of orally  PD-0332991, 125 mg/day, 21 days on/7 days off, in patients with documented disease  progression while on therapy with 2nd line sunitinib for unresectable and/or metastatic GIST.  Indeed, the usual treatment for advanced Gastrointestinal Stromal Tumors Refractory to  Imatinib and Sunitinib is best supportive care for which outcome data are already available  (Demetri et al., 2012; Italiano et al., 2012). Sixty three patients will be included in 10  centres of the French Sarcoma Group over a period of 18 months of enrolment.  Patients will be evaluated at scheduled visits in up to three study periods:    -  Pre-treatment (PRE TT): from signature of informed consent to the first treatment by     PD-0332991.    -  Treatment (TT): from the first treatment by PD-0332991 to the first 28 days following     the last PD-0332991 administration.    -  Follow-up (FUP): after treatment discontinuation, all patients must be followed up for     28 days after the last dose of the study drug for safety assessment (AEs and/or SAEs).",
                "brief_title": "Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib",
                "condition": "Advanced Gastrointestinal Stromal Tumors",
                "country": "France",
                "geneName": "RB1",
                "intervention_name": "PD-0332991 will be administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.",
                "intervention_type": "Drug",
                "nct_num": "NCT01907607",
                "overall_status": "Unknown status",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "July 25, 2013"
            },
            {
                "brief_summary": "  The treatment of advanced GIST patients is based on imatinib followed with sunitinib in case  of resistance/intolerance. However, the median progression-free survival (PFS) on sunitinib  is frequently short, and after failure with both imatinib and sunitinib, treatment remains  controversial.  Previous studies on GISTs have linked 9p21 alterations to tumor progression (El-Rifai et al.  2000; Kim et al., 2000; Schneider-Stock et al., 2003; Schneider-Stock et al., 2005; Romeo et  al. 2009; Haller et al., 2008) but the driver gene was not positively identified (CDKN2A,  CDKN2B, or MTAP) (Astolfi et al., 2010; Belinsky et al., 2009; Perrone et al., 2005; Assamaki  et al. 2007; Huang et al., 2009). A recent study has shown that homozygous 9p21 deletions  target CDKN2A and more specifically p16INK4a 4. Most of the CINSARC genes are known to be  under the transcriptional control of E2F. RB1 sequesters E2F, which is released from the  complex upon RB1 phosphorylation by CDK4. CDK4 is, in turn, inhibited by p16INK4a. Hence, we  hypothesize that alteration of the restriction point via deletion of p16INK4a (and more  rarely of RB1: 20% of cases) gene in GISTs is likely to be a causative event that leads to  the overexpression of CINSARC genes, which in turn induce chromosome instability and  ultimately metastasis. Low p16INK4a expression was associated with response to PD-0332991 in  several in vitro tumor model(Konecny et al. 2011; Katsumi et al. 2011; Finn et al. 2009).  Considering our molecular data, we believed that PD-0332991 warrants clinical investigation  in advanced gastrointestinal stromal tumors with alteration of p16INK4a. This alteration is  detectable by comparative genomic hybridization which is a technique highly manageable in the  context of routine clinical care and clinical trial.  Exploratory, one-arm, multicenter, phase II clinical trial based on twostage Simon's design  To assess the antitumor activity of PD-0332991 in terms of non-progression at 16 weeks (after  centralized review) in patients with documented disease progression while on therapy with  imatinib and sunitinib for unresectable and/or metastatic GIST.  This is a multicentre single-arm Phase II study evaluating the efficacy and safety of orally  PD-0332991, 125 mg/day, 21 days on/7 days off, in patients with documented disease  progression while on therapy with 2nd line sunitinib for unresectable and/or metastatic GIST.  Indeed, the usual treatment for advanced Gastrointestinal Stromal Tumors Refractory to  Imatinib and Sunitinib is best supportive care for which outcome data are already available  (Demetri et al., 2012; Italiano et al., 2012). Sixty three patients will be included in 10  centres of the French Sarcoma Group over a period of 18 months of enrolment.  Patients will be evaluated at scheduled visits in up to three study periods:    -  Pre-treatment (PRE TT): from signature of informed consent to the first treatment by     PD-0332991.    -  Treatment (TT): from the first treatment by PD-0332991 to the first 28 days following     the last PD-0332991 administration.    -  Follow-up (FUP): after treatment discontinuation, all patients must be followed up for     28 days after the last dose of the study drug for safety assessment (AEs and/or SAEs).",
                "brief_title": "Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib",
                "condition": "Advanced Gastrointestinal Stromal Tumors",
                "country": "France",
                "geneName": "RB1",
                "intervention_name": "PD-0332991 will be administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.",
                "intervention_type": "Drug",
                "nct_num": "NCT01907607",
                "overall_status": "Unknown status",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "July 25, 2013"
            },
            {
                "brief_summary": "  A window of opportunity study which would allow brief treatment of HPV negative SCCHN with a  CDK4/6 inhibitor, in the pre-operative setting, with biomarker analyses of pre and post  treatment tissue. Given that the standard treatment for this population is surgical  resection, this would not impact or alter standard therapy for this population. The goal will  be to learn more about the alterations in pRB1 levels, as well as other signaling markers, in  order to be able to eventually plan a biomarker driven treatment study.",
                "brief_title": "Impact of Ribociclib on Head and Neck Squamous Cell Cancer",
                "condition": "Squamous Cell Carcinoma of the Head and Neck",
                "country": "United States",
                "geneName": "RB1",
                "intervention_name": "Ribociclib",
                "intervention_type": "Drug",
                "nct_num": "NCT03179956",
                "overall_status": "Terminated",
                "phase": "Early Phase 1",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "June 7, 2017"
            },
            {
                "brief_summary": "  Trial Design    -  Patients with stage IV non-small cell lung cancer are randomized to nivolumab/ipilimumab     plus either sequential or concurrent stereotactic body radiotherapy (SBRT).    -  The primary endpoint is the phase I safety endpoint of SBRT dose for each body site.    -  The same starting SBRT dose levels are used in each arm. If two or more patients     experience a dose-limiting toxicity (DLT) at the starting dose level, then the reduced     dose level will be used (Section 7.1—Page 72).    -  DLT is defined as any grade ≥3 toxicity possibly, likely, or definitely related to SBRT     plus nivolumab/ipilimumab (the combination and not the individual components).    -  Irradiated metastases will be grouped into one of five locations, which have different     SBRT doses, and the DLTs will be attributed to the relevant organ system.    -  The starting and decreased SBRT dose levels are found in Table 2 (Page 20).    -  SBRT will be delivered in 3-5 fractions over the course of 1-1.5 weeks.    -  Patients in the sequential arm will begin immunotherapy between 1-7 days after     completion of SBRT    -  Given the accrual data for IRB15-1130, the investigators anticipate that approximately     1/3 of patients will contribute metastasis to 2 locations. Since there are 2 arms, and 5     metastasis locations with 6 patients per location for the starting dose level, this     translates to 40 patients for the starting dose level, and another 40 patients should     each of the 5 locations require de-escalation to the lower dose level.    -  Secondary endpoints include comparisons of efficacy and toxicity between the arms, as     well as interrogation of changes in the immune microenvironment induced by the two     approaches.",
                "brief_title": "Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer",
                "condition": "Stage IV Small Cell Lung Cancer",
                "country": "United States",
                "geneName": "RB1",
                "intervention_name": "Ipilimumab;Nivolumab;Stereotactic body radiation therapy",
                "intervention_type": "Drug;Radiation",
                "nct_num": "NCT03223155",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "July 21, 2017"
            },
            {
                "brief_summary": "  Trial Design    -  Patients with stage IV non-small cell lung cancer are randomized to nivolumab/ipilimumab     plus either sequential or concurrent stereotactic body radiotherapy (SBRT).    -  The primary endpoint is the phase I safety endpoint of SBRT dose for each body site.    -  The same starting SBRT dose levels are used in each arm. If two or more patients     experience a dose-limiting toxicity (DLT) at the starting dose level, then the reduced     dose level will be used (Section 7.1—Page 72).    -  DLT is defined as any grade ≥3 toxicity possibly, likely, or definitely related to SBRT     plus nivolumab/ipilimumab (the combination and not the individual components).    -  Irradiated metastases will be grouped into one of five locations, which have different     SBRT doses, and the DLTs will be attributed to the relevant organ system.    -  The starting and decreased SBRT dose levels are found in Table 2 (Page 20).    -  SBRT will be delivered in 3-5 fractions over the course of 1-1.5 weeks.    -  Patients in the sequential arm will begin immunotherapy between 1-7 days after     completion of SBRT    -  Given the accrual data for IRB15-1130, the investigators anticipate that approximately     1/3 of patients will contribute metastasis to 2 locations. Since there are 2 arms, and 5     metastasis locations with 6 patients per location for the starting dose level, this     translates to 40 patients for the starting dose level, and another 40 patients should     each of the 5 locations require de-escalation to the lower dose level.    -  Secondary endpoints include comparisons of efficacy and toxicity between the arms, as     well as interrogation of changes in the immune microenvironment induced by the two     approaches.",
                "brief_title": "Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer",
                "condition": "Stage IV Small Cell Lung Cancer",
                "country": "United States",
                "geneName": "RB1",
                "intervention_name": "Ipilimumab;Nivolumab;Stereotactic body radiation therapy",
                "intervention_type": "Drug;Radiation",
                "nct_num": "NCT03223155",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "July 21, 2017"
            },
            {
                "brief_summary": "  -  Gefitinib is an orally active epidermal growth factor receptor-tyrosine kinase inhibitor     (EGFR-TKI). However, 20-30% of patients with EGFR-activating mutations show intrinsic     resistance to EGFR-TKI.    -  EGFR-mutant non-small cell lung cancer (NSCLC) cells with BIM (BCL2L11) deletion     polymorphism show the impaired generation of BIM with the proapoptotic BH3 domain, as     well as resistance to EGFR-TKI-induced apoptosis.    -  Both BIM polymorphism (12.9%) and EGFR mutations (50% in lung adenocarcinoma) are more     prevalent in the East Asian than in Caucasian populations. BIM is a BH3-only     proapoptotic member of the Bcl-2 protein family. BIM upregulation is required for     apoptosis induction by EGFR-TKI in EGFR-mutant NSCLC.    -  Vorinostat (suberoylanilide hydroxamic acid [SAHA]) is a small-molecule inhibitor of     histone deacetylase (HDAC) and induces cell differentiation, cell cycle arrest, and     apoptosis in several tumor cells. HDAC inhibition can epigenetically restore BIM     function and death sensitivity of EGFR-TKI in patients with EGFR-mutant NSCLC in whom     resistance to EGFR-TKI is associated with a common BIM polymorphism. EGFR-TKI resistance     due to the BIM polymorphism may be able to be circumvented in combination with HDAC     inhibition of vorinostat with gefitinib in NSCLC.",
                "brief_title": "Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer",
                "condition": "Non-Small-Cell Lung Carcinoma",
                "country": "Japan",
                "geneName": "BCL2L11",
                "intervention_name": "Vorinostat, gefitinib",
                "intervention_type": "Drug",
                "nct_num": "NCT02151721",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-33",
                "study_first_posted": "May 30, 2014"
            }
        ],
        "cms": [
            {
                "age": "28",
                "agentName": "魏尔啸-杭州",
                "areaAgentName": "潘缪春",
                "backStatus": "1",
                "backStatusShow": "未返款",
                "barcode": "2007140918283",
                "bedNumber": ".",
                "bingli": ".",
                "birthday": ".",
                "checkTime": ".",
                "contact": ".",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": ".",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-22 12:02:00",
                "expressName": "顺丰",
                "expressNum": "SF1192359182323",
                "fenziBingli": ".",
                "financeId": "232720",
                "gender": "女",
                "historyNum": "0",
                "hospitalName": ".",
                "idCard": ".",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-14 09:19:17",
                "invoiceApplyMoney": "0.00",
                "invoiceName": ".",
                "invoiceReceivePhone": ".",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "0",
                "invoiceTypeShow": ".",
                "itemName": "0201028.OncoDrug-Seq全实体瘤110基因（组织/细胞学样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-14 09:18:30",
                "medicalRecord": ".",
                "name": "陈子欣",
                "nickName": "杭州魏尔啸",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "2",
                "paymentTypeShow": "月结",
                "receiveStatus": "1",
                "receiveStatusShow": "未收款",
                "receiveTime": "2020-07-15 12:02:27",
                "remark": ".",
                "reportAddress": ".",
                "reportAddressName": ".",
                "reportCheckTime": ".",
                "reportEmail": ".",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": ".",
                "reportStyle": "电子",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "234242",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200715-33",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": ".",
                "sickAge": ".",
                "sickFamilyHistory": ".",
                "source": "石蜡组织卷 石蜡组织切片",
                "sourceFrom": ".",
                "testDoctor": ".",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "甲状腺癌",
                "treatHistory": ".",
                "treatID": "TS09",
                "treatResult": "甲状腺癌",
                "treatmentNo": ".",
                "unitAgentName": "杭州魏尔啸",
                "url": "[]",
                "userId": "1447",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [
            {
                "AA_change": "缺失",
                "NM_ID": "NM_138621",
                "VCF_Line": ".",
                "alteration": "缺失",
                "cancerType": ".",
                "chr": "chr2",
                "cnaRatio": "0.5",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "缺失",
                "geneInfo": "BCL2L11编码BIM，BCL是BCL2蛋白家族中的促凋亡肿瘤抑制因子，其抑制BCL2抗细胞凋亡活性（PMID：9731710,9430630）。细胞中BIM和BCL2的相对水平调节下游凋亡途径，因此参与细胞存活，组织稳态和癌症进展（PMID：9430630,10576740,25176652）。 BIM表达在慢性粒细胞白血病和急性淋巴细胞白血病中表观遗传（PMID：19403302,20647567）。此外，BIM表达已被证明是各种肿瘤类型中酪氨酸激酶抑制剂（TKIs）反应的预测因子（PMID：22145099），因此Bcl-2同源3（BH3）模拟物可能对TKI耐药的癌症有效。通过BIM依赖机制（PMID：18949058）。",
                "geneName": "BCL2L11",
                "geneVar": "BCL2L11基因缺失",
                "immune": ".",
                "oncoTreeCode": ".",
                "posEnd": "Exon4",
                "posStart": "Exon1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33"
            }
        ],
        "fusion": [],
        "heredity": [],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:4.92%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "4.92%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 3,
                "percent": 4.92,
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-33",
                "totalSites": 61
            }
        ],
        "qc": [
            {
                "cleanBases": 1760296719,
                "cleanReads": 13191970,
                "coverage>0.2x": 98.7,
                "coverage>0.5x": 88.25,
                "effectCoverage500": 94.51,
                "effectDepth": 1259,
                "insert": 165.9,
                "mapping": 99.87,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 2023351500,
                "rawDuplication": 21.04,
                "rawReads": 13489010,
                "readPercent": 97.8,
                "samplePurity": "20.9",
                "sampleSn": "NGS200715-33",
                "sampleType": "FFPE",
                "targetMapping": 65.71,
                "trimDuplication": 25.14,
                "tumorCoverage": 99.82,
                "tumorDepth": 1767,
                "tumorQ30": 91.33
            }
        ],
        "target": [
            {
                "1000g2015aug_all": "0.000199681002413854",
                "AA_change": ".",
                "DNA_change": ".",
                "ExAC_nonpsych_ALL": "1.104e-05",
                "GeneName": ".",
                "NM_ID": ".",
                "ajsGb": "p.Arg650Lys",
                "alt": "T",
                "alteration": "R650K",
                "avsnp150": "rs190125817",
                "cancerType": ".",
                "chr": "chr5",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.464",
                "funcRefgene": "exonic",
                "geneInfo": "TERT基因编码端粒酶的催化亚基，端粒酶是维持端粒长度和基因组完整性的酶。体细胞中TERT表达低或不存在;然而，端粒酶活性在绝大多数肿瘤中上调，并可能导致癌细胞永生（PMID：24657534,9282118）。 TERT启动子的测序鉴定了许多癌症类型中的活化突变，包括黑素瘤，肝细胞癌，尿路上皮癌，成神经管细胞瘤和神经胶质瘤（PMID：23348506,23530248）。具有高度复发性TERT启动子突变的肿瘤倾向于源自具有较低自我更新率的组织（PMID：23530248）。 TERT启动子突变，C228T和C250T，占大多数体细胞TERT启动子改变，并分别在TERT的ATG起始密码子上游发生124和146个碱基对。两种启动子突变均产生针对成红细胞转化特异性（ETS）/ T细胞因子（TCF）转录因子的结合基序并增强端粒酶活性（PMID：23348503,23348506,26194807）。除了启动子突变，位于染色体5p上的TERT在许多癌症类型中被扩增（PMID：20164920）。",
                "geneName": "TERT",
                "geneType": "geneQt",
                "geneVar": "TERT基因exon4第1949位碱基G置换为A使得第650位氨基酸由精氨酸转变成了赖氨酸",
                "hgsGb": "c.1949G>A",
                "hgvs": "TERT:NM_198253:exon4:c.1949G>A:p.Arg650Lys",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "1280274",
                "posStart": "1280274",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-33",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:860,744:0.465:509,449:351,295:29:184,183:60:21:0.449,0.460,0.464:0.013,0.006,0.981",
                "wxz": "exon4",
                "zlb": "NM_198253"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": ".",
                "DNA_change": ".",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": ".",
                "NM_ID": ".",
                "ajsGb": "p.Gln1173Pro",
                "alt": "G",
                "alteration": "Q1173P",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr6",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.469",
                "funcRefgene": "exonic",
                "geneInfo": "ROS1基因编码具有细胞内酪氨酸激酶活性的跨膜蛋白（PMID：18778756）。 ROS1是酪氨酸激酶胰岛素受体基因的七个亚家族的成员之一（PMID：27256160）。这种蛋白质在人类中的正常生理作用及其配体目前是未知的（PMID：23814043）。ROS1中激酶结构域被保留的重排（PMID：22327623）出现在人的上皮癌症中，包括胆管癌（PMID：21253578），卵巢癌（PMID：22163003），胃癌（PMID：23400546），血管肉瘤（PMID： 23637631），最常见于非小细胞肺癌（PMID：22215748）。虽然ROS1重排在人脑胶质瘤细胞系（PMID：2827175）首先发现，然而人脑胶质瘤（PMID：24999209）ROS1重排罕见。 ROS1重排导致激酶活性失调的机制尚不清楚，因为其配体尚未被确认;然而，理论上认为其因结构型改变导致激酶活化（PMID：18083107）。",
                "geneName": "ROS1",
                "geneType": "geneBx",
                "geneVar": "ROS1基因exon23第3518位碱基A置换为C使得第1173位氨基酸由谷氨酰胺转变成了脯氨酸",
                "hgsGb": "c.3518A>C",
                "hgvs": "ROS1:NM_002944:exon23:c.3518A>C:p.Gln1173Pro",
                "intervarAutomated": "Likely_pathogenic",
                "level": "3（临床意义未明）",
                "posEnd": "117681102",
                "posStart": "117681102",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-33",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:336,297:0.471:177,179:159,118:31:166,175:60:32:0.460,0.454,0.469:0.007,0.019,0.974",
                "wxz": "exon23",
                "zlb": "NM_002944"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "V600E",
                "DNA_change": "V600E",
                "ExAC_nonpsych_ALL": "2.208e-05",
                "GeneName": "BRAF",
                "NM_ID": "NM_004333",
                "ajsGb": "p.Val600Glu",
                "alt": "T",
                "alteration": "V600E",
                "avsnp150": "rs113488022",
                "cancerType": "结直肠癌",
                "chr": "chr7",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM476\\x3bOCCURENCE\\x3d3(adrenal_gland)",
                "drugLevel": "R1",
                "drugs": "Panitumumab[帕尼单抗]，西妥昔单抗",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.057",
                "funcRefgene": "exonic",
                "geneInfo": "BRAF蛋白是在丝裂原活化蛋白激酶（MAPK）级联（PMID：15520807）的调节中起关键作用的丝氨酸/苏氨酸激酶，其在生理条件下调节涉及细胞功能的基因的表达，包括细胞增殖 （PMID：24202393）。 BRAF的基因改变首先见于黑色素瘤和甲状腺癌以及一小部分肺癌和结肠直肠癌。最常见的BRAF点突变是V600E，它可以调节蛋白激酶活性，从而导致组成型BRAF激活，因为BRAF V600E可以独立于RAS或上游激活发出单体信号（PMID：20179705）。 已发现其他BRAF突变影响蛋白质的二聚化倾向（PMID：16858395,26343582,12068308）。 这些改变的产物是BRAF激酶，其可以以不受调节的方式激活MAPK信号传导，并且在某些情况下直接导致癌症生长（PMID：15520807）。",
                "geneName": "BRAF",
                "geneType": "geneBx",
                "geneVar": "BRAF基因exon15第1799位碱基T置换为A使得第600位氨基酸由缬氨酸转变成了谷氨酸",
                "hgsGb": "c.1799T>A",
                "hgvs": "BRAF:NM_004333:exon15:c.1799T>A:p.Val600Glu",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "140453136",
                "posStart": "140453136",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-33",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:630,38:0.073:348,17:282,21:30:162,168:60:31:0.048,0.054,0.057:0.005,0.002,0.992",
                "wxz": "exon15",
                "zlb": "NM_004333"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "V600E",
                "DNA_change": "V600E",
                "ExAC_nonpsych_ALL": "2.208e-05",
                "GeneName": "BRAF",
                "NM_ID": "NM_004333",
                "ajsGb": "p.Val600Glu",
                "alt": "T",
                "alteration": "V600E",
                "avsnp150": "rs113488022",
                "cancerType": "非小细胞肺癌",
                "chr": "chr7",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM476\\x3bOCCURENCE\\x3d3(adrenal_gland)",
                "drugLevel": "1",
                "drugs": "达拉非尼+曲美替尼",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.057",
                "funcRefgene": "exonic",
                "geneInfo": "BRAF蛋白是在丝裂原活化蛋白激酶（MAPK）级联（PMID：15520807）的调节中起关键作用的丝氨酸/苏氨酸激酶，其在生理条件下调节涉及细胞功能的基因的表达，包括细胞增殖 （PMID：24202393）。 BRAF的基因改变首先见于黑色素瘤和甲状腺癌以及一小部分肺癌和结肠直肠癌。最常见的BRAF点突变是V600E，它可以调节蛋白激酶活性，从而导致组成型BRAF激活，因为BRAF V600E可以独立于RAS或上游激活发出单体信号（PMID：20179705）。 已发现其他BRAF突变影响蛋白质的二聚化倾向（PMID：16858395,26343582,12068308）。 这些改变的产物是BRAF激酶，其可以以不受调节的方式激活MAPK信号传导，并且在某些情况下直接导致癌症生长（PMID：15520807）。",
                "geneName": "BRAF",
                "geneType": "geneBx",
                "geneVar": "BRAF基因exon15第1799位碱基T置换为A使得第600位氨基酸由缬氨酸转变成了谷氨酸",
                "hgsGb": "c.1799T>A",
                "hgvs": "BRAF:NM_004333:exon15:c.1799T>A:p.Val600Glu",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "140453136",
                "posStart": "140453136",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-33",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:630,38:0.073:348,17:282,21:30:162,168:60:31:0.048,0.054,0.057:0.005,0.002,0.992",
                "wxz": "exon15",
                "zlb": "NM_004333"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "V600E",
                "DNA_change": "V600E",
                "ExAC_nonpsych_ALL": "2.208e-05",
                "GeneName": "BRAF",
                "NM_ID": "NM_004333",
                "ajsGb": "p.Val600Glu",
                "alt": "T",
                "alteration": "V600E",
                "avsnp150": "rs113488022",
                "cancerType": "甲状腺癌",
                "chr": "chr7",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM476\\x3bOCCURENCE\\x3d3(adrenal_gland)",
                "drugLevel": "1",
                "drugs": "达拉非尼+曲美替尼",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.057",
                "funcRefgene": "exonic",
                "geneInfo": "BRAF蛋白是在丝裂原活化蛋白激酶（MAPK）级联（PMID：15520807）的调节中起关键作用的丝氨酸/苏氨酸激酶，其在生理条件下调节涉及细胞功能的基因的表达，包括细胞增殖 （PMID：24202393）。 BRAF的基因改变首先见于黑色素瘤和甲状腺癌以及一小部分肺癌和结肠直肠癌。最常见的BRAF点突变是V600E，它可以调节蛋白激酶活性，从而导致组成型BRAF激活，因为BRAF V600E可以独立于RAS或上游激活发出单体信号（PMID：20179705）。 已发现其他BRAF突变影响蛋白质的二聚化倾向（PMID：16858395,26343582,12068308）。 这些改变的产物是BRAF激酶，其可以以不受调节的方式激活MAPK信号传导，并且在某些情况下直接导致癌症生长（PMID：15520807）。",
                "geneName": "BRAF",
                "geneType": "geneBx",
                "geneVar": "BRAF基因exon15第1799位碱基T置换为A使得第600位氨基酸由缬氨酸转变成了谷氨酸",
                "hgsGb": "c.1799T>A",
                "hgvs": "BRAF:NM_004333:exon15:c.1799T>A:p.Val600Glu",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "140453136",
                "posStart": "140453136",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-33",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:630,38:0.073:348,17:282,21:30:162,168:60:31:0.048,0.054,0.057:0.005,0.002,0.992",
                "wxz": "exon15",
                "zlb": "NM_004333"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "V600E",
                "DNA_change": "V600E",
                "ExAC_nonpsych_ALL": "2.208e-05",
                "GeneName": "BRAF",
                "NM_ID": "NM_004333",
                "ajsGb": "p.Val600Glu",
                "alt": "T",
                "alteration": "V600E",
                "avsnp150": "rs113488022",
                "cancerType": "结直肠癌",
                "chr": "chr7",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM476\\x3bOCCURENCE\\x3d3(adrenal_gland)",
                "drugLevel": "1",
                "drugs": "Encorafenib[恩哥拉非尼]+西妥昔单抗，Encorafenib[恩哥拉非尼]+Panitumumab[帕尼单抗]",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.057",
                "funcRefgene": "exonic",
                "geneInfo": "BRAF蛋白是在丝裂原活化蛋白激酶（MAPK）级联（PMID：15520807）的调节中起关键作用的丝氨酸/苏氨酸激酶，其在生理条件下调节涉及细胞功能的基因的表达，包括细胞增殖 （PMID：24202393）。 BRAF的基因改变首先见于黑色素瘤和甲状腺癌以及一小部分肺癌和结肠直肠癌。最常见的BRAF点突变是V600E，它可以调节蛋白激酶活性，从而导致组成型BRAF激活，因为BRAF V600E可以独立于RAS或上游激活发出单体信号（PMID：20179705）。 已发现其他BRAF突变影响蛋白质的二聚化倾向（PMID：16858395,26343582,12068308）。 这些改变的产物是BRAF激酶，其可以以不受调节的方式激活MAPK信号传导，并且在某些情况下直接导致癌症生长（PMID：15520807）。",
                "geneName": "BRAF",
                "geneType": "geneBx",
                "geneVar": "BRAF基因exon15第1799位碱基T置换为A使得第600位氨基酸由缬氨酸转变成了谷氨酸",
                "hgsGb": "c.1799T>A",
                "hgvs": "BRAF:NM_004333:exon15:c.1799T>A:p.Val600Glu",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "140453136",
                "posStart": "140453136",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-33",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:630,38:0.073:348,17:282,21:30:162,168:60:31:0.048,0.054,0.057:0.005,0.002,0.992",
                "wxz": "exon15",
                "zlb": "NM_004333"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "V600E",
                "DNA_change": "V600E",
                "ExAC_nonpsych_ALL": "2.208e-05",
                "GeneName": "BRAF",
                "NM_ID": "NM_004333",
                "ajsGb": "p.Val600Glu",
                "alt": "T",
                "alteration": "V600E",
                "avsnp150": "rs113488022",
                "cancerType": "非小细胞肺癌",
                "chr": "chr7",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM476\\x3bOCCURENCE\\x3d3(adrenal_gland)",
                "drugLevel": "R2",
                "drugs": "厄洛替尼，阿法替尼，吉非替尼，埃克替尼，奥希替尼，达可替尼，厄洛替尼+贝伐珠单抗，厄洛替尼+Ramucirumab[雷莫芦单抗]",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.057",
                "funcRefgene": "exonic",
                "geneInfo": "BRAF蛋白是在丝裂原活化蛋白激酶（MAPK）级联（PMID：15520807）的调节中起关键作用的丝氨酸/苏氨酸激酶，其在生理条件下调节涉及细胞功能的基因的表达，包括细胞增殖 （PMID：24202393）。 BRAF的基因改变首先见于黑色素瘤和甲状腺癌以及一小部分肺癌和结肠直肠癌。最常见的BRAF点突变是V600E，它可以调节蛋白激酶活性，从而导致组成型BRAF激活，因为BRAF V600E可以独立于RAS或上游激活发出单体信号（PMID：20179705）。 已发现其他BRAF突变影响蛋白质的二聚化倾向（PMID：16858395,26343582,12068308）。 这些改变的产物是BRAF激酶，其可以以不受调节的方式激活MAPK信号传导，并且在某些情况下直接导致癌症生长（PMID：15520807）。",
                "geneName": "BRAF",
                "geneType": "geneBx",
                "geneVar": "BRAF基因exon15第1799位碱基T置换为A使得第600位氨基酸由缬氨酸转变成了谷氨酸",
                "hgsGb": "c.1799T>A",
                "hgvs": "BRAF:NM_004333:exon15:c.1799T>A:p.Val600Glu",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "140453136",
                "posStart": "140453136",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-33",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:630,38:0.073:348,17:282,21:30:162,168:60:31:0.048,0.054,0.057:0.005,0.002,0.992",
                "wxz": "exon15",
                "zlb": "NM_004333"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "V600E",
                "DNA_change": "V600E",
                "ExAC_nonpsych_ALL": "2.208e-05",
                "GeneName": "BRAF",
                "NM_ID": "NM_004333",
                "ajsGb": "p.Val600Glu",
                "alt": "T",
                "alteration": "V600E",
                "avsnp150": "rs113488022",
                "cancerType": "埃尔德海姆-切斯特病",
                "chr": "chr7",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM476\\x3bOCCURENCE\\x3d3(adrenal_gland)",
                "drugLevel": "1",
                "drugs": "维莫非尼",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.057",
                "funcRefgene": "exonic",
                "geneInfo": "BRAF蛋白是在丝裂原活化蛋白激酶（MAPK）级联（PMID：15520807）的调节中起关键作用的丝氨酸/苏氨酸激酶，其在生理条件下调节涉及细胞功能的基因的表达，包括细胞增殖 （PMID：24202393）。 BRAF的基因改变首先见于黑色素瘤和甲状腺癌以及一小部分肺癌和结肠直肠癌。最常见的BRAF点突变是V600E，它可以调节蛋白激酶活性，从而导致组成型BRAF激活，因为BRAF V600E可以独立于RAS或上游激活发出单体信号（PMID：20179705）。 已发现其他BRAF突变影响蛋白质的二聚化倾向（PMID：16858395,26343582,12068308）。 这些改变的产物是BRAF激酶，其可以以不受调节的方式激活MAPK信号传导，并且在某些情况下直接导致癌症生长（PMID：15520807）。",
                "geneName": "BRAF",
                "geneType": "geneBx",
                "geneVar": "BRAF基因exon15第1799位碱基T置换为A使得第600位氨基酸由缬氨酸转变成了谷氨酸",
                "hgsGb": "c.1799T>A",
                "hgvs": "BRAF:NM_004333:exon15:c.1799T>A:p.Val600Glu",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "140453136",
                "posStart": "140453136",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-33",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:630,38:0.073:348,17:282,21:30:162,168:60:31:0.048,0.054,0.057:0.005,0.002,0.992",
                "wxz": "exon15",
                "zlb": "NM_004333"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "V600E",
                "DNA_change": "V600E",
                "ExAC_nonpsych_ALL": "2.208e-05",
                "GeneName": "BRAF",
                "NM_ID": "NM_004333",
                "ajsGb": "p.Val600Glu",
                "alt": "T",
                "alteration": "V600E",
                "avsnp150": "rs113488022",
                "cancerType": "毛细胞白血病",
                "chr": "chr7",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM476\\x3bOCCURENCE\\x3d3(adrenal_gland)",
                "drugLevel": "2A",
                "drugs": "维莫非尼",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.057",
                "funcRefgene": "exonic",
                "geneInfo": "BRAF蛋白是在丝裂原活化蛋白激酶（MAPK）级联（PMID：15520807）的调节中起关键作用的丝氨酸/苏氨酸激酶，其在生理条件下调节涉及细胞功能的基因的表达，包括细胞增殖 （PMID：24202393）。 BRAF的基因改变首先见于黑色素瘤和甲状腺癌以及一小部分肺癌和结肠直肠癌。最常见的BRAF点突变是V600E，它可以调节蛋白激酶活性，从而导致组成型BRAF激活，因为BRAF V600E可以独立于RAS或上游激活发出单体信号（PMID：20179705）。 已发现其他BRAF突变影响蛋白质的二聚化倾向（PMID：16858395,26343582,12068308）。 这些改变的产物是BRAF激酶，其可以以不受调节的方式激活MAPK信号传导，并且在某些情况下直接导致癌症生长（PMID：15520807）。",
                "geneName": "BRAF",
                "geneType": "geneBx",
                "geneVar": "BRAF基因exon15第1799位碱基T置换为A使得第600位氨基酸由缬氨酸转变成了谷氨酸",
                "hgsGb": "c.1799T>A",
                "hgvs": "BRAF:NM_004333:exon15:c.1799T>A:p.Val600Glu",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "140453136",
                "posStart": "140453136",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-33",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:630,38:0.073:348,17:282,21:30:162,168:60:31:0.048,0.054,0.057:0.005,0.002,0.992",
                "wxz": "exon15",
                "zlb": "NM_004333"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "V600E",
                "DNA_change": "V600E",
                "ExAC_nonpsych_ALL": "2.208e-05",
                "GeneName": "BRAF",
                "NM_ID": "NM_004333",
                "ajsGb": "p.Val600Glu",
                "alt": "T",
                "alteration": "V600E",
                "avsnp150": "rs113488022",
                "cancerType": "黑色素瘤",
                "chr": "chr7",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM476\\x3bOCCURENCE\\x3d3(adrenal_gland)",
                "drugLevel": "1",
                "drugs": "维莫非尼，达拉非尼，达拉非尼+曲美替尼，维莫非尼+Cobimetinib[考比替尼]，曲美替尼，Encorafenib[恩哥拉非尼]+Binimetinib[比美替尼]",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.057",
                "funcRefgene": "exonic",
                "geneInfo": "BRAF蛋白是在丝裂原活化蛋白激酶（MAPK）级联（PMID：15520807）的调节中起关键作用的丝氨酸/苏氨酸激酶，其在生理条件下调节涉及细胞功能的基因的表达，包括细胞增殖 （PMID：24202393）。 BRAF的基因改变首先见于黑色素瘤和甲状腺癌以及一小部分肺癌和结肠直肠癌。最常见的BRAF点突变是V600E，它可以调节蛋白激酶活性，从而导致组成型BRAF激活，因为BRAF V600E可以独立于RAS或上游激活发出单体信号（PMID：20179705）。 已发现其他BRAF突变影响蛋白质的二聚化倾向（PMID：16858395,26343582,12068308）。 这些改变的产物是BRAF激酶，其可以以不受调节的方式激活MAPK信号传导，并且在某些情况下直接导致癌症生长（PMID：15520807）。",
                "geneName": "BRAF",
                "geneType": "geneBx",
                "geneVar": "BRAF基因exon15第1799位碱基T置换为A使得第600位氨基酸由缬氨酸转变成了谷氨酸",
                "hgsGb": "c.1799T>A",
                "hgvs": "BRAF:NM_004333:exon15:c.1799T>A:p.Val600Glu",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "140453136",
                "posStart": "140453136",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-33",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:630,38:0.073:348,17:282,21:30:162,168:60:31:0.048,0.054,0.057:0.005,0.002,0.992",
                "wxz": "exon15",
                "zlb": "NM_004333"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "V600E",
                "DNA_change": "V600E",
                "ExAC_nonpsych_ALL": "2.208e-05",
                "GeneName": "BRAF",
                "NM_ID": "NM_004333",
                "ajsGb": "p.Val600Glu",
                "alt": "T",
                "alteration": "V600E",
                "avsnp150": "rs113488022",
                "cancerType": "胃肠道间质瘤",
                "chr": "chr7",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM476\\x3bOCCURENCE\\x3d3(adrenal_gland)",
                "drugLevel": "R2",
                "drugs": "伊马替尼",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.057",
                "funcRefgene": "exonic",
                "geneInfo": "BRAF蛋白是在丝裂原活化蛋白激酶（MAPK）级联（PMID：15520807）的调节中起关键作用的丝氨酸/苏氨酸激酶，其在生理条件下调节涉及细胞功能的基因的表达，包括细胞增殖 （PMID：24202393）。 BRAF的基因改变首先见于黑色素瘤和甲状腺癌以及一小部分肺癌和结肠直肠癌。最常见的BRAF点突变是V600E，它可以调节蛋白激酶活性，从而导致组成型BRAF激活，因为BRAF V600E可以独立于RAS或上游激活发出单体信号（PMID：20179705）。 已发现其他BRAF突变影响蛋白质的二聚化倾向（PMID：16858395,26343582,12068308）。 这些改变的产物是BRAF激酶，其可以以不受调节的方式激活MAPK信号传导，并且在某些情况下直接导致癌症生长（PMID：15520807）。",
                "geneName": "BRAF",
                "geneType": "geneBx",
                "geneVar": "BRAF基因exon15第1799位碱基T置换为A使得第600位氨基酸由缬氨酸转变成了谷氨酸",
                "hgsGb": "c.1799T>A",
                "hgvs": "BRAF:NM_004333:exon15:c.1799T>A:p.Val600Glu",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "140453136",
                "posStart": "140453136",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-33",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:630,38:0.073:348,17:282,21:30:162,168:60:31:0.048,0.054,0.057:0.005,0.002,0.992",
                "wxz": "exon15",
                "zlb": "NM_004333"
            }
        ],
        "tmb": [],
        "tnb": []
    },
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "G/G",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，需较高剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较高，神经毒性综合征的严重程度可能降低",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "G/G",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "del/del",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "A/G",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/T",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/C",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "del/del",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "G/G",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/C",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "A/A",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "del/del",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "C/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "G/T",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/G",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/6TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢增加",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "C/T",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/A",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "G/G",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "G/A",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/A",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副高，代谢降低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/T",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/T",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/T",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/T",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/T",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/T",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-38",
                "updateTime": "."
            }
        ],
        "clinical": [
            {
                "brief_summary": "  The reason for this study is to see if the study drug LY3499446 is safe and effective in  participants with solid tumors with KRAS G12C mutation.",
                "brief_title": "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation",
                "condition": "Advanced Solid Tumor;Non-Small Cell Lung Cancer;Colorectal Cancer",
                "country": "Spain;Australia;Canada;United States",
                "geneName": "KRAS",
                "intervention_name": "Docetaxel;Cetuximab;LY3499446;Erlotinib;Abemaciclib",
                "intervention_type": "Drug",
                "nct_num": "NCT04165031",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "November 15, 2019"
            },
            {
                "brief_summary": "  The reason for this study is to see if the study drug LY3499446 is safe and effective in  participants with solid tumors with KRAS G12C mutation.",
                "brief_title": "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation",
                "condition": "Advanced Solid Tumor;Non-Small Cell Lung Cancer;Colorectal Cancer",
                "country": "Spain;Australia;Canada;United States",
                "geneName": "KRAS",
                "intervention_name": "Docetaxel;Cetuximab;LY3499446;Erlotinib;Abemaciclib",
                "intervention_type": "Drug",
                "nct_num": "NCT04165031",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "November 15, 2019"
            },
            {
                "brief_summary": "  The reason for this study is to see if the study drug LY3499446 is safe and effective in  participants with solid tumors with KRAS G12C mutation.",
                "brief_title": "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation",
                "condition": "Advanced Solid Tumor;Non-Small Cell Lung Cancer;Colorectal Cancer",
                "country": "Spain;Australia;Canada;United States",
                "geneName": "KRAS",
                "intervention_name": "Docetaxel;Cetuximab;LY3499446;Erlotinib;Abemaciclib",
                "intervention_type": "Drug",
                "nct_num": "NCT04165031",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "November 15, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies the best dose of hydroxychloroquine when given together with  binimetinib in treating patients with KRAS gene mutated pancreatic cancer that has spread to  other places in the body (metastatic). Binimetinib may stop the growth of tumor cells by  blocking some of the enzymes needed for cell growth. Hydroxychloroquine may prevent  autophagy, a normal process in which a cell destroys proteins and other substances which may  lead to cell death. Autophagy may prevent normal cells from developing into tumor cells, but  it may also protect tumor cells by destroying anticancer drugs or substances taken up by  them. Giving hydroxychloroquine together with binimetinib may work better in treating  patients with pancreatic cancer compared to binimetinib alone.",
                "brief_title": "Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer",
                "condition": "Metastatic Pancreatic Adenocarcinoma;KRAS Gene Mutation;Stage IV Pancreatic Cancer AJCC v8",
                "country": "United States",
                "geneName": "KRAS",
                "intervention_name": "Binimetinib;Hydroxychloroquine",
                "intervention_type": "Drug",
                "nct_num": "NCT04132505",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "October 18, 2019"
            },
            {
                "brief_summary": "  Phase 1 study for patients with resected PDAC and mismatch repair (MMR)-p colorectal cancer  (CRC) to evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS  peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab after  adjuvant standard of care treatment.",
                "brief_title": "Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer",
                "condition": "Pancreatic Cancer;Colorectal Cancer",
                "country": "United States",
                "geneName": "KRAS",
                "intervention_name": "Ipilimumab;KRAS peptide vaccine;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT04117087",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "October 7, 2019"
            },
            {
                "brief_summary": "  Phase 1 study for patients with resected PDAC and mismatch repair (MMR)-p colorectal cancer  (CRC) to evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS  peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab after  adjuvant standard of care treatment.",
                "brief_title": "Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer",
                "condition": "Pancreatic Cancer;Colorectal Cancer",
                "country": "United States",
                "geneName": "KRAS",
                "intervention_name": "Ipilimumab;KRAS peptide vaccine;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT04117087",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "October 7, 2019"
            },
            {
                "brief_summary": "  This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab)  works for the treatment of patients with colorectal cancer that cannot be removed by surgery  (unresectable), has spread to nearby tissue or lymph nodes (locally advanced), or has spread  to other places in the body (metastatic). Regorafenib may stop the growth of cancer cells by  blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab  or panitumumab, may interfere with the ability of cancer cells to grow and spread. Drugs used  in chemotherapy, such as irinotecan, work in different ways to stop the growth of cancer  cells, either by killing the cells, by stopping them from dividing, or by stopping them from  spreading. The purpose of this research study is to compare the effects, good and/or bad, of  taking regorafenib follow by cetuximab or panitumumab, to those that receive cetuximab or  panitumumab before regorafenib.",
                "brief_title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
                "condition": "KRAS Gene Mutation Negative;BRAF V600E Negative;Stage IIIA Colorectal Cancer AJCC v8;Stage IVA Colorectal Cancer AJCC v8;Locally Advanced Unresectable Colorectal Adenocarcinoma;Stage IV Colorectal Cancer AJCC v8;Stage IIIB Colorectal Cancer AJCC v8;Stage IVC Colorectal Cancer AJCC v8;Stage IVB Colorectal Cancer AJCC v8;NRAS Gene Mutation Negative;Stage III Colorectal Cancer AJCC v8;Metastatic Colorectal Adenocarcinoma;Stage IIIC Colorectal Cancer AJCC v8",
                "country": "United States",
                "geneName": "KRAS",
                "intervention_name": "Panitumumab;Cetuximab;Regorafenib;Irinotecan",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04117945",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "October 7, 2019"
            },
            {
                "brief_summary": "  This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab)  works for the treatment of patients with colorectal cancer that cannot be removed by surgery  (unresectable), has spread to nearby tissue or lymph nodes (locally advanced), or has spread  to other places in the body (metastatic). Regorafenib may stop the growth of cancer cells by  blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab  or panitumumab, may interfere with the ability of cancer cells to grow and spread. Drugs used  in chemotherapy, such as irinotecan, work in different ways to stop the growth of cancer  cells, either by killing the cells, by stopping them from dividing, or by stopping them from  spreading. The purpose of this research study is to compare the effects, good and/or bad, of  taking regorafenib follow by cetuximab or panitumumab, to those that receive cetuximab or  panitumumab before regorafenib.",
                "brief_title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
                "condition": "KRAS Gene Mutation Negative;BRAF V600E Negative;Stage IIIA Colorectal Cancer AJCC v8;Stage IVA Colorectal Cancer AJCC v8;Locally Advanced Unresectable Colorectal Adenocarcinoma;Stage IV Colorectal Cancer AJCC v8;Stage IIIB Colorectal Cancer AJCC v8;Stage IVC Colorectal Cancer AJCC v8;Stage IVB Colorectal Cancer AJCC v8;NRAS Gene Mutation Negative;Stage III Colorectal Cancer AJCC v8;Metastatic Colorectal Adenocarcinoma;Stage IIIC Colorectal Cancer AJCC v8",
                "country": "United States",
                "geneName": "KRAS",
                "intervention_name": "Panitumumab;Cetuximab;Regorafenib;Irinotecan",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04117945",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "October 7, 2019"
            },
            {
                "brief_summary": "  This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab)  works for the treatment of patients with colorectal cancer that cannot be removed by surgery  (unresectable), has spread to nearby tissue or lymph nodes (locally advanced), or has spread  to other places in the body (metastatic). Regorafenib may stop the growth of cancer cells by  blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab  or panitumumab, may interfere with the ability of cancer cells to grow and spread. Drugs used  in chemotherapy, such as irinotecan, work in different ways to stop the growth of cancer  cells, either by killing the cells, by stopping them from dividing, or by stopping them from  spreading. The purpose of this research study is to compare the effects, good and/or bad, of  taking regorafenib follow by cetuximab or panitumumab, to those that receive cetuximab or  panitumumab before regorafenib.",
                "brief_title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
                "condition": "KRAS Gene Mutation Negative;BRAF V600E Negative;Stage IIIA Colorectal Cancer AJCC v8;Stage IVA Colorectal Cancer AJCC v8;Locally Advanced Unresectable Colorectal Adenocarcinoma;Stage IV Colorectal Cancer AJCC v8;Stage IIIB Colorectal Cancer AJCC v8;Stage IVC Colorectal Cancer AJCC v8;Stage IVB Colorectal Cancer AJCC v8;NRAS Gene Mutation Negative;Stage III Colorectal Cancer AJCC v8;Metastatic Colorectal Adenocarcinoma;Stage IIIC Colorectal Cancer AJCC v8",
                "country": "United States",
                "geneName": "KRAS",
                "intervention_name": "Panitumumab;Cetuximab;Regorafenib;Irinotecan",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04117945",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "October 7, 2019"
            },
            {
                "brief_summary": "  The primary objective of this trial is to determine the maximum tolerated dose (MTD) and/or  recommended Phase II dose (RP2D) of BI 1701963 as monotherapy and in combination with  trametinib in patients with KRAS mutated solid tumours.  Secondary objectives are to evaluate the safety and tolerability of BI 1701963 as monotherapy  and in combination with trametinib, to characterise pharmacokinetics and pharmacodynamics,  and to evaluate first efficacy signals.",
                "brief_title": "A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)",
                "condition": "Solid Tumors, KRAS Mutation",
                "country": "Netherlands",
                "geneName": "KRAS",
                "intervention_name": "BI 1701963;Trametinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04111458",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "October 1, 2019"
            },
            {
                "brief_summary": "  The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP  regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.",
                "brief_title": "Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.",
                "condition": "Sintilimab;TP53 Mutation;Diffuse Large B-Cell Lymphoma",
                "country": ".",
                "geneName": "TP53",
                "intervention_name": "Sintilimab-R-CHOP",
                "intervention_type": "Drug",
                "nct_num": "NCT04023916",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "July 18, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  CLL is an incurable disease with conventional chemotherapy. In the absence of TP53  disruption, a chemoimmunotherapy (CIT) regimen is recommended as front-line and second-line  treatment in those patients who attained a long progression-free survival (PFS) with the  previous regimen. Bendamustine and rituximab (BR) is one of the most widely adopted CIT  regimens, including second-line treatment. Unfortunately, durations of remission following BR  combination therapy tend to be short in patients with heavily pre-treated disease or who have  already received rituximab. The incorporation of a maintenance following induction  chemotherapy to overcome the shorter remission durations in this population is a reasonable  option.",
                "brief_title": "Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia",
                "condition": "Chronic Lymphocytic Leukemia",
                "country": "Russian Federation",
                "geneName": "TP53",
                "intervention_name": "BR as Maintenance",
                "intervention_type": "Drug",
                "nct_num": "NCT03847727",
                "overall_status": "Active, not recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "February 20, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission  tomography (PET) and osimertinib works in evaluating glucose utilization in patients with  EGFR activated glioblastoma. Osimertinib may stop the growth of tumor cells by blocking some  of the enzymes needed for cell growth. 18F-FDG PET imaging may help to detect changes in  tumor glucose utilization, which may allow investigators to obtain an early read out on the  impact of osimertinib on recurrent glioblastoma patients whose tumors have EGFR activation.",
                "brief_title": "18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma",
                "condition": "EGFR Gene Mutation;Recurrent Glioblastoma;TP53 wt Allele;EGFR Gene Amplification;Supratentorial Glioblastoma;Glioblastoma",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Fludeoxyglucose F-18;Osimertinib;Positron Emission Tomography",
                "intervention_type": "Procedure;Drug;Other",
                "nct_num": "NCT03732352",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "November 6, 2018"
            },
            {
                "brief_summary": "  Recent preclinical studies suggest that combining MEK and MDM2 inhibition synergize to induce  apoptosis in RAS/BRAF-mutant and TP53 wild-type CRC models. In vitro, in RKO cell lines  (poorly differentiated colon carcinoma cell line resistant to single agent targeting MDM2 and  MEK and BRAF inhibition), the MDM2 plus MEK inhibitor combination generated a synergistic  increase in apoptotic index. In vivo, in mice harboring human RKO colon tumor xenografts the  combination of MDM2 plus MEK inhibition elicited 93% decreases in tumor volume.  This trial is to conduct a single-center, Phase 1 dose escalation study of trametinib  combined with HDM201 (a HDM2 inhibitor) in patients with advanced/metastatic RAS/RAF mutant  and TP53 wt CRC.",
                "brief_title": "Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type",
                "condition": "Advanced Cancer;Metastatic Cancer;Colorectal Cancer",
                "country": "France",
                "geneName": "TP53",
                "intervention_name": "Trametinib;HDM201",
                "intervention_type": "Drug",
                "nct_num": "NCT03714958",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "October 22, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in  treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that  is untreated or has come back. Quizartinib may stop the growth of cancer cells by blocking  some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine  and venetoclax, work in different ways to stop the growth of cancer cells, either by killing  the cells, by stopping them from dividing, or by stopping them from spreading. Giving  quizartinib and decitabine may work better at treating acute myeloid leukemia and  myelodysplastic syndrome.",
                "brief_title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",
                "condition": "TP53 Gene Deletion;Blasts More Than 10 Percent of Peripheral Blood White Cells;Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;TP53 Gene Mutation;Myelodysplastic Syndrome;Recurrent Acute Myeloid Leukemia;Acute Myeloid Leukemia;High Risk Myelodysplastic Syndrome;Recurrent Myelodysplastic Syndrome;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Quizartinib;Venetoclax;Decitabine",
                "intervention_type": "Drug",
                "nct_num": "NCT03661307",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "September 7, 2018"
            },
            {
                "brief_summary": "  Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the  treatment of advanced refractory solid tumors with TP53 harmful mutations.",
                "brief_title": "Treatment of Carrying TP53 Harmful Mutations",
                "condition": "Advanced Cancer",
                "country": "China",
                "geneName": "TP53",
                "intervention_name": "Fluzoparib combined with Apatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03645200",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "August 24, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  This phase II trial studies how well pembrolizumab works in treating participants with cancer  that has spread to other places in the body, has come back or has spread to nearby tissues or  lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of  tumor cells to grow and spread.",
                "brief_title": "Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability",
                "condition": "Stage IIIA Ovarian Cancer AJCC v8;Stage IIIB Ovarian Cancer AJCC v8;Stage III Ovarian Cancer AJCC v8;Recurrent Ovarian Carcinoma;Locally Advanced Solid Neoplasm;BRCA2 Gene Mutation;Stage IVA Ovarian Cancer AJCC v8;Stage IV Breast Cancer AJCC v6 and v7;Stage IIIB Breast Cancer AJCC v7;Metastatic Malignant Solid Neoplasm;Stage IVB Ovarian Cancer AJCC v8;Stage IIIA Breast Cancer AJCC v7;POLE Gene Mutation;BRCA1 Gene Mutation;Stage IIIC Breast Cancer AJCC v7;POLD1 Gene Mutation;Recurrent Malignant Solid Neoplasm;Stage III Breast Cancer AJCC v7;Stage IV Ovarian Cancer AJCC v8;Stage IIIC Ovarian Cancer AJCC v8",
                "country": "United States",
                "geneName": "POLD1",
                "intervention_name": "Pembrolizumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Other",
                "nct_num": "NCT03428802",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "February 12, 2018"
            },
            {
                "brief_summary": "  The purpose of this study is to determine the safety and effectiveness of nivolumab alone or  in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring  mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA.  Nivolumab and ipilimumab have been given to patients across multiple types of cancer, and  safe doses and schedules have been determined.",
                "brief_title": "Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)",
                "condition": "Advanced Solid Tumors",
                "country": "Canada;United States",
                "geneName": "POLD1",
                "intervention_name": "Ipilimumab;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03461952",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "March 12, 2018"
            },
            {
                "brief_summary": "  The purpose of this study is to determine the safety and effectiveness of nivolumab alone or  in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring  mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA.  Nivolumab and ipilimumab have been given to patients across multiple types of cancer, and  safe doses and schedules have been determined.",
                "brief_title": "Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)",
                "condition": "Advanced Solid Tumors",
                "country": "Canada;United States",
                "geneName": "POLD1",
                "intervention_name": "Ipilimumab;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03461952",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-38",
                "study_first_posted": "March 12, 2018"
            }
        ],
        "cms": [
            {
                "age": "57",
                "agentName": "福建省人民医院",
                "areaAgentName": "孙霄飞",
                "backStatus": "1",
                "backStatusShow": "未返款",
                "barcode": "2007151224258",
                "bedNumber": ".",
                "bingli": ".",
                "birthday": ".",
                "checkTime": ".",
                "contact": "18650899197",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": ".",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-22 13:21:00",
                "expressName": ".",
                "expressNum": "362663432308",
                "fenziBingli": ".",
                "financeId": "233342",
                "gender": "男",
                "historyNum": "0",
                "hospitalName": "福建省人民医院",
                "idCard": ".",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-15 12:25:33",
                "invoiceApplyMoney": "0.00",
                "invoiceName": ".",
                "invoiceReceivePhone": ".",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "0",
                "invoiceTypeShow": ".",
                "itemName": "0201028.OncoDrug-Seq全实体瘤110基因（组织/细胞学样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-13 12:24:38",
                "medicalRecord": ".",
                "name": "谢晓波",
                "nickName": "徐水春",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "2",
                "paymentTypeShow": "月结",
                "receiveStatus": "1",
                "receiveStatusShow": "未收款",
                "receiveTime": "2020-07-15 13:21:49",
                "remark": ".",
                "reportAddress": ".",
                "reportAddressName": "徐水春",
                "reportCheckTime": ".",
                "reportEmail": ".",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": ".",
                "reportStyle": "电子 纸质",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "234820",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200715-38",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": ".",
                "sickAge": ".",
                "sickFamilyHistory": "父亲肺癌，姐姐肾癌",
                "source": "新鲜组织(专用保存液)",
                "sourceFrom": ".",
                "testDoctor": ".",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "结直肠癌",
                "treatHistory": "7.3手术",
                "treatID": "TS05",
                "treatResult": "肠癌",
                "treatmentNo": ".",
                "unitAgentName": "徐水春",
                "url": "[]",
                "userId": "1512",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [],
        "fusion": [],
        "heredity": [
            {
                "aachangeRefgene": ".",
                "ajsGb": ".",
                "alt": ".",
                "alteration": ".",
                "barcode": ".",
                "chr": ".",
                "clinsig": ".",
                "description": ".",
                "diseaseInfo": ".",
                "evidenceLevel": ".",
                "exonicfuncRefgene": ".",
                "freq": ".",
                "funcRefgene": ".",
                "geneInfo": ".",
                "geneName": ".",
                "geneType": ".",
                "geneVar": ".",
                "geneYcType": ".",
                "hgsGb": ".",
                "hgvs": ".",
                "intervarAutomated": ".",
                "level": ".",
                "mutationType": ".",
                "ominId": ".",
                "posEnd": ".",
                "posStart": ".",
                "projectAbbr": "DE",
                "ref": ".",
                "relativeDisease": ".",
                "riskLevel": ".",
                "sampleSn": "NGS200715-38",
                "tumorProfiles": ".",
                "vcfFormat": ".",
                "vcfFormatInfo": ".",
                "wxz": ".",
                "zlb": "."
            }
        ],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:1.56%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "1.56%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "如果使用免疫检查点抑制剂治疗，疗效可能较好",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "检测到变异/基因突变（NM_033360:exon2:c.38G>A:p.Gly13Asp）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": "KRAS:NM_033360:exon2:c.38G>A:p.Gly13Asp",
                "Unnamed: 8": ".",
                "Unnamed: 9": "NGS200715-38",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "如果使用免疫检查点抑制剂治疗，疗效可能较好",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "检测到变异/基因突变（NM_000546:exon7:c.772G>T:p.Glu258Ter）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": "TP53:NM_000546:exon7:c.772G>T:p.Glu258Ter",
                "Unnamed: 8": ".",
                "Unnamed: 9": "NGS200715-38",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 1,
                "percent": 1.56,
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-38",
                "totalSites": 64
            }
        ],
        "qc": [
            {
                "cleanBases": 1611840850,
                "cleanReads": 11567838,
                "coverage>0.2x": 92.84,
                "coverage>0.5x": 74.6,
                "effectCoverage500": 82.0,
                "effectDepth": 1300,
                "insert": 199.3,
                "mapping": 99.9,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 1773836100,
                "rawDuplication": 16.91,
                "rawReads": 11825574,
                "readPercent": 97.82,
                "samplePurity": "34.23",
                "sampleSn": "NGS200715-38",
                "sampleType": "Tissue",
                "targetMapping": 66.45,
                "trimDuplication": 20.17,
                "tumorCoverage": 99.68,
                "tumorDepth": 1654,
                "tumorQ30": 91.91
            }
        ],
        "target": [
            {
                "1000g2015aug_all": ".",
                "AA_change": "G13D",
                "DNA_change": "G13D",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "KRAS",
                "NM_ID": "NM_033360",
                "ajsGb": "p.Gly13Asp",
                "alt": "T",
                "alteration": "G13D",
                "avsnp150": "rs112445441",
                "cancerType": "实体瘤",
                "chr": "chr12",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM1140132",
                "drugLevel": "4",
                "drugs": "Cobimetinib[考比替尼]，Binimetinib[比美替尼]，曲美替尼",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.323",
                "funcRefgene": "exonic",
                "geneInfo": "KRAS为小GTP酶的RAS家族成员之一，其催化GTP水解为GDP。在生理条件下，这些RAS蛋白在活化的（GTP结合的）和不活化的（GDP结合的）状态之间循环，以激活受体酪氨酸激酶（RTK）（PMID：22189424）下游的MAPK和PI3K致癌途径信号传导。 RAS酶的功能由鸟嘌呤核苷酸交换因子（GEFs）调节，如SOS，它使GDP能够交换GTP，也可通过激活的GTP酶调节，如NF1，它们增加RAS水解GTP的能力。一旦RAS被激活，将通过不同的细胞内信号传导途径（包括RAF / MEK / ERK和PI3K / AKT / mTOR途径）介导细胞增殖和其他细胞功能的调节。 KRAS中的转化突变常见于胰腺癌，结肠癌，子宫内膜癌，卵巢癌和胆管癌；几乎所有这些突变都导致KRAS的结构型活化，从而促进细胞增殖（PMID：21993244,24651010）。 KRAS突变主要发生在三个主要热点G12，G13和Q61中，其中前两个发生在GTP-结构域中，后者干扰NF1结合和调节KRAS的能力（PMID：22589270,21993244,24651010） 。其他的突变如A146T / V / P和L19F也已被鉴定，并发现它们存在低频的激活（PMID：20147967,20432530,20570890）。胚系KRAS突变是努南综合征（NS）和心-面-皮肤综合征（CFC）PMID：16474405,16474404,19467855,17056636）的病因（PMID：16474405,16474404,19467855,17056636） ，其与MAPK信号通路过度激活相关，导致独特的临床特征与癌症倾向 (PMID: 19467855, 17704260)。",
                "geneName": "KRAS",
                "geneType": "geneBx,geneMy",
                "geneVar": "KRAS基因exon2第38位碱基G置换为A使得第13位氨基酸由甘氨酸转变成了天冬氨酸",
                "hgsGb": "c.38G>A",
                "hgvs": "KRAS:NM_033360:exon2:c.38G>A:p.Gly13Asp",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "25398281",
                "posStart": "25398281",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-38",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:321,153:0.331:189,85:132,68:29:181,179:60:29:0.313,0.306,0.323:0.006,0.016,0.977",
                "wxz": "exon2",
                "zlb": "NM_033360"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "G13D",
                "DNA_change": "G13D",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "KRAS",
                "NM_ID": "NM_033360",
                "ajsGb": "p.Gly13Asp",
                "alt": "T",
                "alteration": "G13D",
                "avsnp150": "rs112445441",
                "cancerType": "结直肠癌",
                "chr": "chr12",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM1140132",
                "drugLevel": "R1",
                "drugs": "Panitumumab[帕尼单抗]，西妥昔单抗",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.323",
                "funcRefgene": "exonic",
                "geneInfo": "KRAS为小GTP酶的RAS家族成员之一，其催化GTP水解为GDP。在生理条件下，这些RAS蛋白在活化的（GTP结合的）和不活化的（GDP结合的）状态之间循环，以激活受体酪氨酸激酶（RTK）（PMID：22189424）下游的MAPK和PI3K致癌途径信号传导。 RAS酶的功能由鸟嘌呤核苷酸交换因子（GEFs）调节，如SOS，它使GDP能够交换GTP，也可通过激活的GTP酶调节，如NF1，它们增加RAS水解GTP的能力。一旦RAS被激活，将通过不同的细胞内信号传导途径（包括RAF / MEK / ERK和PI3K / AKT / mTOR途径）介导细胞增殖和其他细胞功能的调节。 KRAS中的转化突变常见于胰腺癌，结肠癌，子宫内膜癌，卵巢癌和胆管癌；几乎所有这些突变都导致KRAS的结构型活化，从而促进细胞增殖（PMID：21993244,24651010）。 KRAS突变主要发生在三个主要热点G12，G13和Q61中，其中前两个发生在GTP-结构域中，后者干扰NF1结合和调节KRAS的能力（PMID：22589270,21993244,24651010） 。其他的突变如A146T / V / P和L19F也已被鉴定，并发现它们存在低频的激活（PMID：20147967,20432530,20570890）。胚系KRAS突变是努南综合征（NS）和心-面-皮肤综合征（CFC）PMID：16474405,16474404,19467855,17056636）的病因（PMID：16474405,16474404,19467855,17056636） ，其与MAPK信号通路过度激活相关，导致独特的临床特征与癌症倾向 (PMID: 19467855, 17704260)。",
                "geneName": "KRAS",
                "geneType": "geneBx,geneMy",
                "geneVar": "KRAS基因exon2第38位碱基G置换为A使得第13位氨基酸由甘氨酸转变成了天冬氨酸",
                "hgsGb": "c.38G>A",
                "hgvs": "KRAS:NM_033360:exon2:c.38G>A:p.Gly13Asp",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "25398281",
                "posStart": "25398281",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-38",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:321,153:0.331:189,85:132,68:29:181,179:60:29:0.313,0.306,0.323:0.006,0.016,0.977",
                "wxz": "exon2",
                "zlb": "NM_033360"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "G13D",
                "DNA_change": "G13D",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "KRAS",
                "NM_ID": "NM_033360",
                "ajsGb": "p.Gly13Asp",
                "alt": "T",
                "alteration": "G13D",
                "avsnp150": "rs112445441",
                "cancerType": "非小细胞肺癌",
                "chr": "chr12",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM1140132",
                "drugLevel": "R1",
                "drugs": "厄洛替尼，阿法替尼，吉非替尼，阿美替尼，埃克替尼，奥希替尼，达可替尼，厄洛替尼+贝伐珠单抗，厄洛替尼+Ramucirumab[雷莫芦单抗]",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.323",
                "funcRefgene": "exonic",
                "geneInfo": "KRAS为小GTP酶的RAS家族成员之一，其催化GTP水解为GDP。在生理条件下，这些RAS蛋白在活化的（GTP结合的）和不活化的（GDP结合的）状态之间循环，以激活受体酪氨酸激酶（RTK）（PMID：22189424）下游的MAPK和PI3K致癌途径信号传导。 RAS酶的功能由鸟嘌呤核苷酸交换因子（GEFs）调节，如SOS，它使GDP能够交换GTP，也可通过激活的GTP酶调节，如NF1，它们增加RAS水解GTP的能力。一旦RAS被激活，将通过不同的细胞内信号传导途径（包括RAF / MEK / ERK和PI3K / AKT / mTOR途径）介导细胞增殖和其他细胞功能的调节。 KRAS中的转化突变常见于胰腺癌，结肠癌，子宫内膜癌，卵巢癌和胆管癌；几乎所有这些突变都导致KRAS的结构型活化，从而促进细胞增殖（PMID：21993244,24651010）。 KRAS突变主要发生在三个主要热点G12，G13和Q61中，其中前两个发生在GTP-结构域中，后者干扰NF1结合和调节KRAS的能力（PMID：22589270,21993244,24651010） 。其他的突变如A146T / V / P和L19F也已被鉴定，并发现它们存在低频的激活（PMID：20147967,20432530,20570890）。胚系KRAS突变是努南综合征（NS）和心-面-皮肤综合征（CFC）PMID：16474405,16474404,19467855,17056636）的病因（PMID：16474405,16474404,19467855,17056636） ，其与MAPK信号通路过度激活相关，导致独特的临床特征与癌症倾向 (PMID: 19467855, 17704260)。",
                "geneName": "KRAS",
                "geneType": "geneBx,geneMy",
                "geneVar": "KRAS基因exon2第38位碱基G置换为A使得第13位氨基酸由甘氨酸转变成了天冬氨酸",
                "hgsGb": "c.38G>A",
                "hgvs": "KRAS:NM_033360:exon2:c.38G>A:p.Gly13Asp",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "25398281",
                "posStart": "25398281",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-38",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:321,153:0.331:189,85:132,68:29:181,179:60:29:0.313,0.306,0.323:0.006,0.016,0.977",
                "wxz": "exon2",
                "zlb": "NM_033360"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "G13D",
                "DNA_change": "G13D",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "KRAS",
                "NM_ID": "NM_033360",
                "ajsGb": "p.Gly13Asp",
                "alt": "T",
                "alteration": "G13D",
                "avsnp150": "rs112445441",
                "cancerType": ".",
                "chr": "chr12",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM1140132",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.323",
                "funcRefgene": "exonic",
                "geneInfo": "KRAS为小GTP酶的RAS家族成员之一，其催化GTP水解为GDP。在生理条件下，这些RAS蛋白在活化的（GTP结合的）和不活化的（GDP结合的）状态之间循环，以激活受体酪氨酸激酶（RTK）（PMID：22189424）下游的MAPK和PI3K致癌途径信号传导。 RAS酶的功能由鸟嘌呤核苷酸交换因子（GEFs）调节，如SOS，它使GDP能够交换GTP，也可通过激活的GTP酶调节，如NF1，它们增加RAS水解GTP的能力。一旦RAS被激活，将通过不同的细胞内信号传导途径（包括RAF / MEK / ERK和PI3K / AKT / mTOR途径）介导细胞增殖和其他细胞功能的调节。 KRAS中的转化突变常见于胰腺癌，结肠癌，子宫内膜癌，卵巢癌和胆管癌；几乎所有这些突变都导致KRAS的结构型活化，从而促进细胞增殖（PMID：21993244,24651010）。 KRAS突变主要发生在三个主要热点G12，G13和Q61中，其中前两个发生在GTP-结构域中，后者干扰NF1结合和调节KRAS的能力（PMID：22589270,21993244,24651010） 。其他的突变如A146T / V / P和L19F也已被鉴定，并发现它们存在低频的激活（PMID：20147967,20432530,20570890）。胚系KRAS突变是努南综合征（NS）和心-面-皮肤综合征（CFC）PMID：16474405,16474404,19467855,17056636）的病因（PMID：16474405,16474404,19467855,17056636） ，其与MAPK信号通路过度激活相关，导致独特的临床特征与癌症倾向 (PMID: 19467855, 17704260)。",
                "geneName": "KRAS",
                "geneType": "geneBx,geneMy",
                "geneVar": "KRAS基因exon2第38位碱基G置换为A使得第13位氨基酸由甘氨酸转变成了天冬氨酸",
                "hgsGb": "c.38G>A",
                "hgvs": "KRAS:NM_033360:exon2:c.38G>A:p.Gly13Asp",
                "intervarAutomated": "Likely_pathogenic",
                "level": "5（致病）",
                "posEnd": "25398281",
                "posStart": "25398281",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-38",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:321,153:0.331:189,85:132,68:29:181,179:60:29:0.313,0.306,0.323:0.006,0.016,0.977",
                "wxz": "exon2",
                "zlb": "NM_033360"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Truncating Mutations",
                "DNA_change": "Truncating Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "TP53",
                "NM_ID": "NM_000546",
                "ajsGb": "p.Glu258Ter",
                "alt": "A",
                "alteration": "E258X",
                "avsnp150": ".",
                "cancerType": "多种实体瘤（卵巢癌和头颈鳞癌）",
                "chr": "chr17",
                "clinsig": "Pathogenic",
                "cosmic70": "ID\\x3dCOSM173138",
                "drugLevel": "3",
                "drugs": "AZD1775",
                "exonicfuncRefgene": "stopgain",
                "freq": "0.549",
                "funcRefgene": "exonic",
                "geneInfo": "TP53通过诱导下游抗肿瘤反应如DNA修复和细胞凋亡（PMID：11099028）编码p53肿瘤抑制蛋白，该蛋白是一种对细胞应激（包括DNA损伤和致癌激活）反应的转录因子。 TP53是人类癌症中最常见的突变基因，并且其胚系突变导致广泛癌症倾向的Li-Fraumeni综合征（PMID：22713868,21765642）。 p53蛋白由N末端反式激活结构域，中央DNA结合结构域，寡聚化结构域和C末端调节结构域（PMID：22713868）组成。",
                "geneName": "TP53",
                "geneType": "geneBx,geneHl,geneMy",
                "geneVar": "TP53基因exon7第772位碱基G置换为T使得第258位氨基酸由谷氨酸转变成了终止",
                "hgsGb": "c.772G>T",
                "hgvs": "TP53:NM_000546:exon7:c.772G>T:p.Glu258Ter",
                "intervarAutomated": "Pathogenic",
                "level": "5（致病）",
                "posEnd": "7577509",
                "posStart": "7577509",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-38",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:328,400:0.547:183,221:145,179:27:201,210:60:35:0.528,0.544,0.549:0.033,0.006,0.961",
                "wxz": "exon7",
                "zlb": "NM_000546"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": ".",
                "DNA_change": ".",
                "ExAC_nonpsych_ALL": "7.95e-05",
                "GeneName": ".",
                "NM_ID": ".",
                "ajsGb": "p.Lys16Glu",
                "alt": "G",
                "alteration": "K16E",
                "avsnp150": "rs765185645",
                "cancerType": ".",
                "chr": "chr19",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.525",
                "funcRefgene": "exonic",
                "geneInfo": "POLD1是DNA聚合酶δ复合物p125的催化亚基。 p125亚基含有聚合酶和3'至5'外切核酸酶活性（PMID：7490075,9030545）。 POLD1参与DNA复制期间的滞后链的DNA合成，聚合期间的校正活性和DNA修复（PMID：18439893,10781066,11027336）。在功能研究中，POLD1的表达降低显示由于DNA复制过程中的误差增加而导致基因组不稳定。此外，POLD1的表达降低与脆弱的位点不稳定性和高频率的染色体畸变相关（PMID：11003646,18591249）。最近的研究表明，POLD1蛋白水平随着年龄的增长而降低，导致DNA修复能力降低（PMID：22915169,21556771）。 POLD1的核酸外切酶结构域中的种系功能丧失突变导致几种疾病，包括以男性皮下脂肪营养不良，耳聋，下颌发育不全和性腺功能减退为特征的独特多系统疾病（PMID：23770608,25131834）。 POLD1的核酸外切酶结构域中的杂合种系突变也使个体易患结肠直肠癌和子宫内膜癌（PMID：23263490,24501277,23528559,26133394）。此外，在一些研究中已经显示了POLD1变体与乳腺癌风险之间的关联（PMID：15113441,25023197,16685647）。 POLD1突变已被确定为超突变的驱动因素，因此，具有POLD1变体的癌症可能对免疫疗法越来越敏感（PMID; 29056344）。",
                "geneName": "POLD1",
                "geneType": "geneYc,geneMy",
                "geneVar": "POLD1基因exon2第46位碱基A置换为G使得第16位氨基酸由赖氨酸转变成了谷氨酸",
                "hgsGb": "c.46A>G",
                "hgvs": "POLD1:NM_001256849:exon2:c.46A>G:p.Lys16Glu",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "50902154",
                "posStart": "50902154",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200715-38",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:627,693:0.525:378,380:249,313:33:207,213:60:32:0.520,0.509,0.525:0.004,0.045,0.951",
                "wxz": "exon2",
                "zlb": "NM_001256849"
            }
        ],
        "tmb": [],
        "tnb": []
    },
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "A/A",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，需较低剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较低，神经毒性综合征的严重程度可能降低",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "C/T",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "del/del",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，药物代谢较快",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/G",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "不需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，药物代谢较快",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "del/del",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "G/G",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/C",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "C/A",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "del/del",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "G/T",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "野生型",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/G",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/6TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢增加",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "C/C",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/A",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "G/A",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/A",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副低，代谢增加",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-43",
                "updateTime": "."
            }
        ],
        "clinical": [
            {
                "brief_summary": "  This phase I trial studies the side effects and best dose of alpha-TEA when given together  with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that  does not respond to treatment (refractory) and has spread to other places in the body  (metastatic). Anti-cancer treatment, such as alpha-TEA, work in different ways to stop the  growth of tumor cells, either by killing the cells, by stopping them from dividing, or by  stopping them from spreading. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Giving alpha-TEA and trastuzumab may work better for the treatment of breast cancer  compared to usual treatments.",
                "brief_title": "Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer",
                "condition": "Refractory Breast Carcinoma;ERBB2 Overexpression;Prognostic Stage IV Breast Cancer AJCC v8;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": "United States",
                "geneName": "ERBB2",
                "intervention_name": "Alpha-tocopheryloxyacetic Acid;Trastuzumab",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04120246",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "October 9, 2019"
            },
            {
                "brief_summary": "  This phase Ib/II trial studies the side effects and best dose of copanlisib when given  together with trastuzumab and pertuzumab and to see how well ithey work after induction  treatment in treating patients with HER2 positive stage IV breast cancer with PIK3CA or PTEN  mutation. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Monoclonal antibodies, such as pertuzumab, may kill tumor cells that are left after  chemotherapy. The addition of copanlisib to the usual treatment (trastuzumab and pertuzumab)  could shrink the cancer or stabilize it for longer duration as compared to the usual  treatment alone.",
                "brief_title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",
                "condition": "ERBB2 Gene Amplification;PTEN Gene Mutation;PIK3CA Gene Mutation;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": ".",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Trastuzumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04108858",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "September 30, 2019"
            },
            {
                "brief_summary": "  This phase Ib/II trial studies the side effects and best dose of copanlisib when given  together with trastuzumab and pertuzumab and to see how well ithey work after induction  treatment in treating patients with HER2 positive stage IV breast cancer with PIK3CA or PTEN  mutation. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Monoclonal antibodies, such as pertuzumab, may kill tumor cells that are left after  chemotherapy. The addition of copanlisib to the usual treatment (trastuzumab and pertuzumab)  could shrink the cancer or stabilize it for longer duration as compared to the usual  treatment alone.",
                "brief_title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",
                "condition": "ERBB2 Gene Amplification;PTEN Gene Mutation;PIK3CA Gene Mutation;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": ".",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Trastuzumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04108858",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "September 30, 2019"
            },
            {
                "brief_summary": "  This phase Ib/II trial studies the side effects and best dose of copanlisib when given  together with trastuzumab and pertuzumab and to see how well ithey work after induction  treatment in treating patients with HER2 positive stage IV breast cancer with PIK3CA or PTEN  mutation. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth. Trastuzumab is a form of &quot;targeted therapy&quot; because it works by  attaching itself to specific molecules (receptors) on the surface of cancer cells, known as  HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells  to grow are blocked and the cancer cell may be marked for destruction by the body's immune  system. Monoclonal antibodies, such as pertuzumab, may kill tumor cells that are left after  chemotherapy. The addition of copanlisib to the usual treatment (trastuzumab and pertuzumab)  could shrink the cancer or stabilize it for longer duration as compared to the usual  treatment alone.",
                "brief_title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",
                "condition": "ERBB2 Gene Amplification;PTEN Gene Mutation;PIK3CA Gene Mutation;Metastatic Breast Carcinoma;Anatomic Stage IV Breast Cancer AJCC v8;HER2 Positive Breast Carcinoma",
                "country": ".",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Trastuzumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04108858",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "September 30, 2019"
            },
            {
                "brief_summary": "  This is a Phase 2, open-label study to evaluate the efficacy and the safety/tolerability of  pyrotinib in previously treated NSCLC patients with EGFR exon 20 insertion mutations or HER2  exon 20 insertion mutations. Patient has had at least one prior systemic treatment for  locally advanced or metastatic NSCLC.",
                "brief_title": "Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation",
                "condition": "Non Small Cell Lung Cancer",
                "country": "China",
                "geneName": "ERBB2",
                "intervention_name": "Pyrotinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04063462",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "August 21, 2019"
            },
            {
                "brief_summary": "  This is a multi-center, observational genomic screening protocol to identify patients whose  tumors harbor somatic mutations in the ERBB2 (HER2) gene, as measured in circulating tumor  DNA (ctDNA) . Patients with histologically confirmed metastatic breast cancer (MBC) or  metastatic cervical cancer (MCC) are eligible for screening at 3 to 6 months intervals, or if  disease progression is suspected/confirmed. Blood samples will be collected from eligible  patients and ctDNA will be extracted and sequenced at a central laboratory, using  HER2-targeted next generation sequencing (NGS). A certified molecular test report will be  issued from the central laboratory and provided to the investigators and the study sponsor.  Patients who are identified with HER2 mutations by this screening protocol will subsequently  have access to an appropriate neratinib treatment protocol, pending medical eligibility.",
                "brief_title": "HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib",
                "condition": "Metastatic Cervical Cancer;Metastatic Breast Cancer",
                "country": "Serbia;Ireland;Spain",
                "geneName": "ERBB2",
                "intervention_name": "Almac HER-Seq Assay Kit",
                "intervention_type": "Diagnostic Test",
                "nct_num": "NCT03786107",
                "overall_status": "Recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "December 24, 2018"
            },
            {
                "brief_summary": "  Lung cancer is the most leading cause of cancer-related mortality worldwide. Most of the  patients with lung cancer are advanced stage at the time of diagnosis.  The two oncogenes that are important in lung cancer are epidermal growth factor receptor  (EGFR) and K-ras, mutated in 10% and 15% of non-small cell lung cancer (NSCLC) patients.  Large-scale DNA sequencing efforts have identified mutations in BRAF, PI3KCA and ERBB2 that  together represent another 5% of NSCLC patients. The success of EGFR tyrosine kinase  inhibitors (TKIs), such as gefitinib or erlotinib, and more recently ALK/MET TKI, crizotinib,  highlights the need to develop more genetically matched therapies. Therefore, genetic  classification of lung cancer has become increasingly important along with the advances with  targeted therapies.  ROS1 is a receptor tyrosine kinase with constitutive kinase activity. ROS1 was previously  discovered in cell lines where ROS1 fused with other proteins to act as a driver oncogene. In  2007, Rikova et al reported ROS1 fusion as driver mutations in NSCLC cell line (HCC78;  SLC34A2-ROS1) and NSCLC patient (CD74-ROS1). Li et al also found about 1% of samples  harboring CD74-ROS1 fusion in 202 resected lung adenocarcinomas from never smokers. The  incidence was as high as 10% in East Asian population. Currently there are now at least 13  ROS1 fusion variants involving 8 fusion partners (CD74-, SLC34A2-, FIG-, TPM3-, SDC4-,  LRIG3-, ERZ-, KDERL2-) identified in ROS1 positive NSCLC.  Interestingly, preclinical and clinical data have shown ROS1-positive tumors are sensitive to  crizotinib, because of potentially high common amino acid residues in the kinase domain  between ALK and ROS1, which explain why crizotinib can inhibit both ROS1 and ALK to similar  extent. Preliminary report from a phase I clinical trial of crizotinib in the ROS1-positive  NSCLC expansion cohort showed an overall response rate (ORR) of 57%. Given that crizotinib  has made remarkable clinical outcomes in phase I trial of ALK-positive NSCLC patients,  clinical development of ROS1 inhibitors, including crizotinib, should be accelerated to  provide targeted therapies to ROS1-positive NSCLC patients.",
                "brief_title": "A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement",
                "condition": "Non-small Cell Lung Cancer Harboring ROS1 Rearrangement",
                "country": "Korea, Republic of",
                "geneName": "ERBB2",
                "intervention_name": "LDK378(Ceritinib)",
                "intervention_type": "Drug",
                "nct_num": "NCT03399487",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "January 16, 2018"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to  cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified  colorectal cancer that has spread from where it started to other places in the body and  cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may  interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,  such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of  tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them  from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and  irinotecan hydrochloride in treating patients with colorectal cancer.",
                "brief_title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
                "condition": "Stage IVA Colon Cancer AJCC v7;Stage IIIA Colon Cancer AJCC v7;Stage IIIB Rectal Cancer AJCC v7;Stage IVB Colon Cancer AJCC v7;Recurrent Colon Carcinoma;Stage III Rectal Cancer AJCC v7;Stage III Colon Cancer AJCC v7;Stage IIIA Rectal Cancer AJCC v7;Stage IIIC Colon Cancer AJCC v7;Recurrent Rectal Carcinoma;Stage IVB Rectal Cancer AJCC v7;Rectal Adenocarcinoma;Colon Adenocarcinoma;ERBB2 Gene Amplification;Stage IVA Rectal Cancer AJCC v7;Stage IIIC Rectal Cancer AJCC v7;Stage IIIB Colon Cancer AJCC v7;Stage IV Rectal Cancer AJCC v7;Stage IV Colon Cancer AJCC v7",
                "country": "Puerto Rico;United States",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Irinotecan Hydrochloride;HER-2 testing;Cetuximab;Trastuzumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Drug;Other;Device",
                "nct_num": "NCT03365882",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "December 7, 2017"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to  cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified  colorectal cancer that has spread from where it started to other places in the body and  cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may  interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,  such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of  tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them  from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and  irinotecan hydrochloride in treating patients with colorectal cancer.",
                "brief_title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
                "condition": "Stage IVA Colon Cancer AJCC v7;Stage IIIA Colon Cancer AJCC v7;Stage IIIB Rectal Cancer AJCC v7;Stage IVB Colon Cancer AJCC v7;Recurrent Colon Carcinoma;Stage III Rectal Cancer AJCC v7;Stage III Colon Cancer AJCC v7;Stage IIIA Rectal Cancer AJCC v7;Stage IIIC Colon Cancer AJCC v7;Recurrent Rectal Carcinoma;Stage IVB Rectal Cancer AJCC v7;Rectal Adenocarcinoma;Colon Adenocarcinoma;ERBB2 Gene Amplification;Stage IVA Rectal Cancer AJCC v7;Stage IIIC Rectal Cancer AJCC v7;Stage IIIB Colon Cancer AJCC v7;Stage IV Rectal Cancer AJCC v7;Stage IV Colon Cancer AJCC v7",
                "country": "Puerto Rico;United States",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Irinotecan Hydrochloride;HER-2 testing;Cetuximab;Trastuzumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Drug;Other;Device",
                "nct_num": "NCT03365882",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "December 7, 2017"
            },
            {
                "brief_summary": "  This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to  cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified  colorectal cancer that has spread from where it started to other places in the body and  cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may  interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,  such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of  tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them  from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and  irinotecan hydrochloride in treating patients with colorectal cancer.",
                "brief_title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
                "condition": "Stage IVA Colon Cancer AJCC v7;Stage IIIA Colon Cancer AJCC v7;Stage IIIB Rectal Cancer AJCC v7;Stage IVB Colon Cancer AJCC v7;Recurrent Colon Carcinoma;Stage III Rectal Cancer AJCC v7;Stage III Colon Cancer AJCC v7;Stage IIIA Rectal Cancer AJCC v7;Stage IIIC Colon Cancer AJCC v7;Recurrent Rectal Carcinoma;Stage IVB Rectal Cancer AJCC v7;Rectal Adenocarcinoma;Colon Adenocarcinoma;ERBB2 Gene Amplification;Stage IVA Rectal Cancer AJCC v7;Stage IIIC Rectal Cancer AJCC v7;Stage IIIB Colon Cancer AJCC v7;Stage IV Rectal Cancer AJCC v7;Stage IV Colon Cancer AJCC v7",
                "country": "Puerto Rico;United States",
                "geneName": "ERBB2",
                "intervention_name": "Pertuzumab;Irinotecan Hydrochloride;HER-2 testing;Cetuximab;Trastuzumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Drug;Other;Device",
                "nct_num": "NCT03365882",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "December 7, 2017"
            },
            {
                "brief_summary": "  The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP  regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.",
                "brief_title": "Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.",
                "condition": "Sintilimab;TP53 Mutation;Diffuse Large B-Cell Lymphoma",
                "country": ".",
                "geneName": "TP53",
                "intervention_name": "Sintilimab-R-CHOP",
                "intervention_type": "Drug",
                "nct_num": "NCT04023916",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "July 18, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  CLL is an incurable disease with conventional chemotherapy. In the absence of TP53  disruption, a chemoimmunotherapy (CIT) regimen is recommended as front-line and second-line  treatment in those patients who attained a long progression-free survival (PFS) with the  previous regimen. Bendamustine and rituximab (BR) is one of the most widely adopted CIT  regimens, including second-line treatment. Unfortunately, durations of remission following BR  combination therapy tend to be short in patients with heavily pre-treated disease or who have  already received rituximab. The incorporation of a maintenance following induction  chemotherapy to overcome the shorter remission durations in this population is a reasonable  option.",
                "brief_title": "Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia",
                "condition": "Chronic Lymphocytic Leukemia",
                "country": "Russian Federation",
                "geneName": "TP53",
                "intervention_name": "BR as Maintenance",
                "intervention_type": "Drug",
                "nct_num": "NCT03847727",
                "overall_status": "Active, not recruiting",
                "phase": ".",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "February 20, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission  tomography (PET) and osimertinib works in evaluating glucose utilization in patients with  EGFR activated glioblastoma. Osimertinib may stop the growth of tumor cells by blocking some  of the enzymes needed for cell growth. 18F-FDG PET imaging may help to detect changes in  tumor glucose utilization, which may allow investigators to obtain an early read out on the  impact of osimertinib on recurrent glioblastoma patients whose tumors have EGFR activation.",
                "brief_title": "18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma",
                "condition": "EGFR Gene Mutation;Recurrent Glioblastoma;TP53 wt Allele;EGFR Gene Amplification;Supratentorial Glioblastoma;Glioblastoma",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Fludeoxyglucose F-18;Osimertinib;Positron Emission Tomography",
                "intervention_type": "Procedure;Drug;Other",
                "nct_num": "NCT03732352",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "November 6, 2018"
            },
            {
                "brief_summary": "  Recent preclinical studies suggest that combining MEK and MDM2 inhibition synergize to induce  apoptosis in RAS/BRAF-mutant and TP53 wild-type CRC models. In vitro, in RKO cell lines  (poorly differentiated colon carcinoma cell line resistant to single agent targeting MDM2 and  MEK and BRAF inhibition), the MDM2 plus MEK inhibitor combination generated a synergistic  increase in apoptotic index. In vivo, in mice harboring human RKO colon tumor xenografts the  combination of MDM2 plus MEK inhibition elicited 93% decreases in tumor volume.  This trial is to conduct a single-center, Phase 1 dose escalation study of trametinib  combined with HDM201 (a HDM2 inhibitor) in patients with advanced/metastatic RAS/RAF mutant  and TP53 wt CRC.",
                "brief_title": "Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type",
                "condition": "Advanced Cancer;Metastatic Cancer;Colorectal Cancer",
                "country": "France",
                "geneName": "TP53",
                "intervention_name": "Trametinib;HDM201",
                "intervention_type": "Drug",
                "nct_num": "NCT03714958",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "October 22, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in  treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that  is untreated or has come back. Quizartinib may stop the growth of cancer cells by blocking  some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine  and venetoclax, work in different ways to stop the growth of cancer cells, either by killing  the cells, by stopping them from dividing, or by stopping them from spreading. Giving  quizartinib and decitabine may work better at treating acute myeloid leukemia and  myelodysplastic syndrome.",
                "brief_title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",
                "condition": "TP53 Gene Deletion;Blasts More Than 10 Percent of Peripheral Blood White Cells;Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;TP53 Gene Mutation;Myelodysplastic Syndrome;Recurrent Acute Myeloid Leukemia;Acute Myeloid Leukemia;High Risk Myelodysplastic Syndrome;Recurrent Myelodysplastic Syndrome;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Quizartinib;Venetoclax;Decitabine",
                "intervention_type": "Drug",
                "nct_num": "NCT03661307",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "September 7, 2018"
            },
            {
                "brief_summary": "  Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the  treatment of advanced refractory solid tumors with TP53 harmful mutations.",
                "brief_title": "Treatment of Carrying TP53 Harmful Mutations",
                "condition": "Advanced Cancer",
                "country": "China",
                "geneName": "TP53",
                "intervention_name": "Fluzoparib combined with Apatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03645200",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "August 24, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  This phase II trial studies how well talazoparib works in treating patients with homologous  recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has  come back after previous treatment. Talazoparib may stop the growth of tumor cells by  blocking some of the enzymes needed for cell growth.",
                "brief_title": "Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer",
                "condition": "FANCM Gene Mutation;BARD1 Gene Mutation;BRCA2 Gene Mutation;Recurrent Squamous Cell Lung Carcinoma;RAD51 Gene Mutation;Stage IV Squamous Cell Lung Carcinoma AJCC v7;FANCD2 Gene Mutation;ATM Gene Mutation;FANCF Gene Mutation;CHEK2 Gene Mutation;BRIP1 Gene Mutation;RAD54L Gene Mutation;NBN Gene Mutation;RAD51B Gene Mutation;FANCC Gene Mutation;PALB2 Gene Mutation;FANCA Gene Mutation;ATR Gene Mutation;BRCA1 Gene Mutation;CHEK1 Gene Mutation;RPA1 Gene Mutation",
                "country": "Canada;United States",
                "geneName": "CHEK1",
                "intervention_name": "Talazoparib;Pharmacological Study;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03377556",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "December 19, 2017"
            },
            {
                "brief_summary": "  Single arm, single site, open-label Phase II study of the effects of oral olaparib in  participants with metastatic renal cell carcinoma that harbor an inactivating mutation in  BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,  RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint  inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1  criteria.",
                "brief_title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",
                "condition": "Kidney Cancer;Renal Carcinoma;Renal Cell Carcinoma;Kidney Cancer Metastatic;Metastatic Renal Cell Carcinoma",
                "country": "United States",
                "geneName": "CHEK1",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03786796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "December 25, 2018"
            },
            {
                "brief_summary": "  This phase II trial studies how well niraparib, when given before surgery, works in treating  patients with high risk prostate cancer that has not spread to other parts of the body  (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may  stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects",
                "condition": "Prostate Carcinoma;DNA Repair Gene Mutation;NBN Gene Mutation;FANCA Gene Mutation;FANCD2 Gene Mutation;BRCA1 Gene Mutation;FANCL Gene Mutation;ATM Gene Mutation;CHEK1 Gene Mutation;RAD51 Gene Mutation;RAD51C Gene Mutation;CHEK2 Gene Mutation;GEN1 Gene Mutation;BRIP1 Gene Mutation;CDK12 Gene Mutation;DNA Damage Response Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "CHEK1",
                "intervention_name": "Niraparib Tosylate Monohydrate;Niraparib;Radical Prostatectomy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT04030559",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-43",
                "study_first_posted": "July 24, 2019"
            }
        ],
        "cms": [
            {
                "age": "84",
                "agentName": "上海华东医院（蔡雯雯）",
                "areaAgentName": "潘缪春",
                "backStatus": "2",
                "backStatusShow": "已返款",
                "barcode": "2007141436495",
                "bedNumber": ".",
                "bingli": ".",
                "birthday": ".",
                "checkTime": ".",
                "contact": "13122489447",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": ".",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-22 11:30:00",
                "expressName": ".",
                "expressNum": "SF1091187301147",
                "fenziBingli": ".",
                "financeId": "232990",
                "gender": "男",
                "historyNum": "0",
                "hospitalName": "华东医院",
                "idCard": ".",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-14 14:45:55",
                "invoiceApplyMoney": "10800.00",
                "invoiceName": ".",
                "invoiceReceivePhone": "13122489447",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "5",
                "invoiceTypeShow": "电子发票",
                "itemName": "0201027.OncoDrug-Seq全实体瘤110基因（血液ctDNA样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-14 14:31:28",
                "medicalRecord": ".",
                "name": "金克仁",
                "nickName": "蔡雯雯",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "1",
                "paymentTypeShow": "现结",
                "receiveStatus": "2",
                "receiveStatusShow": "已收款",
                "receiveTime": "2020-07-15 11:30:24",
                "remark": ".",
                "reportAddress": "上海市延安西路139号华东医院1楼肿瘤科",
                "reportAddressName": "赵洪",
                "reportCheckTime": ".",
                "reportEmail": ".",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": "13122489447",
                "reportStyle": "电子 纸质",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "234497",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200715-43",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": ".",
                "sickAge": ".",
                "sickFamilyHistory": ".",
                "source": "血液(cfDNA)",
                "sourceFrom": ".",
                "testDoctor": ".",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "非小细胞肺癌",
                "treatHistory": ".",
                "treatID": "TS0101",
                "treatResult": "肺癌",
                "treatmentNo": ".",
                "unitAgentName": "蔡雯雯",
                "url": "[]",
                "userId": "11257",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [],
        "fusion": [],
        "heredity": [
            {
                "aachangeRefgene": ".",
                "ajsGb": ".",
                "alt": ".",
                "alteration": ".",
                "barcode": ".",
                "chr": ".",
                "clinsig": ".",
                "description": ".",
                "diseaseInfo": ".",
                "evidenceLevel": ".",
                "exonicfuncRefgene": ".",
                "freq": ".",
                "funcRefgene": ".",
                "geneInfo": ".",
                "geneName": ".",
                "geneType": ".",
                "geneVar": ".",
                "geneYcType": ".",
                "hgsGb": ".",
                "hgvs": ".",
                "intervarAutomated": ".",
                "level": ".",
                "mutationType": ".",
                "ominId": ".",
                "posEnd": ".",
                "posStart": ".",
                "projectAbbr": "DE",
                "ref": ".",
                "relativeDisease": ".",
                "riskLevel": ".",
                "sampleSn": "NGS200715-43",
                "tumorProfiles": ".",
                "vcfFormat": ".",
                "vcfFormatInfo": ".",
                "wxz": ".",
                "zlb": "."
            }
        ],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:0.0%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "0.0%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "如果使用免疫检查点抑制剂治疗，疗效可能较好",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "检测到变异/基因突变（NM_000546:intron5:c.559+1G>A）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": "TP53:",
                "Unnamed: 8": ".",
                "Unnamed: 9": "NGS200715-43",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 0,
                "percent": 0.0,
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-43",
                "totalSites": 66
            }
        ],
        "qc": [
            {
                "cleanBases": 4386824389,
                "cleanReads": 31420786,
                "coverage>0.2x": 99.16,
                "coverage>0.5x": 92.89,
                "effectCoverage500": 97.91,
                "effectDepth": 2643,
                "insert": 197.5,
                "mapping": 99.93,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 4782402000,
                "rawDuplication": 18.74,
                "rawReads": 31882680,
                "readPercent": 98.55,
                "samplePurity": ".",
                "sampleSn": "NGS200715-43",
                "sampleType": "ctDNA",
                "targetMapping": 72.36,
                "trimDuplication": 0.0,
                "tumorCoverage": 99.86,
                "tumorDepth": 4846,
                "tumorQ30": 93.47
            }
        ],
        "target": [
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "TP53",
                "NM_ID": "NM_000546",
                "ajsGb": "c.559+1G>A",
                "alt": "T",
                "alteration": ".",
                "avsnp150": ".",
                "cancerType": "卵巢癌",
                "chr": "chr17",
                "clinsig": "Pathogenic|Likely_pathogenic",
                "cosmic70": "ID\\x3dCOSM131535",
                "drugLevel": "3A",
                "drugs": "AZD1775",
                "exonicfuncRefgene": ".",
                "freq": "0.058",
                "funcRefgene": "splicing",
                "geneInfo": "TP53通过诱导下游抗肿瘤反应如DNA修复和细胞凋亡（PMID：11099028）编码p53肿瘤抑制蛋白，该蛋白是一种对细胞应激（包括DNA损伤和致癌激活）反应的转录因子。 TP53是人类癌症中最常见的突变基因，并且其胚系突变导致广泛癌症倾向的Li-Fraumeni综合征（PMID：22713868,21765642）。 p53蛋白由N末端反式激活结构域，中央DNA结合结构域，寡聚化结构域和C末端调节结构域（PMID：22713868）组成。",
                "geneName": "TP53",
                "geneType": "geneBx,geneHl,geneMy",
                "geneVar": "TP53基因intron5第559+1位G碱基置换为A",
                "hgsGb": "c.559+1G>A",
                "hgvs": "TP53:NM_000546:intron5:c.559+1G>A",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "7578370",
                "posStart": "7578370",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-43",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:1923,119:0.072:995,64:928,55:30:175,155:60:35:0.056,0.051,0.058:0.001,0.009,0.991",
                "wxz": "intron5",
                "zlb": "NM_000546"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "TP53",
                "NM_ID": "NM_000546",
                "ajsGb": "c.559+1G>A",
                "alt": "T",
                "alteration": ".",
                "avsnp150": ".",
                "cancerType": "头颈鳞癌",
                "chr": "chr17",
                "clinsig": "Pathogenic|Likely_pathogenic",
                "cosmic70": "ID\\x3dCOSM131535",
                "drugLevel": "3A",
                "drugs": "AZD1775",
                "exonicfuncRefgene": ".",
                "freq": "0.058",
                "funcRefgene": "splicing",
                "geneInfo": "TP53通过诱导下游抗肿瘤反应如DNA修复和细胞凋亡（PMID：11099028）编码p53肿瘤抑制蛋白，该蛋白是一种对细胞应激（包括DNA损伤和致癌激活）反应的转录因子。 TP53是人类癌症中最常见的突变基因，并且其胚系突变导致广泛癌症倾向的Li-Fraumeni综合征（PMID：22713868,21765642）。 p53蛋白由N末端反式激活结构域，中央DNA结合结构域，寡聚化结构域和C末端调节结构域（PMID：22713868）组成。",
                "geneName": "TP53",
                "geneType": "geneBx,geneHl,geneMy",
                "geneVar": "TP53基因intron5第559+1位G碱基置换为A",
                "hgsGb": "c.559+1G>A",
                "hgvs": "TP53:NM_000546:intron5:c.559+1G>A",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "7578370",
                "posStart": "7578370",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-43",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:1923,119:0.072:995,64:928,55:30:175,155:60:35:0.056,0.051,0.058:0.001,0.009,0.991",
                "wxz": "intron5",
                "zlb": "NM_000546"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "E770_K831ins",
                "DNA_change": "Exon 20 insertions",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "ERBB2",
                "NM_ID": "NM_004448",
                "ajsGb": "p.Tyr772_Ala775dup",
                "alt": "GCATACGTGATG",
                "alteration": "Y772_A775dup",
                "avsnp150": "rs397516975",
                "cancerType": "非小细胞肺癌",
                "chr": "chr17",
                "clinsig": "Likely_pathogenic",
                "cosmic70": ".",
                "drugLevel": "2A",
                "drugs": "恩美曲妥珠单抗",
                "exonicfuncRefgene": "nonframeshift_insertion",
                "freq": "0.315",
                "funcRefgene": "exonic",
                "geneInfo": "ERBB2，是EGFR酪氨酸激酶家族的成员，在一些癌症中会发生异常扩增或者过表达，这些癌症包括乳腺癌，胃癌/食道癌或子宫内膜癌 (PMID:19536107) 。ERBB2/HER2很独特，它不直接结合自己的配体。相反，它强力活化其他配体结合到ErbB受体，如EGFR（ErbB1）或ErbB3（PMID：12620236）。事实上，ERBB2是所有ERBB受体同种型（PMID：10220407,9130710）的优选结合配偶体，ERBB2 / ERBB3复合物通过激活下游致癌PI3K途径（PMID：12853564）显示出高促有丝分裂活性。或者，ERBB2可同源二聚化并启动细胞内有丝分裂级联，包括RAS / MAPK，PI3K / AKT / mTOR，SRC和STAT信号传导途径（PMID：22785351）。大约17% to 30%的乳腺癌患者会发生ERBB2基因的扩增，这与预后不良和复发相关(PMID: 3798106, 23000897,9552035, 9469329)。扩增的ERBB2与ERBB3异源二聚化以激活PI3K / AKT / mTOR信号传导并驱动乳腺癌中的肿瘤发生（PMID：12853564,23204226,12124352,18632642）。ERBB2在约20％胃或胃食管癌（PMID：24943493,21468131）中也被扩增，并且其过度表达被多种可用药物（例如曲妥珠单抗，阿托珠单抗埃米替宁，拉帕替尼和培妥珠单抗）靶向（PMID：24799465） 。ERBB2扩增的发生率很低在非小细胞细胞肺癌，膀胱癌，宫颈癌，子宫内膜癌，结直肠癌，胰腺癌，涎腺导管癌，软组织癌和胆管癌中(reviewed in PMID: 24656976)。激活的ERBB2突变最近在许多肿瘤中被确定是低频率的，包括肺腺癌，小叶性乳腺癌，膀胱癌，胃癌和子宫内膜癌，其中热点变异主要发生在胞外区和激酶活性区(PMID: 23000897, 23220880, 22908275)。临床前研究表明具有这些突变的患者对FDA批准的用于ERBB2靶向治疗较为敏感。临床试验正在ERBB2突变队列中进行，有一些ERBB2靶向激酶抑制剂功效的阳性证据。结肠直肠癌ERBB2突变常与RAS突变共同发生。",
                "geneName": "ERBB2",
                "geneType": "geneBx",
                "geneVar": "ERBB2基因exon20第2313_2324位碱基重复使得第772_775位氨基酸重复",
                "hgsGb": "c.2313_2324dup",
                "hgvs": "ERBB2:NM_004448:exon20:c.2313_2324dup:p.Tyr772_Ala775dup",
                "intervarAutomated": ".",
                "level": "4（可能致病）",
                "posEnd": "37880981",
                "posStart": "37880981",
                "projectAbbr": "DE",
                "ref": "-",
                "sampleSn": "NGS200715-43",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:1673,769:0.328:895,400:778,369:32:172,143:60:27:0.310,0.307,0.315:0.003,0.011,0.986",
                "wxz": "exon20",
                "zlb": "NM_004448"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "E770_K831ins",
                "DNA_change": "Exon 20 insertions",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "ERBB2",
                "NM_ID": "NM_004448",
                "ajsGb": "p.Tyr772_Ala775dup",
                "alt": "GCATACGTGATG",
                "alteration": "Y772_A775dup",
                "avsnp150": "rs397516975",
                "cancerType": "非小细胞肺癌",
                "chr": "chr17",
                "clinsig": "Likely_pathogenic",
                "cosmic70": ".",
                "drugLevel": "3A",
                "drugs": "奈拉替尼",
                "exonicfuncRefgene": "nonframeshift_insertion",
                "freq": "0.315",
                "funcRefgene": "exonic",
                "geneInfo": "ERBB2，是EGFR酪氨酸激酶家族的成员，在一些癌症中会发生异常扩增或者过表达，这些癌症包括乳腺癌，胃癌/食道癌或子宫内膜癌 (PMID:19536107) 。ERBB2/HER2很独特，它不直接结合自己的配体。相反，它强力活化其他配体结合到ErbB受体，如EGFR（ErbB1）或ErbB3（PMID：12620236）。事实上，ERBB2是所有ERBB受体同种型（PMID：10220407,9130710）的优选结合配偶体，ERBB2 / ERBB3复合物通过激活下游致癌PI3K途径（PMID：12853564）显示出高促有丝分裂活性。或者，ERBB2可同源二聚化并启动细胞内有丝分裂级联，包括RAS / MAPK，PI3K / AKT / mTOR，SRC和STAT信号传导途径（PMID：22785351）。大约17% to 30%的乳腺癌患者会发生ERBB2基因的扩增，这与预后不良和复发相关(PMID: 3798106, 23000897,9552035, 9469329)。扩增的ERBB2与ERBB3异源二聚化以激活PI3K / AKT / mTOR信号传导并驱动乳腺癌中的肿瘤发生（PMID：12853564,23204226,12124352,18632642）。ERBB2在约20％胃或胃食管癌（PMID：24943493,21468131）中也被扩增，并且其过度表达被多种可用药物（例如曲妥珠单抗，阿托珠单抗埃米替宁，拉帕替尼和培妥珠单抗）靶向（PMID：24799465） 。ERBB2扩增的发生率很低在非小细胞细胞肺癌，膀胱癌，宫颈癌，子宫内膜癌，结直肠癌，胰腺癌，涎腺导管癌，软组织癌和胆管癌中(reviewed in PMID: 24656976)。激活的ERBB2突变最近在许多肿瘤中被确定是低频率的，包括肺腺癌，小叶性乳腺癌，膀胱癌，胃癌和子宫内膜癌，其中热点变异主要发生在胞外区和激酶活性区(PMID: 23000897, 23220880, 22908275)。临床前研究表明具有这些突变的患者对FDA批准的用于ERBB2靶向治疗较为敏感。临床试验正在ERBB2突变队列中进行，有一些ERBB2靶向激酶抑制剂功效的阳性证据。结肠直肠癌ERBB2突变常与RAS突变共同发生。",
                "geneName": "ERBB2",
                "geneType": "geneBx",
                "geneVar": "ERBB2基因exon20第2313_2324位碱基重复使得第772_775位氨基酸重复",
                "hgsGb": "c.2313_2324dup",
                "hgvs": "ERBB2:NM_004448:exon20:c.2313_2324dup:p.Tyr772_Ala775dup",
                "intervarAutomated": ".",
                "level": "4（可能致病）",
                "posEnd": "37880981",
                "posStart": "37880981",
                "projectAbbr": "DE",
                "ref": "-",
                "sampleSn": "NGS200715-43",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:1673,769:0.328:895,400:778,369:32:172,143:60:27:0.310,0.307,0.315:0.003,0.011,0.986",
                "wxz": "exon20",
                "zlb": "NM_004448"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "E770_K831ins",
                "DNA_change": "Exon 20 insertions",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "ERBB2",
                "NM_ID": "NM_004448",
                "ajsGb": "p.Tyr772_Ala775dup",
                "alt": "GCATACGTGATG",
                "alteration": "Y772_A775dup",
                "avsnp150": "rs397516975",
                "cancerType": "乳腺癌",
                "chr": "chr17",
                "clinsig": "Likely_pathogenic",
                "cosmic70": ".",
                "drugLevel": "3A",
                "drugs": "奈拉替尼",
                "exonicfuncRefgene": "nonframeshift_insertion",
                "freq": "0.315",
                "funcRefgene": "exonic",
                "geneInfo": "ERBB2，是EGFR酪氨酸激酶家族的成员，在一些癌症中会发生异常扩增或者过表达，这些癌症包括乳腺癌，胃癌/食道癌或子宫内膜癌 (PMID:19536107) 。ERBB2/HER2很独特，它不直接结合自己的配体。相反，它强力活化其他配体结合到ErbB受体，如EGFR（ErbB1）或ErbB3（PMID：12620236）。事实上，ERBB2是所有ERBB受体同种型（PMID：10220407,9130710）的优选结合配偶体，ERBB2 / ERBB3复合物通过激活下游致癌PI3K途径（PMID：12853564）显示出高促有丝分裂活性。或者，ERBB2可同源二聚化并启动细胞内有丝分裂级联，包括RAS / MAPK，PI3K / AKT / mTOR，SRC和STAT信号传导途径（PMID：22785351）。大约17% to 30%的乳腺癌患者会发生ERBB2基因的扩增，这与预后不良和复发相关(PMID: 3798106, 23000897,9552035, 9469329)。扩增的ERBB2与ERBB3异源二聚化以激活PI3K / AKT / mTOR信号传导并驱动乳腺癌中的肿瘤发生（PMID：12853564,23204226,12124352,18632642）。ERBB2在约20％胃或胃食管癌（PMID：24943493,21468131）中也被扩增，并且其过度表达被多种可用药物（例如曲妥珠单抗，阿托珠单抗埃米替宁，拉帕替尼和培妥珠单抗）靶向（PMID：24799465） 。ERBB2扩增的发生率很低在非小细胞细胞肺癌，膀胱癌，宫颈癌，子宫内膜癌，结直肠癌，胰腺癌，涎腺导管癌，软组织癌和胆管癌中(reviewed in PMID: 24656976)。激活的ERBB2突变最近在许多肿瘤中被确定是低频率的，包括肺腺癌，小叶性乳腺癌，膀胱癌，胃癌和子宫内膜癌，其中热点变异主要发生在胞外区和激酶活性区(PMID: 23000897, 23220880, 22908275)。临床前研究表明具有这些突变的患者对FDA批准的用于ERBB2靶向治疗较为敏感。临床试验正在ERBB2突变队列中进行，有一些ERBB2靶向激酶抑制剂功效的阳性证据。结肠直肠癌ERBB2突变常与RAS突变共同发生。",
                "geneName": "ERBB2",
                "geneType": "geneBx",
                "geneVar": "ERBB2基因exon20第2313_2324位碱基重复使得第772_775位氨基酸重复",
                "hgsGb": "c.2313_2324dup",
                "hgvs": "ERBB2:NM_004448:exon20:c.2313_2324dup:p.Tyr772_Ala775dup",
                "intervarAutomated": ".",
                "level": "4（可能致病）",
                "posEnd": "37880981",
                "posStart": "37880981",
                "projectAbbr": "DE",
                "ref": "-",
                "sampleSn": "NGS200715-43",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:1673,769:0.328:895,400:778,369:32:172,143:60:27:0.310,0.307,0.315:0.003,0.011,0.986",
                "wxz": "exon20",
                "zlb": "NM_004448"
            }
        ],
        "tmb": [],
        "tnb": []
    },
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副中度",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "G/A",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，需较低剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较高，神经毒性综合征的严重程度可能降低",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/G",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，药物代谢较快",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "A/A",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/G",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，药物代谢较快",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/T",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "T/G",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "A/A",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "C/C",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "C/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/T",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "野生型",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/G",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/6TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "T/T",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢降低",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "T/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/A",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "G/G",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/A",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副低，代谢增加",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-45",
                "updateTime": "."
            }
        ],
        "clinical": [
            {
                "brief_summary": "  This is a phase 1 study of atezolizumab in combination with D2C7-IT, a dual-specific  monoclonal antibody (mAB) with a high affinity for both EGFRwt- and EGFRvIII-expressing  cells, in patients with recurrent World Health Organization (WHO) grade IV malignant glioma  at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.",
                "brief_title": "D2C7-IT With Atezolizumab for Recurrent Gliomas",
                "condition": "Malignant Glioma",
                "country": "United States",
                "geneName": "EGFR",
                "intervention_name": "D2C7-IT (6920 ng/mL via convection-enhanced delivery);Atezolizumab (1200 mg every three weeks)",
                "intervention_type": "Drug",
                "nct_num": "NCT04160494",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "November 13, 2019"
            },
            {
                "brief_summary": "  The esophageal squamous cell carcinoma (ESCC) has high prevalence and mortality in China,  which become a severe challenge for public health. The molecular imaging technology has been  developed for intra-operative visualization and precise resection of the tumors. The imaging  probe possess high affinity to the tumor specific targets. Among the tumor related proteins,  EGFR is located on the cell membrane and over expresses in more than 50% ESCC which has been  used as an ideal target for molecular imaging.  Cetuximab is an EGFR targeting antibody for anti cancer therapy. When labeled with an  commercial available fluorescence dye IRDye800, cetuximab has been used as molecular imaging  probe in clinical trials for surgical navigation of cancers including head and neck squamous  cell cancers and gliomas. Previous studies shown high safety when using this probe and  excellence sensitivity for cancer detection, which bring great promise in translational  medicine.  This is a single-center prospective sequential trial. It is the first attempt to apply  cetuximab-IRDye800 probe in ESCC surgery. This probe will be produced under clinical Good  Manufacturing Practice (cGMP) conditions. The ESCC patients will be recruited with strict  criteria.Patients population is planned to be 40 cases between18 and 65 years old, without  gender limit. The patients will be divided into four groups : control group without probe  administration, 1% dose group (1% of therapeutic cetuximab dose; 2.5 Mg/m2) and 10% dose  groups (10%of therapeutic cetuximab dose ;25mg/m2) and 25% dose group (25%of therapeutic  cetuximab dose; 62.5mg/m2), 10 cases are sequential assigned to each group. After informed  consent, patients will receive a systemic infusion of the study drug 2 days before surgery.  Primary (safety and efficiency) and secondary endpoints (tissue EGFR expression) will be  recorded. Preoperative management and surgical procedures will been performed according to  conventional protocols. Intra-operative imaging of the surgical field will be performed in  real time at 2 time points: before and post tumor resection. The postoperative specimens will  be subjected to pathological analysis including correlation study of fluorescence signal and  tumor tissue in pathology slice.  A protocol for managing any allergic reaction related to systemic infusion of cetuximab has  been established. The patient's vital signs and ECG will be closely monitored post probe  administration. The blood, liver and kidney, coagulation function and cardiotoxicity will be  evaluated before and post surgery.  This clinical trial is anticipated to validate the concept that intra-operative fluorescent  imaging of esophageal squamous cell carcinoma with cetuximab-IRDye800 can facilitate the  demarcation of tumor boundary and identification of metastatic lymph nodes and testify its  safety.",
                "brief_title": "Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer",
                "condition": "Drug Safety ; Drug Specificity",
                "country": "China",
                "geneName": "EGFR",
                "intervention_name": "Cetuximab-IRDye800",
                "intervention_type": "Drug",
                "nct_num": "NCT04161560",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "November 13, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies the side effects of ESK981 and nivolumab and to see how well they  work for the treatment of castration resistant prostate cancer that has spread to other  places in the body (metastatic). ESK981 is an investigational drug that targets several  important pathways that are believed to play a role in the spread of cancer. Immunotherapy  with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the  cancer, and may interfere with the ability of tumor cells to grow and spread. This study is  being done to see if giving ESK981 and nivolumab together works better in treating metastatic  castration resistant prostate cancer compared to usual treatments.",
                "brief_title": "ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer",
                "condition": "Prostate Carcinoma Metastatic in the Bone;Castration-Resistant Prostate Carcinoma;Stage IVB Prostate Cancer AJCC v8;Metastatic Prostate Carcinoma;Castration Levels of Testosterone",
                "country": "United States",
                "geneName": "EGFR",
                "intervention_name": "Nivolumab;Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04159896",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "November 11, 2019"
            },
            {
                "brief_summary": "  The study aims to find whether patients with advanced HCC can get more benefits from RFA  +PD-1 immunosuppressant (carrizumab) and VEGFR-2 suppressant (apatinib) compared with  carrizumab and apatinib alone, considering with the result of PFS.",
                "brief_title": "RFA Plus Carrizumab and Apatinib vs Carrizumab and Apatinib Alone for HCC",
                "condition": "Immunosuppression;Radiofrequency Ablation;Tumor Immunity",
                "country": "China",
                "geneName": "EGFR",
                "intervention_name": "radiofrequency ablation",
                "intervention_type": "Combination Product",
                "nct_num": "NCT04150744",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "November 5, 2019"
            },
            {
                "brief_summary": "  Leptomeningeal metastasis (LM) is a devastating and terminal complication of advanced  non-small-cell lung cancer (NSCLC), especially in patients harboring epidermal growth factor  receptor (EGFR) mutations. Osimertinib is an oral,third-generation, irreversible epidermal  growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both  EGFR-TKI-sensitizing and EGFR T790M resistance mutations .AURA I/II study and other  preclinical study suggested that Osimertinib exhibited a better blood-brain barrier(BBB)  penetration than the other EGFR-TKIs (gefitinib, erlotinib, or afatinib).The BLOOM 、AURA and  FLURA study demonstrated that osimertinib showed encouraging activity and manageable  tolerability in pretreated EGFR-mutant NSCLC patients with LM. Bevacizumab is a monoclonal  antibody against vascular endothelial growth factor (VEGF). Animal study and autopsy  specimens showed that VEGF is an essential factor in LM. Recently study showed EGFR-TKIs plus  bevacizumab prolonged PFS and OS in patients with EGFR-mutant NSCLC and multiple brain  mteastasis when compared with EGFR-TKIs alone. Howerver osimertinib combined with bevacizumab  could benefit patients with LM from EGFR- mutant NSCLC remains undetermined. Therefore, the  purpose of the study is to evaluate the safety and efficacy of osimertinib combined with  bevacizumab for EGFR- mutant non-small cell lung cancer with leptomeningeal metastasis",
                "brief_title": "Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis",
                "condition": "Non-small Cell Lung Cancer;Leptomeningeal Metastasis;EGFR Activating Mutation",
                "country": ".",
                "geneName": "EGFR",
                "intervention_name": "Bevacizumab;Osimertinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04148898",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "November 4, 2019"
            },
            {
                "brief_summary": "  Leptomeningeal metastasis (LM) is a devastating and terminal complication of advanced  non-small-cell lung cancer (NSCLC), especially in patients harboring epidermal growth factor  receptor (EGFR) mutations. Osimertinib is an oral,third-generation, irreversible epidermal  growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both  EGFR-TKI-sensitizing and EGFR T790M resistance mutations .AURA I/II study and other  preclinical study suggested that Osimertinib exhibited a better blood-brain barrier(BBB)  penetration than the other EGFR-TKIs (gefitinib, erlotinib, or afatinib).The BLOOM 、AURA and  FLURA study demonstrated that osimertinib showed encouraging activity and manageable  tolerability in pretreated EGFR-mutant NSCLC patients with LM. Bevacizumab is a monoclonal  antibody against vascular endothelial growth factor (VEGF). Animal study and autopsy  specimens showed that VEGF is an essential factor in LM. Recently study showed EGFR-TKIs plus  bevacizumab prolonged PFS and OS in patients with EGFR-mutant NSCLC and multiple brain  mteastasis when compared with EGFR-TKIs alone. Howerver osimertinib combined with bevacizumab  could benefit patients with LM from EGFR- mutant NSCLC remains undetermined. Therefore, the  purpose of the study is to evaluate the safety and efficacy of osimertinib combined with  bevacizumab for EGFR- mutant non-small cell lung cancer with leptomeningeal metastasis",
                "brief_title": "Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis",
                "condition": "Non-small Cell Lung Cancer;Leptomeningeal Metastasis;EGFR Activating Mutation",
                "country": ".",
                "geneName": "EGFR",
                "intervention_name": "Bevacizumab;Osimertinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04148898",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "November 4, 2019"
            },
            {
                "brief_summary": "  using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and  pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC)  after failure of EGFR tyrosine kinase inhibitors.",
                "brief_title": "A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.",
                "condition": "NSCLC Stage IIIB~IV",
                "country": ".",
                "geneName": "EGFR",
                "intervention_name": "Atezolizumab Injection; bevacizumab Injection",
                "intervention_type": "Drug",
                "nct_num": "NCT04147351",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "November 1, 2019"
            },
            {
                "brief_summary": "  using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and  pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC)  after failure of EGFR tyrosine kinase inhibitors.",
                "brief_title": "A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.",
                "condition": "NSCLC Stage IIIB~IV",
                "country": ".",
                "geneName": "EGFR",
                "intervention_name": "Atezolizumab Injection; bevacizumab Injection",
                "intervention_type": "Drug",
                "nct_num": "NCT04147351",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "November 1, 2019"
            },
            {
                "brief_summary": "  using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and  pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC)  after failure of EGFR tyrosine kinase inhibitors.",
                "brief_title": "A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.",
                "condition": "NSCLC Stage IIIB~IV",
                "country": ".",
                "geneName": "EGFR",
                "intervention_name": "Atezolizumab Injection; bevacizumab Injection",
                "intervention_type": "Drug",
                "nct_num": "NCT04147351",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "November 1, 2019"
            },
            {
                "brief_summary": "  To assess the efficacy and safety of ASK120067 versus a standard of care epidermal growth  factor receptor tyrosine kinase inhibitor Gefitinib in patients with locally advanced or  Metastatic Non Small Cell Lung Cancer",
                "brief_title": "ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC NSCLC",
                "condition": "Locally Advanced or Metastatic NSCLC",
                "country": "China",
                "geneName": "EGFR",
                "intervention_name": "Gefitinib + placebo ASK120067;Placebo Gefitinib 250 mg;Placebo ASK120067;Gefitinib 250 mg;ASK120067 + placebo",
                "intervention_type": "Drug",
                "nct_num": "NCT04143607",
                "overall_status": "Recruiting",
                "phase": "Phase 3",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "October 29, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well talazoparib works in treating patients with cancers that  have returned after a period of improvement, do not respond to treatment, or have spread to  other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes.  Talazoparib may cause tumor cells to die by blocking an enzyme that protects the tumor cells  from damage.",
                "brief_title": "Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes",
                "condition": "PALB2 Gene Mutation;Metastatic Malignant Neoplasm;Recurrent Malignant Neoplasm;Refractory Malignant Neoplasm;BRCA1 Gene Mutation;ATM Gene Mutation;Advanced Malignant Neoplasm;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "PALB2",
                "intervention_name": "Talazoparib;Pharmacological Study;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT02286687",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "November 10, 2014"
            },
            {
                "brief_summary": "  This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men  with metastatic castration resistant prostate cancer (mCRPC). Patients with tumors that have  ATM, BRCA1 and/or BRCA2 mutations/deletions/loss of heterozygosity will be randomized in a  1:1:1 fashion to each arm. Patients with mutations in noncanonical DNA repair genes including  FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2,  MSH6, BRIP1, or FAM175A defects will be assigned to Arm IV with single agent olaparib.",
                "brief_title": "Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects",
                "condition": "Metastatic Prostate Carcinoma;Abnormal DNA Repair;Stage IV Prostate Cancer;Prostate Cancer Metastatic Castration-Resistant",
                "country": "United States",
                "geneName": "PALB2",
                "intervention_name": "Olaparib;Abiraterone Acetate;Prednisone",
                "intervention_type": "Drug",
                "nct_num": "NCT03012321",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "January 6, 2017"
            },
            {
                "brief_summary": "  The main purpose of this study is to look at the effectiveness, safety, and antitumor  activity (preventing growth of the tumor) of the experimental study drug rucaparib (also  known as CO-338) on subjects and on their pancreatic cancer.",
                "brief_title": "Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy",
                "condition": "Pancreatic Cancer",
                "country": "United States",
                "geneName": "PALB2",
                "intervention_name": "RUCAPARIB",
                "intervention_type": "Drug",
                "nct_num": "NCT03140670",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "May 4, 2017"
            },
            {
                "brief_summary": "  This research study is for patients with metastatic breast cancer.    -  Metastatic means that the cancer has spread beyond the breast. In addition, through     genetic testing of the blood or tumor, an altered gene has been found that suggests the     tumor may not be able to repair its genetic material (DNA) when it becomes damaged.    -  This aspect of the cancer may cause it to be more sensitive - that is, more effectively     killed by certain types of drugs such as the study agent being evaluated in this trial,     Olaparib.     -  Olaparib is a type of drug known as a PARP inhibitor. Some types of breast cancer      and ovarian cancer share some basic features that make them sensitive to similar      treatments. Information from those other research studies suggests that this drug      may help to treat metastatic breast cancer.      -  This study will evaluate whether olaparib is effective in breast cancer       patients whose tumor has a mutation in one of the other genes that function       with BRCA1 and BRCA2 to repair damaged DNA .This mutation may have been       inherited from a parent, or may have developed only in the tumor.      -  This study will also evaluate whether olaparib is effective in breast cancer       patients whose tumor has a mutation in BRCA1 or BRCA2 that was acquired by the       tumor, but not inherited.",
                "brief_title": "Olaparib In Metastatic Breast Cancer",
                "condition": "PALB2 Gene Mutation;NBN Gene Mutation;Somatic Mutation Breast Cancer (BRCA1);Invasive Breast Cancer;Somatic Mutation Breast Cancer (BRCA2);ATM Gene Mutation;RAD51 Gene Mutation;CHEK2 Gene Mutation;BRIP1 Gene Mutation;Metastatic Breast Cancer",
                "country": "United States",
                "geneName": "PALB2",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03344965",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "November 17, 2017"
            },
            {
                "brief_summary": "  This phase II trial studies how well talazoparib works in treating patients with homologous  recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has  come back after previous treatment. Talazoparib may stop the growth of tumor cells by  blocking some of the enzymes needed for cell growth.",
                "brief_title": "Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer",
                "condition": "FANCM Gene Mutation;BARD1 Gene Mutation;BRCA2 Gene Mutation;Recurrent Squamous Cell Lung Carcinoma;RAD51 Gene Mutation;Stage IV Squamous Cell Lung Carcinoma AJCC v7;FANCD2 Gene Mutation;ATM Gene Mutation;FANCF Gene Mutation;CHEK2 Gene Mutation;BRIP1 Gene Mutation;RAD54L Gene Mutation;NBN Gene Mutation;RAD51B Gene Mutation;FANCC Gene Mutation;PALB2 Gene Mutation;FANCA Gene Mutation;ATR Gene Mutation;BRCA1 Gene Mutation;CHEK1 Gene Mutation;RPA1 Gene Mutation",
                "country": "Canada;United States",
                "geneName": "PALB2",
                "intervention_name": "Talazoparib;Pharmacological Study;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03377556",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "December 19, 2017"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib works in treating participants with prostate  cancer that has not spread to other parts of the body. Olaparib may stop the growth of tumor  cells by interfering with the activity of a substance called PARP, which is inside cells.  Giving olaparib before surgery may make the tumor smaller and reduce the amount of normal  tissue that needs to be removed.",
                "brief_title": "Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer",
                "condition": "PALB2 Gene Mutation;FANCA Biallelic Inactivation;Stage II Prostate Cancer AJCC v8;Stage IIC Prostate Cancer AJCC v8;ATM Biallelic Inactivation;BRCA1 Gene Mutation;Homologous Recombination Deficiency;Prostate Adenocarcinoma Without Evidence of Neuroendocrine Differentiation;ATM Gene Mutation;Stage IIB Prostate Cancer AJCC v8;Stage I Prostate Cancer AJCC v8;BRCA2 Biallelic Inactivation;BRCA1 Biallelic Inactivation;PALB2 Biallelic Inactivation;Stage IIA Prostate Cancer AJCC v8;BRCA2 Gene Mutation;ATM Monoallelic Inactivation",
                "country": "United States",
                "geneName": "PALB2",
                "intervention_name": "Olaparib;Radical Prostatectomy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT03570476",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "June 27, 2018"
            },
            {
                "brief_summary": "  Single arm, single site, open-label Phase II study of the effects of oral olaparib in  participants with metastatic renal cell carcinoma that harbor an inactivating mutation in  BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,  RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint  inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1  criteria.",
                "brief_title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",
                "condition": "Kidney Cancer;Renal Carcinoma;Renal Cell Carcinoma;Kidney Cancer Metastatic;Metastatic Renal Cell Carcinoma",
                "country": "United States",
                "geneName": "PALB2",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03786796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "December 25, 2018"
            },
            {
                "brief_summary": "  This phase II trial studies how well olaparib works in treating patients with biliary tract  cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair  gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes  needed for cell growth.",
                "brief_title": "Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations",
                "condition": "PALB2 Gene Mutation;NBN Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;PTEN Gene Deletion;ATR Gene Mutation;BRCA1 Gene Mutation;ATM Gene Mutation;Metastatic Bile Duct Carcinoma;ARID1A Gene Mutation;RAD51 Gene Mutation;CHEK2 Gene Mutation;MRE11 Gene Mutation;BRIP1 Gene Mutation;Bile Duct Adenocarcinoma;EMSY Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "PALB2",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT04042831",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "August 2, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well talazoparib works in treating patients with homologous  recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has  come back after previous treatment. Talazoparib may stop the growth of tumor cells by  blocking some of the enzymes needed for cell growth.",
                "brief_title": "Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer",
                "condition": "FANCM Gene Mutation;BARD1 Gene Mutation;BRCA2 Gene Mutation;Recurrent Squamous Cell Lung Carcinoma;RAD51 Gene Mutation;Stage IV Squamous Cell Lung Carcinoma AJCC v7;FANCD2 Gene Mutation;ATM Gene Mutation;FANCF Gene Mutation;CHEK2 Gene Mutation;BRIP1 Gene Mutation;RAD54L Gene Mutation;NBN Gene Mutation;RAD51B Gene Mutation;FANCC Gene Mutation;PALB2 Gene Mutation;FANCA Gene Mutation;ATR Gene Mutation;BRCA1 Gene Mutation;CHEK1 Gene Mutation;RPA1 Gene Mutation",
                "country": "Canada;United States",
                "geneName": "BARD1",
                "intervention_name": "Talazoparib;Pharmacological Study;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03377556",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "December 19, 2017"
            },
            {
                "brief_summary": "  Single arm, single site, open-label Phase II study of the effects of oral olaparib in  participants with metastatic renal cell carcinoma that harbor an inactivating mutation in  BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,  RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint  inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1  criteria.",
                "brief_title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",
                "condition": "Kidney Cancer;Renal Carcinoma;Renal Cell Carcinoma;Kidney Cancer Metastatic;Metastatic Renal Cell Carcinoma",
                "country": "United States",
                "geneName": "BARD1",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03786796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "December 25, 2018"
            },
            {
                "brief_summary": "  This phase II trial studies how well talazoparib works in treating patients with homologous  recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has  come back after previous treatment. Talazoparib may stop the growth of tumor cells by  blocking some of the enzymes needed for cell growth.",
                "brief_title": "Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer",
                "condition": "FANCM Gene Mutation;BARD1 Gene Mutation;BRCA2 Gene Mutation;Recurrent Squamous Cell Lung Carcinoma;RAD51 Gene Mutation;Stage IV Squamous Cell Lung Carcinoma AJCC v7;FANCD2 Gene Mutation;ATM Gene Mutation;FANCF Gene Mutation;CHEK2 Gene Mutation;BRIP1 Gene Mutation;RAD54L Gene Mutation;NBN Gene Mutation;RAD51B Gene Mutation;FANCC Gene Mutation;PALB2 Gene Mutation;FANCA Gene Mutation;ATR Gene Mutation;BRCA1 Gene Mutation;CHEK1 Gene Mutation;RPA1 Gene Mutation",
                "country": "Canada;United States",
                "geneName": "CHEK1",
                "intervention_name": "Talazoparib;Pharmacological Study;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT03377556",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "December 19, 2017"
            },
            {
                "brief_summary": "  Single arm, single site, open-label Phase II study of the effects of oral olaparib in  participants with metastatic renal cell carcinoma that harbor an inactivating mutation in  BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,  RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint  inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1  criteria.",
                "brief_title": "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",
                "condition": "Kidney Cancer;Renal Carcinoma;Renal Cell Carcinoma;Kidney Cancer Metastatic;Metastatic Renal Cell Carcinoma",
                "country": "United States",
                "geneName": "CHEK1",
                "intervention_name": "Olaparib",
                "intervention_type": "Drug",
                "nct_num": "NCT03786796",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "December 25, 2018"
            },
            {
                "brief_summary": "  This phase II trial studies how well niraparib, when given before surgery, works in treating  patients with high risk prostate cancer that has not spread to other parts of the body  (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may  stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",
                "brief_title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects",
                "condition": "Prostate Carcinoma;DNA Repair Gene Mutation;NBN Gene Mutation;FANCA Gene Mutation;FANCD2 Gene Mutation;BRCA1 Gene Mutation;FANCL Gene Mutation;ATM Gene Mutation;CHEK1 Gene Mutation;RAD51 Gene Mutation;RAD51C Gene Mutation;CHEK2 Gene Mutation;GEN1 Gene Mutation;BRIP1 Gene Mutation;CDK12 Gene Mutation;DNA Damage Response Gene Mutation;BRCA2 Gene Mutation",
                "country": "United States",
                "geneName": "CHEK1",
                "intervention_name": "Niraparib Tosylate Monohydrate;Niraparib;Radical Prostatectomy",
                "intervention_type": "Procedure;Drug",
                "nct_num": "NCT04030559",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-45",
                "study_first_posted": "July 24, 2019"
            }
        ],
        "cms": [
            {
                "age": "67",
                "agentName": "河北医科大第四医院（温医博）",
                "areaAgentName": "刘帅（管理）",
                "backStatus": "1",
                "backStatusShow": "未返款",
                "barcode": "2007131705579",
                "bedNumber": ".",
                "bingli": ".",
                "birthday": ".",
                "checkTime": ".",
                "contact": "13383316338",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": ".",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-22 11:19:00",
                "expressName": ".",
                "expressNum": "SF1081564338453",
                "fenziBingli": ".",
                "financeId": "232547",
                "gender": "男",
                "historyNum": "0",
                "hospitalName": "河北医科大学第四医院",
                "idCard": "1323361954112000012",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-13 17:18:58",
                "invoiceApplyMoney": "0.00",
                "invoiceName": ".",
                "invoiceReceivePhone": ".",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "0",
                "invoiceTypeShow": ".",
                "itemName": "0201027.OncoDrug-Seq全实体瘤110基因（血液ctDNA样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-13 16:05:38",
                "medicalRecord": ".",
                "name": "祁丑脏",
                "nickName": "郑珍珍",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "1",
                "paymentTypeShow": "现结",
                "receiveStatus": "1",
                "receiveStatusShow": "未收款",
                "receiveTime": "2020-07-15 11:19:07",
                "remark": ".",
                "reportAddress": "河北省石家庄市灵寿县北环路中天商厦3楼",
                "reportAddressName": "董晓丽",
                "reportCheckTime": ".",
                "reportEmail": "519010064@qq.com",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": "13383316338",
                "reportStyle": ".",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "234069",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200715-45",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": ".",
                "sickAge": ".",
                "sickFamilyHistory": ".",
                "source": "血液(cfDNA)",
                "sourceFrom": ".",
                "testDoctor": ".",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "非小细胞肺癌",
                "treatHistory": ".",
                "treatID": "TS0101",
                "treatResult": "肺癌",
                "treatmentNo": ".",
                "unitAgentName": "温医博",
                "url": "[]",
                "userId": "10790",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [],
        "fusion": [],
        "heredity": [
            {
                "aachangeRefgene": "PALB2:NM_024675:exon5:c.2162C>T:p.Thr721Ile",
                "ajsGb": "p.Thr721Ile",
                "alt": "A",
                "alteration": "T721I",
                "barcode": ".",
                "chr": "chr16",
                "clinsig": ".",
                "description": "该基因的胚系致病性突变可能引起乳腺癌风险升高，并以常染色体显性方式遗传。",
                "diseaseInfo": ".",
                "evidenceLevel": "尚不明确",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.5076",
                "funcRefgene": "exonic",
                "geneInfo": "PALB2（BRCA2的配偶体和定位剂，也称为FANCN）编码DNA修复因子和BRCA2结合蛋白（PMID：16793542）。 PALB2在同源重组（HR）途径中充当支架蛋白，用于修复双链DNA断裂，可能介导受损基因座处的BRCA2和RAD51的募集（PMID：19423707）。 PALB2还与BRCA1相互作用，可能作为HR途径中BRCA1和BRCA2之间的中间因子起作用（PMID：19268590,19584259）。临床前数据显示，BRCA1和BRCA2的突变可以消除与PALB2的相互作用并破坏HR介导的DNA修复（PMID：19369211,16793542）。 PALB2的种系双等位基因突变与遗传性疾病Fanconi贫血有关，其易患各种癌症（PMID：20858716,17200671,17200672）。 PALB2是乳腺癌易感基因，其具有在卵巢癌，胰腺癌，前列腺癌和黑素瘤中较小作用的一些迹象（PMID：17200668,17287723,17420451,18053174,25099575,20858716,19264984,24448499）。尽管罕见，但在各种肿瘤类型中观察到PALB2中的有害体细胞变体。",
                "geneName": "PALB2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "PALB2基因exon5第2162位碱基C置换为T使得第721位氨基酸由苏氨酸转变成了异亮氨酸",
                "geneYcType": "常染色体显性遗传（AD）",
                "hgsGb": "c.2162C>T",
                "hgvs": "PALB2:NM_024675:exon5:c.2162C>T:p.Thr721Ile",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "mutationType": "杂合突变",
                "ominId": "610355",
                "posEnd": "23641313",
                "posStart": "23641313",
                "projectAbbr": "DE",
                "ref": "G",
                "relativeDisease": "乳腺癌易感",
                "riskLevel": "不确定",
                "sampleSn": "NGS200715-45",
                "tumorProfiles": ".",
                "vcfFormat": "GT:AD:DP:GQ:PL",
                "vcfFormatInfo": "0/1:1789,1844:3633:99:37279,0,39774",
                "wxz": "exon5",
                "zlb": "NM_024675"
            }
        ],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:1.49%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "1.49%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": "EGFR:NM_005228:exon19:c.2240_2254del:p.Leu747_Thr751del",
                "Unnamed: 8": ".",
                "Unnamed: 9": "NGS200715-45",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": "EGFR:NM_005228:exon20:c.2369C>T:p.Thr790Met",
                "Unnamed: 8": ".",
                "Unnamed: 9": "NGS200715-45",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "如果使用免疫检查点抑制剂治疗，疗效可能较差",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "检测到变异/基因突变（NM_005228:exon19:c.2240_2254del:p.Leu747_Thr751del）（NM_005228:exon20:c.2369C>T:p.Thr790Met）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 1,
                "percent": 1.49,
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-45",
                "totalSites": 67
            }
        ],
        "qc": [
            {
                "cleanBases": 4443626843,
                "cleanReads": 31750154,
                "coverage>0.2x": 98.9,
                "coverage>0.5x": 91.79,
                "effectCoverage500": 98.07,
                "effectDepth": 3023,
                "insert": 198.4,
                "mapping": 99.91,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 4846989900,
                "rawDuplication": 14.87,
                "rawReads": 32313266,
                "readPercent": 98.26,
                "samplePurity": ".",
                "sampleSn": "NGS200715-45",
                "sampleType": "ctDNA",
                "targetMapping": 73.1,
                "trimDuplication": 0.0,
                "tumorCoverage": 99.95,
                "tumorDepth": 4989,
                "tumorQ30": 93.07
            }
        ],
        "target": [
            {
                "1000g2015aug_all": "0.005391370039433241",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "0.0072",
                "GeneName": "BARD1",
                "NM_ID": "NM_000465",
                "ajsGb": "p.Arg658Cys",
                "alt": "A",
                "alteration": "R658C",
                "avsnp150": "rs3738888",
                "cancerType": ".",
                "chr": "chr2",
                "clinsig": "Conflicting_interpretations_of_pathogenicity",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.491",
                "funcRefgene": "exonic",
                "geneInfo": "BARD1 (BRCA1 Associated RING Domain 1，BRCA1相关的RING结构域1)是一个蛋白质编码基因。与之相关的疾病包括乳腺癌和Bard1相关乳腺癌易感性。与之相关的途径包括影响BARD1信号传导和DNA双链断裂修复。GO（Gene Ontology基因本体论）对其功能注释包括影响蛋白质同源二聚化活性和蛋白质异源二聚化活性。",
                "geneName": "BARD1",
                "geneType": "geneQt,geneHRD",
                "geneVar": "BARD1基因exon10第1972位碱基C置换为T使得第658位氨基酸由精氨酸转变成了半胱氨酸",
                "hgsGb": "c.1972C>T",
                "hgvs": "BARD1:NM_000465:exon10:c.1972C>T:p.Arg658Cys",
                "intervarAutomated": "Benign",
                "level": "3（临床意义未明）",
                "posEnd": "215595164",
                "posStart": "215595164",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:889,856:0.491:507,504:382,352:29:171,172:60:37:0.460,0.488,0.491:0.346,0.001,0.652",
                "wxz": "exon10",
                "zlb": "NM_000465"
            },
            {
                "1000g2015aug_all": "0.005391370039433241",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "0.0072",
                "GeneName": "BARD1",
                "NM_ID": "NM_000465",
                "ajsGb": "p.Arg658Cys",
                "alt": "A",
                "alteration": "R658C",
                "avsnp150": "rs3738888",
                "cancerType": ".",
                "chr": "chr2",
                "clinsig": "Conflicting_interpretations_of_pathogenicity",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.491",
                "funcRefgene": "exonic",
                "geneInfo": "BARD1 (BRCA1 Associated RING Domain 1，BRCA1相关的RING结构域1)是一个蛋白质编码基因。与之相关的疾病包括乳腺癌和Bard1相关乳腺癌易感性。与之相关的途径包括影响BARD1信号传导和DNA双链断裂修复。GO（Gene Ontology基因本体论）对其功能注释包括影响蛋白质同源二聚化活性和蛋白质异源二聚化活性。",
                "geneName": "BARD1",
                "geneType": "geneQt,geneHRD",
                "geneVar": "BARD1基因exon10第1972位碱基C置换为T使得第658位氨基酸由精氨酸转变成了半胱氨酸",
                "hgsGb": "c.1972C>T",
                "hgvs": "BARD1:NM_000465:exon10:c.1972C>T:p.Arg658Cys",
                "intervarAutomated": "Benign",
                "level": "3（临床意义未明）",
                "posEnd": "215595164",
                "posStart": "215595164",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:889,856:0.491:507,504:382,352:29:171,172:60:37:0.460,0.488,0.491:0.346,0.001,0.652",
                "wxz": "exon10",
                "zlb": "NM_000465"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "729_761del",
                "DNA_change": "Exon 19 deletion",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "EGFR",
                "NM_ID": "NM_005228",
                "ajsGb": "p.Leu747_Thr751del",
                "alt": "-",
                "alteration": "L747_T751del",
                "avsnp150": "rs121913442",
                "cancerType": "非小细胞肺癌",
                "chr": "chr7",
                "clinsig": "drug_response",
                "cosmic70": "ID\\x3dCOSM23571",
                "drugLevel": "3",
                "drugs": "阿美替尼",
                "exonicfuncRefgene": "nonframeshift_deletion",
                "freq": "0.024",
                "funcRefgene": "exonic",
                "geneInfo": "EGFR编码表皮生长因子受体。表皮生长因子受体结合的配体，包括表皮生长因子（EGF）、转化生长因子（TGF-α），激活下游的信号转导通路包括典型致癌MAPK和PI3K/Akt/mTOR信号级联反应，最终导致细胞的增殖、迁移和分化的变化（PMID：18045542）。虽然EGFR通常在正常成人组织中以低水平表达，但是在许多癌症类型例如肺癌，脑癌，结直肠癌和头颈癌（PMID：10880430）中发现通过突变和/或EGFR基因的扩增使该受体过度激活。 在脑癌和结直肠癌中，EGFR基因的拷贝数扩增导致受体过表达（PMID：11426640）。然而，在肺癌中，最普遍的EGFR改变是激酶结构域中的突变，导致受体的结构性激活形式（PMID：15329413）。在胰腺癌和结直肠癌中偶尔发现EGFR的激活突变（PMID：24827134）。",
                "geneName": "EGFR",
                "geneType": "geneBx,geneMy",
                "geneVar": "EGFR基因exon19第2240_2254位碱基缺失使得第747_751位氨基酸缺失",
                "hgsGb": "c.2240_2254del",
                "hgvs": "EGFR:NM_005228:exon19:c.2240_2254del:p.Leu747_Thr751del",
                "intervarAutomated": ".",
                "level": "3（临床意义未明）",
                "posEnd": "55242482",
                "posStart": "55242468",
                "projectAbbr": "DE",
                "ref": "ATTAAGAGAAGCAAC",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:2095,51:0.045:1148,24:947,27:31:171,182:60:37:0.022,0.020,0.024:0.001,0.003,0.996",
                "wxz": "exon19",
                "zlb": "NM_005228"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "729_761del",
                "DNA_change": "Exon 19 deletion",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "EGFR",
                "NM_ID": "NM_005228",
                "ajsGb": "p.Leu747_Thr751del",
                "alt": "-",
                "alteration": "L747_T751del",
                "avsnp150": "rs121913442",
                "cancerType": "非小细胞肺癌",
                "chr": "chr7",
                "clinsig": "drug_response",
                "cosmic70": "ID\\x3dCOSM23571",
                "drugLevel": "1",
                "drugs": "厄洛替尼，阿法替尼，奥希替尼，达可替尼，吉非替尼，埃克替尼",
                "exonicfuncRefgene": "nonframeshift_deletion",
                "freq": "0.024",
                "funcRefgene": "exonic",
                "geneInfo": "EGFR编码表皮生长因子受体。表皮生长因子受体结合的配体，包括表皮生长因子（EGF）、转化生长因子（TGF-α），激活下游的信号转导通路包括典型致癌MAPK和PI3K/Akt/mTOR信号级联反应，最终导致细胞的增殖、迁移和分化的变化（PMID：18045542）。虽然EGFR通常在正常成人组织中以低水平表达，但是在许多癌症类型例如肺癌，脑癌，结直肠癌和头颈癌（PMID：10880430）中发现通过突变和/或EGFR基因的扩增使该受体过度激活。 在脑癌和结直肠癌中，EGFR基因的拷贝数扩增导致受体过表达（PMID：11426640）。然而，在肺癌中，最普遍的EGFR改变是激酶结构域中的突变，导致受体的结构性激活形式（PMID：15329413）。在胰腺癌和结直肠癌中偶尔发现EGFR的激活突变（PMID：24827134）。",
                "geneName": "EGFR",
                "geneType": "geneBx,geneMy",
                "geneVar": "EGFR基因exon19第2240_2254位碱基缺失使得第747_751位氨基酸缺失",
                "hgsGb": "c.2240_2254del",
                "hgvs": "EGFR:NM_005228:exon19:c.2240_2254del:p.Leu747_Thr751del",
                "intervarAutomated": ".",
                "level": "3（临床意义未明）",
                "posEnd": "55242482",
                "posStart": "55242468",
                "projectAbbr": "DE",
                "ref": "ATTAAGAGAAGCAAC",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:2095,51:0.045:1148,24:947,27:31:171,182:60:37:0.022,0.020,0.024:0.001,0.003,0.996",
                "wxz": "exon19",
                "zlb": "NM_005228"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Exon 19 deletion",
                "DNA_change": "Exon 19 deletion",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "EGFR",
                "NM_ID": "NM_005228",
                "ajsGb": "p.Leu747_Thr751del",
                "alt": "-",
                "alteration": "L747_T751del",
                "avsnp150": "rs121913442",
                "cancerType": "非小细胞肺癌",
                "chr": "chr7",
                "clinsig": "drug_response",
                "cosmic70": "ID\\x3dCOSM23571",
                "drugLevel": "2A",
                "drugs": "厄洛替尼+Ramucirumab[雷莫芦单抗]",
                "exonicfuncRefgene": "nonframeshift_deletion",
                "freq": "0.024",
                "funcRefgene": "exonic",
                "geneInfo": "EGFR编码表皮生长因子受体。表皮生长因子受体结合的配体，包括表皮生长因子（EGF）、转化生长因子（TGF-α），激活下游的信号转导通路包括典型致癌MAPK和PI3K/Akt/mTOR信号级联反应，最终导致细胞的增殖、迁移和分化的变化（PMID：18045542）。虽然EGFR通常在正常成人组织中以低水平表达，但是在许多癌症类型例如肺癌，脑癌，结直肠癌和头颈癌（PMID：10880430）中发现通过突变和/或EGFR基因的扩增使该受体过度激活。 在脑癌和结直肠癌中，EGFR基因的拷贝数扩增导致受体过表达（PMID：11426640）。然而，在肺癌中，最普遍的EGFR改变是激酶结构域中的突变，导致受体的结构性激活形式（PMID：15329413）。在胰腺癌和结直肠癌中偶尔发现EGFR的激活突变（PMID：24827134）。",
                "geneName": "EGFR",
                "geneType": "geneBx,geneMy",
                "geneVar": "EGFR基因exon19第2240_2254位碱基缺失使得第747_751位氨基酸缺失",
                "hgsGb": "c.2240_2254del",
                "hgvs": "EGFR:NM_005228:exon19:c.2240_2254del:p.Leu747_Thr751del",
                "intervarAutomated": ".",
                "level": "3（临床意义未明）",
                "posEnd": "55242482",
                "posStart": "55242468",
                "projectAbbr": "DE",
                "ref": "ATTAAGAGAAGCAAC",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:2095,51:0.045:1148,24:947,27:31:171,182:60:37:0.022,0.020,0.024:0.001,0.003,0.996",
                "wxz": "exon19",
                "zlb": "NM_005228"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Exon 19 deletion",
                "DNA_change": "Exon 19 deletion",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "EGFR",
                "NM_ID": "NM_005228",
                "ajsGb": "p.Leu747_Thr751del",
                "alt": "-",
                "alteration": "L747_T751del",
                "avsnp150": "rs121913442",
                "cancerType": "非小细胞肺癌",
                "chr": "chr7",
                "clinsig": "drug_response",
                "cosmic70": "ID\\x3dCOSM23571",
                "drugLevel": "2B",
                "drugs": "厄洛替尼+贝伐珠单抗",
                "exonicfuncRefgene": "nonframeshift_deletion",
                "freq": "0.024",
                "funcRefgene": "exonic",
                "geneInfo": "EGFR编码表皮生长因子受体。表皮生长因子受体结合的配体，包括表皮生长因子（EGF）、转化生长因子（TGF-α），激活下游的信号转导通路包括典型致癌MAPK和PI3K/Akt/mTOR信号级联反应，最终导致细胞的增殖、迁移和分化的变化（PMID：18045542）。虽然EGFR通常在正常成人组织中以低水平表达，但是在许多癌症类型例如肺癌，脑癌，结直肠癌和头颈癌（PMID：10880430）中发现通过突变和/或EGFR基因的扩增使该受体过度激活。 在脑癌和结直肠癌中，EGFR基因的拷贝数扩增导致受体过表达（PMID：11426640）。然而，在肺癌中，最普遍的EGFR改变是激酶结构域中的突变，导致受体的结构性激活形式（PMID：15329413）。在胰腺癌和结直肠癌中偶尔发现EGFR的激活突变（PMID：24827134）。",
                "geneName": "EGFR",
                "geneType": "geneBx,geneMy",
                "geneVar": "EGFR基因exon19第2240_2254位碱基缺失使得第747_751位氨基酸缺失",
                "hgsGb": "c.2240_2254del",
                "hgvs": "EGFR:NM_005228:exon19:c.2240_2254del:p.Leu747_Thr751del",
                "intervarAutomated": ".",
                "level": "3（临床意义未明）",
                "posEnd": "55242482",
                "posStart": "55242468",
                "projectAbbr": "DE",
                "ref": "ATTAAGAGAAGCAAC",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:2095,51:0.045:1148,24:947,27:31:171,182:60:37:0.022,0.020,0.024:0.001,0.003,0.996",
                "wxz": "exon19",
                "zlb": "NM_005228"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "T790M",
                "DNA_change": "T790M",
                "ExAC_nonpsych_ALL": "5.517e-05",
                "GeneName": "EGFR",
                "NM_ID": "NM_005228",
                "ajsGb": "p.Thr790Met",
                "alt": "T",
                "alteration": "T790M",
                "avsnp150": "rs121434569",
                "cancerType": "非小细胞肺癌",
                "chr": "chr7",
                "clinsig": "drug_response",
                "cosmic70": "ID\\x3dCOSM6240\\x3bOCCURENCE\\x3d1(biliary_tract)",
                "drugLevel": "R1",
                "drugs": "阿法替尼，厄洛替尼，吉非替尼，埃克替尼，达可替尼，厄洛替尼+贝伐珠单抗，厄洛替尼+Ramucirumab[雷莫芦单抗]",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.01",
                "funcRefgene": "exonic",
                "geneInfo": "EGFR编码表皮生长因子受体。表皮生长因子受体结合的配体，包括表皮生长因子（EGF）、转化生长因子（TGF-α），激活下游的信号转导通路包括典型致癌MAPK和PI3K/Akt/mTOR信号级联反应，最终导致细胞的增殖、迁移和分化的变化（PMID：18045542）。虽然EGFR通常在正常成人组织中以低水平表达，但是在许多癌症类型例如肺癌，脑癌，结直肠癌和头颈癌（PMID：10880430）中发现通过突变和/或EGFR基因的扩增使该受体过度激活。 在脑癌和结直肠癌中，EGFR基因的拷贝数扩增导致受体过表达（PMID：11426640）。然而，在肺癌中，最普遍的EGFR改变是激酶结构域中的突变，导致受体的结构性激活形式（PMID：15329413）。在胰腺癌和结直肠癌中偶尔发现EGFR的激活突变（PMID：24827134）。",
                "geneName": "EGFR",
                "geneType": "geneBx,geneMy",
                "geneVar": "EGFR基因exon20第2369位碱基C置换为T使得第790位氨基酸由苏氨酸转变成了甲硫氨酸",
                "hgsGb": "c.2369C>T",
                "hgvs": "EGFR:NM_005228:exon20:c.2369C>T:p.Thr790Met",
                "intervarAutomated": "Pathogenic",
                "level": "3（临床意义未明）",
                "posEnd": "55249071",
                "posStart": "55249071",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:2366,24:0.029:1295,11:1071,13:30:173,163:60:23:0.005,0.010,0.010:0.025,0.000,0.975",
                "wxz": "exon20",
                "zlb": "NM_005228"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "T790M",
                "DNA_change": "T790M",
                "ExAC_nonpsych_ALL": "5.517e-05",
                "GeneName": "EGFR",
                "NM_ID": "NM_005228",
                "ajsGb": "p.Thr790Met",
                "alt": "T",
                "alteration": "T790M",
                "avsnp150": "rs121434569",
                "cancerType": "非小细胞肺癌",
                "chr": "chr7",
                "clinsig": "drug_response",
                "cosmic70": "ID\\x3dCOSM6240\\x3bOCCURENCE\\x3d1(biliary_tract)",
                "drugLevel": "1",
                "drugs": "奥希替尼",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.01",
                "funcRefgene": "exonic",
                "geneInfo": "EGFR编码表皮生长因子受体。表皮生长因子受体结合的配体，包括表皮生长因子（EGF）、转化生长因子（TGF-α），激活下游的信号转导通路包括典型致癌MAPK和PI3K/Akt/mTOR信号级联反应，最终导致细胞的增殖、迁移和分化的变化（PMID：18045542）。虽然EGFR通常在正常成人组织中以低水平表达，但是在许多癌症类型例如肺癌，脑癌，结直肠癌和头颈癌（PMID：10880430）中发现通过突变和/或EGFR基因的扩增使该受体过度激活。 在脑癌和结直肠癌中，EGFR基因的拷贝数扩增导致受体过表达（PMID：11426640）。然而，在肺癌中，最普遍的EGFR改变是激酶结构域中的突变，导致受体的结构性激活形式（PMID：15329413）。在胰腺癌和结直肠癌中偶尔发现EGFR的激活突变（PMID：24827134）。",
                "geneName": "EGFR",
                "geneType": "geneBx,geneMy",
                "geneVar": "EGFR基因exon20第2369位碱基C置换为T使得第790位氨基酸由苏氨酸转变成了甲硫氨酸",
                "hgsGb": "c.2369C>T",
                "hgvs": "EGFR:NM_005228:exon20:c.2369C>T:p.Thr790Met",
                "intervarAutomated": "Pathogenic",
                "level": "3（临床意义未明）",
                "posEnd": "55249071",
                "posStart": "55249071",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:2366,24:0.029:1295,11:1071,13:30:173,163:60:23:0.005,0.010,0.010:0.025,0.000,0.975",
                "wxz": "exon20",
                "zlb": "NM_005228"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "T790M",
                "DNA_change": "T790M",
                "ExAC_nonpsych_ALL": "5.517e-05",
                "GeneName": "EGFR",
                "NM_ID": "NM_005228",
                "ajsGb": "p.Thr790Met",
                "alt": "T",
                "alteration": "T790M",
                "avsnp150": "rs121434569",
                "cancerType": "非小细胞肺癌",
                "chr": "chr7",
                "clinsig": "drug_response",
                "cosmic70": "ID\\x3dCOSM6240\\x3bOCCURENCE\\x3d1(biliary_tract)",
                "drugLevel": "1",
                "drugs": "奥希替尼，阿美替尼",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.01",
                "funcRefgene": "exonic",
                "geneInfo": "EGFR编码表皮生长因子受体。表皮生长因子受体结合的配体，包括表皮生长因子（EGF）、转化生长因子（TGF-α），激活下游的信号转导通路包括典型致癌MAPK和PI3K/Akt/mTOR信号级联反应，最终导致细胞的增殖、迁移和分化的变化（PMID：18045542）。虽然EGFR通常在正常成人组织中以低水平表达，但是在许多癌症类型例如肺癌，脑癌，结直肠癌和头颈癌（PMID：10880430）中发现通过突变和/或EGFR基因的扩增使该受体过度激活。 在脑癌和结直肠癌中，EGFR基因的拷贝数扩增导致受体过表达（PMID：11426640）。然而，在肺癌中，最普遍的EGFR改变是激酶结构域中的突变，导致受体的结构性激活形式（PMID：15329413）。在胰腺癌和结直肠癌中偶尔发现EGFR的激活突变（PMID：24827134）。",
                "geneName": "EGFR",
                "geneType": "geneBx,geneMy",
                "geneVar": "EGFR基因exon20第2369位碱基C置换为T使得第790位氨基酸由苏氨酸转变成了甲硫氨酸",
                "hgsGb": "c.2369C>T",
                "hgvs": "EGFR:NM_005228:exon20:c.2369C>T:p.Thr790Met",
                "intervarAutomated": "Pathogenic",
                "level": "3（临床意义未明）",
                "posEnd": "55249071",
                "posStart": "55249071",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:2366,24:0.029:1295,11:1071,13:30:173,163:60:23:0.005,0.010,0.010:0.025,0.000,0.975",
                "wxz": "exon20",
                "zlb": "NM_005228"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": ".",
                "DNA_change": ".",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": ".",
                "NM_ID": ".",
                "ajsGb": "p.Ser288Ile",
                "alt": "T",
                "alteration": "S288I",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr11",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.491",
                "funcRefgene": "exonic",
                "geneInfo": "CHEK1（Checkpoint Kinase 1，检测点激酶1）是一个蛋白质编码基因。与CHEK1相关的疾病包括共济失调性毛细血管扩张症和乳腺癌。与其相关的途径包括DNA双链断裂修复和昼夜节律途径。GO(Gene Ontology基因本体论)对其功能注释包括影响转移酶活性，含磷基团转移和蛋白酪氨酸激酶活性。",
                "geneName": "CHEK1",
                "geneType": "geneMy,geneHRD",
                "geneVar": "CHEK1基因exon9第863位碱基G置换为T使得第288位氨基酸由丝氨酸转变成了异亮氨酸",
                "hgsGb": "c.863G>T",
                "hgvs": "CHEK1:NM_001114121:exon9:c.863G>T:p.Ser288Ile",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "125513735",
                "posStart": "125513735",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:467,450:0.489:258,261:209,189:29:173,172:60:35:0.483,0.477,0.491:0.006,0.022,0.973",
                "wxz": "exon9",
                "zlb": "NM_001114121"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "PALB2",
                "NM_ID": "NM_024675",
                "ajsGb": "p.Thr721Ile",
                "alt": "A",
                "alteration": "T721I",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr16",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.502",
                "funcRefgene": "exonic",
                "geneInfo": "PALB2（BRCA2的配偶体和定位剂，也称为FANCN）编码DNA修复因子和BRCA2结合蛋白（PMID：16793542）。 PALB2在同源重组（HR）途径中充当支架蛋白，用于修复双链DNA断裂，可能介导受损基因座处的BRCA2和RAD51的募集（PMID：19423707）。 PALB2还与BRCA1相互作用，可能作为HR途径中BRCA1和BRCA2之间的中间因子起作用（PMID：19268590,19584259）。临床前数据显示，BRCA1和BRCA2的突变可以消除与PALB2的相互作用并破坏HR介导的DNA修复（PMID：19369211,16793542）。 PALB2的种系双等位基因突变与遗传性疾病Fanconi贫血有关，其易患各种癌症（PMID：20858716,17200671,17200672）。 PALB2是乳腺癌易感基因，其具有在卵巢癌，胰腺癌，前列腺癌和黑素瘤中较小作用的一些迹象（PMID：17200668,17287723,17420451,18053174,25099575,20858716,19264984,24448499）。尽管罕见，但在各种肿瘤类型中观察到PALB2中的有害体细胞变体。",
                "geneName": "PALB2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "PALB2基因exon5第2162位碱基C置换为T使得第721位氨基酸由苏氨酸转变成了异亮氨酸",
                "hgsGb": "c.2162C>T",
                "hgvs": "PALB2:NM_024675:exon5:c.2162C>T:p.Thr721Ile",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "23641313",
                "posStart": "23641313",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:1155,1163:0.501:633,640:522,523:25:172,171:60:33:0.493,0.497,0.502:0.011,0.005,0.984",
                "wxz": "exon5",
                "zlb": "NM_024675"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "PALB2",
                "NM_ID": "NM_024675",
                "ajsGb": "p.Thr721Ile",
                "alt": "A",
                "alteration": "T721I",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr16",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.502",
                "funcRefgene": "exonic",
                "geneInfo": "PALB2（BRCA2的配偶体和定位剂，也称为FANCN）编码DNA修复因子和BRCA2结合蛋白（PMID：16793542）。 PALB2在同源重组（HR）途径中充当支架蛋白，用于修复双链DNA断裂，可能介导受损基因座处的BRCA2和RAD51的募集（PMID：19423707）。 PALB2还与BRCA1相互作用，可能作为HR途径中BRCA1和BRCA2之间的中间因子起作用（PMID：19268590,19584259）。临床前数据显示，BRCA1和BRCA2的突变可以消除与PALB2的相互作用并破坏HR介导的DNA修复（PMID：19369211,16793542）。 PALB2的种系双等位基因突变与遗传性疾病Fanconi贫血有关，其易患各种癌症（PMID：20858716,17200671,17200672）。 PALB2是乳腺癌易感基因，其具有在卵巢癌，胰腺癌，前列腺癌和黑素瘤中较小作用的一些迹象（PMID：17200668,17287723,17420451,18053174,25099575,20858716,19264984,24448499）。尽管罕见，但在各种肿瘤类型中观察到PALB2中的有害体细胞变体。",
                "geneName": "PALB2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "PALB2基因exon5第2162位碱基C置换为T使得第721位氨基酸由苏氨酸转变成了异亮氨酸",
                "hgsGb": "c.2162C>T",
                "hgvs": "PALB2:NM_024675:exon5:c.2162C>T:p.Thr721Ile",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "23641313",
                "posStart": "23641313",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:1155,1163:0.501:633,640:522,523:25:172,171:60:33:0.493,0.497,0.502:0.011,0.005,0.984",
                "wxz": "exon5",
                "zlb": "NM_024675"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "PALB2",
                "NM_ID": "NM_024675",
                "ajsGb": "p.Thr721Ile",
                "alt": "A",
                "alteration": "T721I",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr16",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.502",
                "funcRefgene": "exonic",
                "geneInfo": "PALB2（BRCA2的配偶体和定位剂，也称为FANCN）编码DNA修复因子和BRCA2结合蛋白（PMID：16793542）。 PALB2在同源重组（HR）途径中充当支架蛋白，用于修复双链DNA断裂，可能介导受损基因座处的BRCA2和RAD51的募集（PMID：19423707）。 PALB2还与BRCA1相互作用，可能作为HR途径中BRCA1和BRCA2之间的中间因子起作用（PMID：19268590,19584259）。临床前数据显示，BRCA1和BRCA2的突变可以消除与PALB2的相互作用并破坏HR介导的DNA修复（PMID：19369211,16793542）。 PALB2的种系双等位基因突变与遗传性疾病Fanconi贫血有关，其易患各种癌症（PMID：20858716,17200671,17200672）。 PALB2是乳腺癌易感基因，其具有在卵巢癌，胰腺癌，前列腺癌和黑素瘤中较小作用的一些迹象（PMID：17200668,17287723,17420451,18053174,25099575,20858716,19264984,24448499）。尽管罕见，但在各种肿瘤类型中观察到PALB2中的有害体细胞变体。",
                "geneName": "PALB2",
                "geneType": "geneBx,geneYc,geneMy,geneHRD",
                "geneVar": "PALB2基因exon5第2162位碱基C置换为T使得第721位氨基酸由苏氨酸转变成了异亮氨酸",
                "hgsGb": "c.2162C>T",
                "hgvs": "PALB2:NM_024675:exon5:c.2162C>T:p.Thr721Ile",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "23641313",
                "posStart": "23641313",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200715-45",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:1155,1163:0.501:633,640:522,523:25:172,171:60:33:0.493,0.497,0.502:0.011,0.005,0.984",
                "wxz": "exon5",
                "zlb": "NM_024675"
            }
        ],
        "tmb": [],
        "tnb": []
    },
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "G/G",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，需较低剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较高，神经毒性综合征的严重程度可能降低",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "A/G",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/G",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/C",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/C",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "T/T",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "C/A",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "T/T",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "C/C",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "G/T",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "野生型",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/G",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副中度",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/7TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢增加",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "C/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "C/T",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/A",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/A",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/A",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副高，代谢降低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200715-51",
                "updateTime": "."
            }
        ],
        "clinical": [
            {
                "brief_summary": "  This phase II trial studies how well pemigatinib works in treating patients with colorectal  cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the  body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the  growth of tumor cells by blocking FGFR, which is needed for cell growth.",
                "brief_title": "Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations",
                "condition": "FGFR3 Gene Translocation;Stage IIIA Colorectal Cancer AJCC v8;FGFR2 Gene Amplification;Stage IIIB Colorectal Cancer AJCC v8;FGFR3 Gene Amplification;Metastatic Colorectal Carcinoma;FGFR1 Gene Mutation;FGFR3 Gene Mutation;FGFR1 Gene Amplification;FGFR2 Gene Mutation;Stage IVA Colorectal Cancer AJCC v8;FGFR1 Gene Translocation;FGFR2 Gene Translocation;Stage IVC Colorectal Cancer AJCC v8;Stage III Colorectal Cancer AJCC v8;Stage IIIC Colorectal Cancer AJCC v8;Unresectable Colorectal Carcinoma;Stage IV Colorectal Cancer AJCC v8;Stage IVB Colorectal Cancer AJCC v8",
                "country": "United States",
                "geneName": "FGFR1",
                "intervention_name": "Pemigatinib;Quality-of-Life Assessment",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT04096417",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-51",
                "study_first_posted": "September 19, 2019"
            },
            {
                "brief_summary": "  This trial studies the side effects and best dose of gemcitabine and cisplatin when given  together with ivosidenib or pemigatinib in treating patients with cholangiocarcinoma that  cannot be removed with surgery (unresectable) or has spread to other places in the body  (metastatic). Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in  different ways to stop the growth of tumor cells, either by killing the cells, by stopping  them from dividing, or by stopping them from spreading. Ivosidenib and pemigatinib may stop  the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving  gemcitabine and cisplatin with ivosidenib or pemigatinib may work better in treating patients  with cholangiocarcinoma compared to gemcitabine and cisplatin alone.",
                "brief_title": "Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma",
                "condition": "IDH1 NP_005887.2:p.R132G;IDH1 NP_005887.2:p.R132C;IDH1 NP_005887.2:p.R132S;FGFR3 Gene Alteration Positive;Metastatic Cholangiocarcinoma;Unresectable Cholangiocarcinoma;FGFR1 Gene Alteration Positive;IDH1 NP_005887.2:p.R132L;IDH1 NP_005887.2:p.R132H;IDH1 Gene Mutation;Advanced Cholangiocarcinoma;FGFR2 Gene Alteration Positive",
                "country": "United States",
                "geneName": "FGFR1",
                "intervention_name": "Pemigatinib;Cisplatin;Ivosidenib;Gemcitabine;Gemcitabine Hydrochloride",
                "intervention_type": "Drug",
                "nct_num": "NCT04088188",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-51",
                "study_first_posted": "September 12, 2019"
            },
            {
                "brief_summary": "  This trial studies the side effects and best dose of gemcitabine and cisplatin when given  together with ivosidenib or pemigatinib in treating patients with cholangiocarcinoma that  cannot be removed with surgery (unresectable) or has spread to other places in the body  (metastatic). Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in  different ways to stop the growth of tumor cells, either by killing the cells, by stopping  them from dividing, or by stopping them from spreading. Ivosidenib and pemigatinib may stop  the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving  gemcitabine and cisplatin with ivosidenib or pemigatinib may work better in treating patients  with cholangiocarcinoma compared to gemcitabine and cisplatin alone.",
                "brief_title": "Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma",
                "condition": "IDH1 NP_005887.2:p.R132G;IDH1 NP_005887.2:p.R132C;IDH1 NP_005887.2:p.R132S;FGFR3 Gene Alteration Positive;Metastatic Cholangiocarcinoma;Unresectable Cholangiocarcinoma;FGFR1 Gene Alteration Positive;IDH1 NP_005887.2:p.R132L;IDH1 NP_005887.2:p.R132H;IDH1 Gene Mutation;Advanced Cholangiocarcinoma;FGFR2 Gene Alteration Positive",
                "country": "United States",
                "geneName": "FGFR1",
                "intervention_name": "Pemigatinib;Cisplatin;Ivosidenib;Gemcitabine;Gemcitabine Hydrochloride",
                "intervention_type": "Drug",
                "nct_num": "NCT04088188",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-51",
                "study_first_posted": "September 12, 2019"
            },
            {
                "brief_summary": "  This trial studies the side effects and best dose of gemcitabine and cisplatin when given  together with ivosidenib or pemigatinib in treating patients with cholangiocarcinoma that  cannot be removed with surgery (unresectable) or has spread to other places in the body  (metastatic). Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in  different ways to stop the growth of tumor cells, either by killing the cells, by stopping  them from dividing, or by stopping them from spreading. Ivosidenib and pemigatinib may stop  the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving  gemcitabine and cisplatin with ivosidenib or pemigatinib may work better in treating patients  with cholangiocarcinoma compared to gemcitabine and cisplatin alone.",
                "brief_title": "Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma",
                "condition": "IDH1 NP_005887.2:p.R132G;IDH1 NP_005887.2:p.R132C;IDH1 NP_005887.2:p.R132S;FGFR3 Gene Alteration Positive;Metastatic Cholangiocarcinoma;Unresectable Cholangiocarcinoma;FGFR1 Gene Alteration Positive;IDH1 NP_005887.2:p.R132L;IDH1 NP_005887.2:p.R132H;IDH1 Gene Mutation;Advanced Cholangiocarcinoma;FGFR2 Gene Alteration Positive",
                "country": "United States",
                "geneName": "FGFR1",
                "intervention_name": "Pemigatinib;Cisplatin;Ivosidenib;Gemcitabine;Gemcitabine Hydrochloride",
                "intervention_type": "Drug",
                "nct_num": "NCT04088188",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-51",
                "study_first_posted": "September 12, 2019"
            },
            {
                "brief_summary": "  Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets  angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated  kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant  inhibitory activities.",
                "brief_title": "Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer",
                "condition": "Squamous Non-small Cell Lung Cancer",
                "country": "China",
                "geneName": "FGFR1",
                "intervention_name": "Placebos;Carboplatin;Paclitaxel;Anlotinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04073537",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 3",
                "sampleSn": "NGS200715-51",
                "study_first_posted": "August 29, 2019"
            },
            {
                "brief_summary": "  Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets  angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated  kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant  inhibitory activities.",
                "brief_title": "Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer",
                "condition": "Small Cell Lung Cancer",
                "country": "China",
                "geneName": "FGFR1",
                "intervention_name": "Placebos;Topotecan;Anlotinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04073550",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 3",
                "sampleSn": "NGS200715-51",
                "study_first_posted": "August 29, 2019"
            },
            {
                "brief_summary": "  Recent advances in acute myeloid leukemia (AML) have been characterized by a better  understanding of disease biology. As such, FMS-like tyrosine kinase 3-internal tandem  duplication (FLT3-ITD) have been recognized as conferring a poor prognosis. The FLT3-ITD  molecular mutation is observed in about one-quarter of patients diagnosed with AML. Patients  presenting with this abnormality are referred for early allogeneic stem-cell transplantation  (allo-SCT). However, some data suggest that FLT3-ITD remains associated with a poor prognosis  even after allo-SCT because of higher risk of relapse and strategies for preventing relapse  in the post-transplant setting are required (Hu et al, Expert Rev Hematol, 2014). For  example, in a large cohort of patients (Brunet et al, JCO, 2012), the incidence of relapse  for FLT3-ITD AML patients after allo-SCT was 30% at 2-years, significantly higher compared to  FLT3-ITD negative patients (p=0.006).  Ponatinib (Iclusig®) is an orally available, tyrosine kinase inhibitor with a unique binding  mechanism allowing inhibition of BCR-ABL kinases, including those with the T315I point  mutation. Ponatinib also has in vitro inhibitory activity against a discrete set of kinases  implicated in the pathogenesis of other hematologic malignancies, including FLT3, KIT,  fibroblast growth factor receptor 1 (FGFR1), and platelet derived growth factor receptor α  (PDGFRα). In vitro activity of ponatinib in AML has been already demonstrated (Gozgit et al,  Mol Cancer Ther, 2011; Smith et al, Blood 2013). If some trials are on-going to test  ponatinib alone or in combination with chemotherapy in FLT3-ITD AML (Clinical.trials.gov), no  study is dedicated to the use of ponatinib in the post-transplant setting in order to prevent  relapse in these patients.  The main goal of this study will be to determine the maximal tolerated dose (MDT) of  ponatinib after allo-SCT in FLT3-ITD AML patients, then to investigate the efficacy of  ponatinib in a larger cohort of patients",
                "brief_title": "Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients",
                "condition": "Leukemia, Myeloid, Acute",
                "country": "France",
                "geneName": "FGFR1",
                "intervention_name": "Ponatinib 30 MG",
                "intervention_type": "Drug",
                "nct_num": "NCT03690115",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-51",
                "study_first_posted": "October 1, 2018"
            },
            {
                "brief_summary": "  The primary objective of this study is to determine the safety, tolerability, maximum  tolerated dose (MTD) or recommended Phase 2 dose (RP2D) and efficacy of rogaratinib in  combination with copanlisib in patients with locally advanced or metastatic solid tumors that  are mRNA-positive for at least one FGFR1-4 subtype.  The secondary objectives of this study are to characterize the pharmacokinetics (PK) of  rogaratinib and copanlisib alone and in combination, and to assess the anti-tumor efficacy of  rogaratinib in combination with copanlisib for locally advanced or metastatic solid tumors  that are mRNA-positive for at least one FGFR1-4 subtype.",
                "brief_title": "Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors",
                "condition": "Advanced or Metastatic Solid Tumor",
                "country": "Belgium;France;Korea, Republic of;Germany;Singapore;Spain;United States",
                "geneName": "FGFR1",
                "intervention_name": "Rogaratinib (BAY1163877);Copanlisib (BAY80-6946)",
                "intervention_type": "Drug",
                "nct_num": "NCT03517956",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200715-51",
                "study_first_posted": "May 8, 2018"
            },
            {
                "brief_summary": "  The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828)  in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1  rearrangement.",
                "brief_title": "A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)",
                "condition": "MPN (Myeloproliferative Neoplasms)",
                "country": "United Kingdom;Austria;Canada;Switzerland;France;Germany;Italy;Spain;United States",
                "geneName": "FGFR1",
                "intervention_name": "Pemigatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03011372",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200715-51",
                "study_first_posted": "January 5, 2017"
            },
            {
                "brief_summary": "  This phase II/III trial studies how well FGFR inhibitor AZD4547 (AZD4547) works in treating  patients with stage IV squamous cell lung cancer that has come back after previous treatment.  This is a sub-study that includes all screened patients positive for the fibroblast growth  factor receptor (FGFR) biomarker. FGFR can cause tumor cells to grow more quickly. AZD4547  may decrease the activity of FGFR and may be able to shrink tumors.",
                "brief_title": "Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer",
                "condition": "FGFR2 Gene Mutation;FGFR2 Gene Amplification;Stage IV Squamous Cell Lung Carcinoma AJCC v7;Recurrent Squamous Cell Lung Carcinoma;FGFR3 Gene Amplification;FGFR1 Gene Mutation;FGFR3 Gene Mutation;FGFR1 Gene Amplification",
                "country": "Canada;United States",
                "geneName": "FGFR1",
                "intervention_name": "FGFR Inhibitor AZD4547;Docetaxel;Laboratory Biomarker Analysis",
                "intervention_type": "Drug;Other",
                "nct_num": "NCT02965378",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2/Phase 3",
                "sampleSn": "NGS200715-51",
                "study_first_posted": "November 16, 2016"
            }
        ],
        "cms": [
            {
                "age": "33",
                "agentName": "不体现医院（宝树科研）",
                "areaAgentName": "孙霄飞",
                "backStatus": "1",
                "backStatusShow": "未返款",
                "barcode": "2007141119653",
                "bedNumber": ".",
                "bingli": ".",
                "birthday": ".",
                "checkTime": ".",
                "contact": "18260163545",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": ".",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-22 13:11:00",
                "expressName": "顺丰",
                "expressNum": "SF1091100018166",
                "fenziBingli": ".",
                "financeId": "232756",
                "gender": "男",
                "historyNum": "0",
                "hospitalName": ".",
                "idCard": ".",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-14 11:20:34",
                "invoiceApplyMoney": "0.00",
                "invoiceName": ".",
                "invoiceReceivePhone": ".",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "0",
                "invoiceTypeShow": ".",
                "itemName": "0201027.OncoDrug-Seq全实体瘤110基因（血液ctDNA样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-11 11:19:07",
                "medicalRecord": ".",
                "name": "徐飞",
                "nickName": "首度基因",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "2",
                "paymentTypeShow": "月结",
                "receiveStatus": "1",
                "receiveStatusShow": "未收款",
                "receiveTime": "2020-07-15 13:11:07",
                "remark": ".",
                "reportAddress": ".",
                "reportAddressName": ".",
                "reportCheckTime": ".",
                "reportEmail": "all@treasuretree.cn,gallici@vip.qq.com",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": ".",
                "reportStyle": "电子",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "234277",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200715-51",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": "2020-07-14 11:20:56",
                "sickAge": ".",
                "sickFamilyHistory": ".",
                "source": "血液(cfDNA)",
                "sourceFrom": ".",
                "testDoctor": ".",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "直肠腺癌",
                "treatHistory": ".",
                "treatID": "TS050201",
                "treatResult": "直肠腺癌",
                "treatmentNo": ".",
                "unitAgentName": "苏州首度基因",
                "url": "[]",
                "userId": "1428",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [],
        "fusion": [],
        "heredity": [
            {
                "aachangeRefgene": ".",
                "ajsGb": ".",
                "alt": ".",
                "alteration": ".",
                "barcode": ".",
                "chr": ".",
                "clinsig": ".",
                "description": ".",
                "diseaseInfo": ".",
                "evidenceLevel": ".",
                "exonicfuncRefgene": ".",
                "freq": ".",
                "funcRefgene": ".",
                "geneInfo": ".",
                "geneName": ".",
                "geneType": ".",
                "geneVar": ".",
                "geneYcType": ".",
                "hgsGb": ".",
                "hgvs": ".",
                "intervarAutomated": ".",
                "level": ".",
                "mutationType": ".",
                "ominId": ".",
                "posEnd": ".",
                "posStart": ".",
                "projectAbbr": "DE",
                "ref": ".",
                "relativeDisease": ".",
                "riskLevel": ".",
                "sampleSn": "NGS200715-51",
                "tumorProfiles": ".",
                "vcfFormat": ".",
                "vcfFormatInfo": ".",
                "wxz": ".",
                "zlb": "."
            }
        ],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:3.17%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "3.17%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 2,
                "percent": 3.17,
                "projectAbbr": "DE",
                "sampleSn": "NGS200715-51",
                "totalSites": 63
            }
        ],
        "qc": [
            {
                "cleanBases": 5900189399,
                "cleanReads": 42116914,
                "coverage>0.2x": 98.6,
                "coverage>0.5x": 91.1,
                "effectCoverage500": 97.65,
                "effectDepth": 2543,
                "insert": 187.2,
                "mapping": 99.92,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 6420114300,
                "rawDuplication": 24.3,
                "rawReads": 42800762,
                "readPercent": 98.4,
                "samplePurity": ".",
                "sampleSn": "NGS200715-51",
                "sampleType": "ctDNA",
                "targetMapping": 74.34,
                "trimDuplication": 0.0,
                "tumorCoverage": 99.77,
                "tumorDepth": 6749,
                "tumorQ30": 93.32
            }
        ],
        "target": [
            {
                "1000g2015aug_all": "0.000199681002413854",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "FGFR1",
                "NM_ID": "NM_001174067",
                "ajsGb": "p.Met565Val",
                "alt": "C",
                "alteration": "M565V",
                "avsnp150": "rs530348127",
                "cancerType": ".",
                "chr": "chr8",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.464",
                "funcRefgene": "exonic",
                "geneInfo": "FGFR1编码成纤维细胞生长因子受体1，一种对有丝分裂和分化重要的受体酪氨酸激酶。 FGFR1由三个免疫球蛋白样细胞外结构域组成，一个跨膜成分和一个通过MAPK途径起作用的胞质酪氨酸激酶结构域（PMID：8622701）。在与成纤维细胞生长因子配体（主要是FGF1和FGF2）结合后，蛋白质迅速二聚并最终内化至细胞核。然而，这种结合作用因组织分布和配体可用性而变化（PMID：16597617）。 FGFR1在组织中广泛表达，并且对于多种功能如胚胎发育，骨骼发生，有丝分裂发生和分化是必需的。先天性突变与身体畸形，智力低下和神经缺陷有关（PMID：23812909）。 FGFR1中的扩增或活化突变在包括肺癌，乳腺癌，前列腺癌，头颈癌和食道癌在内的多种癌症中发生频率不同（PMID：21160078,0919196,14614009,16807070,12147242）。在转移性肾细胞癌中，FGF信号传导已经被假设为介导辅助获得的治疗耐受，通过生成血管逃脱来自VEGF的靶向治疗（PMID：24387233）。目前，许多FGFR蛋白的小分子抑制剂正在使用中，其中主要区别在于它们对FGFR相对于其他受体酪氨酸激酶（RTK）的特异性（PMID：PMID：23696246,24265351）。",
                "geneName": "FGFR1",
                "geneType": "geneBx",
                "geneVar": "FGFR1基因exon13第1693位碱基A置换为G使得第565位氨基酸由甲硫氨酸转变成了缬氨酸",
                "hgsGb": "c.1693A>G",
                "hgvs": "FGFR1:NM_001174067:exon13:c.1693A>G:p.Met565Val",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "38274887",
                "posStart": "38274887",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200715-51",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:1104,954:0.470:579,491:525,463:33:172,173:60:35:0.454,0.458,0.464:0.012,0.004,0.984",
                "wxz": "exon13",
                "zlb": "NM_001174067"
            }
        ],
        "tmb": [],
        "tnb": []
    },
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副中度",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "G/A",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，需较高剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较高，神经毒性综合征的严重程度可能降低",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，药物代谢较快",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "A/G",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/T",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/C",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，药物代谢较快",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/T",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "T/T",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "C/A",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "C/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "C/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "A/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "野生型",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "野生型",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/G",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/6TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢降低",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "T/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "C/T",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/A",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "G/G",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/A",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/C",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副低，代谢增加",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/A",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200716-48",
                "updateTime": "."
            }
        ],
        "clinical": [
            {
                "brief_summary": "  This is a phase 1 study of atezolizumab in combination with D2C7-IT, a dual-specific  monoclonal antibody (mAB) with a high affinity for both EGFRwt- and EGFRvIII-expressing  cells, in patients with recurrent World Health Organization (WHO) grade IV malignant glioma  at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.",
                "brief_title": "D2C7-IT With Atezolizumab for Recurrent Gliomas",
                "condition": "Malignant Glioma",
                "country": "United States",
                "geneName": "EGFR",
                "intervention_name": "D2C7-IT (6920 ng/mL via convection-enhanced delivery);Atezolizumab (1200 mg every three weeks)",
                "intervention_type": "Drug",
                "nct_num": "NCT04160494",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "November 13, 2019"
            },
            {
                "brief_summary": "  The esophageal squamous cell carcinoma (ESCC) has high prevalence and mortality in China,  which become a severe challenge for public health. The molecular imaging technology has been  developed for intra-operative visualization and precise resection of the tumors. The imaging  probe possess high affinity to the tumor specific targets. Among the tumor related proteins,  EGFR is located on the cell membrane and over expresses in more than 50% ESCC which has been  used as an ideal target for molecular imaging.  Cetuximab is an EGFR targeting antibody for anti cancer therapy. When labeled with an  commercial available fluorescence dye IRDye800, cetuximab has been used as molecular imaging  probe in clinical trials for surgical navigation of cancers including head and neck squamous  cell cancers and gliomas. Previous studies shown high safety when using this probe and  excellence sensitivity for cancer detection, which bring great promise in translational  medicine.  This is a single-center prospective sequential trial. It is the first attempt to apply  cetuximab-IRDye800 probe in ESCC surgery. This probe will be produced under clinical Good  Manufacturing Practice (cGMP) conditions. The ESCC patients will be recruited with strict  criteria.Patients population is planned to be 40 cases between18 and 65 years old, without  gender limit. The patients will be divided into four groups : control group without probe  administration, 1% dose group (1% of therapeutic cetuximab dose; 2.5 Mg/m2) and 10% dose  groups (10%of therapeutic cetuximab dose ;25mg/m2) and 25% dose group (25%of therapeutic  cetuximab dose; 62.5mg/m2), 10 cases are sequential assigned to each group. After informed  consent, patients will receive a systemic infusion of the study drug 2 days before surgery.  Primary (safety and efficiency) and secondary endpoints (tissue EGFR expression) will be  recorded. Preoperative management and surgical procedures will been performed according to  conventional protocols. Intra-operative imaging of the surgical field will be performed in  real time at 2 time points: before and post tumor resection. The postoperative specimens will  be subjected to pathological analysis including correlation study of fluorescence signal and  tumor tissue in pathology slice.  A protocol for managing any allergic reaction related to systemic infusion of cetuximab has  been established. The patient's vital signs and ECG will be closely monitored post probe  administration. The blood, liver and kidney, coagulation function and cardiotoxicity will be  evaluated before and post surgery.  This clinical trial is anticipated to validate the concept that intra-operative fluorescent  imaging of esophageal squamous cell carcinoma with cetuximab-IRDye800 can facilitate the  demarcation of tumor boundary and identification of metastatic lymph nodes and testify its  safety.",
                "brief_title": "Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer",
                "condition": "Drug Safety ; Drug Specificity",
                "country": "China",
                "geneName": "EGFR",
                "intervention_name": "Cetuximab-IRDye800",
                "intervention_type": "Drug",
                "nct_num": "NCT04161560",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "November 13, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies the side effects of ESK981 and nivolumab and to see how well they  work for the treatment of castration resistant prostate cancer that has spread to other  places in the body (metastatic). ESK981 is an investigational drug that targets several  important pathways that are believed to play a role in the spread of cancer. Immunotherapy  with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the  cancer, and may interfere with the ability of tumor cells to grow and spread. This study is  being done to see if giving ESK981 and nivolumab together works better in treating metastatic  castration resistant prostate cancer compared to usual treatments.",
                "brief_title": "ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer",
                "condition": "Prostate Carcinoma Metastatic in the Bone;Castration-Resistant Prostate Carcinoma;Stage IVB Prostate Cancer AJCC v8;Metastatic Prostate Carcinoma;Castration Levels of Testosterone",
                "country": "United States",
                "geneName": "EGFR",
                "intervention_name": "Nivolumab;Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT04159896",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "November 11, 2019"
            },
            {
                "brief_summary": "  The study aims to find whether patients with advanced HCC can get more benefits from RFA  +PD-1 immunosuppressant (carrizumab) and VEGFR-2 suppressant (apatinib) compared with  carrizumab and apatinib alone, considering with the result of PFS.",
                "brief_title": "RFA Plus Carrizumab and Apatinib vs Carrizumab and Apatinib Alone for HCC",
                "condition": "Immunosuppression;Radiofrequency Ablation;Tumor Immunity",
                "country": "China",
                "geneName": "EGFR",
                "intervention_name": "radiofrequency ablation",
                "intervention_type": "Combination Product",
                "nct_num": "NCT04150744",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "November 5, 2019"
            },
            {
                "brief_summary": "  Leptomeningeal metastasis (LM) is a devastating and terminal complication of advanced  non-small-cell lung cancer (NSCLC), especially in patients harboring epidermal growth factor  receptor (EGFR) mutations. Osimertinib is an oral,third-generation, irreversible epidermal  growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both  EGFR-TKI-sensitizing and EGFR T790M resistance mutations .AURA I/II study and other  preclinical study suggested that Osimertinib exhibited a better blood-brain barrier(BBB)  penetration than the other EGFR-TKIs (gefitinib, erlotinib, or afatinib).The BLOOM 、AURA and  FLURA study demonstrated that osimertinib showed encouraging activity and manageable  tolerability in pretreated EGFR-mutant NSCLC patients with LM. Bevacizumab is a monoclonal  antibody against vascular endothelial growth factor (VEGF). Animal study and autopsy  specimens showed that VEGF is an essential factor in LM. Recently study showed EGFR-TKIs plus  bevacizumab prolonged PFS and OS in patients with EGFR-mutant NSCLC and multiple brain  mteastasis when compared with EGFR-TKIs alone. Howerver osimertinib combined with bevacizumab  could benefit patients with LM from EGFR- mutant NSCLC remains undetermined. Therefore, the  purpose of the study is to evaluate the safety and efficacy of osimertinib combined with  bevacizumab for EGFR- mutant non-small cell lung cancer with leptomeningeal metastasis",
                "brief_title": "Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis",
                "condition": "Non-small Cell Lung Cancer;Leptomeningeal Metastasis;EGFR Activating Mutation",
                "country": ".",
                "geneName": "EGFR",
                "intervention_name": "Bevacizumab;Osimertinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04148898",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "November 4, 2019"
            },
            {
                "brief_summary": "  Leptomeningeal metastasis (LM) is a devastating and terminal complication of advanced  non-small-cell lung cancer (NSCLC), especially in patients harboring epidermal growth factor  receptor (EGFR) mutations. Osimertinib is an oral,third-generation, irreversible epidermal  growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both  EGFR-TKI-sensitizing and EGFR T790M resistance mutations .AURA I/II study and other  preclinical study suggested that Osimertinib exhibited a better blood-brain barrier(BBB)  penetration than the other EGFR-TKIs (gefitinib, erlotinib, or afatinib).The BLOOM 、AURA and  FLURA study demonstrated that osimertinib showed encouraging activity and manageable  tolerability in pretreated EGFR-mutant NSCLC patients with LM. Bevacizumab is a monoclonal  antibody against vascular endothelial growth factor (VEGF). Animal study and autopsy  specimens showed that VEGF is an essential factor in LM. Recently study showed EGFR-TKIs plus  bevacizumab prolonged PFS and OS in patients with EGFR-mutant NSCLC and multiple brain  mteastasis when compared with EGFR-TKIs alone. Howerver osimertinib combined with bevacizumab  could benefit patients with LM from EGFR- mutant NSCLC remains undetermined. Therefore, the  purpose of the study is to evaluate the safety and efficacy of osimertinib combined with  bevacizumab for EGFR- mutant non-small cell lung cancer with leptomeningeal metastasis",
                "brief_title": "Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis",
                "condition": "Non-small Cell Lung Cancer;Leptomeningeal Metastasis;EGFR Activating Mutation",
                "country": ".",
                "geneName": "EGFR",
                "intervention_name": "Bevacizumab;Osimertinib",
                "intervention_type": "Drug",
                "nct_num": "NCT04148898",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "November 4, 2019"
            },
            {
                "brief_summary": "  using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and  pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC)  after failure of EGFR tyrosine kinase inhibitors.",
                "brief_title": "A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.",
                "condition": "NSCLC Stage IIIB~IV",
                "country": ".",
                "geneName": "EGFR",
                "intervention_name": "Atezolizumab Injection; bevacizumab Injection",
                "intervention_type": "Drug",
                "nct_num": "NCT04147351",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "November 1, 2019"
            },
            {
                "brief_summary": "  using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and  pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC)  after failure of EGFR tyrosine kinase inhibitors.",
                "brief_title": "A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.",
                "condition": "NSCLC Stage IIIB~IV",
                "country": ".",
                "geneName": "EGFR",
                "intervention_name": "Atezolizumab Injection; bevacizumab Injection",
                "intervention_type": "Drug",
                "nct_num": "NCT04147351",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "November 1, 2019"
            },
            {
                "brief_summary": "  using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and  pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC)  after failure of EGFR tyrosine kinase inhibitors.",
                "brief_title": "A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.",
                "condition": "NSCLC Stage IIIB~IV",
                "country": ".",
                "geneName": "EGFR",
                "intervention_name": "Atezolizumab Injection; bevacizumab Injection",
                "intervention_type": "Drug",
                "nct_num": "NCT04147351",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "November 1, 2019"
            },
            {
                "brief_summary": "  To assess the efficacy and safety of ASK120067 versus a standard of care epidermal growth  factor receptor tyrosine kinase inhibitor Gefitinib in patients with locally advanced or  Metastatic Non Small Cell Lung Cancer",
                "brief_title": "ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC NSCLC",
                "condition": "Locally Advanced or Metastatic NSCLC",
                "country": "China",
                "geneName": "EGFR",
                "intervention_name": "Gefitinib + placebo ASK120067;Placebo Gefitinib 250 mg;Placebo ASK120067;Gefitinib 250 mg;ASK120067 + placebo",
                "intervention_type": "Drug",
                "nct_num": "NCT04143607",
                "overall_status": "Recruiting",
                "phase": "Phase 3",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "October 29, 2019"
            },
            {
                "brief_summary": "  The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP  regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.",
                "brief_title": "Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.",
                "condition": "Sintilimab;TP53 Mutation;Diffuse Large B-Cell Lymphoma",
                "country": ".",
                "geneName": "TP53",
                "intervention_name": "Sintilimab-R-CHOP",
                "intervention_type": "Drug",
                "nct_num": "NCT04023916",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "July 18, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  This phase I trial studies best dose and how well copanlisib when given together with  nivolumab works in treating participants with Richter's transformation or transformed  indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking  some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may  interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab  may work better in treating participants with Richter's transformation or transformed  non-Hodgkin's lymphoma.",
                "brief_title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
                "condition": "Marginal Zone Lymphoma;Indolent Non-hodgkin Lymphoma;Follicular Lymphoma;TP53 Gene Mutation;Loss of Chromosome 17p;Diffuse Large B Cell Lymphoma;Lymphoplasmacytic Lymphoma;Richter Syndrome;Chronic Lymphocytic Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Nivolumab;Copanlisib",
                "intervention_type": "Biological;Drug",
                "nct_num": "NCT03884998",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "March 21, 2019"
            },
            {
                "brief_summary": "  CLL is an incurable disease with conventional chemotherapy. In the absence of TP53  disruption, a chemoimmunotherapy (CIT) regimen is recommended as front-line and second-line  treatment in those patients who attained a long progression-free survival (PFS) with the  previous regimen. Bendamustine and rituximab (BR) is one of the most widely adopted CIT  regimens, including second-line treatment. Unfortunately, durations of remission following BR  combination therapy tend to be short in patients with heavily pre-treated disease or who have  already received rituximab. The incorporation of a maintenance following induction  chemotherapy to overcome the shorter remission durations in this population is a reasonable  option.",
                "brief_title": "Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia",
                "condition": "Chronic Lymphocytic Leukemia",
                "country": "Russian Federation",
                "geneName": "TP53",
                "intervention_name": "BR as Maintenance",
                "intervention_type": "Drug",
                "nct_num": "NCT03847727",
                "overall_status": "Active, not recruiting",
                "phase": ".",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "February 20, 2019"
            },
            {
                "brief_summary": "  This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission  tomography (PET) and osimertinib works in evaluating glucose utilization in patients with  EGFR activated glioblastoma. Osimertinib may stop the growth of tumor cells by blocking some  of the enzymes needed for cell growth. 18F-FDG PET imaging may help to detect changes in  tumor glucose utilization, which may allow investigators to obtain an early read out on the  impact of osimertinib on recurrent glioblastoma patients whose tumors have EGFR activation.",
                "brief_title": "18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma",
                "condition": "EGFR Gene Mutation;Recurrent Glioblastoma;TP53 wt Allele;EGFR Gene Amplification;Supratentorial Glioblastoma;Glioblastoma",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Fludeoxyglucose F-18;Osimertinib;Positron Emission Tomography",
                "intervention_type": "Procedure;Drug;Other",
                "nct_num": "NCT03732352",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "November 6, 2018"
            },
            {
                "brief_summary": "  Recent preclinical studies suggest that combining MEK and MDM2 inhibition synergize to induce  apoptosis in RAS/BRAF-mutant and TP53 wild-type CRC models. In vitro, in RKO cell lines  (poorly differentiated colon carcinoma cell line resistant to single agent targeting MDM2 and  MEK and BRAF inhibition), the MDM2 plus MEK inhibitor combination generated a synergistic  increase in apoptotic index. In vivo, in mice harboring human RKO colon tumor xenografts the  combination of MDM2 plus MEK inhibition elicited 93% decreases in tumor volume.  This trial is to conduct a single-center, Phase 1 dose escalation study of trametinib  combined with HDM201 (a HDM2 inhibitor) in patients with advanced/metastatic RAS/RAF mutant  and TP53 wt CRC.",
                "brief_title": "Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type",
                "condition": "Advanced Cancer;Metastatic Cancer;Colorectal Cancer",
                "country": "France",
                "geneName": "TP53",
                "intervention_name": "Trametinib;HDM201",
                "intervention_type": "Drug",
                "nct_num": "NCT03714958",
                "overall_status": "Recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "October 22, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in  treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that  is untreated or has come back. Quizartinib may stop the growth of cancer cells by blocking  some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine  and venetoclax, work in different ways to stop the growth of cancer cells, either by killing  the cells, by stopping them from dividing, or by stopping them from spreading. Giving  quizartinib and decitabine may work better at treating acute myeloid leukemia and  myelodysplastic syndrome.",
                "brief_title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",
                "condition": "TP53 Gene Deletion;Blasts More Than 10 Percent of Peripheral Blood White Cells;Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;TP53 Gene Mutation;Myelodysplastic Syndrome;Recurrent Acute Myeloid Leukemia;Acute Myeloid Leukemia;High Risk Myelodysplastic Syndrome;Recurrent Myelodysplastic Syndrome;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Quizartinib;Venetoclax;Decitabine",
                "intervention_type": "Drug",
                "nct_num": "NCT03661307",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "September 7, 2018"
            },
            {
                "brief_summary": "  Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the  treatment of advanced refractory solid tumors with TP53 harmful mutations.",
                "brief_title": "Treatment of Carrying TP53 Harmful Mutations",
                "condition": "Advanced Cancer",
                "country": "China",
                "geneName": "TP53",
                "intervention_name": "Fluzoparib combined with Apatinib",
                "intervention_type": "Drug",
                "nct_num": "NCT03645200",
                "overall_status": "Not yet recruiting",
                "phase": "Phase 1",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "August 24, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  This phase I/II trial studies the side effects and best dose of milademetan tosylate and to  see how well it works with cytarabine in treating participants with acute myeloid leukemia  that has come back (recurrent) or that does not respond to treatment (refractory).  Milademetan tosylate may stop the growth of cancer cells by blocking some of the enzymes  needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different  ways to stop the growth of cancer cells, either by killing the cells, by stopping them from  dividing, or by stopping them from spreading. Giving milademetan tosylate and low-dose  cytarabine may work better in treating participants with recurrent or refractory acute  myeloid leukemia.",
                "brief_title": "Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",
                "condition": "Recurrent Acute Myeloid Leukemia;TP53 wt Allele;Refractory Acute Myeloid Leukemia",
                "country": "United States",
                "geneName": "TP53",
                "intervention_name": "Cytarabine;Milademetan Tosylate",
                "intervention_type": "Drug",
                "nct_num": "NCT03634228",
                "overall_status": "Recruiting",
                "phase": "Phase 1/Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "August 16, 2018"
            },
            {
                "brief_summary": "  This phase II trial studies how well pembrolizumab works in treating participants with cancer  that has spread to other places in the body, has come back or has spread to nearby tissues or  lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of  tumor cells to grow and spread.",
                "brief_title": "Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability",
                "condition": "Stage IIIA Ovarian Cancer AJCC v8;Stage IIIB Ovarian Cancer AJCC v8;Stage III Ovarian Cancer AJCC v8;Recurrent Ovarian Carcinoma;Locally Advanced Solid Neoplasm;BRCA2 Gene Mutation;Stage IVA Ovarian Cancer AJCC v8;Stage IV Breast Cancer AJCC v6 and v7;Stage IIIB Breast Cancer AJCC v7;Metastatic Malignant Solid Neoplasm;Stage IVB Ovarian Cancer AJCC v8;Stage IIIA Breast Cancer AJCC v7;POLE Gene Mutation;BRCA1 Gene Mutation;Stage IIIC Breast Cancer AJCC v7;POLD1 Gene Mutation;Recurrent Malignant Solid Neoplasm;Stage III Breast Cancer AJCC v7;Stage IV Ovarian Cancer AJCC v8;Stage IIIC Ovarian Cancer AJCC v8",
                "country": "United States",
                "geneName": "POLD1",
                "intervention_name": "Pembrolizumab;Laboratory Biomarker Analysis",
                "intervention_type": "Biological;Other",
                "nct_num": "NCT03428802",
                "overall_status": "Recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "February 12, 2018"
            },
            {
                "brief_summary": "  The purpose of this study is to determine the safety and effectiveness of nivolumab alone or  in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring  mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA.  Nivolumab and ipilimumab have been given to patients across multiple types of cancer, and  safe doses and schedules have been determined.",
                "brief_title": "Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)",
                "condition": "Advanced Solid Tumors",
                "country": "Canada;United States",
                "geneName": "POLD1",
                "intervention_name": "Ipilimumab;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03461952",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "March 12, 2018"
            },
            {
                "brief_summary": "  The purpose of this study is to determine the safety and effectiveness of nivolumab alone or  in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring  mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA.  Nivolumab and ipilimumab have been given to patients across multiple types of cancer, and  safe doses and schedules have been determined.",
                "brief_title": "Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)",
                "condition": "Advanced Solid Tumors",
                "country": "Canada;United States",
                "geneName": "POLD1",
                "intervention_name": "Ipilimumab;Nivolumab",
                "intervention_type": "Drug",
                "nct_num": "NCT03461952",
                "overall_status": "Active, not recruiting",
                "phase": "Phase 2",
                "sampleSn": "NGS200716-48",
                "study_first_posted": "March 12, 2018"
            }
        ],
        "cms": [
            {
                "age": "34",
                "agentName": "不体现送检单位（张志利）",
                "areaAgentName": "强祖冬",
                "backStatus": "1",
                "backStatusShow": "未返款",
                "barcode": "2007171243816",
                "bedNumber": ".",
                "bingli": ".",
                "birthday": ".",
                "checkTime": ".",
                "contact": "13112812223",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": ".",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-23 13:39:00",
                "expressName": ".",
                "expressNum": "1093615607641",
                "fenziBingli": ".",
                "financeId": "234287",
                "gender": "男",
                "historyNum": "0",
                "hospitalName": ".",
                "idCard": ".",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-17 12:44:34",
                "invoiceApplyMoney": "0.00",
                "invoiceName": ".",
                "invoiceReceivePhone": ".",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "0",
                "invoiceTypeShow": ".",
                "itemName": "0201027.OncoDrug-Seq全实体瘤110基因（血液ctDNA样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-15 12:43:02",
                "medicalRecord": ".",
                "name": "欧阳文清",
                "nickName": "张志利",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "1",
                "paymentTypeShow": "现结",
                "receiveStatus": "2",
                "receiveStatusShow": "已收款",
                "receiveTime": "2020-07-16 13:39:38",
                "remark": ".",
                "reportAddress": "江西省肿瘤医院新住院部21楼消化内科二病区，收件人：涂云，电话：13907093822",
                "reportAddressName": ".",
                "reportCheckTime": ".",
                "reportEmail": ".",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": ".",
                "reportStyle": ".",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "235677",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200716-48",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": ".",
                "sickAge": ".",
                "sickFamilyHistory": ".",
                "source": "血液(cfDNA)",
                "sourceFrom": ".",
                "testDoctor": ".",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "肝癌",
                "treatHistory": ".",
                "treatID": "TS2101",
                "treatResult": "肝癌",
                "treatmentNo": ".",
                "unitAgentName": "张志利",
                "url": "[]",
                "userId": "1067",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [],
        "fusion": [],
        "heredity": [
            {
                "aachangeRefgene": ".",
                "ajsGb": ".",
                "alt": ".",
                "alteration": ".",
                "barcode": ".",
                "chr": ".",
                "clinsig": ".",
                "description": ".",
                "diseaseInfo": ".",
                "evidenceLevel": ".",
                "exonicfuncRefgene": ".",
                "freq": ".",
                "funcRefgene": ".",
                "geneInfo": ".",
                "geneName": ".",
                "geneType": ".",
                "geneVar": ".",
                "geneYcType": ".",
                "hgsGb": ".",
                "hgvs": ".",
                "intervarAutomated": ".",
                "level": ".",
                "mutationType": ".",
                "ominId": ".",
                "posEnd": ".",
                "posStart": ".",
                "projectAbbr": "DE",
                "ref": ".",
                "relativeDisease": ".",
                "riskLevel": ".",
                "sampleSn": "NGS200716-48",
                "tumorProfiles": ".",
                "vcfFormat": ".",
                "vcfFormatInfo": ".",
                "wxz": ".",
                "zlb": "."
            }
        ],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:0.0%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "0.0%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "如果使用免疫检查点抑制剂治疗，疗效可能较好",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "检测到变异/基因突变（NM_000546:exon8:c.868_878del:p.Arg290Glyfs*12）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": "TP53:",
                "Unnamed: 8": ".",
                "Unnamed: 9": "NGS200716-48",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 0,
                "percent": 0.0,
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-48",
                "totalSites": 66
            }
        ],
        "qc": [
            {
                "cleanBases": 5755190663,
                "cleanReads": 41432728,
                "coverage>0.2x": 98.58,
                "coverage>0.5x": 89.33,
                "effectCoverage500": 98.84,
                "effectDepth": 4574,
                "insert": 172.7,
                "mapping": 99.94,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 6309572100,
                "rawDuplication": 11.52,
                "rawReads": 42063814,
                "readPercent": 98.5,
                "samplePurity": ".",
                "sampleSn": "NGS200716-48",
                "sampleType": "ctDNA",
                "targetMapping": 75.28,
                "trimDuplication": 0.0,
                "tumorCoverage": 99.95,
                "tumorDepth": 6702,
                "tumorQ30": 93.66
            }
        ],
        "target": [
            {
                "1000g2015aug_all": ".",
                "AA_change": ".",
                "DNA_change": ".",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": ".",
                "NM_ID": ".",
                "ajsGb": "p.Ala460Thr",
                "alt": "A",
                "alteration": "A460T",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr2",
                "clinsig": ".",
                "cosmic70": "ID\\x3dCOSM164581\\x3bOCCURENCE\\x3d1(NS)",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.051",
                "funcRefgene": "exonic",
                "geneInfo": "SPTBN1（Spectrin Beta，Non-Erythrocytic 1）是蛋白质编码基因。Spectrin是肌动蛋白交联和分子支架蛋白，其将质膜与肌动蛋白细胞骨架连接，并且在确定细胞形状，跨膜蛋白的排列和细胞器组织中起作用。它由两个反向平行的α-和β-亚基二聚体组成。该基因是β-血影蛋白基因家族的一员。编码的蛋白质含有N末端肌动蛋白结合结构域和17个参与二聚体形成的血影蛋白重复序列​​。与SPTBN1相关的疾病包括Beckwith-Wiedemann综合征。其相关途径包括Nephrin相互作用和RET信号传导。",
                "geneName": "SPTBN1",
                "geneType": "g,e,n,e,Q,t",
                "geneVar": "SPTBN1基因exon12第1378位碱基G置换为A使得第460位氨基酸由丙氨酸转变成了苏氨酸",
                "hgsGb": "c.1378G>A",
                "hgvs": "SPTBN1:NM_003128:exon12:c.1378G>A:p.Ala460Thr",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "54853105",
                "posStart": "54853105",
                "projectAbbr": "DE",
                "ref": "G",
                "sampleSn": "NGS200716-48",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:2770,149:0.093:1429,79:1341,70:29:166,162:60:29:0.045,0.050,0.051:0.009,0.001,0.990",
                "wxz": "exon12",
                "zlb": "NM_003128"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "Oncogenic Mutations",
                "DNA_change": "Oncogenic Mutations",
                "ExAC_nonpsych_ALL": "1.11e-05",
                "GeneName": "RAD50",
                "NM_ID": "NM_005732",
                "ajsGb": "p.Arg763Cys",
                "alt": "T",
                "alteration": "R763C",
                "avsnp150": "rs369996457",
                "cancerType": ".",
                "chr": "chr5",
                "clinsig": "Uncertain_significance",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.442",
                "funcRefgene": "exonic",
                "geneInfo": "RAD50是MRE11 / RAD50 / NBS1（MRN）复合物的亚基。 MRN复合物作为DNA损伤反应（DDR）的一部分被募集到DNA双链断裂（DSB）位点，并通过同源重组（HR）或非同源末端在损伤修复中起关键作用。 -joining（NHEJ）途径（PMID：2659437,15309560）。在这个复合体中，RAD50具有ATP酶活性的灵活和动态二聚体。生物化学研究已经证明RAD50通过将多个RAD50分子桥接至DNA并随后将MRN复合物募集至受损染色质而起到维持基因组完整性的作用（PMID：21458667,21511873,21441914,12152085,25576492）。 RAD50还具有直接功能，可以通过NHEJ桥接DNA末端（PMID：15309560）。已经在患有Nijmegen破裂综合征样疾病的患者中鉴定了RAD50中的种系突变，其特征在于进行性小头畸形，身材矮小和癌症风险增加（PMID：19409520）。 RAD50中的突变增加肿瘤易感性，类似于其他DNA修复酶中的突变，并且已在几种人类癌症中鉴定出RAD50体细胞突变（PMID：16385572,24894818）。预计RAD50突变是功能丧失导致DNA损伤诱导的MRN病灶形成的能力降低（PMID：19409520）。",
                "geneName": "RAD50",
                "geneType": "geneYc,geneMy,geneHRD",
                "geneVar": "RAD50基因exon14第2287位碱基C置换为T使得第763位氨基酸由精氨酸转变成了半胱氨酸",
                "hgsGb": "c.2287C>T",
                "hgvs": "RAD50:NM_005732:exon14:c.2287C>T:p.Arg763Cys",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "131939071",
                "posStart": "131939071",
                "projectAbbr": "DE",
                "ref": "C",
                "sampleSn": "NGS200716-48",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:843,669:0.448:430,356:413,313:28:166,166:60:18:0.399,0.440,0.442:0.207,0.002,0.791",
                "wxz": "exon14",
                "zlb": "NM_005732"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "F856L",
                "DNA_change": "F856L",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "EGFR",
                "NM_ID": "NM_005228",
                "ajsGb": "p.Phe856Leu",
                "alt": "G",
                "alteration": "F856L",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": "chr7",
                "clinsig": ".",
                "cosmic70": "ID\\x3dCOSM1550028\\x3bOCCURENCE\\x3d1(lung)",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.003",
                "funcRefgene": "exonic",
                "geneInfo": "EGFR编码表皮生长因子受体。表皮生长因子受体结合的配体，包括表皮生长因子（EGF）、转化生长因子（TGF-α），激活下游的信号转导通路包括典型致癌MAPK和PI3K/Akt/mTOR信号级联反应，最终导致细胞的增殖、迁移和分化的变化（PMID：18045542）。虽然EGFR通常在正常成人组织中以低水平表达，但是在许多癌症类型例如肺癌，脑癌，结直肠癌和头颈癌（PMID：10880430）中发现通过突变和/或EGFR基因的扩增使该受体过度激活。 在脑癌和结直肠癌中，EGFR基因的拷贝数扩增导致受体过表达（PMID：11426640）。然而，在肺癌中，最普遍的EGFR改变是激酶结构域中的突变，导致受体的结构性激活形式（PMID：15329413）。在胰腺癌和结直肠癌中偶尔发现EGFR的激活突变（PMID：24827134）。",
                "geneName": "EGFR",
                "geneType": "geneBx,geneMy",
                "geneVar": "EGFR基因exon21第2568位碱基T置换为G使得第856位氨基酸由苯丙氨酸转变成了亮氨酸",
                "hgsGb": "c.2568T>G",
                "hgvs": "EGFR:NM_005228:exon21:c.2568T>G:p.Phe856Leu",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "55259510",
                "posStart": "55259510",
                "projectAbbr": "DE",
                "ref": "T",
                "sampleSn": "NGS200716-48",
                "vcfFilter": ".",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:2742,8:0.019:1361,4:1292,4:34:166,157:60:34:0.010,0.010,0.003:0.001,0.000,0.999",
                "wxz": "exon21",
                "zlb": "NM_005228"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": ".",
                "DNA_change": ".",
                "ExAC_nonpsych_ALL": "3.309e-05",
                "GeneName": ".",
                "NM_ID": ".",
                "ajsGb": "p.Phe1702Val",
                "alt": "C",
                "alteration": "F1702V",
                "avsnp150": "rs760128306",
                "cancerType": ".",
                "chr": "chr8",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": "nonsynonymous_SNV",
                "freq": "0.382",
                "funcRefgene": "exonic",
                "geneInfo": "CSMD3（CUB and Sushi Multiple Domains 3）是蛋白质编码基因。 与CSMD3相关的疾病包括良性成人家族性肌阵挛性癫痫和Trichorhinophalangeal综合征，Ii型。有研究发现，CSMD3基因突变可能与亚洲及中国人群中食管鳞癌患者较好的预后有关。在亚洲患者中，CSMD3基因突变型患者的生存时间较野生型更长，在中国患者中这一结果更为明显，在高加索患者中就没有发现相似的现象。另有研究报道，在中国肺鳞状细胞癌患者中CSMD3基因突变也与更好的预后相关。",
                "geneName": "CSMD3",
                "geneType": "g,e,n,e,Q,t",
                "geneVar": "CSMD3基因exon31第5104位碱基T置换为G使得第1702位氨基酸由苯丙氨酸转变成了缬氨酸",
                "hgsGb": "c.5104T>G",
                "hgvs": "CSMD3:NM_198123:exon31:c.5104T>G:p.Phe1702Val",
                "intervarAutomated": "Uncertain_significance",
                "level": "3（临床意义未明）",
                "posEnd": "113504892",
                "posStart": "113504892",
                "projectAbbr": "DE",
                "ref": "A",
                "sampleSn": "NGS200716-48",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:1495,924:0.384:786,482:709,442:26:166,168:60:35:0.379,0.362,0.382:0.002,0.035,0.963",
                "wxz": "exon31",
                "zlb": "NM_198123"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "R290G",
                "DNA_change": "R290G",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "TP53",
                "NM_ID": "NM_000546",
                "ajsGb": "p.Arg290Glyfs*12",
                "alt": "-",
                "alteration": "R290Gfs*12",
                "avsnp150": ".",
                "cancerType": "卵巢癌",
                "chr": "chr17",
                "clinsig": ".",
                "cosmic70": "ID\\x3dCOSM44744\\x3bOCCURENCE\\x3d1(large_intestine)",
                "drugLevel": "3A",
                "drugs": "AZD1775",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.123",
                "funcRefgene": "exonic",
                "geneInfo": "TP53通过诱导下游抗肿瘤反应如DNA修复和细胞凋亡（PMID：11099028）编码p53肿瘤抑制蛋白，该蛋白是一种对细胞应激（包括DNA损伤和致癌激活）反应的转录因子。 TP53是人类癌症中最常见的突变基因，并且其胚系突变导致广泛癌症倾向的Li-Fraumeni综合征（PMID：22713868,21765642）。 p53蛋白由N末端反式激活结构域，中央DNA结合结构域，寡聚化结构域和C末端调节结构域（PMID：22713868）组成。",
                "geneName": "TP53",
                "geneType": "geneBx,geneHl,geneMy",
                "geneVar": "TP53基因exon8第868_878位碱基缺失使得第290位氨基酸由精氨酸转变成了甘氨酸且发生移码",
                "hgsGb": "c.868_878del",
                "hgvs": "TP53:NM_000546:exon8:c.868_878del:p.Arg290Glyfs*12",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "7577070",
                "posStart": "7577060",
                "projectAbbr": "DE",
                "ref": "CCTTTCTTGCG",
                "sampleSn": "NGS200716-48",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:3937,552:0.129:2012,279:1925,273:31:166,174:60:38:0.119,0.120,0.123:0.002,0.002,0.996",
                "wxz": "exon8",
                "zlb": "NM_000546"
            },
            {
                "1000g2015aug_all": ".",
                "AA_change": "R290G",
                "DNA_change": "R290G",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": "TP53",
                "NM_ID": "NM_000546",
                "ajsGb": "p.Arg290Glyfs*12",
                "alt": "-",
                "alteration": "R290Gfs*12",
                "avsnp150": ".",
                "cancerType": "头颈鳞癌",
                "chr": "chr17",
                "clinsig": ".",
                "cosmic70": "ID\\x3dCOSM44744\\x3bOCCURENCE\\x3d1(large_intestine)",
                "drugLevel": "3A",
                "drugs": "AZD1775",
                "exonicfuncRefgene": "frameshift_deletion",
                "freq": "0.123",
                "funcRefgene": "exonic",
                "geneInfo": "TP53通过诱导下游抗肿瘤反应如DNA修复和细胞凋亡（PMID：11099028）编码p53肿瘤抑制蛋白，该蛋白是一种对细胞应激（包括DNA损伤和致癌激活）反应的转录因子。 TP53是人类癌症中最常见的突变基因，并且其胚系突变导致广泛癌症倾向的Li-Fraumeni综合征（PMID：22713868,21765642）。 p53蛋白由N末端反式激活结构域，中央DNA结合结构域，寡聚化结构域和C末端调节结构域（PMID：22713868）组成。",
                "geneName": "TP53",
                "geneType": "geneBx,geneHl,geneMy",
                "geneVar": "TP53基因exon8第868_878位碱基缺失使得第290位氨基酸由精氨酸转变成了甘氨酸且发生移码",
                "hgsGb": "c.868_878del",
                "hgvs": "TP53:NM_000546:exon8:c.868_878del:p.Arg290Glyfs*12",
                "intervarAutomated": ".",
                "level": "5（致病）",
                "posEnd": "7577070",
                "posStart": "7577060",
                "projectAbbr": "DE",
                "ref": "CCTTTCTTGCG",
                "sampleSn": "NGS200716-48",
                "vcfFilter": "PASS",
                "vcfFormat": "GT:AD:AF:F1R2:F2R1:MBQ:MFRL:MMQ:MPOS:SA_MAP_AF:SA_POST_PROB",
                "vcfFormatInfo": "0/1:3937,552:0.129:2012,279:1925,273:31:166,174:60:38:0.119,0.120,0.123:0.002,0.002,0.996",
                "wxz": "exon8",
                "zlb": "NM_000546"
            }
        ],
        "tmb": [],
        "tnb": []
    },
    {
        "chemical": [
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副中度",
                "evidenceLevel": "3",
                "geneName": "CBR3",
                "geneType": "G/A",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs8133052",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/T",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低，需较高剂量",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "甲氨喋呤",
                "medicineType": "剂量，疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "粘膜炎严重程度可能会降低",
                "evidenceLevel": "3",
                "geneName": "DHFR",
                "geneType": "G/G",
                "medicineName": "甲氨喋呤",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1650723",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "血小板减少症的风险较低，神经毒性综合征的严重程度可能降低",
                "evidenceLevel": "3",
                "geneName": "ABCC2",
                "geneType": "C/T",
                "medicineName": "奥沙利铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs717620",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs13181",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "奥沙利铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较低",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "表柔比星",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "3",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "CYP3A4",
                "geneType": "A/A",
                "medicineName": "多西他赛(即多西紫杉醇)",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs2740574",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "/",
                "geneName": "NQO1",
                "geneType": "G/G",
                "medicineName": "丝裂霉素",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1131341",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "T/T",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801265",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "氟尿嘧啶",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "2A",
                "geneName": "GSTP1",
                "geneType": "A/A",
                "medicineName": "氟尿嘧啶",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1695",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "A/A",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2279343",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "需减少剂量",
                "evidenceLevel": "3",
                "geneName": "CYP2B6",
                "geneType": "G/G",
                "medicineName": "环磷酰胺",
                "medicineType": "剂量",
                "projectAbbreviation": "DE",
                "rsId": "rs3745274",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2A",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "环磷酰胺",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "SOD2",
                "geneType": "T/T",
                "medicineName": "环磷酰胺",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4880",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "RRM1",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042858",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CDA",
                "geneType": "A/A",
                "medicineName": "吉西他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2072671",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "卡铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高，药物代谢较慢",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "卡培他滨",
                "medicineType": "疗效，毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低，药物代谢较快",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "卡培他滨",
                "medicineType": "毒性，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "卡培他滨",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2A",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "卡培他滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "CYP19A1",
                "geneType": "G/G",
                "medicineName": "来曲唑",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs4646",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "ESR1",
                "geneType": "T/C",
                "medicineName": "来曲唑",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2234693",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "雷替曲塞",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "GALNT14",
                "geneType": "C/A",
                "medicineName": "米托蒽醌",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs9679162",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "MTHFR",
                "geneType": "C/C",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1801133",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "TTAAAG/del",
                "medicineName": "培美曲塞",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs151264360",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效中度，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "T/C",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11615",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "TPMT",
                "geneType": "A/A",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs1142345",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "1B",
                "geneName": "XPC",
                "geneType": "C/A",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs2228001",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "TP53",
                "geneType": "C/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1042522",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "ERCC1",
                "geneType": "G/T",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3212986",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2B",
                "geneName": "XRCC1",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs25487",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差",
                "evidenceLevel": "3",
                "geneName": "ERCC2",
                "geneType": "G/G",
                "medicineName": "顺铂",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1799793",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "2B",
                "geneName": "GSTM1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "GSTM1基因缺陷",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "GSTT1",
                "geneType": "纯合缺陷突变",
                "medicineName": "顺铂",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "GSTT1基因缺陷",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好，毒副较高",
                "evidenceLevel": "2A",
                "geneName": "CYP2D6",
                "geneType": "G/G",
                "medicineName": "他莫昔芬",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3892097",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副较低",
                "evidenceLevel": "3",
                "geneName": "TYMS",
                "geneType": "3R/3R",
                "medicineName": "替加氟",
                "medicineType": "疗效，毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs34743033",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替加氟",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "G/A",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs4148323",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副中度",
                "evidenceLevel": "2A",
                "geneName": "UGT1A1",
                "geneType": "6TA/7TA",
                "medicineName": "伊立替康",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs3064744",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "代谢降低",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "T/C",
                "medicineName": "依托泊苷",
                "medicineType": "代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1045642",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "SLCO1B1",
                "geneType": "C/T",
                "medicineName": "依托泊苷",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2291075",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "2B",
                "geneName": "DYNC2H1",
                "geneType": "A/A",
                "medicineName": "依托泊苷",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs716274",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "长春瑞滨",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "G/A",
                "medicineName": "长春新碱",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs10276036",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "MTR",
                "geneType": "A/A",
                "medicineName": "长春新碱",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs1805087",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "CASP7",
                "geneType": "C/G",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2227310",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较低",
                "evidenceLevel": "3",
                "geneName": "CYP2C8",
                "geneType": "G/G",
                "medicineName": "紫杉醇",
                "medicineType": "毒性",
                "projectAbbreviation": "DE",
                "rsId": "rs11572080",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较好",
                "evidenceLevel": "3",
                "geneName": "ABCB1",
                "geneType": "A/T",
                "medicineName": "紫杉醇",
                "medicineType": "疗效",
                "projectAbbreviation": "DE",
                "rsId": "rs2032582",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副低，代谢增加",
                "evidenceLevel": "1A",
                "geneName": "DPYD",
                "geneType": "G/G",
                "medicineName": "替吉奥",
                "medicineType": "毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs3918290",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "疗效较差，毒副高，代谢降低",
                "evidenceLevel": "3",
                "geneName": "DPYD",
                "geneType": "A/G",
                "medicineName": "替吉奥",
                "medicineType": "疗效，毒副作用，代谢",
                "projectAbbreviation": "DE",
                "rsId": "rs1801159",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "阿霉素(即多柔比星)",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "表柔比星",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs7853758",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            },
            {
                "barcode": ".",
                "clinicalGuide": "毒副较高",
                "evidenceLevel": "2B",
                "geneName": "SLC28A3",
                "geneType": "C/C",
                "medicineName": "米托蒽醌",
                "medicineType": "毒副作用",
                "projectAbbreviation": "DE",
                "rsId": "rs885004",
                "sampleSn": "NGS200716-53",
                "updateTime": "."
            }
        ],
        "clinical": [],
        "cms": [
            {
                "age": "66",
                "agentName": "不体现医院（宝树科研）",
                "areaAgentName": "孙霄飞",
                "backStatus": "1",
                "backStatusShow": "未返款",
                "barcode": "2007150950987",
                "bedNumber": ".",
                "bingli": ".",
                "birthday": ".",
                "checkTime": ".",
                "contact": "18260163545",
                "contactAddr": ".",
                "diseaseLocation": ".",
                "division": ".",
                "download": "0",
                "downloadReport": "True",
                "estimateEndTime": "2020-07-23 13:20:00",
                "expressName": "顺丰",
                "expressNum": "SF1091100018175",
                "fenziBingli": ".",
                "financeId": "233238",
                "gender": "男",
                "historyNum": "0",
                "hospitalName": ".",
                "idCard": ".",
                "idNum": ".",
                "imageList": "[]",
                "inHospitalNum": ".",
                "inpatientWard": ".",
                "inputTime": "2020-07-15 09:52:28",
                "invoiceApplyMoney": "0.00",
                "invoiceName": ".",
                "invoiceReceivePhone": ".",
                "invoiceStatus": "1",
                "invoiceStatusShow": "未开票",
                "invoiceType": "0",
                "invoiceTypeShow": ".",
                "itemName": "0201027.OncoDrug-Seq全实体瘤110基因（血液ctDNA样本）",
                "itemNum": "1",
                "labName": "浙江湖州医学检验所",
                "labRemark": ".",
                "lockList": "[]",
                "lockStatus": "0",
                "makeTime": "2020-07-12 09:50:29",
                "medicalRecord": ".",
                "name": "毛孝发",
                "nickName": "首度基因",
                "orderStatus": "1",
                "orderStatusShow": "未审核",
                "outLabName": ".",
                "paymentType": "2",
                "paymentTypeShow": "月结",
                "receiveStatus": "1",
                "receiveStatusShow": "未收款",
                "receiveTime": "2020-07-16 13:20:20",
                "remark": ".",
                "reportAddress": ".",
                "reportAddressName": ".",
                "reportCheckTime": ".",
                "reportEmail": "all@treasuretree.cn,gallici@vip.qq.com",
                "reportEmailStatus": "0",
                "reportEmailStatusShow": "未发送",
                "reportExpressName": ".",
                "reportExpressNum": ".",
                "reportExpressTime": ".",
                "reportPaperPrint": "0",
                "reportPaperPrintShow": "未打印",
                "reportPaperStatus": "0",
                "reportPaperStatusShow": "未寄送",
                "reportPhone": ".",
                "reportStyle": "电子",
                "reportTime": ".",
                "saleUserNickName": ".",
                "sampleId": "234738",
                "sampleLocation": ".",
                "sampleQuality": "符合检测要求",
                "sampleSn": "NGS200716-53",
                "sampleStatus": "JCZ",
                "sampleStatusShow": "检测中",
                "sendTime": "2020-07-15 09:52:55",
                "sickAge": ".",
                "sickFamilyHistory": ".",
                "source": "血液(cfDNA)",
                "sourceFrom": ".",
                "testDoctor": ".",
                "testDoctorContact": ".",
                "testHistory": ".",
                "treatCateName": "结肠癌",
                "treatHistory": ".",
                "treatID": "TS0501",
                "treatResult": "升结肠癌",
                "treatmentNo": ".",
                "unitAgentName": "苏州首度基因",
                "url": "[]",
                "userId": "1428",
                "waringTime": ".",
                "workflowList": "[]",
                "workflowStatus": "1",
                "workflowStatusShow": "已开启",
                "yunDay": "0",
                "zlType": "."
            }
        ],
        "cnA": [],
        "fusion": [],
        "heredity": [
            {
                "aachangeRefgene": ".",
                "ajsGb": ".",
                "alt": ".",
                "alteration": ".",
                "barcode": ".",
                "chr": ".",
                "clinsig": ".",
                "description": ".",
                "diseaseInfo": ".",
                "evidenceLevel": ".",
                "exonicfuncRefgene": ".",
                "freq": ".",
                "funcRefgene": ".",
                "geneInfo": ".",
                "geneName": ".",
                "geneType": ".",
                "geneVar": ".",
                "geneYcType": ".",
                "hgsGb": ".",
                "hgvs": ".",
                "intervarAutomated": ".",
                "level": ".",
                "mutationType": ".",
                "ominId": ".",
                "posEnd": ".",
                "posStart": ".",
                "projectAbbr": "DE",
                "ref": ".",
                "relativeDisease": ".",
                "riskLevel": ".",
                "sampleSn": "NGS200716-53",
                "tumorProfiles": ".",
                "vcfFormat": ".",
                "vcfFormatInfo": ".",
                "wxz": ".",
                "zlb": "."
            }
        ],
        "hla": [],
        "hrr": [],
        "immune": [
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "微卫星高度不稳定（MSI-H）的患者接受免疫检查点抑制剂治疗获益；FDA批准Pembrolizumab用于MSI-H（或dMMR]）的实体瘤患者，批准Nivolumab用于不可切除或转移性的MSI-H（或dMMR）的结直肠癌患者。",
                "dataInfo": "msiScore:4.55%;msiResult:微卫星稳定，MSS",
                "effect": "较差",
                "geneName": "微卫星分析",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "4.55%（微卫星稳定，MSS）",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MLH1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "MSH6",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA错配修复（MMR）基因。FDA批准帕博利珠单抗用于dMMR（或MSI-H）的实体瘤患者，批准纳武利尤单抗用于不可切除或转移性的dMMR（或MSI-H）的结直肠癌患者。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PMS2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "ATM",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRCA2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "BRIP1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "CHEK2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "PALB2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "DNA损伤修复（DDR，DNA Damage Repair ）基因。携带DDR基因突变的晚期转移性尿路上皮癌患者患者更易从PD-1/PD-L1抑制剂（纳武利尤单抗或阿特珠单抗）治疗中获益，且比DDR基因野生型患者的无进展生存期更长。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "RAD51C",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "相比KRAS野生型患者，携带KRAS突变的晚期非小细胞肺癌患者更可能受益于PD-1抑制剂治疗。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "KRAS",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有TP53或者KRAS突变的非小细胞肺癌患者，尤其是共突变的患者，对PD-1抑制剂治疗更敏感。",
                "dataInfo": "正向",
                "effect": "—",
                "geneName": "TP53",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有ALK融合的晚期非小细胞肺癌患者相比野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "ALK",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有EGFR突变的晚期非小细胞肺癌患者相比EGFR野生型患者，接受PD-1/PD-L1抑制剂治疗的疗效差。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "EGFR",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "携带有STK11或STK11和KRAS双突变的非小细胞肺癌患者，接受PD-1/PD-L1抑制剂治疗的疗效差，与无突变的患者相比无进展生存期缩短。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "STK11",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "MDM2扩增的膀胱癌、乳腺癌、子宫内膜间质肉瘤、肺腺癌、下咽鳞状细胞癌患者可能与免疫检查点抑制剂治疗引起的超进展相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "MDM2",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "WNT/β- catenin信号通路，发生功能激活突变可能导致在黑色素瘤中对免疫检查点抑制剂治疗耐药。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "CTNNB1",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            },
            {
                "Unnamed: 10": ".",
                "Unnamed: 8": ".",
                "Unnamed: 9": ".",
                "clinicalGuide": "PTEN缺失的黑色素瘤患者与免疫检查点抑制剂治疗疗效差相关。",
                "dataInfo": "负向",
                "effect": "—",
                "geneName": "PTEN",
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "testResult": "未检测到变异",
                "updateTime": "."
            }
        ],
        "mlpa": [],
        "msi": [
            {
                "clinicalDiagnosis": ".",
                "level": "MSS",
                "msiSites": 3,
                "percent": 4.55,
                "projectAbbr": "DE",
                "sampleSn": "NGS200716-53",
                "totalSites": 66
            }
        ],
        "qc": [
            {
                "cleanBases": 4316530025,
                "cleanReads": 30781352,
                "coverage>0.2x": 98.33,
                "coverage>0.5x": 88.74,
                "effectCoverage500": 95.5,
                "effectDepth": 2616,
                "insert": 252.3,
                "mapping": 99.93,
                "normalCoverage": ".",
                "normalDepth": ".",
                "normalQ30": ".",
                "projectAbbr": "DE",
                "rawBases": 4731777000,
                "rawDuplication": 15.14,
                "rawReads": 31545180,
                "readPercent": 97.58,
                "samplePurity": ".",
                "sampleSn": "NGS200716-53",
                "sampleType": "ctDNA",
                "targetMapping": 66.72,
                "trimDuplication": 0.0,
                "tumorCoverage": 99.82,
                "tumorDepth": 4443,
                "tumorQ30": 92.18
            }
        ],
        "target": [
            {
                "1000g2015aug_all": ".",
                "AA_change": ".",
                "DNA_change": ".",
                "ExAC_nonpsych_ALL": ".",
                "GeneName": ".",
                "NM_ID": ".",
                "ajsGb": ".",
                "alt": ".",
                "alteration": ".",
                "avsnp150": ".",
                "cancerType": ".",
                "chr": ".",
                "clinsig": ".",
                "cosmic70": ".",
                "drugLevel": ".",
                "drugs": ".",
                "exonicfuncRefgene": ".",
                "freq": ".",
                "funcRefgene": ".",
                "geneInfo": ".",
                "geneName": ".",
                "geneType": ".",
                "geneVar": ".",
                "hgsGb": ".",
                "hgvs": ".",
                "intervarAutomated": ".",
                "level": ".",
                "posEnd": ".",
                "posStart": ".",
                "projectAbbr": "DE",
                "ref": ".",
                "sampleSn": "NGS200716-53",
                "vcfFilter": ".",
                "vcfFormat": ".",
                "vcfFormatInfo": ".",
                "wxz": ".",
                "zlb": "."
            }
        ],
        "tmb": [],
        "tnb": []
    }
]